{"docstore/data": {"ced60568-d2a5-47ca-be3f-4b1221fadfd8": {"__data__": {"id_": "ced60568-d2a5-47ca-be3f-4b1221fadfd8", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc7d7933-c282-4a34-8135-fd2e56d54c53", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d35f13849ff8cc663b50b75b7b21dc929421e0bcc7753810032dfd3bde04b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f93757a5-cf45-4801-a31c-6c6a9603263e", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": "(MCK ) \nQ3 2020 Earnings Call    "}, "hash": "f923d2b8e5d342a766e43c6b356804d45c537e4ad34bc3f02b9988af9b0a4f64", "class_name": "RelatedNodeInfo"}}, "text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f93757a5-cf45-4801-a31c-6c6a9603263e": {"__data__": {"id_": "f93757a5-cf45-4801-a31c-6c6a9603263e", "embedding": null, "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": "(MCK ) \nQ3 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "dc7d7933-c282-4a34-8135-fd2e56d54c53", "node_type": "4", "metadata": {"page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d35f13849ff8cc663b50b75b7b21dc929421e0bcc7753810032dfd3bde04b8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ced60568-d2a5-47ca-be3f-4b1221fadfd8", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "987c7e288c0b65e4c3821bf9fedc10e428f8fbc23faa89363f6f62614c6141f0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6d32b0cd-7263-4886-815b-9fecfeda0165", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  "}, "hash": "79200165141ff69a19c93ea238540e4aab343aad2069c5aef897b37d45336447", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call    ", "start_char_idx": 165, "end_char_idx": 198, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6d32b0cd-7263-4886-815b-9fecfeda0165": {"__data__": {"id_": "6d32b0cd-7263-4886-815b-9fecfeda0165", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f93757a5-cf45-4801-a31c-6c6a9603263e", "node_type": "1", "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": "(MCK ) \nQ3 2020 Earnings Call    ", "page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a9156ff0853df186f2ee9e42ee650a53712d44d56a0c21a2e38e7833193f7f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "923e453d-a810-4637-b4b0-5fce72db64be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n"}, "hash": "948b22e0c3523f8f875dcaf4396c13cb5ce848b0162ebcd0119e0e27375f2157", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "923e453d-a810-4637-b4b0-5fce72db64be": {"__data__": {"id_": "923e453d-a810-4637-b4b0-5fce72db64be", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6d32b0cd-7263-4886-815b-9fecfeda0165", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cc2f24b77ee1671a72fec1179f4821eb10b5f3e52a89d5ed4772d831128eb55f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9120cb7-3882-4ab7-8fc5-54aedddaa045", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "f69bed0bdbe77be8d7a2f92c77fb90519dd1002a0732e706c942d68d1b202b04", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "start_char_idx": 16, "end_char_idx": 283, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9120cb7-3882-4ab7-8fc5-54aedddaa045": {"__data__": {"id_": "f9120cb7-3882-4ab7-8fc5-54aedddaa045", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "923e453d-a810-4637-b4b0-5fce72db64be", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a188e2719ebb327f60d52ea570c33b02df9e7bc216baff96123c9b5c406604f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fb197f69-95e0-42ef-a5bb-06add7183c67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n "}, "hash": "7a6a3916f00c24d763f63bed178e5822469c6a46bc994598a72c4ef9af39dc23", "class_name": "RelatedNodeInfo"}}, "text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 283, "end_char_idx": 352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fb197f69-95e0-42ef-a5bb-06add7183c67": {"__data__": {"id_": "fb197f69-95e0-42ef-a5bb-06add7183c67", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9120cb7-3882-4ab7-8fc5-54aedddaa045", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a9ac6e8af7cad895081d4dea0733e34fd0153a5ebdb5880a5910cce1859b263", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51d8c595-1c3a-45b7-9a74-50807989b1e4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "2e557d56ff5a7b809f557102aefbef6d4a5744f4aad91fe6ce7ed26050e4f732", "class_name": "RelatedNodeInfo"}}, "text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "start_char_idx": 352, "end_char_idx": 442, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51d8c595-1c3a-45b7-9a74-50807989b1e4": {"__data__": {"id_": "51d8c595-1c3a-45b7-9a74-50807989b1e4", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fb197f69-95e0-42ef-a5bb-06add7183c67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1cbfba8727526b6039f278f30c8003833788abfbb3e0a77505bdeb1afb683fbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262e0884-7237-4ab6-ab3e-8bd8f06bafb4", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "095c367b6852834e6b678928fb3811be20a47358a90e1a0d19d4db2b74d70309", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 442, "end_char_idx": 776, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262e0884-7237-4ab6-ab3e-8bd8f06bafb4": {"__data__": {"id_": "262e0884-7237-4ab6-ab3e-8bd8f06bafb4", "embedding": null, "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51d8c595-1c3a-45b7-9a74-50807989b1e4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ff457d5100564757527a13edb301dbbf07927e4a42f309bebecd14f9ef0172c3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5a85869-f8a4-41dc-ae80-7f2bde26822b", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "4f5f8273dc05bc4054c62172ef4dcfd6777b853f175a2e9694ca9e1c2559ddb1", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 776, "end_char_idx": 875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5a85869-f8a4-41dc-ae80-7f2bde26822b": {"__data__": {"id_": "b5a85869-f8a4-41dc-ae80-7f2bde26822b", "embedding": null, "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262e0884-7237-4ab6-ab3e-8bd8f06bafb4", "node_type": "1", "metadata": {"window": "Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "original_text": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df7d6a8e18f78f6cdec39356325f12760b8fadba8c5f29d2bc8e8773115cd44b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n", "original_text": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n"}, "hash": "9292908cf7018e0b6ab14707e7c3b1f0e1c6519a5c481f4ef945f23ac7b4e3ef", "class_name": "RelatedNodeInfo"}}, "text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 875, "end_char_idx": 984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a": {"__data__": {"id_": "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n", "original_text": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5a85869-f8a4-41dc-ae80-7f2bde26822b", "node_type": "1", "metadata": {"window": "Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "original_text": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32d60ab913025df85ba280ef22fd944eb448b0a437ec7e2dfb924db19c132799", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "36689c9b-7624-43fe-9171-e5144f273d62", "node_type": "1", "metadata": {"window": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss. ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n"}, "hash": "7aeea864c3b8f3e36e32d321c7a5239ed7227a5911065e2573a01048d5d36b43", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "start_char_idx": 984, "end_char_idx": 1101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "36689c9b-7624-43fe-9171-e5144f273d62": {"__data__": {"id_": "36689c9b-7624-43fe-9171-e5144f273d62", "embedding": null, "metadata": {"window": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss. ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOTHER PARTICIPANTS  \n \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n", "original_text": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3cdf5a6e7d3c09ea4e39882c465739a7f8fefc7a7bdbc41a1d35cb649553e66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27d2efbe-ba82-41e2-8467-daccdeb2d41a", "node_type": "1", "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n ", "original_text": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. "}, "hash": "be38a2ef25023001b6d968fee33326df96bebdbfc7b94ebced1fbcb2e46bfa4c", "class_name": "RelatedNodeInfo"}}, "text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "start_char_idx": 1101, "end_char_idx": 1151, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27d2efbe-ba82-41e2-8467-daccdeb2d41a": {"__data__": {"id_": "27d2efbe-ba82-41e2-8467-daccdeb2d41a", "embedding": null, "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n ", "original_text": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "36689c9b-7624-43fe-9171-e5144f273d62", "node_type": "1", "metadata": {"window": "LLC  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss. ", "original_text": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "796ad71e1b425241d500ebc3c6b7f7d37dbda7b0a72f35c0cf0b8ec646780b2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b29be67-ab79-4289-8b64-b7f6e000750c", "node_type": "1", "metadata": {"window": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n"}, "hash": "0f2b1cdde0b33babfff09e4705224675198410c78e82f3622e3bf266489f5837", "class_name": "RelatedNodeInfo"}}, "text": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "start_char_idx": 1151, "end_char_idx": 1621, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b29be67-ab79-4289-8b64-b7f6e000750c": {"__data__": {"id_": "2b29be67-ab79-4289-8b64-b7f6e000750c", "embedding": null, "metadata": {"window": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27d2efbe-ba82-41e2-8467-daccdeb2d41a", "node_type": "1", "metadata": {"window": "LLC  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  \nRicky R. Gold wasser  \nAnalyst, Morgan Stanley & Co.  LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n ", "original_text": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d6334f8b7f78041b3e09ee1bc62f362db5245256b44e3f49adbef24964a4342", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "62ef3b72-cb05-40af-bd47-c95689bdc8cd", "node_type": "1", "metadata": {"window": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack. ", "original_text": "At this time, I'd like to turn the call over to Holly Weiss. "}, "hash": "d08687781d68dbada2d6fe060d1a7b26d499cd90df4f12a6815b92bd89f55608", "class_name": "RelatedNodeInfo"}}, "text": "Today's conference is being recorded.  \n \n", "start_char_idx": 1621, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "62ef3b72-cb05-40af-bd47-c95689bdc8cd": {"__data__": {"id_": "62ef3b72-cb05-40af-bd47-c95689bdc8cd", "embedding": null, "metadata": {"window": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack. ", "original_text": "At this time, I'd like to turn the call over to Holly Weiss. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b29be67-ab79-4289-8b64-b7f6e000750c", "node_type": "1", "metadata": {"window": "LLC  Elizabeth Anderson  \nAnalyst, Evercore Group LLC  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  \n Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "original_text": "Today's conference is being recorded.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "911f1fb07ce611e6176badcd4620b928089c2fc5ad414a99d51a72950467a321", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb", "node_type": "1", "metadata": {"window": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead . \n "}, "hash": "4b92c29b8d33d5c29e61fdae1fcd31126c2135cb58402869add85725885656d3", "class_name": "RelatedNodeInfo"}}, "text": "At this time, I'd like to turn the call over to Holly Weiss. ", "start_char_idx": 1663, "end_char_idx": 1724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb": {"__data__": {"id_": "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb", "embedding": null, "metadata": {"window": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead . \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "62ef3b72-cb05-40af-bd47-c95689bdc8cd", "node_type": "1", "metadata": {"window": "Michael Cherny  \nAnalyst, BofA Securities, Inc.  \n Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack. ", "original_text": "At this time, I'd like to turn the call over to Holly Weiss. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8589c028b642c8fdacb34d8ec08c4de8a445c906d73cc185f95da41ec2e678d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "706f697d-3016-4076-abac-e26a188a943d", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n"}, "hash": "5a1284373e2b6f1f4c511f244a5362ae0b8207dce52a00a773edbb8281114bbe", "class_name": "RelatedNodeInfo"}}, "text": "Please go ahead . \n ", "start_char_idx": 1724, "end_char_idx": 1744, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "706f697d-3016-4076-abac-e26a188a943d": {"__data__": {"id_": "706f697d-3016-4076-abac-e26a188a943d", "embedding": null, "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb", "node_type": "1", "metadata": {"window": "Stephen Baxter  \nAnalyst, Wolfe Research LLC  \nEric Percher  \nAnalyst,  Nephron Research LLC  \n ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nMANAGEMENT DISCUSSION SECTION  \n  \nOperator : Good day, and welcome to McKesson's Q3 Earnings Call.  Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "original_text": "Please go ahead . \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69ef59c85c21b23f098fb7f664c070135f83ea171b17b10be0181392bb9a5fa1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c4822d5-9562-40e8-9bc9-762928d2afc4", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jack. "}, "hash": "22afa259ec7da31fc55a18115382e518fa64a411f15bd421f4144df310eca288", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "start_char_idx": 1744, "end_char_idx": 2090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c4822d5-9562-40e8-9bc9-762928d2afc4": {"__data__": {"id_": "6c4822d5-9562-40e8-9bc9-762928d2afc4", "embedding": null, "metadata": {"window": "At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jack. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "706f697d-3016-4076-abac-e26a188a943d", "node_type": "1", "metadata": {"window": "Today's conference is being recorded.  \n \n At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f8b983bf0a42fd87efaf85499f59e503aa1f65a0f8d75e461505cdbfcb40a15", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb9915d5-3b0a-44db-a83c-a64dcaf6b259", "node_type": "1", "metadata": {"window": "Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n"}, "hash": "8e01a15b2f97860d1aa72b848196ece65b33802cb0740cae8bae32944c3378a3", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Jack. ", "start_char_idx": 2090, "end_char_idx": 2107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb9915d5-3b0a-44db-a83c-a64dcaf6b259": {"__data__": {"id_": "cb9915d5-3b0a-44db-a83c-a64dcaf6b259", "embedding": null, "metadata": {"window": "Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c4822d5-9562-40e8-9bc9-762928d2afc4", "node_type": "1", "metadata": {"window": "At this time, I'd like to turn the call over to Holly Weiss.  Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "original_text": "Thank you, Jack. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e02b6f1205f35e2cb191e006c09028f4320eff7e1ab4f2c19eb4683eb124f91", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e002c511-4c8f-43e9-bf9c-118b53b87606", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. "}, "hash": "c24ea1b2e6d304a95013c50f43229fc30874bf7bf5a941aeb95a5debfef16854", "class_name": "RelatedNodeInfo"}}, "text": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "start_char_idx": 2107, "end_char_idx": 2199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e002c511-4c8f-43e9-bf9c-118b53b87606": {"__data__": {"id_": "e002c511-4c8f-43e9-bf9c-118b53b87606", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb9915d5-3b0a-44db-a83c-a64dcaf6b259", "node_type": "1", "metadata": {"window": "Please go ahead . \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "original_text": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1cab8fe7448295bce94297fe0a6a833cef8e30846424ea87f40ca2bfec20ded", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f854ef70-9f71-4308-a71e-77e18f4bd6a8", "node_type": "1", "metadata": {"window": "Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n"}, "hash": "2d05b422e873b2aff1158013a2cb9977b64231564b8d8c3789809068043092b7", "class_name": "RelatedNodeInfo"}}, "text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "start_char_idx": 2199, "end_char_idx": 2311, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f854ef70-9f71-4308-a71e-77e18f4bd6a8": {"__data__": {"id_": "f854ef70-9f71-4308-a71e-77e18f4bd6a8", "embedding": null, "metadata": {"window": "Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e002c511-4c8f-43e9-bf9c-118b53b87606", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "original_text": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f9c4931ce5f88f45fc861faea3272b2ddf6b7aec5d7d1c1ba820b4c6dc48526", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "035781c3-efd8-4b95-a686-b6d979acab16", "node_type": "1", "metadata": {"window": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. "}, "hash": "b2fff5aa25a39a4e3bf73a0fadb876e32bba0eee922ccd0007fede778534d535", "class_name": "RelatedNodeInfo"}}, "text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "start_char_idx": 2311, "end_char_idx": 2413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "035781c3-efd8-4b95-a686-b6d979acab16": {"__data__": {"id_": "035781c3-efd8-4b95-a686-b6d979acab16", "embedding": null, "metadata": {"window": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f854ef70-9f71-4308-a71e-77e18f4bd6a8", "node_type": "1", "metadata": {"window": "Thank you, Jack.  Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures. ", "original_text": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9d1b72cc0c6821be478fdcd27014ad63f036650b9ed5e03e3f4e72f6dea8b630", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "798a678e-58bf-4d8a-b752-3014afada9fc", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n"}, "hash": "89cf6b9556cbefcc03e29fba8e8552c676d4e495d6b196d3eb312b135b1722e4", "class_name": "RelatedNodeInfo"}}, "text": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "start_char_idx": 2413, "end_char_idx": 2539, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "798a678e-58bf-4d8a-b752-3014afada9fc": {"__data__": {"id_": "798a678e-58bf-4d8a-b752-3014afada9fc", "embedding": null, "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "035781c3-efd8-4b95-a686-b6d979acab16", "node_type": "1", "metadata": {"window": "Good morning and welcome, everyone, to McKesson's third quarter fiscal 2020 earnings call. \n Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7ba69d9dfae3f628ed3d49551c12c94f0226527f5789f1672e29c2118ce0e3d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a2ba373-1221-4a97-979e-477dbbaebb14", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. "}, "hash": "4e52c98e8c0c0b99d0d4578aacc57304372f81a64d6f0a6a176dceac172b8090", "class_name": "RelatedNodeInfo"}}, "text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "start_char_idx": 2539, "end_char_idx": 2855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a2ba373-1221-4a97-979e-477dbbaebb14": {"__data__": {"id_": "3a2ba373-1221-4a97-979e-477dbbaebb14", "embedding": null, "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "798a678e-58bf-4d8a-b752-3014afada9fc", "node_type": "1", "metadata": {"window": "Today I'm joined by Brian Tyler, our Chief Executive Officer; and Britt Vi talone, our Chief Financial Officer.  Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42516fca600e571a8b446d8a605adb60567596a24cc8f56e4b73af85f1250a69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n "}, "hash": "97599f976634307d62c9721870bd52ad2db74b880c62891645eb9b4f0df219a1", "class_name": "RelatedNodeInfo"}}, "text": "During this call, we will discuss non -GAAP financial measures. ", "start_char_idx": 2855, "end_char_idx": 2919, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73": {"__data__": {"id_": "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73", "embedding": null, "metadata": {"window": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "bc62fdef-a641-4781-a6ff-25b209fd307c", "node_type": "4", "metadata": {"page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26279c7ddb15d52979f62f638dc9d8ae2e38aff3f35dc3ce738b65306cbab4c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a2ba373-1221-4a97-979e-477dbbaebb14", "node_type": "1", "metadata": {"window": "Brian \nwill lead off, followed by Britt, and then we will move to a question -and-answer session.  \n \n Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "During this call, we will discuss non -GAAP financial measures. ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db42c09a9b50df0b86c36c3d79fcf9e581d9eeb02a50a5e52e6daf12c8b3254d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "original_text": "McKesson Corp.  "}, "hash": "1d717d7b9a5e6f837f2091c6fdc3c01729437f60a5249bfb05aa400924af5401", "class_name": "RelatedNodeInfo"}}, "text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "start_char_idx": 2919, "end_char_idx": 3172, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03": {"__data__": {"id_": "f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73", "node_type": "1", "metadata": {"window": "Today's discussion will include forward -looking statements such as forecast about McKesson's operations and \nfuture results.  Please refer to the cautionary statements in today's press release and our slide presentation and to \nthe Risk Factors section of our periodic SEC filings for additional information concerning risk factors that could \ncause our actual results to mat erially differ from those in our forward -looking statements.  \n \n During this call, we will discuss non -GAAP financial measures.  Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "original_text": "Additional information about our non -GAAP \nfinancial measures, including a reconciliation of those measures to GAAP results, is included in today's press \nrelease and presentation slides, which are available on our website at investor.mckesson.com.  \n ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c06981ed47a46ac669586f60312a754f3306b32f053888b7da7fee33107397e0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02407821-4d90-4305-a7b5-90cfa1748685", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n "}, "hash": "0ca0d41ba5ed1a92a14c803102a7dd1b54fb7204497892e7ee54940a9443aa92", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02407821-4d90-4305-a7b5-90cfa1748685": {"__data__": {"id_": "02407821-4d90-4305-a7b5-90cfa1748685", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4934e967a53a78d03eb0781a4e9d031916b8302dd1b4d5564e5a28bf9a8acfd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "228b8f36-c823-4e7e-bb7f-2ba39e83eb25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "8ba8378744540d9e57d4ea6033b369a5c09d924fae1c2b10ded6864e73e4e885", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "start_char_idx": 16, "end_char_idx": 221, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "228b8f36-c823-4e7e-bb7f-2ba39e83eb25": {"__data__": {"id_": "228b8f36-c823-4e7e-bb7f-2ba39e83eb25", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02407821-4d90-4305-a7b5-90cfa1748685", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb5bcef976d9587e5009dee53f992ae4c9ab50ddf5edca41f76cff43d330240e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "original_text": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. "}, "hash": "de5e042c34c7a61e06852e6659d52aa4f6789724dbb49acd09c9c6706c9dcbfa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 221, "end_char_idx": 563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1": {"__data__": {"id_": "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "original_text": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "228b8f36-c823-4e7e-bb7f-2ba39e83eb25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfd3158281cc92dd9b29631a4847146a2a4da8591326207160d6837a6b43f339", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c4389c4-7289-42db-9c6d-e685de368647", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "original_text": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. "}, "hash": "59b627e2b29272e67e6649e6fa7abf44fda2163f9d9667bdb2b4195c897a25e0", "class_name": "RelatedNodeInfo"}}, "text": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "start_char_idx": 563, "end_char_idx": 663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c4389c4-7289-42db-9c6d-e685de368647": {"__data__": {"id_": "2c4389c4-7289-42db-9c6d-e685de368647", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "original_text": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "original_text": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aee2ab3fe7b59c6437392580927815b5a6579cbb3f213357709fb8d5ee5c2ef5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "748e5c38-70f5-45e6-abf5-3263fbf692ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "original_text": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n"}, "hash": "495a0b44c817a578e2f639ca86afe25bddd7f4eb6f8334a061960a3046638fac", "class_name": "RelatedNodeInfo"}}, "text": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "start_char_idx": 663, "end_char_idx": 788, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "748e5c38-70f5-45e6-abf5-3263fbf692ff": {"__data__": {"id_": "748e5c38-70f5-45e6-abf5-3263fbf692ff", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "original_text": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c4389c4-7289-42db-9c6d-e685de368647", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "original_text": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "14835956af05f23849010637c4efeda56cb833a74d3a1670a6602b073ff7d2d7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c60a684-2d8b-4608-9d82-85876988f958", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "original_text": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n"}, "hash": "1e0f7c2709684b5efbbeccee41650e188a556a21198cfd4e1159f18c33a53bdc", "class_name": "RelatedNodeInfo"}}, "text": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "start_char_idx": 788, "end_char_idx": 997, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c60a684-2d8b-4608-9d82-85876988f958": {"__data__": {"id_": "2c60a684-2d8b-4608-9d82-85876988f958", "embedding": null, "metadata": {"window": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "original_text": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "748e5c38-70f5-45e6-abf5-3263fbf692ff", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "original_text": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b517faa850f26cdb7f162de0be2ee1ea29e6d78c877089781bfbf1ae0a4f5d8b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f9e613-59fb-4149-9abb-ee3a32216087", "node_type": "1", "metadata": {"window": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n", "original_text": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. "}, "hash": "723adf4f23c66734ce3b9994b69980cb93c5586d3af9a1f9490b32afa25d8668", "class_name": "RelatedNodeInfo"}}, "text": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "start_char_idx": 997, "end_char_idx": 1110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f9e613-59fb-4149-9abb-ee3a32216087": {"__data__": {"id_": "83f9e613-59fb-4149-9abb-ee3a32216087", "embedding": null, "metadata": {"window": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n", "original_text": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c60a684-2d8b-4608-9d82-85876988f958", "node_type": "1", "metadata": {"window": "Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning.  Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "original_text": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2b75062bbd7340d422ca2c24808eed30347ddea25a57dca03bf0c0a4a1abee25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "243247a7-e2f7-47d1-8fdf-f2115acfa41b", "node_type": "1", "metadata": {"window": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results. ", "original_text": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. "}, "hash": "07eb43a992149d2cea1a7019f8401b11746142a1c9e2a5796c7aae538976f1cf", "class_name": "RelatedNodeInfo"}}, "text": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "start_char_idx": 1110, "end_char_idx": 1369, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "243247a7-e2f7-47d1-8fdf-f2115acfa41b": {"__data__": {"id_": "243247a7-e2f7-47d1-8fdf-f2115acfa41b", "embedding": null, "metadata": {"window": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results. ", "original_text": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f9e613-59fb-4149-9abb-ee3a32216087", "node_type": "1", "metadata": {"window": "Before I get \ninto our third quarter results, I wanted to take a few minutes to provide a brief update on opioid litigation.  As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n", "original_text": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c34a352adbc2a3e81ca9b64292b3134c901e444a444ff7f55f5e80342b598c8a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc10af32-8265-4675-a8e2-e41dda73bb0b", "node_type": "1", "metadata": {"window": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n", "original_text": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. "}, "hash": "b4e9457128727492aad4689c9bec980fb577467a64510e1fe567d8674d8de568", "class_name": "RelatedNodeInfo"}}, "text": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "start_char_idx": 1369, "end_char_idx": 1459, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc10af32-8265-4675-a8e2-e41dda73bb0b": {"__data__": {"id_": "dc10af32-8265-4675-a8e2-e41dda73bb0b", "embedding": null, "metadata": {"window": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n", "original_text": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "243247a7-e2f7-47d1-8fdf-f2115acfa41b", "node_type": "1", "metadata": {"window": "As you \nknow, we've been engaged in complex discussions with t he state attorneys generals and others about a \nsettlement framework with the goal of achieving a broad resolution of opioid -related claims.  \n \n Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results. ", "original_text": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b6af468bea4f62f8d311f968573c0a065690ea6467bee0b383d454e0214eadd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cdecaa3a-46d1-4013-9c74-e2845a9fbe31", "node_type": "1", "metadata": {"window": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81. ", "original_text": "I \ndo appreciate your understanding.  \n \n"}, "hash": "d6345c7e04a322b526710a0168ecd49d989cf9d150163ce8fe5006d3140a5d89", "class_name": "RelatedNodeInfo"}}, "text": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "start_char_idx": 1459, "end_char_idx": 1563, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cdecaa3a-46d1-4013-9c74-e2845a9fbe31": {"__data__": {"id_": "cdecaa3a-46d1-4013-9c74-e2845a9fbe31", "embedding": null, "metadata": {"window": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81. ", "original_text": "I \ndo appreciate your understanding.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc10af32-8265-4675-a8e2-e41dda73bb0b", "node_type": "1", "metadata": {"window": "Those discussions continue to narrow what's left to address to achieve resolution on all the items that remain. \n However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n", "original_text": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7a81e146e6c3cd0b1a83910ccbf3b422e8602cde423dca2220c028ef017b98b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc", "node_type": "1", "metadata": {"window": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "original_text": "Now, let's get to our busines s results. "}, "hash": "7f7781dacd3d87844b9068034bf10f69f15017d373e93ab12f36a7286ccbf5a0", "class_name": "RelatedNodeInfo"}}, "text": "I \ndo appreciate your understanding.  \n \n", "start_char_idx": 1563, "end_char_idx": 1604, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc": {"__data__": {"id_": "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc", "embedding": null, "metadata": {"window": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "original_text": "Now, let's get to our busines s results. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cdecaa3a-46d1-4013-9c74-e2845a9fbe31", "node_type": "1", "metadata": {"window": "However, to the extent our efforts to reach a broad resolution settlement framework are unsuccessful, McKesson \ncontinues to be prepared to litigate and vigorously defend the mischaracterization that our company drove the \ndemand for opioids in this country.  Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81. ", "original_text": "I \ndo appreciate your understanding.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b5e956f3174b2b041e490e24e9fa68e0b14fcf29f5353fe78eb834f25e2dbf56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a794559-ba39-44c5-88ad-a4457c07e397", "node_type": "1", "metadata": {"window": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "original_text": "Today, we reported third quarter total company revenues of $59.2 billion. \n"}, "hash": "121f00d7335078ed91931fd08bff653be45df509b628c194a394aa7335398e60", "class_name": "RelatedNodeInfo"}}, "text": "Now, let's get to our busines s results. ", "start_char_idx": 1604, "end_char_idx": 1645, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a794559-ba39-44c5-88ad-a4457c07e397": {"__data__": {"id_": "0a794559-ba39-44c5-88ad-a4457c07e397", "embedding": null, "metadata": {"window": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "original_text": "Today, we reported third quarter total company revenues of $59.2 billion. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc", "node_type": "1", "metadata": {"window": "Mc Kesson remains firmly committed to being part of the broader solution to \nthis crisis.  Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "original_text": "Now, let's get to our busines s results. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "169c8242876237a4cb9b45bfedb9495a3cf34c50bf9b6fc6503da0fe9e3bfa73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "696be706-3282-4950-b48f-f6368125c874", "node_type": "1", "metadata": {"window": "I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "original_text": "Our adjusted earnings per diluted share was $3.81. "}, "hash": "eff74c59192d8c0065f8d0fd13840fc89867969e4a246bf9ca290e9b0bdc5ad7", "class_name": "RelatedNodeInfo"}}, "text": "Today, we reported third quarter total company revenues of $59.2 billion. \n", "start_char_idx": 1645, "end_char_idx": 1720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "696be706-3282-4950-b48f-f6368125c874": {"__data__": {"id_": "696be706-3282-4950-b48f-f6368125c874", "embedding": null, "metadata": {"window": "I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "original_text": "Our adjusted earnings per diluted share was $3.81. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a794559-ba39-44c5-88ad-a4457c07e397", "node_type": "1", "metadata": {"window": "Given, however, the discussions and litigation are ongoing, I'll be somewhat limited in what I can say.  I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "original_text": "Today, we reported third quarter total company revenues of $59.2 billion. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "935452d948c78dd422216f804558150752ddcc8223e85a8612bad9306262874f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8", "node_type": "1", "metadata": {"window": "Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "original_text": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. "}, "hash": "1ff3e99b1688bc90c3b4c6c29fa4a4166bd67a0189cdba82254a3745f8f839f7", "class_name": "RelatedNodeInfo"}}, "text": "Our adjusted earnings per diluted share was $3.81. ", "start_char_idx": 1720, "end_char_idx": 1771, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8": {"__data__": {"id_": "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8", "embedding": null, "metadata": {"window": "Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "original_text": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "696be706-3282-4950-b48f-f6368125c874", "node_type": "1", "metadata": {"window": "I \ndo appreciate your understanding.  \n \n Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "original_text": "Our adjusted earnings per diluted share was $3.81. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1d7612fd4c84d4602d6d3c0f4dc8e22f5d051ecac31ab6b29880432a72b2b4c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b6db494-c3dd-4aa3-9a94-4b34518c8488", "node_type": "1", "metadata": {"window": "Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint. ", "original_text": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n"}, "hash": "4e5a9537e135885e44e38280c2aebdf0d1515568fbe7dd0ea7bb1a376659e531", "class_name": "RelatedNodeInfo"}}, "text": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "start_char_idx": 1771, "end_char_idx": 1898, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b6db494-c3dd-4aa3-9a94-4b34518c8488": {"__data__": {"id_": "4b6db494-c3dd-4aa3-9a94-4b34518c8488", "embedding": null, "metadata": {"window": "Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint. ", "original_text": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8", "node_type": "1", "metadata": {"window": "Now, let's get to our busines s results.  Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "original_text": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c1252a0f02c98584296ca12779e502364c51967db9b9ca937057993b11b03b8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70b3ef6c-15a7-4405-8808-9fad2534990c", "node_type": "1", "metadata": {"window": "Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "original_text": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. "}, "hash": "fad31a5b82400688f77204a18549f12eeac211f339b53d124ca41d1326b15044", "class_name": "RelatedNodeInfo"}}, "text": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "start_char_idx": 1898, "end_char_idx": 2062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70b3ef6c-15a7-4405-8808-9fad2534990c": {"__data__": {"id_": "70b3ef6c-15a7-4405-8808-9fad2534990c", "embedding": null, "metadata": {"window": "Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "original_text": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b6db494-c3dd-4aa3-9a94-4b34518c8488", "node_type": "1", "metadata": {"window": "Today, we reported third quarter total company revenues of $59.2 billion. \n Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint. ", "original_text": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "043c9b4c5c1ffaed06fcf0768739aa5428138fd3724aa263492268adc99bece9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "29b25ca0-82dc-4b88-9f0d-8111883f6457", "node_type": "1", "metadata": {"window": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market. ", "original_text": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n"}, "hash": "cb8ecca315c524ff6c0421ac6a2e957cd0bbb67eec43eec44dfc2f83a8cf2583", "class_name": "RelatedNodeInfo"}}, "text": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "start_char_idx": 2062, "end_char_idx": 2354, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "29b25ca0-82dc-4b88-9f0d-8111883f6457": {"__data__": {"id_": "29b25ca0-82dc-4b88-9f0d-8111883f6457", "embedding": null, "metadata": {"window": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market. ", "original_text": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70b3ef6c-15a7-4405-8808-9fad2534990c", "node_type": "1", "metadata": {"window": "Our adjusted earnings per diluted share was $3.81.  And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "original_text": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28187e0ba07defe5085c240f5ac502d20b32cb94db2f572a10bccf9d1e502e0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "331eab10-1ea9-4dc8-9d58-0061c6d25d73", "node_type": "1", "metadata": {"window": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "original_text": "Let me walk you through the recent trends from an industry fundamental standpoint. "}, "hash": "052664732f14c524e77919be3e2f6ee2e360b131ca7629019b43c20c2fc95a18", "class_name": "RelatedNodeInfo"}}, "text": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "start_char_idx": 2354, "end_char_idx": 2580, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "331eab10-1ea9-4dc8-9d58-0061c6d25d73": {"__data__": {"id_": "331eab10-1ea9-4dc8-9d58-0061c6d25d73", "embedding": null, "metadata": {"window": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "original_text": "Let me walk you through the recent trends from an industry fundamental standpoint. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "29b25ca0-82dc-4b88-9f0d-8111883f6457", "node_type": "1", "metadata": {"window": "And I'm pleased with our third quarter and year -to-date \nexecution across the majority of our businesses in our fiscal 20 20.  Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market. ", "original_text": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ef9bf6cc6f32c9cbbcc119bbf6f7ee8df0f1b8ee8ca9a2391828df7ae7bcb5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "60a24f84-17ea-4dc2-a16d-3be05e13eb1e", "node_type": "1", "metadata": {"window": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "original_text": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n"}, "hash": "945284302df314b7b0df7fbaefbdcf42b8b6c402d4e45223734c7dbfa235ae8f", "class_name": "RelatedNodeInfo"}}, "text": "Let me walk you through the recent trends from an industry fundamental standpoint. ", "start_char_idx": 2580, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "60a24f84-17ea-4dc2-a16d-3be05e13eb1e": {"__data__": {"id_": "60a24f84-17ea-4dc2-a16d-3be05e13eb1e", "embedding": null, "metadata": {"window": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "original_text": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "331eab10-1ea9-4dc8-9d58-0061c6d25d73", "node_type": "1", "metadata": {"window": "Also today, we reaffirmed our fiscal 2020 full \nyear outlook of $14.60 to $14.80 of adjusted earnings per diluted share, which we first provided on January 13.  \n \n This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "original_text": "Let me walk you through the recent trends from an industry fundamental standpoint. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0da3f7abb9dd1f4dfd8ed08ad96740a22edf44a4e4a6f802338bb6dff3ce81d4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f1c2916d-507e-4554-ba98-dc7dcb016a57", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "original_text": "For generics, we remain disciplined in our approach to the market. "}, "hash": "60008f547ab42dc7a9cc0b37ff1b4194be5b6b36de7166d668d94ed290b7140a", "class_name": "RelatedNodeInfo"}}, "text": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "start_char_idx": 2663, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f1c2916d-507e-4554-ba98-dc7dcb016a57": {"__data__": {"id_": "f1c2916d-507e-4554-ba98-dc7dcb016a57", "embedding": null, "metadata": {"window": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "original_text": "For generics, we remain disciplined in our approach to the market. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "60a24f84-17ea-4dc2-a16d-3be05e13eb1e", "node_type": "1", "metadata": {"window": "This update reflects our outlook for growth in our US Pharmaceutical and Specialty Solutions  segment, primarily \ndriven by specialty; strength in our Medical -Surgical segment; lower -than-anticipated corporate expenses; and the \nbenefit from share repurchase activity in the third quarter.  Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "original_text": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "689b8fa326fd6f4e70c1e535c08a3532f9945d17f41d9b182735584db6e08dce", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e719689e-396d-415d-9be1-fce19a97e9df", "node_type": "1", "metadata": {"window": "Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "original_text": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. "}, "hash": "d1cbd0e8e4a19d47814050eb81af6b72c3af67ce54298b282e2e6622bee04e59", "class_name": "RelatedNodeInfo"}}, "text": "For generics, we remain disciplined in our approach to the market. ", "start_char_idx": 2864, "end_char_idx": 2931, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e719689e-396d-415d-9be1-fce19a97e9df": {"__data__": {"id_": "e719689e-396d-415d-9be1-fce19a97e9df", "embedding": null, "metadata": {"window": "Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "original_text": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f1c2916d-507e-4554-ba98-dc7dcb016a57", "node_type": "1", "metadata": {"window": "Our US Pharmaceutical and Specialty Solutions \nsegment perform ed well in the quarter, reflecting stable macro fundamentals and good execution and was aided \nby the continued strong growth across our specialty businesses.  \n \n Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "original_text": "For generics, we remain disciplined in our approach to the market. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "008aa0ab83a1393542b9694df70207dad7ac265e112f4f8b6908594e37c2fc17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02e199f1-36ad-4514-bb1d-ff520df80464", "node_type": "1", "metadata": {"window": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "original_text": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n"}, "hash": "f1753a45d1677605586c24de918a214d1b596a548901b206a4b74880ad8b3f7e", "class_name": "RelatedNodeInfo"}}, "text": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "start_char_idx": 2931, "end_char_idx": 3048, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02e199f1-36ad-4514-bb1d-ff520df80464": {"__data__": {"id_": "02e199f1-36ad-4514-bb1d-ff520df80464", "embedding": null, "metadata": {"window": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "original_text": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e719689e-396d-415d-9be1-fce19a97e9df", "node_type": "1", "metadata": {"window": "Let me walk you through the recent trends from an industry fundamental standpoint.  For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "original_text": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e0c2a9206d0f5b5af8e9f2a107ed568e5d2bb616281ed193781fc1c11bc8b51", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e6c50d46-a50b-4d90-a8f9-99617a1e18ce", "node_type": "1", "metadata": {"window": "For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "original_text": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. "}, "hash": "08d87c3bc2b8026983e9dd0920a50fdee246895d59beb5b9e96f59340e34c731", "class_name": "RelatedNodeInfo"}}, "text": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "start_char_idx": 3048, "end_char_idx": 3244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e6c50d46-a50b-4d90-a8f9-99617a1e18ce": {"__data__": {"id_": "e6c50d46-a50b-4d90-a8f9-99617a1e18ce", "embedding": null, "metadata": {"window": "For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "original_text": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02e199f1-36ad-4514-bb1d-ff520df80464", "node_type": "1", "metadata": {"window": "For the third quarter, we saw \nbranded price increases tracking in line with our expectations and we continue to assume mid -single -digit \nbranded price increases year -over-year for fiscal 2020.  \n \n For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "original_text": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e874bd5b352ae02b925ef78f13f85386e31a27ce3cf5b584be709c8386ac477", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "008275fb-510a-4b44-b171-84e5743a61b7", "node_type": "1", "metadata": {"window": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "original_text": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n"}, "hash": "febfbd8b8f8fbcb2d06b95e7001bb5d6c8774f9bf28b3430c3704e7b1d1ecdc1", "class_name": "RelatedNodeInfo"}}, "text": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "start_char_idx": 3244, "end_char_idx": 3386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "008275fb-510a-4b44-b171-84e5743a61b7": {"__data__": {"id_": "008275fb-510a-4b44-b171-84e5743a61b7", "embedding": null, "metadata": {"window": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "original_text": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e6c50d46-a50b-4d90-a8f9-99617a1e18ce", "node_type": "1", "metadata": {"window": "For generics, we remain disciplined in our approach to the market.  We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "original_text": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d64a8eb4b8cecb0939f496babe73519ccebd1dfc93a736220e96aeff534254c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad9802a6-3ab2-46f6-9006-7c93859bf5db", "node_type": "1", "metadata": {"window": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service. ", "original_text": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n"}, "hash": "41e730e167402d94fc68c5951a7de6ae69175d594d8eb4e941573a93fdd30840", "class_name": "RelatedNodeInfo"}}, "text": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "start_char_idx": 3386, "end_char_idx": 3532, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad9802a6-3ab2-46f6-9006-7c93859bf5db": {"__data__": {"id_": "ad9802a6-3ab2-46f6-9006-7c93859bf5db", "embedding": null, "metadata": {"window": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service. ", "original_text": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "008275fb-510a-4b44-b171-84e5743a61b7", "node_type": "1", "metadata": {"window": "We are sou rcing effectively through our scaled \nsourcing venture and the sell side remains competitive, but stable.  I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "original_text": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9589815122dedaad819e710bebabb424f5516215515fab9dfe95640daa8e36ee", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f23f74c-6530-41af-a529-d0597cd58617", "node_type": "1", "metadata": {"window": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n"}, "hash": "c7add69a3fd69136e4ca8a25e8510aef1840a20b2d3c3c4784d53f169cbb921a", "class_name": "RelatedNodeInfo"}}, "text": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "start_char_idx": 3532, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f23f74c-6530-41af-a529-d0597cd58617": {"__data__": {"id_": "3f23f74c-6530-41af-a529-d0597cd58617", "embedding": null, "metadata": {"window": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad9802a6-3ab2-46f6-9006-7c93859bf5db", "node_type": "1", "metadata": {"window": "I'd like to take a moment to acknowledge how \npleased we are that the VA announced in December it had again selected McKesson to be the prime \npharmaceut ical vendor beginning in August 2020.  \n \n We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service. ", "original_text": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ea3ebcc408282abaefe7044d7087313ae52af2994d16d9053be8ef080d7d546b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e684b7f-25ac-4b45-a3ef-056c631acff2", "node_type": "1", "metadata": {"window": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. "}, "hash": "53e61fbfc3f39782f7aa7a66d3ba7c7bd16fa9373bfbf258aa821987237f3f5e", "class_name": "RelatedNodeInfo"}}, "text": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "start_char_idx": 3643, "end_char_idx": 3832, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e684b7f-25ac-4b45-a3ef-056c631acff2": {"__data__": {"id_": "7e684b7f-25ac-4b45-a3ef-056c631acff2", "embedding": null, "metadata": {"window": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f23f74c-6530-41af-a529-d0597cd58617", "node_type": "1", "metadata": {"window": "We have been the VA's prime pharmaceutical vendor for veterans' hospitals and the department's mail order \npharmacies for more than 15 years.  This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0076d0ab527406e453b4989bb92207b2974158140e507994119ecbef5cae126", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "542f369e-e3fd-46d3-80eb-a2abf9b51161", "node_type": "1", "metadata": {"window": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "I want to thank McKesson's veterans, and every veteran really, for their service. "}, "hash": "a936d675f825ce4edbabf4f93351184c34c5d4e593bed49ef4180806dd3ef664", "class_name": "RelatedNodeInfo"}}, "text": "MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "start_char_idx": 3832, "end_char_idx": 4074, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "542f369e-e3fd-46d3-80eb-a2abf9b51161": {"__data__": {"id_": "542f369e-e3fd-46d3-80eb-a2abf9b51161", "embedding": null, "metadata": {"window": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "I want to thank McKesson's veterans, and every veteran really, for their service. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e684b7f-25ac-4b45-a3ef-056c631acff2", "node_type": "1", "metadata": {"window": "This is a great point of pride for McKesson and we're dedicated to hiring \nveterans and helping them build their careers after their service.  \n \n At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3e2bf6479f2bf6bc913fc418147d89cfec9edf6ae311a93bb086080f0a674d20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23652aee-ac78-4dec-ba80-ab762845eba1", "node_type": "1", "metadata": {"window": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  "}, "hash": "3d03c8821f734f775be9dbc0da9c61636921584c417c77d44d5a2736975bfeb5", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank McKesson's veterans, and every veteran really, for their service. ", "start_char_idx": 4074, "end_char_idx": 4156, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23652aee-ac78-4dec-ba80-ab762845eba1": {"__data__": {"id_": "23652aee-ac78-4dec-ba80-ab762845eba1", "embedding": null, "metadata": {"window": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd", "node_type": "4", "metadata": {"page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f013253e1b5090accf99d59bb7df9c2dacc8b2c5c556b439b72d4163834bd836", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "542f369e-e3fd-46d3-80eb-a2abf9b51161", "node_type": "1", "metadata": {"window": "At McKesson, we have many employee resource groups celebrating and leveraging the diversity of our workforce. \n The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "I want to thank McKesson's veterans, and every veteran really, for their service. ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7523a4435ded7fadfc20b4e74d4aaa0af91f9b874a7fe3df314e6ef33e113d6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6bd57c28-8f4d-47cf-bfac-d5048adba4c7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "original_text": "McKesson Corp.  "}, "hash": "8a04f5bbaa57501b99fd86c142f3731b9a72c83eba7de94dd236778d5eaae511", "class_name": "RelatedNodeInfo"}}, "text": "We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "start_char_idx": 4156, "end_char_idx": 4256, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6bd57c28-8f4d-47cf-bfac-d5048adba4c7": {"__data__": {"id_": "6bd57c28-8f4d-47cf-bfac-d5048adba4c7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23652aee-ac78-4dec-ba80-ab762845eba1", "node_type": "1", "metadata": {"window": "The McKesson Military Resource Group or MMRG, as we refer to it internally, prov ides opportunities for all \nemployees to recognize and welcome veterans and their families to McKesson.  \n \n MMRG offers networking opportunities, facilitates personal and professional development, supports McKesson's \nrecruitment, hiring and retention of vetera ns, and sponsors events within our communities for active -duty military \nand veterans.  I want to thank McKesson's veterans, and every veteran really, for their service.  We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "original_text": "We're very proud \nto serve the VA and we look forward to continuing our longstanding part nership.  ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e23d5383a3cf1327996858ccc389ec7eecf8bc6bdbe8d800d33d3805132cdf70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77efcc44-c8ca-42f8-9ad1-7090756c6ef6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments. "}, "hash": "5b3efc886ed944f7fd2c7e420eb1be89a1b65e91d7083c5ee516a2e99e879edb", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77efcc44-c8ca-42f8-9ad1-7090756c6ef6": {"__data__": {"id_": "77efcc44-c8ca-42f8-9ad1-7090756c6ef6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6bd57c28-8f4d-47cf-bfac-d5048adba4c7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3152d89eefcac906594ee481e7c09c3db7779b3301322987952fb5b116834e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b66986ce-51b3-4775-90f5-1a95ed787e93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "original_text": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies. "}, "hash": "4e27351f98fbc253b8fb5748a8c19df3e7f925f509732ae575d9d0d08c2c70eb", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments. ", "start_char_idx": 16, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b66986ce-51b3-4775-90f5-1a95ed787e93": {"__data__": {"id_": "b66986ce-51b3-4775-90f5-1a95ed787e93", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "original_text": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77efcc44-c8ca-42f8-9ad1-7090756c6ef6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d46bbeb00814e1f841a4bee43d798889da2cf7bf70373d49f6c25b46ab82b7e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ae8de4a-1e05-483f-95bb-6c29593911b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "original_text": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. "}, "hash": "9f3a1d2c3cf996915d53afd4aca56d6098cee68f4c9f8ca8c4b61530651fa7f0", "class_name": "RelatedNodeInfo"}}, "text": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies. ", "start_char_idx": 395, "end_char_idx": 515, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ae8de4a-1e05-483f-95bb-6c29593911b6": {"__data__": {"id_": "3ae8de4a-1e05-483f-95bb-6c29593911b6", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "original_text": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b66986ce-51b3-4775-90f5-1a95ed787e93", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "original_text": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c025d02ab36ff0fff68e0a25fb69523fa9440c35bb7ccb41d868499dce21c26", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1a6fb5f-1ce3-4848-968e-22e99bd657f4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "original_text": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n"}, "hash": "1b654867a9caa76932f3213f820ac268ef8ce6d9d9ec194f97e7a477ea9522cb", "class_name": "RelatedNodeInfo"}}, "text": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "start_char_idx": 515, "end_char_idx": 649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1a6fb5f-1ce3-4848-968e-22e99bd657f4": {"__data__": {"id_": "d1a6fb5f-1ce3-4848-968e-22e99bd657f4", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "original_text": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ae8de4a-1e05-483f-95bb-6c29593911b6", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "original_text": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c59250b8cc58ac4c3affe7b4f8f92f9ca80a33fcbea18aa3f6fc776919c80874", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ad6187d8-da53-47fd-9fe4-8463549d97be", "node_type": "1", "metadata": {"window": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "original_text": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. "}, "hash": "ec05b6830c209ecbee6834426abff96bfc279de2ca1d45dabaa272e95df116b2", "class_name": "RelatedNodeInfo"}}, "text": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "start_char_idx": 649, "end_char_idx": 824, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ad6187d8-da53-47fd-9fe4-8463549d97be": {"__data__": {"id_": "ad6187d8-da53-47fd-9fe4-8463549d97be", "embedding": null, "metadata": {"window": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "original_text": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1a6fb5f-1ce3-4848-968e-22e99bd657f4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "original_text": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5121ea76dc42eec6121acc94b2cd8369955cab9f04b769cdfcc67c15209adec1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7054372a-94a3-40e5-82e8-251c2412890e", "node_type": "1", "metadata": {"window": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "original_text": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. "}, "hash": "c0697fd80a769fa675b7d190351d4221a99bcb944873a33d2218997db14f225a", "class_name": "RelatedNodeInfo"}}, "text": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "start_char_idx": 824, "end_char_idx": 980, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7054372a-94a3-40e5-82e8-251c2412890e": {"__data__": {"id_": "7054372a-94a3-40e5-82e8-251c2412890e", "embedding": null, "metadata": {"window": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "original_text": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ad6187d8-da53-47fd-9fe4-8463549d97be", "node_type": "1", "metadata": {"window": "First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "original_text": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ba68f65835e03640b6544546e3bbdd485f058b1332673ded18bb30bb455f33c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49d80812-3669-4ad0-b1d8-4fe739f4ec4c", "node_type": "1", "metadata": {"window": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "original_text": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. "}, "hash": "9c5a7aabfbf00893deb6e40d211e55188ca5ca047d383d5331d5b2c74311bf32", "class_name": "RelatedNodeInfo"}}, "text": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "start_char_idx": 980, "end_char_idx": 1196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49d80812-3669-4ad0-b1d8-4fe739f4ec4c": {"__data__": {"id_": "49d80812-3669-4ad0-b1d8-4fe739f4ec4c", "embedding": null, "metadata": {"window": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "original_text": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7054372a-94a3-40e5-82e8-251c2412890e", "node_type": "1", "metadata": {"window": "And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars.  Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "original_text": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe0b6c7f720ed5d04886d26d9fedc879a01aa7f53d3805d3e313ea509c380e0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f542059b-79ff-41e3-b535-d4d7f791c092", "node_type": "1", "metadata": {"window": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment. ", "original_text": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n"}, "hash": "c36861a008d3d6a01fb7328424377bac0f260c030bbc1af5e93553bc4681890b", "class_name": "RelatedNodeInfo"}}, "text": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "start_char_idx": 1196, "end_char_idx": 1303, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f542059b-79ff-41e3-b535-d4d7f791c092": {"__data__": {"id_": "f542059b-79ff-41e3-b535-d4d7f791c092", "embedding": null, "metadata": {"window": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment. ", "original_text": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49d80812-3669-4ad0-b1d8-4fe739f4ec4c", "node_type": "1", "metadata": {"window": "Next, we distribute specialty products th at are primarily infused in the community -based setting and \ntypically require special handling, including temperature control.  \n \n We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "original_text": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4181eb218a6d07b8dcd75244630af0187514a52f6987624fe520843b27925e32", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba6f7c46-3502-4d82-abda-63e8c14237ac", "node_type": "1", "metadata": {"window": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "original_text": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. "}, "hash": "1ed2bb0ddb1be3fa9bcacde1a7cfa1e3feb443633eb44d407ec9a2b123db0b32", "class_name": "RelatedNodeInfo"}}, "text": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "start_char_idx": 1303, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba6f7c46-3502-4d82-abda-63e8c14237ac": {"__data__": {"id_": "ba6f7c46-3502-4d82-abda-63e8c14237ac", "embedding": null, "metadata": {"window": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "original_text": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f542059b-79ff-41e3-b535-d4d7f791c092", "node_type": "1", "metadata": {"window": "We also provide other services like group purchase organization activities, data and technology services in \noncology and other m ulti-specialty practices.  And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment. ", "original_text": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "89ebfec32cdb17d19686c5a9dbd7ed4cf1112942a89dacf903504cbfeb013936", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31e7144f-1e0e-4675-ba02-c120c3408fa3", "node_type": "1", "metadata": {"window": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "original_text": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. "}, "hash": "862b13ac764ccf012e313029b6ad414a6e9e717633e58186457ab4141b491f88", "class_name": "RelatedNodeInfo"}}, "text": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "start_char_idx": 1390, "end_char_idx": 1694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31e7144f-1e0e-4675-ba02-c120c3408fa3": {"__data__": {"id_": "31e7144f-1e0e-4675-ba02-c120c3408fa3", "embedding": null, "metadata": {"window": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "original_text": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba6f7c46-3502-4d82-abda-63e8c14237ac", "node_type": "1", "metadata": {"window": "And then, we have our leading practice management business, \nspecifically, The US Oncology Network, which now includes more than 1,200 oncology physicians providing 12% \nto 13% of all community -based oncology care.  We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "original_text": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c59564854c1be9225fb98ddb4c8ae6b6f9395e7413eeb557583ebcda92f22355", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f2187bc-6339-45e0-94a2-b57726c6f299", "node_type": "1", "metadata": {"window": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "original_text": "This results in a patient getting the best \npossible outcome from their treatment. "}, "hash": "e221d95e1b351b8252d102a7d125c9f576b5146468802774942f653f97a9e457", "class_name": "RelatedNodeInfo"}}, "text": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "start_char_idx": 1694, "end_char_idx": 1905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f2187bc-6339-45e0-94a2-b57726c6f299": {"__data__": {"id_": "7f2187bc-6339-45e0-94a2-b57726c6f299", "embedding": null, "metadata": {"window": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "original_text": "This results in a patient getting the best \npossible outcome from their treatment. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31e7144f-1e0e-4675-ba02-c120c3408fa3", "node_type": "1", "metadata": {"window": "We handle all asp ects of managing the practice, so that the \nphysician can focus on treating the patient.  In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "original_text": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "434924a57f52ac5ea36921a8fe75a13a2c784b400ee4fe8a20448c5cda7ad3c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bb5d328-7485-4e1c-b2fd-a326b63a20d8", "node_type": "1", "metadata": {"window": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe. ", "original_text": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n"}, "hash": "f18d9acee08475a3e4a9a02dc339c8fa884e570ee6ae3d64d1564fb316f2f21c", "class_name": "RelatedNodeInfo"}}, "text": "This results in a patient getting the best \npossible outcome from their treatment. ", "start_char_idx": 1905, "end_char_idx": 1988, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bb5d328-7485-4e1c-b2fd-a326b63a20d8": {"__data__": {"id_": "2bb5d328-7485-4e1c-b2fd-a326b63a20d8", "embedding": null, "metadata": {"window": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe. ", "original_text": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f2187bc-6339-45e0-94a2-b57726c6f299", "node_type": "1", "metadata": {"window": "In addition, we're active in clinical trials, research and formulary \ndevelopment.  \n \n The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "original_text": "This results in a patient getting the best \npossible outcome from their treatment. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26cd3c9d76d5e9bf5040873a2863de4a52bffb318302377edbd987859969ef10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1140797a-c9e4-42fc-a735-4e0498464078", "node_type": "1", "metadata": {"window": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "original_text": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. "}, "hash": "58c65a236df8e406049f0d6ace77d9355331fe84c2153444a8df2744d3c849f3", "class_name": "RelatedNodeInfo"}}, "text": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "start_char_idx": 1988, "end_char_idx": 2124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1140797a-c9e4-42fc-a735-4e0498464078": {"__data__": {"id_": "1140797a-c9e4-42fc-a735-4e0498464078", "embedding": null, "metadata": {"window": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "original_text": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bb5d328-7485-4e1c-b2fd-a326b63a20d8", "node_type": "1", "metadata": {"window": "The practice management business, combined with the wholesale distribution and specia lty product distribution \nand services business, are the scaled channels we leverage to provide services and solutions to our many \nbiopharma partners, including commercialization, hub and patient assistance services.  We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe. ", "original_text": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b592e5d56059346586b467680983d3ff1029d2d7215247b7cdfc76f82afb2463", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e218340-1e20-4721-b0c0-bce878e0f156", "node_type": "1", "metadata": {"window": "This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "original_text": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n"}, "hash": "b7f3a2b8f96c026ecff849ee888e492fd6d5b5b75c52688a84c1857b66d9c784", "class_name": "RelatedNodeInfo"}}, "text": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "start_char_idx": 2124, "end_char_idx": 2279, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e218340-1e20-4721-b0c0-bce878e0f156": {"__data__": {"id_": "4e218340-1e20-4721-b0c0-bce878e0f156", "embedding": null, "metadata": {"window": "This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "original_text": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1140797a-c9e4-42fc-a735-4e0498464078", "node_type": "1", "metadata": {"window": "We help manufacturers \nfind patients that  are appropriate and relevant for care, help them get started on that therapy sooner, and work to \nkeep them adherent to that therapy for the course of their treatment.  This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "original_text": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eae60b3e5287842f657f161a7ab3225e2ef9a721edc215921d691bdc2506f8d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ffb07214-cd0f-4606-87fd-e69805e35360", "node_type": "1", "metadata": {"window": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "original_text": "Now, let me turn to Europe. "}, "hash": "a14db326089a4a7e9e86eccc31fd4d89a63063fa957f0c916772cda8d429fd2b", "class_name": "RelatedNodeInfo"}}, "text": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "start_char_idx": 2279, "end_char_idx": 2449, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ffb07214-cd0f-4606-87fd-e69805e35360": {"__data__": {"id_": "ffb07214-cd0f-4606-87fd-e69805e35360", "embedding": null, "metadata": {"window": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "original_text": "Now, let me turn to Europe. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e218340-1e20-4721-b0c0-bce878e0f156", "node_type": "1", "metadata": {"window": "This results in a patient getting the best \npossible outcome from their treatment.  These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "original_text": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42f8e41375105bf02b04ba572590373b68285a90f2c4218ca72b160acfe87178", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "763edc00-db98-49eb-bbfb-4999a266ee1b", "node_type": "1", "metadata": {"window": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "original_text": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. "}, "hash": "cf6c52397e050feba1e806a9a42e09feedb8f34bd2e3fe1be90fcd8df1cbc5fe", "class_name": "RelatedNodeInfo"}}, "text": "Now, let me turn to Europe. ", "start_char_idx": 2449, "end_char_idx": 2477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "763edc00-db98-49eb-bbfb-4999a266ee1b": {"__data__": {"id_": "763edc00-db98-49eb-bbfb-4999a266ee1b", "embedding": null, "metadata": {"window": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "original_text": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ffb07214-cd0f-4606-87fd-e69805e35360", "node_type": "1", "metadata": {"window": "These services not only support better outcomes for patients, but they also \nprovide tremendous value to our manufacturer partners.  \n \n We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "original_text": "Now, let me turn to Europe. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b29d7a75966d4aaeb1b5e9d54a97637ff5b5a7cecaf3e7e47718c917719cd563", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678", "node_type": "1", "metadata": {"window": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "original_text": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n"}, "hash": "28c55330b30c96b63ec285eae62b7d819b613632912fc4a58a4348806dcacd1d", "class_name": "RelatedNodeInfo"}}, "text": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "start_char_idx": 2477, "end_char_idx": 2639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678": {"__data__": {"id_": "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678", "embedding": null, "metadata": {"window": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "original_text": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "763edc00-db98-49eb-bbfb-4999a266ee1b", "node_type": "1", "metadata": {"window": "We're really pleased with the growth we're seeing across these businesses, and we remain focused on specialty \nas a key tenet of ou r strategic direction.  We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "original_text": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a55e589b61cf0efee305ab8ea711feba2431842a3e33da5c3378911093ec19eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f9b8020-9bf1-45c9-a6a9-dd476a19314d", "node_type": "1", "metadata": {"window": "Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "original_text": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. "}, "hash": "50afd82591f54dd9cfffec4c08c757752da0d001d9386807d5a06b6585c5e455", "class_name": "RelatedNodeInfo"}}, "text": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "start_char_idx": 2639, "end_char_idx": 2883, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f9b8020-9bf1-45c9-a6a9-dd476a19314d": {"__data__": {"id_": "4f9b8020-9bf1-45c9-a6a9-dd476a19314d", "embedding": null, "metadata": {"window": "Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "original_text": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678", "node_type": "1", "metadata": {"window": "We're also pleased that we're returning to growth in the US \nPharmaceutical and Specialty Solutions segment in fiscal 2020, while continuing to invest in our future.  \n \n Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "original_text": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dcd2eae8a25f0abd755aa788ce6f7beeb515938778b6eaad19263eaa6d9849b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c", "node_type": "1", "metadata": {"window": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "original_text": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n"}, "hash": "ba7cee615114bb82a03eae9977c62579f10d0799498ba09e64d58416644e1cca", "class_name": "RelatedNodeInfo"}}, "text": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "start_char_idx": 2883, "end_char_idx": 3037, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c": {"__data__": {"id_": "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c", "embedding": null, "metadata": {"window": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "original_text": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f9b8020-9bf1-45c9-a6a9-dd476a19314d", "node_type": "1", "metadata": {"window": "Now, let me turn to Europe.  In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "original_text": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "11e32330d7b72a22d7c5929529a595fa48b0492bbc3d3fe54a9cd4dee3a62cd3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b963208-fcc3-49a9-8be8-63c04eecef1a", "node_type": "1", "metadata": {"window": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "original_text": "In the UK, we continue to monitor the retail pharmacy funding dynamics. "}, "hash": "b393ac1e51944a3e5fa00efa738693b42b2213c49d6c432502e7c2863b5a9ea5", "class_name": "RelatedNodeInfo"}}, "text": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "start_char_idx": 3037, "end_char_idx": 3143, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b963208-fcc3-49a9-8be8-63c04eecef1a": {"__data__": {"id_": "3b963208-fcc3-49a9-8be8-63c04eecef1a", "embedding": null, "metadata": {"window": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "original_text": "In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c", "node_type": "1", "metadata": {"window": "In mid -December, McKesson and Walgreens  announced a joint venture agreement \nthat we expect will bring together our respective wholesale operations in Germany.  After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "original_text": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a9f4162a1eb6613938ac97e7a620e4d809ad3f4bd1c2d37ced66eb9337d2300", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "584ffdc4-f3d6-471c-91bf-89610d0c9b48", "node_type": "1", "metadata": {"window": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "original_text": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. "}, "hash": "0fab746669474132fcf44d54e33a52957c0dc7671889247c12117c8d2124cc0f", "class_name": "RelatedNodeInfo"}}, "text": "In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "start_char_idx": 3143, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "584ffdc4-f3d6-471c-91bf-89610d0c9b48": {"__data__": {"id_": "584ffdc4-f3d6-471c-91bf-89610d0c9b48", "embedding": null, "metadata": {"window": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "original_text": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b963208-fcc3-49a9-8be8-63c04eecef1a", "node_type": "1", "metadata": {"window": "After review of our business in \nGermany, we believe this is the right course of action, as the combined business will have large reach a nd scale, \ndriving increased efficiency and performance in a market where scale is vitally important.  \n \n The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "original_text": "In the UK, we continue to monitor the retail pharmacy funding dynamics. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd443ef2f385b42348e7088e7ca5000d754fb0c19c250513b2a521ca7aacc446", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "742e36d7-c88b-45e8-a5af-a7fb097aa325", "node_type": "1", "metadata": {"window": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "original_text": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. "}, "hash": "044c57f35ca2f48a84a429d691acebb2b8c13d1fac64feccbe82fa3ed7fec510", "class_name": "RelatedNodeInfo"}}, "text": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "start_char_idx": 3215, "end_char_idx": 3346, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "742e36d7-c88b-45e8-a5af-a7fb097aa325": {"__data__": {"id_": "742e36d7-c88b-45e8-a5af-a7fb097aa325", "embedding": null, "metadata": {"window": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "original_text": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "584ffdc4-f3d6-471c-91bf-89610d0c9b48", "node_type": "1", "metadata": {"window": "The transaction is subject to merger clearance and approval, and that process is expected to take at least six \nmonths from the time of the announcement.  A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "original_text": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe7e8a240c2aa045cdfbb06f96fee7d805d0ad6553e72fb58934840af9736a42", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e", "node_type": "1", "metadata": {"window": "In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "original_text": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. "}, "hash": "fbf507810226f536d65af1242b66e9bdd0fc3662cd57165d9b2dc436ddd2008a", "class_name": "RelatedNodeInfo"}}, "text": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "start_char_idx": 3346, "end_char_idx": 3470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e": {"__data__": {"id_": "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e", "embedding": null, "metadata": {"window": "In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "original_text": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "742e36d7-c88b-45e8-a5af-a7fb097aa325", "node_type": "1", "metadata": {"window": "A s such, this transaction will not have any impact on adjusted \nearnings in our current fiscal year.  \n \n In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "original_text": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00c6dd12be70e7bb293da4870809d1a89471037cc25f3c93ab10a4f1071bc1e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2129200a-dd3c-4518-9cf7-43cd34153a0e", "node_type": "1", "metadata": {"window": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n"}, "hash": "b1f611e81b002ff708cebc991c2cf5e6e01402d8672abc96c9692a342e9fb410", "class_name": "RelatedNodeInfo"}}, "text": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "start_char_idx": 3470, "end_char_idx": 3692, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2129200a-dd3c-4518-9cf7-43cd34153a0e": {"__data__": {"id_": "2129200a-dd3c-4518-9cf7-43cd34153a0e", "embedding": null, "metadata": {"window": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e", "node_type": "1", "metadata": {"window": "In the UK, we continue to monitor the retail pharmacy funding dynamics.  As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "original_text": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8ae886b7a5c7f30110027912054172d1bf4c35de5da3d3aed335c85ee94c65b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "70048add-722e-4e15-91af-02a11d9ecc5b", "node_type": "1", "metadata": {"window": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. "}, "hash": "aa1e5b14dfb25a6c309eba7804c0165a11830d62d935eb56fd36fc5383dab258", "class_name": "RelatedNodeInfo"}}, "text": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "start_char_idx": 3692, "end_char_idx": 3823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "70048add-722e-4e15-91af-02a11d9ecc5b": {"__data__": {"id_": "70048add-722e-4e15-91af-02a11d9ecc5b", "embedding": null, "metadata": {"window": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2129200a-dd3c-4518-9cf7-43cd34153a0e", "node_type": "1", "metadata": {"window": "As we detailed earlier in the fiscal year, \nthe retail pharmacy industry experienced underfunding by the NHS in our first quarter.  While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "39f2855fe6917180e0f7c29c8ce0ca15019a6aa2609a89d164f762def2cbaf6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "53cf669f-ea88-4cbd-9282-a147573eb31a", "node_type": "1", "metadata": {"window": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. "}, "hash": "8dcceb912922c20bb3585ed06b40d4c6f13ab211fc72ab6c4365688e0a1657a1", "class_name": "RelatedNodeInfo"}}, "text": "Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "start_char_idx": 3823, "end_char_idx": 4052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "53cf669f-ea88-4cbd-9282-a147573eb31a": {"__data__": {"id_": "53cf669f-ea88-4cbd-9282-a147573eb31a", "embedding": null, "metadata": {"window": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "70048add-722e-4e15-91af-02a11d9ecc5b", "node_type": "1", "metadata": {"window": "While there was a modest \nimprovement in our fiscal second quarter, further upward revisions have not yet been implemented.  We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3eada8569166107b5f6934455c7ae5741f86adc55dd8a9094b6aec2512cb77b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8", "node_type": "1", "metadata": {"window": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "We differentiate ourselves in the marketplace through innovation and a focus "}, "hash": "4b8081388aa0e81b682c9fa92397f5bc682d516ffd3ccfef9e467299614326d5", "class_name": "RelatedNodeInfo"}}, "text": "Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "start_char_idx": 4052, "end_char_idx": 4189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8": {"__data__": {"id_": "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8", "embedding": null, "metadata": {"window": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "We differentiate ourselves in the marketplace through innovation and a focus ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f", "node_type": "4", "metadata": {"page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a8507d26d8236593b73f41833240df59624d950972826af445f9ce24d866d6d5", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "53cf669f-ea88-4cbd-9282-a147573eb31a", "node_type": "1", "metadata": {"window": "We continue \nto monitor the situation in the UK closely and engage in active dialogue wi th the NHS related to industry funding \nand the role pharmacy can play in managing NHS's overall cost quality and access challenges.  Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients. ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1ef132f65a2a3694cf645820bcd5f8dea58df7ac53fd78d0596932ec070a2b7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5bacfb9-bac0-4f46-a923-aa1e2c545285", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "original_text": "McKesson Corp.  "}, "hash": "a58f2ad680730742d632c31793de16455cc25969b509ccd5973478bb093dd92a", "class_name": "RelatedNodeInfo"}}, "text": "We differentiate ourselves in the marketplace through innovation and a focus ", "start_char_idx": 4189, "end_char_idx": 4266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5bacfb9-bac0-4f46-a923-aa1e2c545285": {"__data__": {"id_": "c5bacfb9-bac0-4f46-a923-aa1e2c545285", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8", "node_type": "1", "metadata": {"window": "Outside of the UK, \nwe're continuing to see performance in line with our expectations for the other countries in this segment . \n \n Next, our Medical -Surgical business; again, this quarter, we had good growth across multiple markets, such as \nour home care delivery business and product categories, including pharmaceutical sales into the primary care \nspace.  Customers are repeatedly ch oosing McKesson because of our relentless focus on providing what they \nneed to take care of their patients.  We differentiate ourselves in the marketplace through innovation and a focus ", "original_text": "We differentiate ourselves in the marketplace through innovation and a focus ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72aadfe2162d5c6be1497f0a55890fc900d3ed47a2b236da4f499c167c5c0eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n"}, "hash": "3d54cf22ebfedfffe4da209752023ae963050bfd14c52e158f1dba99b1aac1e8", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d": {"__data__": {"id_": "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5bacfb9-bac0-4f46-a923-aa1e2c545285", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f614a2aaac87c180b216ed4ff6b03bd9116b13c66809bf3000f12e33c54f915a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "deec39da-6b9d-4338-8ebb-08c53cce1d18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "original_text": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration. "}, "hash": "1e321fd7150a5149a7d1671fd0675dc76e38da76b8388c31fd0259a9268bdf6b", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n", "start_char_idx": 16, "end_char_idx": 332, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "deec39da-6b9d-4338-8ebb-08c53cce1d18": {"__data__": {"id_": "deec39da-6b9d-4338-8ebb-08c53cce1d18", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "original_text": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "17133b05e6ad82cab3e7f94cf1d611c8d335a0ef17a554c7d7d56632489efc93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81350765-839b-46f5-accb-09041989406d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "original_text": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. "}, "hash": "137a0126411004402cc530df3cdb6eee56ff73b6dc802d5346fd5c5c41123235", "class_name": "RelatedNodeInfo"}}, "text": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration. ", "start_char_idx": 332, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81350765-839b-46f5-accb-09041989406d": {"__data__": {"id_": "81350765-839b-46f5-accb-09041989406d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "original_text": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "deec39da-6b9d-4338-8ebb-08c53cce1d18", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "original_text": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29bcc3fdbd5625b033109010f33f97aeb86825f52607ccf5f9e582bc29dd657b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65f90d57-842d-4905-b505-5b42c157c1a4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "original_text": "This acquisition continues to perform in \nline with its business case.  \n \n"}, "hash": "ff9f83c3eef7eb26592ca56c80a017a796556611e83b28bdd9da38efc5873df8", "class_name": "RelatedNodeInfo"}}, "text": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "start_char_idx": 468, "end_char_idx": 639, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65f90d57-842d-4905-b505-5b42c157c1a4": {"__data__": {"id_": "65f90d57-842d-4905-b505-5b42c157c1a4", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "original_text": "This acquisition continues to perform in \nline with its business case.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81350765-839b-46f5-accb-09041989406d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "original_text": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3d1f50a13e5af6a25f30b066760c499cc3bfadbb16538cff956da606601cdcfe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2", "node_type": "1", "metadata": {"window": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "original_text": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. "}, "hash": "a43864aaf9d0ae56c72ae29b1db6ab581bc2d4bbe45851e8b9cd4c969f7cd4ee", "class_name": "RelatedNodeInfo"}}, "text": "This acquisition continues to perform in \nline with its business case.  \n \n", "start_char_idx": 639, "end_char_idx": 714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2": {"__data__": {"id_": "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2", "embedding": null, "metadata": {"window": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "original_text": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65f90d57-842d-4905-b505-5b42c157c1a4", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "original_text": "This acquisition continues to perform in \nline with its business case.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed78ba35010bbddd9d6011dcfc8e00753b6393200b53ae0a8d2a8e1b4b27940d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68071114-212c-496d-9e3c-75b6dd60415c", "node_type": "1", "metadata": {"window": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "original_text": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n"}, "hash": "6a66965f7771c810e7e5a81853b626e7e2b4f0eaf20db392b3508f5b9b49d75e", "class_name": "RelatedNodeInfo"}}, "text": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "start_char_idx": 714, "end_char_idx": 886, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68071114-212c-496d-9e3c-75b6dd60415c": {"__data__": {"id_": "68071114-212c-496d-9e3c-75b6dd60415c", "embedding": null, "metadata": {"window": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "original_text": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2", "node_type": "1", "metadata": {"window": "We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "original_text": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7ad8dc892e4e013a61fdd9ecd42262ed85f62ea8a8c2a6c85db2c805c04ccac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2202fa4-6b31-4620-b8b2-c652416d649b", "node_type": "1", "metadata": {"window": "This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "original_text": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. "}, "hash": "6e29f92888c4b0228fb0484bbc25d65281e9ba404008f3678b6010cbf57fd14a", "class_name": "RelatedNodeInfo"}}, "text": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "start_char_idx": 886, "end_char_idx": 1113, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2202fa4-6b31-4620-b8b2-c652416d649b": {"__data__": {"id_": "a2202fa4-6b31-4620-b8b2-c652416d649b", "embedding": null, "metadata": {"window": "This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "original_text": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68071114-212c-496d-9e3c-75b6dd60415c", "node_type": "1", "metadata": {"window": "In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies.  This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "original_text": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18095414eaa7d69c9f1e16846cd50c1b3f8616526b49b5fbb71509d08c316652", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "234487e3-a96b-459e-b2a7-fd9dfb6777a2", "node_type": "1", "metadata": {"window": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare. ", "original_text": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n"}, "hash": "8ba01a9d32192618edb5cf98159ddd44d55d434e5dd487bc812302327a827119", "class_name": "RelatedNodeInfo"}}, "text": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "start_char_idx": 1113, "end_char_idx": 1223, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "234487e3-a96b-459e-b2a7-fd9dfb6777a2": {"__data__": {"id_": "234487e3-a96b-459e-b2a7-fd9dfb6777a2", "embedding": null, "metadata": {"window": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare. ", "original_text": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2202fa4-6b31-4620-b8b2-c652416d649b", "node_type": "1", "metadata": {"window": "This acquisition continues to perform in \nline with its business case.  \n \n Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "original_text": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dc53c75219340d4a56ede1680a6e1c9899e7b67a8b9d7c367921927d2a02fcaf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "98c65698-b495-4bdb-918e-3501f0f578a2", "node_type": "1", "metadata": {"window": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "original_text": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. "}, "hash": "44e720b50e31cfbb59a9f8bae700a2bde8ca011c52ce9796c070a3ffb545bbcb", "class_name": "RelatedNodeInfo"}}, "text": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "start_char_idx": 1223, "end_char_idx": 1402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "98c65698-b495-4bdb-918e-3501f0f578a2": {"__data__": {"id_": "98c65698-b495-4bdb-918e-3501f0f578a2", "embedding": null, "metadata": {"window": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "original_text": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "234487e3-a96b-459e-b2a7-fd9dfb6777a2", "node_type": "1", "metadata": {"window": "Turning to Other, which primarily consists of Canada, McKesson Prescription Technology Solutions, sometimes \nreferred to as MRxTS, and our investment in Change Healthcare.  In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare. ", "original_text": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5ac904988109073022ed3bdea8d9b81057c848cb22a3adc2c6ad0bce75bca90", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dbaefb05-0d4e-48a5-ad94-040d32fe6deb", "node_type": "1", "metadata": {"window": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC. ", "original_text": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n"}, "hash": "90c1905d6b8a176da8b5bcfd8e2857be20c68ff172c2413b01109fb150fc0a60", "class_name": "RelatedNodeInfo"}}, "text": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "start_char_idx": 1402, "end_char_idx": 1710, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dbaefb05-0d4e-48a5-ad94-040d32fe6deb": {"__data__": {"id_": "dbaefb05-0d4e-48a5-ad94-040d32fe6deb", "embedding": null, "metadata": {"window": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC. ", "original_text": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "98c65698-b495-4bdb-918e-3501f0f578a2", "node_type": "1", "metadata": {"window": "In Canada, we're now capturing the benefits of \nprevious actions we've taken, including our investments in people and in reconfigured pharma cy formats as \ncommunity pharmacy plays an important role in Canadian healthcare.  \n \n And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "original_text": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67ea3cdc70ce51179a46fb6ab48d562d6bbb773326fb1288e63e926a1c407a0f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0cfa0fdb-815f-467f-ba36-985ab967adff", "node_type": "1", "metadata": {"window": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "original_text": "Let's move on to Change Healthcare. "}, "hash": "d2e7b28e78c6ff505b3505f43c08047570c83b5e104aed3dfcc22e92cdf19b92", "class_name": "RelatedNodeInfo"}}, "text": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "start_char_idx": 1710, "end_char_idx": 1906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0cfa0fdb-815f-467f-ba36-985ab967adff": {"__data__": {"id_": "0cfa0fdb-815f-467f-ba36-985ab967adff", "embedding": null, "metadata": {"window": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "original_text": "Let's move on to Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dbaefb05-0d4e-48a5-ad94-040d32fe6deb", "node_type": "1", "metadata": {"window": "And market fundamentals are stable, which helped to drive growth in our wholesale operations year -over-year.  In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC. ", "original_text": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef6aa8a13935abfd323be3aa07b3477b4ffccf1d04f0ebf6b9ea0c82b644ecec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc", "node_type": "1", "metadata": {"window": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "original_text": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. "}, "hash": "4d2d9483c2576eccfd1807000121c28ff887ff4c070b7c7f05d9d8c0714b002a", "class_name": "RelatedNodeInfo"}}, "text": "Let's move on to Change Healthcare. ", "start_char_idx": 1906, "end_char_idx": 1942, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc": {"__data__": {"id_": "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc", "embedding": null, "metadata": {"window": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "original_text": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0cfa0fdb-815f-467f-ba36-985ab967adff", "node_type": "1", "metadata": {"window": "In \naddition, McKesson Canada also has broad specialty assets, and  capabilities and we are well positioned to \nparticipate in the growth of specialty in the Canadian market.  \n \n Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "original_text": "Let's move on to Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae1371a673cbde557fb926f0bde504d48f3817320998bc3da7500d346baf236d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cb392381-f1b0-460e-9b77-13a2531b340c", "node_type": "1", "metadata": {"window": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n", "original_text": "As part of the exit process, registration statements were \nfiled today with the SEC. "}, "hash": "b1f197912225d252e27f0bc04dd91929d84cbcad09d0b5416380694810662682", "class_name": "RelatedNodeInfo"}}, "text": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "start_char_idx": 1942, "end_char_idx": 2069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cb392381-f1b0-460e-9b77-13a2531b340c": {"__data__": {"id_": "cb392381-f1b0-460e-9b77-13a2531b340c", "embedding": null, "metadata": {"window": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n", "original_text": "As part of the exit process, registration statements were \nfiled today with the SEC. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc", "node_type": "1", "metadata": {"window": "Moving on to MRxTS, which is a key area of investment, we're making investments to ensure we have the right \nproduct and personnel resources in place  to support the growth trajectory of these businesses, and we're looking \nto launch new products that leverage our existing technologies and build upon them.  As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "original_text": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "29e2e35dd558264e7072758bca88e57ea007188ceec666a6277fdf82bfb57e36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e", "node_type": "1", "metadata": {"window": "Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "original_text": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n"}, "hash": "3cf497c8fa0bcfb6266719f777f640793b3aca8bbc41ec22cf8bdf5a88c46a08", "class_name": "RelatedNodeInfo"}}, "text": "As part of the exit process, registration statements were \nfiled today with the SEC. ", "start_char_idx": 2069, "end_char_idx": 2154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e": {"__data__": {"id_": "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e", "embedding": null, "metadata": {"window": "Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "original_text": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cb392381-f1b0-460e-9b77-13a2531b340c", "node_type": "1", "metadata": {"window": "As we look at how MRxTS is \nperforming year -to-date, we're pleased with the growth in the business, which is net of several investments we are \nmaking to drive and support our future growth.  \n \n Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n", "original_text": "As part of the exit process, registration statements were \nfiled today with the SEC. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36597c34baba248bcc3c1a6892df724ee8cfc16d9c1fa01b068d675db7ce4889", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "305f67c4-1b99-49ee-ad08-2b9662b84708", "node_type": "1", "metadata": {"window": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "original_text": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. "}, "hash": "0254c745cc5826a25fba697a5619864e746eea926cf528ab44f60fd9e5a7d38c", "class_name": "RelatedNodeInfo"}}, "text": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "start_char_idx": 2154, "end_char_idx": 2333, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "305f67c4-1b99-49ee-ad08-2b9662b84708": {"__data__": {"id_": "305f67c4-1b99-49ee-ad08-2b9662b84708", "embedding": null, "metadata": {"window": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "original_text": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e", "node_type": "1", "metadata": {"window": "Let's move on to Change Healthcare.  As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "original_text": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "134da4730013139ce0635e205a800147e3f035c498d44bb08e4ced845fe33cf3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e704bf9-a3c8-4bed-8596-147902a3a3da", "node_type": "1", "metadata": {"window": "As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization. ", "original_text": "We've been transforming and energizing the culture at McKesson. \n"}, "hash": "afe754d695307057739f2da6ea5a6290d00434819dfb8a0db97a6d798e7f9552", "class_name": "RelatedNodeInfo"}}, "text": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "start_char_idx": 2333, "end_char_idx": 2489, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e704bf9-a3c8-4bed-8596-147902a3a3da": {"__data__": {"id_": "0e704bf9-a3c8-4bed-8596-147902a3a3da", "embedding": null, "metadata": {"window": "As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization. ", "original_text": "We've been transforming and energizing the culture at McKesson. \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "305f67c4-1b99-49ee-ad08-2b9662b84708", "node_type": "1", "metadata": {"window": "As we've discussed previously, we continue to take the customary steps \ntoward an exit of our investment in Change Healthcare.  As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "original_text": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6497b8deefeb089ac9068ac15ea0c672c73007bbd4808f76f46446b66ee9ee03", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9d5ef85-b95c-4972-8eff-95abcead9391", "node_type": "1", "metadata": {"window": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "original_text": "We've got a great collaborative works pace at our new headquarters in the Dallas area. "}, "hash": "a3a768f82846c701ec1b68d2dc765143354f9f1cd047a6bec5db7dad1dde026b", "class_name": "RelatedNodeInfo"}}, "text": "We've been transforming and energizing the culture at McKesson. \n", "start_char_idx": 2489, "end_char_idx": 2554, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9d5ef85-b95c-4972-8eff-95abcead9391": {"__data__": {"id_": "a9d5ef85-b95c-4972-8eff-95abcead9391", "embedding": null, "metadata": {"window": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "original_text": "We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e704bf9-a3c8-4bed-8596-147902a3a3da", "node_type": "1", "metadata": {"window": "As part of the exit process, registration statements were \nfiled today with the SEC.  The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization. ", "original_text": "We've been transforming and energizing the culture at McKesson. \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13dc7138160d0abaeb80c57f9fdad4f33c6ee2fd64808482129c9cf1e95a90a8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e40d0dc-95b0-46af-9ece-f077e336ea9c", "node_type": "1", "metadata": {"window": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "original_text": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n"}, "hash": "a9d84ff9cea2fc0579d4c5aac94f2375fc149ddb29ee45afcefff61647765a2a", "class_name": "RelatedNodeInfo"}}, "text": "We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "start_char_idx": 2554, "end_char_idx": 2641, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e40d0dc-95b0-46af-9ece-f077e336ea9c": {"__data__": {"id_": "2e40d0dc-95b0-46af-9ece-f077e336ea9c", "embedding": null, "metadata": {"window": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "original_text": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9d5ef85-b95c-4972-8eff-95abcead9391", "node_type": "1", "metadata": {"window": "The previously discussed timing expectations are unchanged and this is simply a \nnecessary step as we move through the process of exiting our investment in Change Healthcare.  \n \n Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "original_text": "We've got a great collaborative works pace at our new headquarters in the Dallas area. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5fd8f4112950fa45d02a6d74651ea19e5c577c375608a4c83a133738414c5c69", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81b3e48c-3874-4c42-9190-364f41de138a", "node_type": "1", "metadata": {"window": "We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "original_text": "We're looking to become a simpler, more focused and nimbler organization. "}, "hash": "7116a80e2cf347c099c3663c8d4ba0d0c4e8b3f64245a59269f7e0714d6cc792", "class_name": "RelatedNodeInfo"}}, "text": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "start_char_idx": 2641, "end_char_idx": 2859, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81b3e48c-3874-4c42-9190-364f41de138a": {"__data__": {"id_": "81b3e48c-3874-4c42-9190-364f41de138a", "embedding": null, "metadata": {"window": "We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "original_text": "We're looking to become a simpler, more focused and nimbler organization. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e40d0dc-95b0-46af-9ece-f077e336ea9c", "node_type": "1", "metadata": {"window": "Recently, you've heard me talk about aligning McKesson under one vision to improve care in every setting; one \nproduct, one partner, one patient at a time.  We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "original_text": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64a751fc846e3704469d3c505fd15b44a8bb8ae56f1399222818de0f2904ff20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71f3a476-c1e2-4ebd-9b7c-8717617ce58a", "node_type": "1", "metadata": {"window": "We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team. ", "original_text": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n"}, "hash": "ad197c1afe6378582e286b09691b8b806df679487dda294915791333671ef08d", "class_name": "RelatedNodeInfo"}}, "text": "We're looking to become a simpler, more focused and nimbler organization. ", "start_char_idx": 2859, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71f3a476-c1e2-4ebd-9b7c-8717617ce58a": {"__data__": {"id_": "71f3a476-c1e2-4ebd-9b7c-8717617ce58a", "embedding": null, "metadata": {"window": "We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team. ", "original_text": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81b3e48c-3874-4c42-9190-364f41de138a", "node_type": "1", "metadata": {"window": "We've been transforming and energizing the culture at McKesson. \n We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "original_text": "We're looking to become a simpler, more focused and nimbler organization. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d174883b847d3606e3eb4beb1eebc10609a80c615a878bd3ced575d18c626a48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8169dcbe-8654-455e-8104-f264f556246c", "node_type": "1", "metadata": {"window": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "original_text": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. "}, "hash": "c66e7de3bff4b01463d2f6aae83b14e2c3b683ea66ac6ec6531a54d889646f32", "class_name": "RelatedNodeInfo"}}, "text": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "start_char_idx": 2933, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8169dcbe-8654-455e-8104-f264f556246c": {"__data__": {"id_": "8169dcbe-8654-455e-8104-f264f556246c", "embedding": null, "metadata": {"window": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "original_text": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71f3a476-c1e2-4ebd-9b7c-8717617ce58a", "node_type": "1", "metadata": {"window": "We've got a great collaborative works pace at our new headquarters in the Dallas area.  We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team. ", "original_text": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c8da1892ad9a5e4dfe9c27ae8cf86fe3eb1a7b318182e555ea38f3e7926f0457", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4ee66e3-878b-4463-9e1a-4d1b264efa10", "node_type": "1", "metadata": {"window": "We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "original_text": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results. "}, "hash": "0597528c3879411839451ed4c8ca6dc331099f23fea4e59057d87c51025bc6b6", "class_name": "RelatedNodeInfo"}}, "text": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "start_char_idx": 3215, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4ee66e3-878b-4463-9e1a-4d1b264efa10": {"__data__": {"id_": "d4ee66e3-878b-4463-9e1a-4d1b264efa10", "embedding": null, "metadata": {"window": "We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "original_text": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8169dcbe-8654-455e-8104-f264f556246c", "node_type": "1", "metadata": {"window": "We've rolled out new \nenterprise behaviors building on the already strong foundation of our ICARE and ILEAD values, and getting \neveryone aligned around our strategy and how we want to work together to execute  it. \n \n We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "original_text": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3602b9116e628181958a1af06603bcfbe413f627c89c658458f2790c377b155b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82a98709-ca1b-4549-987d-034bb2aa9612", "node_type": "1", "metadata": {"window": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about. ", "original_text": "I could not be prouder of the McKesson team. "}, "hash": "0a62586276ac85fb6dd26decc4664854808b985257b3296a78a2786030c8f8d6", "class_name": "RelatedNodeInfo"}}, "text": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "start_char_idx": 3413, "end_char_idx": 3513, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82a98709-ca1b-4549-987d-034bb2aa9612": {"__data__": {"id_": "82a98709-ca1b-4549-987d-034bb2aa9612", "embedding": null, "metadata": {"window": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about. ", "original_text": "I could not be prouder of the McKesson team. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4ee66e3-878b-4463-9e1a-4d1b264efa10", "node_type": "1", "metadata": {"window": "We're looking to become a simpler, more focused and nimbler organization.  We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "original_text": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fe19332a3fa4e1e34b25eabe7656e6105337de8221482bbce205468cea46ff93", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71639d0d-cf0c-4866-8706-e8cf235c5088", "node_type": "1", "metadata": {"window": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n"}, "hash": "acfb277549d52523fb28dddf460cdbaa352371441156ac2476118b4ba8a7d21a", "class_name": "RelatedNodeInfo"}}, "text": "I could not be prouder of the McKesson team. ", "start_char_idx": 3513, "end_char_idx": 3558, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71639d0d-cf0c-4866-8706-e8cf235c5088": {"__data__": {"id_": "71639d0d-cf0c-4866-8706-e8cf235c5088", "embedding": null, "metadata": {"window": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82a98709-ca1b-4549-987d-034bb2aa9612", "node_type": "1", "metadata": {"window": "We've centralized some of our \nfunctions and are looking at ways to work more efficiently and to utilize technology for day -to-day tasks that can \nbe automated, freeing up time t o focus on strategy, work that drives value for the organization and better \nleverages our teams.  \n \n We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about. ", "original_text": "I could not be prouder of the McKesson team. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dac30a818d36c304b7df544171f860bed7ff5ed2e3df928975eaccb4b1f9efe2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1", "node_type": "1", "metadata": {"window": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "As we look forward, we're in the initial stages of planning for our fiscal 2021. "}, "hash": "e5af8c245dc5e9b5e32aa5075657681ba9ab27581397903b2f1faf7f4886b2c0", "class_name": "RelatedNodeInfo"}}, "text": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "start_char_idx": 3558, "end_char_idx": 3704, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1": {"__data__": {"id_": "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1", "embedding": null, "metadata": {"window": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71639d0d-cf0c-4866-8706-e8cf235c5088", "node_type": "1", "metadata": {"window": "We're seeing great execution across the enterprise, including cost savings, as we track towards our target of $400 \nmillion to $500 million in gross pre -tax sa vings by the end of our fiscal 2021.  Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07db1da3b5a52b5c5838fa520ae4f7a21a45bd2dd4c289ec487d72a7cacc96f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a", "node_type": "1", "metadata": {"window": "I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "Let me walk through some of the \nthings we're thinking about. "}, "hash": "f662db00c445d261d6c160bbd16cb6109e67493869947d0b6355187263d142a4", "class_name": "RelatedNodeInfo"}}, "text": "As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "start_char_idx": 3704, "end_char_idx": 3785, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a": {"__data__": {"id_": "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a", "embedding": null, "metadata": {"window": "I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "Let me walk through some of the \nthings we're thinking about. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1", "node_type": "1", "metadata": {"window": "Our organization has rallied around \nthese efforts and it's showing in the culture and the results.  I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "As we look forward, we're in the initial stages of planning for our fiscal 2021. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a3d450f2ea935ae1bd16a7ed0dc24552b9e6bbea960d852deed8b40c05457622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b4d9d93-003c-478d-b8b6-5699701eb202", "node_type": "1", "metadata": {"window": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "The timing and impact of the exit of our investm ent in Change Healthcare, as exit "}, "hash": "3edbcf0d109f048f09ab51e5962de539ded9e7522e660a3340f1432adb435dd5", "class_name": "RelatedNodeInfo"}}, "text": "Let me walk through some of the \nthings we're thinking about. ", "start_char_idx": 3785, "end_char_idx": 3847, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b4d9d93-003c-478d-b8b6-5699701eb202": {"__data__": {"id_": "9b4d9d93-003c-478d-b8b6-5699701eb202", "embedding": null, "metadata": {"window": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f", "node_type": "4", "metadata": {"page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885eac5f186ce183c8018e0b45257f9eef2551a55b17edbf2078506cf01bd55b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a", "node_type": "1", "metadata": {"window": "I could not be prouder of the McKesson team.  And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "Let me walk through some of the \nthings we're thinking about. ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f75d7e0a165782cda5ee72bcd60e99b2e3580ba758e7f8ca81850551b2a1132b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31827d05-8548-47d2-9c4d-411d21bc7437", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "89956550f4e20aedd3e74152770e457a9f375cd7ff1e961f58c9dece14cf383e", "class_name": "RelatedNodeInfo"}}, "text": "The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "start_char_idx": 3847, "end_char_idx": 3930, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31827d05-8548-47d2-9c4d-411d21bc7437": {"__data__": {"id_": "31827d05-8548-47d2-9c4d-411d21bc7437", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b4d9d93-003c-478d-b8b6-5699701eb202", "node_type": "1", "metadata": {"window": "And \nwith one quarter to go in fiscal 2020, I'm confident in our reaffirmed adjusted earnings outlook of $14.60 to $14.80 \nper diluted share.  \n \n As we look forward, we're in the initial stages of planning for our fiscal 2021.  Let me walk through some of the \nthings we're thinking about.  The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "original_text": "The timing and impact of the exit of our investm ent in Change Healthcare, as exit ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7138147055848b1c950bf76091af065bbfdb6bc9a67333bc56e44a97a949fc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d8ce46b-4137-46a3-9f18-78062de9f2f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway. "}, "hash": "4dec53f072b683d1d00cfa5095d8c5f39a1920e6817d259a66e4ce5740865435", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d8ce46b-4137-46a3-9f18-78062de9f2f7": {"__data__": {"id_": "7d8ce46b-4137-46a3-9f18-78062de9f2f7", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31827d05-8548-47d2-9c4d-411d21bc7437", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "580059057f748e79e4fa20484e249339530225ced398fb0242f4f48d5fbd9780", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef5864e4-acf9-4b69-adbe-5a81e0074089", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "original_text": "For customer renewals, the VA contract goes into effect in August 2020. "}, "hash": "7d79236b4ed034ed40292767c03fe5b1f3c49b160e4bff2a89d914a97385c113", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway. ", "start_char_idx": 16, "end_char_idx": 215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef5864e4-acf9-4b69-adbe-5a81e0074089": {"__data__": {"id_": "ef5864e4-acf9-4b69-adbe-5a81e0074089", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "original_text": "For customer renewals, the VA contract goes into effect in August 2020. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d8ce46b-4137-46a3-9f18-78062de9f2f7", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "350a03b9f297a74910442cde2a9f3a410e5b88c8512b8f0d8d3d1174f1282999", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "original_text": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n"}, "hash": "0b9d8f4d8e9f97ba2b6cae1531ddc268e304ff7b3beb57dabfb94833cb61b143", "class_name": "RelatedNodeInfo"}}, "text": "For customer renewals, the VA contract goes into effect in August 2020. ", "start_char_idx": 215, "end_char_idx": 287, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27": {"__data__": {"id_": "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "original_text": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef5864e4-acf9-4b69-adbe-5a81e0074089", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "original_text": "For customer renewals, the VA contract goes into effect in August 2020. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32794af3894f97cc23e3163648cc7e469e054968491aa8613bade1d2dda94a77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a8fff23-b45d-4479-ba01-634e3dcc48ba", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "original_text": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. "}, "hash": "ab421b2104b0d4e30f4c17e399dcd7c5e8dab4c1131d864c01ea1725421c31d4", "class_name": "RelatedNodeInfo"}}, "text": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "start_char_idx": 287, "end_char_idx": 405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a8fff23-b45d-4479-ba01-634e3dcc48ba": {"__data__": {"id_": "0a8fff23-b45d-4479-ba01-634e3dcc48ba", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "original_text": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "original_text": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "338c213592e11c8d1a06efb973c9e25d9a0ea97d5fa618a55e0e73ce4bb757a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0722793a-e822-4153-a05d-eccd1bf3aacb", "node_type": "1", "metadata": {"window": "For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "original_text": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n"}, "hash": "e0cd838a9dffbd29c1d8fa12adc00d0d5b65542c1434a049c3332400f27ff552", "class_name": "RelatedNodeInfo"}}, "text": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "start_char_idx": 405, "end_char_idx": 570, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0722793a-e822-4153-a05d-eccd1bf3aacb": {"__data__": {"id_": "0722793a-e822-4153-a05d-eccd1bf3aacb", "embedding": null, "metadata": {"window": "For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "original_text": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a8fff23-b45d-4479-ba01-634e3dcc48ba", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "original_text": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73421871c9d027cc80a2c3aa0e8603961b7cd40bf2d0723c053106ecfee4646c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88decd3d-1571-49be-8955-775df235c366", "node_type": "1", "metadata": {"window": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "original_text": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. "}, "hash": "abc64f9d9af7f5036e71c42bcca521e24e05c5391d74186d80c99eb85d3e1e01", "class_name": "RelatedNodeInfo"}}, "text": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "start_char_idx": 570, "end_char_idx": 706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88decd3d-1571-49be-8955-775df235c366": {"__data__": {"id_": "88decd3d-1571-49be-8955-775df235c366", "embedding": null, "metadata": {"window": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "original_text": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0722793a-e822-4153-a05d-eccd1bf3aacb", "node_type": "1", "metadata": {"window": "For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "original_text": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3f88c45ec11c1507ab72e5f1f12e55d24827d33469abc9b969bc05cb6689960c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27ad5bcd-7e15-4e0b-94b7-2b460620c925", "node_type": "1", "metadata": {"window": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "original_text": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. "}, "hash": "bab73710951691c09b8adfbe74e7e6de7ae1ffb4aeb28b542c97eeb74753286c", "class_name": "RelatedNodeInfo"}}, "text": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "start_char_idx": 706, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27ad5bcd-7e15-4e0b-94b7-2b460620c925": {"__data__": {"id_": "27ad5bcd-7e15-4e0b-94b7-2b460620c925", "embedding": null, "metadata": {"window": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "original_text": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88decd3d-1571-49be-8955-775df235c366", "node_type": "1", "metadata": {"window": "As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "original_text": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e8e163b74d3b5b4f3a1713f9cc1ae43820fb61e9c411a9cb3d62b9bfba492b7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e63d6d-5d38-4727-868b-7d54ac2451ed", "node_type": "1", "metadata": {"window": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "original_text": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n"}, "hash": "858d84be31f67c513d6ad1f0c3e7fcb17c819a96f9c8e47cb7f75a1fbca4830c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "start_char_idx": 947, "end_char_idx": 1104, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e63d6d-5d38-4727-868b-7d54ac2451ed": {"__data__": {"id_": "a4e63d6d-5d38-4727-868b-7d54ac2451ed", "embedding": null, "metadata": {"window": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "original_text": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27ad5bcd-7e15-4e0b-94b7-2b460620c925", "node_type": "1", "metadata": {"window": "We are continuing to progress against our cost savings target with a portion of those savings falling to the bottom \nline and a portion being reinvested for growth.  And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "original_text": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "465e56fa880f94581c4874ff8345e888bc7b845a5a5192804f81a9e0e3ade3ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cc917a1d-06f4-4ce8-9729-0ddcd732cc67", "node_type": "1", "metadata": {"window": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "original_text": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. "}, "hash": "4cdc61efb7104a0968f52a91d689d29cc421146acc0c74fe9571808ce32149cd", "class_name": "RelatedNodeInfo"}}, "text": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "start_char_idx": 1104, "end_char_idx": 1213, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cc917a1d-06f4-4ce8-9729-0ddcd732cc67": {"__data__": {"id_": "cc917a1d-06f4-4ce8-9729-0ddcd732cc67", "embedding": null, "metadata": {"window": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "original_text": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e63d6d-5d38-4727-868b-7d54ac2451ed", "node_type": "1", "metadata": {"window": "And finally, from a capital allocation perspective, we would \nanticipate benefits from share r epurchases completed in fiscal 2020.  \n \n As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "original_text": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9cafc4f457d3bfdd17ace3c488d2745b43cf1e5568933adc95ca7a0cf9f02f1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b2c7871-23b9-49d6-b007-6b2cbffebf28", "node_type": "1", "metadata": {"window": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n", "original_text": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n"}, "hash": "9aea00b4e009a3857facba5ab53333f780a992e157282ff60162febafbc128b6", "class_name": "RelatedNodeInfo"}}, "text": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "start_char_idx": 1213, "end_char_idx": 1337, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b2c7871-23b9-49d6-b007-6b2cbffebf28": {"__data__": {"id_": "7b2c7871-23b9-49d6-b007-6b2cbffebf28", "embedding": null, "metadata": {"window": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n", "original_text": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cc917a1d-06f4-4ce8-9729-0ddcd732cc67", "node_type": "1", "metadata": {"window": "As you think about the market and the macro perspective in the US, we're entering an election year and we'll \nmake assumptions related to any potential impact we might expect based on our analysis, including related to \ndrug pricing trends.  McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "original_text": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91eaac36929e899ced1cf7cdbe0f8066cc3655079817ac328727c79213aa2d6b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e645370d-57c0-4b17-92f1-c97c670702ac", "node_type": "1", "metadata": {"window": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "original_text": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. "}, "hash": "820592183ac7f9c0e28672669e515c5e3d1c62d59fa5d2e1befc7100671f03b1", "class_name": "RelatedNodeInfo"}}, "text": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "start_char_idx": 1337, "end_char_idx": 1547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e645370d-57c0-4b17-92f1-c97c670702ac": {"__data__": {"id_": "e645370d-57c0-4b17-92f1-c97c670702ac", "embedding": null, "metadata": {"window": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "original_text": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b2c7871-23b9-49d6-b007-6b2cbffebf28", "node_type": "1", "metadata": {"window": "McKesson will continue to engage with policy makers and industry partners to ensure that any \nreforms support solutions to improve cost, quality and access.  The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n", "original_text": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26ac226fdfe650664a19a7ffb29d9026699b2b4b1a2b40b40f1eda701147923a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795", "node_type": "1", "metadata": {"window": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "original_text": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. "}, "hash": "153c13276268fd66ed723eb446359d9db795bbab7bf6afad61fc45b4ddd7e5e5", "class_name": "RelatedNodeInfo"}}, "text": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "start_char_idx": 1547, "end_char_idx": 1674, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795": {"__data__": {"id_": "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795", "embedding": null, "metadata": {"window": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "original_text": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e645370d-57c0-4b17-92f1-c97c670702ac", "node_type": "1", "metadata": {"window": "The policy landscape remains a dynamic \nenvironment and we remain confident in M cKesson's path forward.  \n \n As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "original_text": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "df5c5e2b52c311bc6e2df45c6783d7205dd63fab3fa9a64d0e96e1139c5babe5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c237bac-9d57-447c-95a4-b924cb38a7a2", "node_type": "1", "metadata": {"window": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n ", "original_text": "Kathy, thank you for your contributions to \nMcKesson.  \n \n"}, "hash": "cee962138a64c5f77081148b24387aa277c14f42cf135dfdf33d31c41d30ac55", "class_name": "RelatedNodeInfo"}}, "text": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "start_char_idx": 1674, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c237bac-9d57-447c-95a4-b924cb38a7a2": {"__data__": {"id_": "9c237bac-9d57-447c-95a4-b924cb38a7a2", "embedding": null, "metadata": {"window": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n ", "original_text": "Kathy, thank you for your contributions to \nMcKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795", "node_type": "1", "metadata": {"window": "As it relates to the UK, we're continuing to monitor the market environment and NHS funding, as well as Brexit \nactivities.  We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "original_text": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3be6a6cec7860b8182e2e913a2b085386ef29eb5386997037384abf4054944bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "803e407c-a537-4a02-8984-818582401345", "node_type": "1", "metadata": {"window": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. "}, "hash": "cbd984f514f5cbc8d0df9c3cbd41ad7980cd79f6fa94a834b4fb3f0bb6e6544d", "class_name": "RelatedNodeInfo"}}, "text": "Kathy, thank you for your contributions to \nMcKesson.  \n \n", "start_char_idx": 1838, "end_char_idx": 1896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "803e407c-a537-4a02-8984-818582401345": {"__data__": {"id_": "803e407c-a537-4a02-8984-818582401345", "embedding": null, "metadata": {"window": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c237bac-9d57-447c-95a4-b924cb38a7a2", "node_type": "1", "metadata": {"window": "We will review our businesses and expectations, including the impact of external factors, and will \nprovide o ur fiscal 2021 outlook in May when we report fourth quarter and full year fiscal 2020 earnings.  \n \n Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n ", "original_text": "Kathy, thank you for your contributions to \nMcKesson.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0596605afbb244246949c57c1981b3b28b4e627cb825a0efec13fd51a2e501d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d90783a4-2239-4204-bbb1-97b40ea127fe", "node_type": "1", "metadata": {"window": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone. ", "original_text": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n"}, "hash": "60d5fe651277a83f7e9efea7fbb719b8a95436f8594777de610ec51ffe833d1d", "class_name": "RelatedNodeInfo"}}, "text": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "start_char_idx": 1896, "end_char_idx": 1998, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d90783a4-2239-4204-bbb1-97b40ea127fe": {"__data__": {"id_": "d90783a4-2239-4204-bbb1-97b40ea127fe", "embedding": null, "metadata": {"window": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone. ", "original_text": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "803e407c-a537-4a02-8984-818582401345", "node_type": "1", "metadata": {"window": "Before I turn the call over to Britt, I want to take just a moment to thank Kathy McElligott, who just retired from \nMcKesson.  In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "original_text": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b298097516ffed0f1c660e328b3278e7450f2c3b13a00f7981745a0612e4b1f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "51a99653-5987-4818-9013-0bf2c25b2bb1", "node_type": "1", "metadata": {"window": "Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "original_text": "And with that, let me turn the call over to Britt to go through the financials.  \n "}, "hash": "2759d2d596cc4bd3a158ba004bca4b63889fd37346a5af656e949d55c51c3b81", "class_name": "RelatedNodeInfo"}}, "text": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "start_char_idx": 1998, "end_char_idx": 2281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "51a99653-5987-4818-9013-0bf2c25b2bb1": {"__data__": {"id_": "51a99653-5987-4818-9013-0bf2c25b2bb1", "embedding": null, "metadata": {"window": "Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "original_text": "And with that, let me turn the call over to Britt to go through the financials.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d90783a4-2239-4204-bbb1-97b40ea127fe", "node_type": "1", "metadata": {"window": "In her role as Chief Information and Technology Officer, she helped McKesson increase its focus on \ndata and analytics and accelerate our technology modernization.  Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone. ", "original_text": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "64f70a2c609579de6b809ee8c84b40983261035dc250c352eb5752b16b8ef505", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "25703993-bd47-494d-82d4-f47449d7793a", "node_type": "1", "metadata": {"window": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n"}, "hash": "1cb76cf7c7ad5e39986ebb2b912b5ae72b1c693672eda301e46a0bcc4700ecec", "class_name": "RelatedNodeInfo"}}, "text": "And with that, let me turn the call over to Britt to go through the financials.  \n ", "start_char_idx": 2281, "end_char_idx": 2364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "25703993-bd47-494d-82d4-f47449d7793a": {"__data__": {"id_": "25703993-bd47-494d-82d4-f47449d7793a", "embedding": null, "metadata": {"window": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "51a99653-5987-4818-9013-0bf2c25b2bb1", "node_type": "1", "metadata": {"window": "Kathy, thank you for your contributions to \nMcKesson.  \n \n And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "original_text": "And with that, let me turn the call over to Britt to go through the financials.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c7489da88b14bae660d70fb77d0bd7930560539e2c80987d26cae0d2afe6a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eeebc3c9-dba1-4183-9ef3-794674d6a634", "node_type": "1", "metadata": {"window": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "original_text": "Well, thank you, Brian, and good morning, everyone. "}, "hash": "c1e3b15ccc1843654fd03a192dae0c5d9f96444ebd3e15ba1707e61bcbb7c88f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "start_char_idx": 2364, "end_char_idx": 2725, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eeebc3c9-dba1-4183-9ef3-794674d6a634": {"__data__": {"id_": "eeebc3c9-dba1-4183-9ef3-794674d6a634", "embedding": null, "metadata": {"window": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "original_text": "Well, thank you, Brian, and good morning, everyone. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "25703993-bd47-494d-82d4-f47449d7793a", "node_type": "1", "metadata": {"window": "And on the flip side, I'd like to also welcome Nancy Flores, who is succ eeding Kathy as CIO and CTO.  Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8257502b4ea36c331d6f080806276c5770caa9260f11dae326080417aa65b9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0169da04-2a54-47ea-b21b-7acd8d043e45", "node_type": "1", "metadata": {"window": "And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "original_text": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. "}, "hash": "baf115385baaa05873c18422a6775893658cf07478c7b1094d67a8ec4f1b0894", "class_name": "RelatedNodeInfo"}}, "text": "Well, thank you, Brian, and good morning, everyone. ", "start_char_idx": 2725, "end_char_idx": 2777, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0169da04-2a54-47ea-b21b-7acd8d043e45": {"__data__": {"id_": "0169da04-2a54-47ea-b21b-7acd8d043e45", "embedding": null, "metadata": {"window": "And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "original_text": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eeebc3c9-dba1-4183-9ef3-794674d6a634", "node_type": "1", "metadata": {"window": "Nancy has \na long track record of success in healthcare IT and we look forward to utilizing her experience, as we remain \nfocused on our mission to improve healthcare in every setting, by leveraging technology solutions for our \ncompany, our customers and our business partners.  \n \n And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "original_text": "Well, thank you, Brian, and good morning, everyone. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "793b58b52e9ae8e74b819fe13128dbca1fbdb84b34a2c22bd753c68c16f8db73", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2c9ce5e-04c7-4631-83cd-41db2588a702", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "original_text": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. "}, "hash": "109b89b97539ab5d5bbcc80ca2c930cd73c586d60b96211f570e844700359554", "class_name": "RelatedNodeInfo"}}, "text": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "start_char_idx": 2777, "end_char_idx": 2864, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2c9ce5e-04c7-4631-83cd-41db2588a702": {"__data__": {"id_": "b2c9ce5e-04c7-4631-83cd-41db2588a702", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "original_text": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0169da04-2a54-47ea-b21b-7acd8d043e45", "node_type": "1", "metadata": {"window": "And with that, let me turn the call over to Britt to go through the financials.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "original_text": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dea69b0c6355b7cd885f6896344f67bf21eb966205bff383cd158e61ede57a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26e70c60-1324-4469-ac59-aad6c272e2a6", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "original_text": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n"}, "hash": "34b9d9793d7afe381a31e1c4783fd439878a37737ad87fcdde4ffef77acf3bfd", "class_name": "RelatedNodeInfo"}}, "text": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "start_char_idx": 2864, "end_char_idx": 3007, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26e70c60-1324-4469-ac59-aad6c272e2a6": {"__data__": {"id_": "26e70c60-1324-4469-ac59-aad6c272e2a6", "embedding": null, "metadata": {"window": "Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "original_text": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2c9ce5e-04c7-4631-83cd-41db2588a702", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "original_text": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9dfd35875107ef1c2af7d2b418a45ad50d833b3cfdd5e2a7e85143682e856771", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7adf702-eb63-4162-ab44-2dc75a9a712b", "node_type": "1", "metadata": {"window": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "original_text": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. "}, "hash": "7bf271e1d586ff6468e09ec3a5417b8a75549a09a7b713a1dcafa5b5671cb24c", "class_name": "RelatedNodeInfo"}}, "text": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "start_char_idx": 3007, "end_char_idx": 3224, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7adf702-eb63-4162-ab44-2dc75a9a712b": {"__data__": {"id_": "a7adf702-eb63-4162-ab44-2dc75a9a712b", "embedding": null, "metadata": {"window": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "original_text": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26e70c60-1324-4469-ac59-aad6c272e2a6", "node_type": "1", "metadata": {"window": "Well, thank you, Brian, and good morning, everyone.  I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "original_text": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6171dcbf434cb86355890d59448a0b0b5a5b6c848fa2773b9da549d479ea835", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d02741a3-f166-4baa-88ad-9c8e26d08a39", "node_type": "1", "metadata": {"window": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "We continue to see momentum \nacross the business as we execute against our strategic initiatives. "}, "hash": "4cabc0f19ad91d81f6d3d5d49494bcf274d3b4634b5ae0bb674d0a3eb402903f", "class_name": "RelatedNodeInfo"}}, "text": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "start_char_idx": 3224, "end_char_idx": 3413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d02741a3-f166-4baa-88ad-9c8e26d08a39": {"__data__": {"id_": "d02741a3-f166-4baa-88ad-9c8e26d08a39", "embedding": null, "metadata": {"window": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7adf702-eb63-4162-ab44-2dc75a9a712b", "node_type": "1", "metadata": {"window": "I'm pleased to be here this morning to talk about a solid third \nquarter for McKesson.  I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "original_text": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b11441f78c9fff02213a501db9a06ad8b9c302a5fe5308a02c626a3e07972f5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7558abc-1155-4cfe-8a4c-d9462e662890", "node_type": "1", "metadata": {"window": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n"}, "hash": "4d3b0cccee7cb53422b567658f303a2164a27c4ca2d2e2ee2377766297f76004", "class_name": "RelatedNodeInfo"}}, "text": "We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "start_char_idx": 3413, "end_char_idx": 3511, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7558abc-1155-4cfe-8a4c-d9462e662890": {"__data__": {"id_": "f7558abc-1155-4cfe-8a4c-d9462e662890", "embedding": null, "metadata": {"window": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d02741a3-f166-4baa-88ad-9c8e26d08a39", "node_type": "1", "metadata": {"window": "I'll focus on our third quarter results and full year fiscal 2020 guidance, including changes \nyou need to consider as you update your models.  Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "We continue to see momentum \nacross the business as we execute against our strategic initiatives. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1478c4bd59c108be65b04aef85abbf3a53804c5bc8990eec4a624e1ac9c4424", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "261849e4-9834-41fa-aedc-9ef218aec488", "node_type": "1", "metadata": {"window": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. "}, "hash": "aa6e14451d05fb3932d55fe19878852e8531bc50f95b9ef11b93a529ae1e0a19", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "start_char_idx": 3511, "end_char_idx": 3874, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "261849e4-9834-41fa-aedc-9ef218aec488": {"__data__": {"id_": "261849e4-9834-41fa-aedc-9ef218aec488", "embedding": null, "metadata": {"window": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7558abc-1155-4cfe-8a4c-d9462e662890", "node_type": "1", "metadata": {"window": "Brian wal ked you through high -level puts and takes as we think \nabout our fiscal 2021 guidance and we'll provide detailed assumptions for fiscal 2021 when we report fourth \nquarter and full year results in May.  \n \n We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6fdf39d6116031f2f032a20cc05b5e598cdcbba62188e3f29bb5291f6ca689b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d21c5de9-e4f5-423d-a036-a6215ded0f93", "node_type": "1", "metadata": {"window": "We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n "}, "hash": "0e2559911983461c114da3d182267c6bde4ca2aacd9a8c53c8dfb5fb03174649", "class_name": "RelatedNodeInfo"}}, "text": "Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "start_char_idx": 3874, "end_char_idx": 4024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d21c5de9-e4f5-423d-a036-a6215ded0f93": {"__data__": {"id_": "d21c5de9-e4f5-423d-a036-a6215ded0f93", "embedding": null, "metadata": {"window": "We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571", "node_type": "4", "metadata": {"page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d3e5d56cd8ec337ab5bef27d9825822a807d5f8ebb9c0e77ea3891baba854507", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "261849e4-9834-41fa-aedc-9ef218aec488", "node_type": "1", "metadata": {"window": "We're pleased with our adjusted operating profit and ad justed earnings per diluted share results in the third \nquarter, which were ahead of our expectations and represent solid execution.  We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website. ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b71d04f424acd5e8d2f72a14ca66f9df196d907b14a94f6ba5d3cdf6a61fa6e4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed49091-f9c9-4402-a6a0-1aa3c77ea148", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "d92c9ff1c18e5266fd96e2200e1f062c6c3198e5eb652b9a19c8932a1b1804ca", "class_name": "RelatedNodeInfo"}}, "text": "Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "start_char_idx": 4024, "end_char_idx": 4178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed49091-f9c9-4402-a6a0-1aa3c77ea148": {"__data__": {"id_": "fed49091-f9c9-4402-a6a0-1aa3c77ea148", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d21c5de9-e4f5-423d-a036-a6215ded0f93", "node_type": "1", "metadata": {"window": "We continue to see momentum \nacross the business as we execute against our strategic initiatives.  As a result of this momentu m and based on \nthe confidence in our fourth quarter outlook, on January 13 we raised and narrowed our fiscal 2020 adjusted \nearnings outlook to a range of $14.60 to $14.80 per diluted share from the previous range of $14 to $14.60 per \ndiluted share and toda y we're reaffirming that adjusted earnings per diluted share guidance.  \n \n Updated guidance assumptions can be found in our third quarter earnings slide presentation, which is posted on \nour Investors section of our website.  Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "original_text": "Before I provide more details on ou r third quarter adjusted results, I want to \naddress one item that impacted our GAAP -only results in the quarter.  \n ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07e7efaa6760bbf692d856eea29def76cfb83dffd00ad887f69263c8fb16d3c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9e7e2961-35f0-4112-9907-24d2868e0b67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n"}, "hash": "0e3775730d32023e645a2d44b8cdf28ca4c0386fdf62301cf4137e8193292087", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9e7e2961-35f0-4112-9907-24d2868e0b67": {"__data__": {"id_": "9e7e2961-35f0-4112-9907-24d2868e0b67", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed49091-f9c9-4402-a6a0-1aa3c77ea148", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c2cf086e50108d37c9c7fbcde74ce61c38de32723a58d4aa31493ab6b742015", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "146a4d98-1b29-490e-86e1-6b54daf7d794", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "Moving now to the adjusted earnings results for the quarter. "}, "hash": "aca4d0d0ffae0deb9cc84ae28dd356f94e3c8b6668188d33941351e357caa062", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n", "start_char_idx": 16, "end_char_idx": 492, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "146a4d98-1b29-490e-86e1-6b54daf7d794": {"__data__": {"id_": "146a4d98-1b29-490e-86e1-6b54daf7d794", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "Moving now to the adjusted earnings results for the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9e7e2961-35f0-4112-9907-24d2868e0b67", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b6fa5770cae91265b46c2af64c479d3703edf8f2b2f7d3e3346fa91b7c907c36", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15da271b-f3f8-4977-a6f7-63c2dbbf39e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "original_text": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n"}, "hash": "95b635b5c5a109e3eda13019759d98872fb58281afd7d77d0bdbc5e26b606aff", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to the adjusted earnings results for the quarter. ", "start_char_idx": 492, "end_char_idx": 553, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15da271b-f3f8-4977-a6f7-63c2dbbf39e8": {"__data__": {"id_": "15da271b-f3f8-4977-a6f7-63c2dbbf39e8", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "original_text": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "146a4d98-1b29-490e-86e1-6b54daf7d794", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "Moving now to the adjusted earnings results for the quarter. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "939476c6e627155e6219b96a8a5e724d164c61b7142813378b6a81b7f108dab7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebc35d8a-ad7a-4935-a759-e935fe5f77d5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4. ", "original_text": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. "}, "hash": "987d3ea790673807adefd9aad60d12e82ef37f5ad1bf7b44686a3d5ff9fe4e9c", "class_name": "RelatedNodeInfo"}}, "text": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "start_char_idx": 553, "end_char_idx": 809, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebc35d8a-ad7a-4935-a759-e935fe5f77d5": {"__data__": {"id_": "ebc35d8a-ad7a-4935-a759-e935fe5f77d5", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4. ", "original_text": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15da271b-f3f8-4977-a6f7-63c2dbbf39e8", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "original_text": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5011bb1e818f1799fb030c6471476af23871289e42ceae97ad5e4747f04139ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d13db75a-1b90-4e25-aed0-98b5b2b7edb2", "node_type": "1", "metadata": {"window": "Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "original_text": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. "}, "hash": "eabacf8c2e3cecf67765ddb6e56e4b69c2675162e43bc8fe6a667fa736ed9ee4", "class_name": "RelatedNodeInfo"}}, "text": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "start_char_idx": 809, "end_char_idx": 1000, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d13db75a-1b90-4e25-aed0-98b5b2b7edb2": {"__data__": {"id_": "d13db75a-1b90-4e25-aed0-98b5b2b7edb2", "embedding": null, "metadata": {"window": "Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "original_text": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebc35d8a-ad7a-4935-a759-e935fe5f77d5", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4. ", "original_text": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68b4f74f378bbe33ba9980e2d3ac95d33a851fa85e240bdb2999e6ecc8b4ad08", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2ce29e6c-b1ff-4048-b542-d066e38c7e46", "node_type": "1", "metadata": {"window": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "original_text": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n"}, "hash": "54610dc3d55ee7f277356d6b151790d568b999c647c881948d1082ca2eae81c0", "class_name": "RelatedNodeInfo"}}, "text": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "start_char_idx": 1000, "end_char_idx": 1219, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2ce29e6c-b1ff-4048-b542-d066e38c7e46": {"__data__": {"id_": "2ce29e6c-b1ff-4048-b542-d066e38c7e46", "embedding": null, "metadata": {"window": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "original_text": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d13db75a-1b90-4e25-aed0-98b5b2b7edb2", "node_type": "1", "metadata": {"window": "Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "original_text": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eef395c11eaad561e30048bb72cd54e90aa1958ae8dfca7d3a6b6cbe363a1046", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "262db2b9-669e-41a4-bd73-14b20acf6ace", "node_type": "1", "metadata": {"window": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "original_text": "Moving to the details of our consolidated re sults on slide 4. "}, "hash": "d112784836082adf9da3f5f1080fecabd5198477aa9724deb1871c82b705d91d", "class_name": "RelatedNodeInfo"}}, "text": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "start_char_idx": 1219, "end_char_idx": 1327, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "262db2b9-669e-41a4-bd73-14b20acf6ace": {"__data__": {"id_": "262db2b9-669e-41a4-bd73-14b20acf6ace", "embedding": null, "metadata": {"window": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "original_text": "Moving to the details of our consolidated re sults on slide 4. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2ce29e6c-b1ff-4048-b542-d066e38c7e46", "node_type": "1", "metadata": {"window": "Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "original_text": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ab090244e323e555f2806862884df54245a4b580e6a6e3eafff154cd1d210e8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "88219d88-297d-4e7d-b83e-9bb58de6a840", "node_type": "1", "metadata": {"window": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "original_text": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. "}, "hash": "9e3cc08e371507157013f92d0b7233592d3600883ee8a9be3ed1a4b880e0a01e", "class_name": "RelatedNodeInfo"}}, "text": "Moving to the details of our consolidated re sults on slide 4. ", "start_char_idx": 1327, "end_char_idx": 1390, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "88219d88-297d-4e7d-b83e-9bb58de6a840": {"__data__": {"id_": "88219d88-297d-4e7d-b83e-9bb58de6a840", "embedding": null, "metadata": {"window": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "original_text": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "262db2b9-669e-41a4-bd73-14b20acf6ace", "node_type": "1", "metadata": {"window": "To better understand our third quarter r esults, let me remind you of two discrete events in our prior year third \nquarter, both within our US Pharmaceutical and Specialty Solutions segment.  First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "original_text": "Moving to the details of our consolidated re sults on slide 4. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dba20388c85a22c35e8bf6ff96bc34710b0f863626f3dc55d132f1e582051890", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4", "node_type": "1", "metadata": {"window": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "original_text": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n"}, "hash": "5719f69d1738516e663799709d22dabf992152374ae82e962e3249c4fdc043f9", "class_name": "RelatedNodeInfo"}}, "text": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "start_char_idx": 1390, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4": {"__data__": {"id_": "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4", "embedding": null, "metadata": {"window": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "original_text": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "88219d88-297d-4e7d-b83e-9bb58de6a840", "node_type": "1", "metadata": {"window": "First, the $60 million pre -tax charge \nrelated to the bankruptcy of Shopko; and second a pre -tax benefit of approximately $17 million related to the \nreversal of accrued New York State Opioid Stewardship Act charges.  If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "original_text": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e6a5e0c854a89b2416cdda850ddcc207fe71d06aeac91089303911843e6b7bac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "285fe989-ff80-4c02-be38-8d52aedcdfd3", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "original_text": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. "}, "hash": "5d878c68708f0fc48ac4c26b32dc9bd7629196efbbb243bbd095bf1334b48192", "class_name": "RelatedNodeInfo"}}, "text": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "start_char_idx": 1653, "end_char_idx": 1768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "285fe989-ff80-4c02-be38-8d52aedcdfd3": {"__data__": {"id_": "285fe989-ff80-4c02-be38-8d52aedcdfd3", "embedding": null, "metadata": {"window": "Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "original_text": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4", "node_type": "1", "metadata": {"window": "If you normalize for these two items, Q3 \nfiscal 2020 adjusted earnings per diluted share increased 7%.  \n \n Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "original_text": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "118249dcdb0f9d947fc7859298c2bdcd88307a3f606864e2cdbea8c8491470d8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7", "node_type": "1", "metadata": {"window": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "original_text": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n"}, "hash": "b3c43be90e308624572eacfaa8531f436a9dec60415dc5a9b3534aa6db97c979", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "start_char_idx": 1768, "end_char_idx": 1951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7": {"__data__": {"id_": "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7", "embedding": null, "metadata": {"window": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "original_text": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "285fe989-ff80-4c02-be38-8d52aedcdfd3", "node_type": "1", "metadata": {"window": "Moving to the details of our consolidated re sults on slide 4.  Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "original_text": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "836e3415acdb5a69c62023f2215897e955b9223c6d940981802ddac16b710572", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73", "node_type": "1", "metadata": {"window": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "original_text": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. "}, "hash": "4a066870662756880ffccf31466eae27b000a3baca09aa06022243df609950ff", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "start_char_idx": 1951, "end_char_idx": 2112, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73": {"__data__": {"id_": "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73", "embedding": null, "metadata": {"window": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "original_text": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7", "node_type": "1", "metadata": {"window": "Consolidated revenues for the third quarter increased \n5% versus the prior period, primarily driven by growth in our US Pharmaceutical and Specialty Solutions segment, \ndriven by branded pharmaceutical price increases and higher retail nati onal account volumes.  We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "original_text": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f4cefe994ba2103d58ba87c3cb6b7e41b51718b93d35f29fa9be3cf50defc43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab", "node_type": "1", "metadata": {"window": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "original_text": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n"}, "hash": "2ff7d0d0138de2d65c353f3dddeaa20b68d47bf631a264dfe7d8a4e39694f022", "class_name": "RelatedNodeInfo"}}, "text": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "start_char_idx": 2112, "end_char_idx": 2243, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab": {"__data__": {"id_": "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab", "embedding": null, "metadata": {"window": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "original_text": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73", "node_type": "1", "metadata": {"window": "We continue to \nanticipate mid - to high -single -digit percent consolidated revenue growth for the full year.  \n \n Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "original_text": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "09ec9f1a5aafa4202f20300ca07e0b5a63febb31f246cbf057c5ef7108574513", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f26ada04-55ae-4cf2-a974-a768f2571fc2", "node_type": "1", "metadata": {"window": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "original_text": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year. "}, "hash": "1bd891c7c1ec66a226d12f90cd41630f9db16852d88fca1f17465d63c1ca2439", "class_name": "RelatedNodeInfo"}}, "text": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "start_char_idx": 2243, "end_char_idx": 2410, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f26ada04-55ae-4cf2-a974-a768f2571fc2": {"__data__": {"id_": "f26ada04-55ae-4cf2-a974-a768f2571fc2", "embedding": null, "metadata": {"window": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "original_text": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab", "node_type": "1", "metadata": {"window": "Third quarter adjusted gross profit increased 4% year -over-year, principally due to organic growth in our Medical -\nSurgical and  US Pharmaceutical and Specialty Solutions segments.  Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "original_text": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3486542acbff65f298e70f86c727c7c08d0d32fabcbf8bfe10895d03fd9b0bed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d9adfe9-0f15-46dc-a218-c2bad5c75c56", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "original_text": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. "}, "hash": "178b6b2c7b155f8a39af687d8700ed71a5d5aaddf78024f415818bbbc0b666e4", "class_name": "RelatedNodeInfo"}}, "text": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "start_char_idx": 2410, "end_char_idx": 2498, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d9adfe9-0f15-46dc-a218-c2bad5c75c56": {"__data__": {"id_": "8d9adfe9-0f15-46dc-a218-c2bad5c75c56", "embedding": null, "metadata": {"window": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "original_text": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f26ada04-55ae-4cf2-a974-a768f2571fc2", "node_type": "1", "metadata": {"window": "Third quarter adjusted operating expenses \nincreased 3% year -over-year, driven by higher corporate expenses, which include planned technology \ninvestments.  \n \n Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "original_text": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e29a0bf87abe940a409160f7e902d36da983c20cdb95f4629d0c36158b3a8380", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6a5f543e-c180-47ce-a1f0-554f4a3b0efe", "node_type": "1", "metadata": {"window": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "original_text": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n"}, "hash": "92aed7949b0e9ac5bacea018d303367196d65b9d21c7234f155bef5faf3ece73", "class_name": "RelatedNodeInfo"}}, "text": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "start_char_idx": 2498, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6a5f543e-c180-47ce-a1f0-554f4a3b0efe": {"__data__": {"id_": "6a5f543e-c180-47ce-a1f0-554f4a3b0efe", "embedding": null, "metadata": {"window": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "original_text": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d9adfe9-0f15-46dc-a218-c2bad5c75c56", "node_type": "1", "metadata": {"window": "Adjusted income from operations was $958 million  for the quarter, which was up 4% year -over-year or 5% on an \nFX-adjusted basis.  As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "original_text": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "13d9c7597263a0268339ecae1ab7def80a9e50c0b1c1264d525272004d002118", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4784347e-3fc7-4f56-9af7-3fab3b0e89d8", "node_type": "1", "metadata": {"window": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8. ", "original_text": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. "}, "hash": "2fff471d409fad3a1e2edb2d3093cb8f9e494d65c2b53f52e4b6df2c942a4015", "class_name": "RelatedNodeInfo"}}, "text": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "start_char_idx": 2619, "end_char_idx": 2711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4784347e-3fc7-4f56-9af7-3fab3b0e89d8": {"__data__": {"id_": "4784347e-3fc7-4f56-9af7-3fab3b0e89d8", "embedding": null, "metadata": {"window": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8. ", "original_text": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6a5f543e-c180-47ce-a1f0-554f4a3b0efe", "node_type": "1", "metadata": {"window": "As a result of this solid performance and our updated outlook, we are guiding full year \nadjusted income from operations to increase a low -single -digit percent.  \n \n Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "original_text": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c5c745540b74edb7ffcfc6d255512557edc5079b6dfc5f9a898c8583b088079", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74c9eaa1-92ad-4206-80cf-14d3feecc874", "node_type": "1", "metadata": {"window": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "original_text": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. "}, "hash": "4fcbb75f7eb10b630cab692705fe42f906d2529807cf3452205c852ec88e6538", "class_name": "RelatedNodeInfo"}}, "text": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "start_char_idx": 2711, "end_char_idx": 2852, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74c9eaa1-92ad-4206-80cf-14d3feecc874": {"__data__": {"id_": "74c9eaa1-92ad-4206-80cf-14d3feecc874", "embedding": null, "metadata": {"window": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "original_text": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4784347e-3fc7-4f56-9af7-3fab3b0e89d8", "node_type": "1", "metadata": {"window": "Interest expens e of $64 million in the quarter declined 4% compared to the prior year.  And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8. ", "original_text": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "77d7d20f4ad4a68b7be69136df5a843ba711adee2eb5476d4625b6c78fec626e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cd7000f0-45b1-4a79-808e-5760f3ba9215", "node_type": "1", "metadata": {"window": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "original_text": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n"}, "hash": "ff7e0cb327a725a4fe0c6a4a567d56a3c1d45e8c437ecb1e1b079807b17c379a", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "start_char_idx": 2852, "end_char_idx": 3003, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cd7000f0-45b1-4a79-808e-5760f3ba9215": {"__data__": {"id_": "cd7000f0-45b1-4a79-808e-5760f3ba9215", "embedding": null, "metadata": {"window": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "original_text": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74c9eaa1-92ad-4206-80cf-14d3feecc874", "node_type": "1", "metadata": {"window": "And our adjusted tax rate \nwas 17.1% for the quarter, which included discrete tax benefits of approximately $36 million.  For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "original_text": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "99e2ba4044cde4edd91f441dc580ceab44786b18a8270e545c410188d8eda9d3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9f74eac9-b3ba-4681-822f-0b9b05bd97c4", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 8. "}, "hash": "e6ce589ab3b694f85f536e2a997cdf7f13ab2f74643d23e6f983f10fdc4dbbb9", "class_name": "RelatedNodeInfo"}}, "text": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "start_char_idx": 3003, "end_char_idx": 3110, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9f74eac9-b3ba-4681-822f-0b9b05bd97c4": {"__data__": {"id_": "9f74eac9-b3ba-4681-822f-0b9b05bd97c4", "embedding": null, "metadata": {"window": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 8. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cd7000f0-45b1-4a79-808e-5760f3ba9215", "node_type": "1", "metadata": {"window": "For the full year, our \nadjusted tax rate assumption remains appr oximately 18% to 19%.  \n \n Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "original_text": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "48d0860aa92eb0e1bc451e1cc0a97bfa45dd8978adc97b7ccf14063484e5e0c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b7fa1d4d-8386-44b4-ac62-fb46d28535c0", "node_type": "1", "metadata": {"window": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "original_text": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. "}, "hash": "6d01913d97701eb0925ee9475991803c97c4e3d134005c366121f7d52e0e49e6", "class_name": "RelatedNodeInfo"}}, "text": "Next, I'll review our segment results, which can be found on slides 5 through 8. ", "start_char_idx": 3110, "end_char_idx": 3191, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b7fa1d4d-8386-44b4-ac62-fb46d28535c0": {"__data__": {"id_": "b7fa1d4d-8386-44b4-ac62-fb46d28535c0", "embedding": null, "metadata": {"window": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "original_text": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9f74eac9-b3ba-4681-822f-0b9b05bd97c4", "node_type": "1", "metadata": {"window": "Wrapping up our consolidated results, our third quarter diluted weighted average shares were 180 million, a \ndecrease of 8% year -over-year.  During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "original_text": "Next, I'll review our segment results, which can be found on slides 5 through 8. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98f686aa127dfe515ed660ba66ef7c59965f8d925658d3111329cf5e9234c86c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8841a76e-f12e-4148-b683-d4b7c71fb55b", "node_type": "1", "metadata": {"window": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n"}, "hash": "71d82397cc0bfb6dacb8f16265f804e445b707676acbaff0ec28431756cc8e64", "class_name": "RelatedNodeInfo"}}, "text": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "start_char_idx": 3191, "end_char_idx": 3373, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8841a76e-f12e-4148-b683-d4b7c71fb55b": {"__data__": {"id_": "8841a76e-f12e-4148-b683-d4b7c71fb55b", "embedding": null, "metadata": {"window": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b7fa1d4d-8386-44b4-ac62-fb46d28535c0", "node_type": "1", "metadata": {"window": "During the quarter, we completed approximately $500 million of share \nrepurchases, bringing our  year-to-date total share repurchases to $1.9 billion.  As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "original_text": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "74bfe3143ce9136aa0390339c1afee726b8056a555a29324ba041eab3e5cc17f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c", "node_type": "1", "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. "}, "hash": "fd545f3a8e242462d7b9e5184e157e0c2e79e9131003133e18a8c2b956b97b32", "class_name": "RelatedNodeInfo"}}, "text": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "start_char_idx": 3373, "end_char_idx": 3562, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c": {"__data__": {"id_": "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c", "embedding": null, "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8841a76e-f12e-4148-b683-d4b7c71fb55b", "node_type": "1", "metadata": {"window": "As a result, we now expect diluted \nweighted average shares of approximately 183 million for the year.  \n \n Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f0cdd8b498fa3f8f41b77148eed8cec9cbbcd59a21e10c0fc40982ecf27492ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bbd23663-091e-427d-b616-55b6c3954660", "node_type": "1", "metadata": {"window": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. "}, "hash": "b0d8e76bb493b7477f55d1ca1a5cd5be29e96cd86d1166561f347bb6b1608e92", "class_name": "RelatedNodeInfo"}}, "text": "While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "start_char_idx": 3562, "end_char_idx": 3713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bbd23663-091e-427d-b616-55b6c3954660": {"__data__": {"id_": "bbd23663-091e-427d-b616-55b6c3954660", "embedding": null, "metadata": {"window": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c", "node_type": "1", "metadata": {"window": "Next, I'll review our segment results, which can be found on slides 5 through 8.  Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2a2b0f1de6b2f4e9f0a5aacfc87d29befda8ea7ee0f3d2e15f3874d9c6f6250b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b054ac7e-38a7-472b-906d-942fbea0a541", "node_type": "1", "metadata": {"window": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n "}, "hash": "dc33fb1d473687c30a8a76a2d9b6c4a56e2bfe07d3ece202794bec0817702265", "class_name": "RelatedNodeInfo"}}, "text": "These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "start_char_idx": 3713, "end_char_idx": 3840, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b054ac7e-38a7-472b-906d-942fbea0a541": {"__data__": {"id_": "b054ac7e-38a7-472b-906d-942fbea0a541", "embedding": null, "metadata": {"window": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5", "node_type": "4", "metadata": {"page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8b38a758b4bedc78e55d99bc8a205d2b01c3cea8e1396e77ba5cbf659d69b074", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bbd23663-091e-427d-b616-55b6c3954660", "node_type": "1", "metadata": {"window": "Before I start wi th my review of the \nsegments, including updated full year guidance, I want to reiterate that we provide full year guidance and do not \nprovide quarterly guidance.  As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items. ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a57f05f441a81197de83741da55dedf3c0061d1c0963bafc71526b715f61dbc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abe55df2-31dd-474a-871b-014bd3b446c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "original_text": "McKesson Corp.  "}, "hash": "1582effdef3edfa28e6015e28705602a7de8725135a9748ec4a04ed29c59f979", "class_name": "RelatedNodeInfo"}}, "text": "We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "start_char_idx": 3840, "end_char_idx": 3932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abe55df2-31dd-474a-871b-014bd3b446c5": {"__data__": {"id_": "abe55df2-31dd-474a-871b-014bd3b446c5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b054ac7e-38a7-472b-906d-942fbea0a541", "node_type": "1", "metadata": {"window": "As a reminder, there are a number of items, particularly in our largest segment US \nPharmaceuti cal and Specialty Solutions, that can cause fluctuations on a quarter -to-quarter basis.  \n \n While this can make comparing year -over-year results on a quarterly basis difficult, these items do tend to \nbalance out over the course of the year.  These items includ e customer volumes, customer and product mix, brand \nprice increases, and the timing of discrete tax items.  We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "original_text": "We anticipate that there could be additional fluctuation in our \nfourth quarter results.  \n ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e40dd17d463f7b08d13f3344596de23bcfb42f3fa268727828b3524e7f14afa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d17a13d-06af-428c-917d-542df32a09f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons. "}, "hash": "1c09f9f63a19eb9d3b47d9c171127e37413c1a2484688d59e5bd5c3a8b5bc964", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d17a13d-06af-428c-917d-542df32a09f3": {"__data__": {"id_": "2d17a13d-06af-428c-917d-542df32a09f3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abe55df2-31dd-474a-871b-014bd3b446c5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b5cea250bece3ae8cb973cddcc998a1d1b4707c3e2b830d0818982bd14d5399", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "abd3c817-cd11-4154-9dea-bc56a443a7cf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "original_text": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions. "}, "hash": "c00f8dc071af7560026753d071dc631aba93b6364fc3801eae9b42fe264f7409", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons. ", "start_char_idx": 16, "end_char_idx": 246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "abd3c817-cd11-4154-9dea-bc56a443a7cf": {"__data__": {"id_": "abd3c817-cd11-4154-9dea-bc56a443a7cf", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "original_text": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d17a13d-06af-428c-917d-542df32a09f3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26800beb0a1e6f73be35fb3f7fcd7ce35357b306e9fe179a5068b01e0229e04a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "original_text": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n"}, "hash": "2942f7c109ed7104abbc20ef759fb342316530f8d8162ff33fe6daed51034ad0", "class_name": "RelatedNodeInfo"}}, "text": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions. ", "start_char_idx": 246, "end_char_idx": 464, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d": {"__data__": {"id_": "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "original_text": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "abd3c817-cd11-4154-9dea-bc56a443a7cf", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "original_text": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b32f51046903e9dc788d5566867311d3122cc511d0c88ba5b2bffd5d0bcb7b63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d206c2fd-23b1-42d9-80bc-53497d0abb16", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "original_text": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. "}, "hash": "4a1141156e3b47c94e33efe88111c240222f9e07bf448b9616dc82f34c8eae5c", "class_name": "RelatedNodeInfo"}}, "text": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "start_char_idx": 464, "end_char_idx": 644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d206c2fd-23b1-42d9-80bc-53497d0abb16": {"__data__": {"id_": "d206c2fd-23b1-42d9-80bc-53497d0abb16", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "original_text": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "original_text": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5c2f7df6893c25446c332c6b9ba2d27d8d9bbc4ec511c366eb0427a3aa259034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b", "node_type": "1", "metadata": {"window": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "original_text": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n"}, "hash": "c4373f27c4a5b983eba6764010a33ad604c9e5251101e0010b061acf9ac3bf91", "class_name": "RelatedNodeInfo"}}, "text": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "start_char_idx": 644, "end_char_idx": 950, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b": {"__data__": {"id_": "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b", "embedding": null, "metadata": {"window": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "original_text": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d206c2fd-23b1-42d9-80bc-53497d0abb16", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "original_text": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43d92ce00cef5acced6332dd023513777b835d48d92389a47e30204061b6697c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c203dd97-1246-4dce-91ed-59bd95ee1019", "node_type": "1", "metadata": {"window": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "original_text": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. "}, "hash": "2dd8911a496d582808fcc74c155e000994c9adf7986076e54c56c008dff1092d", "class_name": "RelatedNodeInfo"}}, "text": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "start_char_idx": 950, "end_char_idx": 1084, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c203dd97-1246-4dce-91ed-59bd95ee1019": {"__data__": {"id_": "c203dd97-1246-4dce-91ed-59bd95ee1019", "embedding": null, "metadata": {"window": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "original_text": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b", "node_type": "1", "metadata": {"window": "Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "original_text": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eae6ef14e75784e65cde78c5d3124017d53aaaf26f9c03814fcc66fa437c6bb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24b85c5c-3c6c-4ccf-a403-44de862098b8", "node_type": "1", "metadata": {"window": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations. ", "original_text": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n"}, "hash": "59b83541e6ba754f954246aa25fcabeb2b0ae6ffab7d203a3a376f9d2cb5dd22", "class_name": "RelatedNodeInfo"}}, "text": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "start_char_idx": 1084, "end_char_idx": 1274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24b85c5c-3c6c-4ccf-a403-44de862098b8": {"__data__": {"id_": "24b85c5c-3c6c-4ccf-a403-44de862098b8", "embedding": null, "metadata": {"window": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations. ", "original_text": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c203dd97-1246-4dce-91ed-59bd95ee1019", "node_type": "1", "metadata": {"window": "Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "original_text": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d23295108699f3580e0a9612381bb2affad5ef7857af19c438f868e1ed067347", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a490ddf-a10b-4641-8938-cb01dd03f681", "node_type": "1", "metadata": {"window": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "On a year -to-date basis, the segment adjusted operating profit is up 7%. "}, "hash": "286859b38dae02eee68799650a1febf0f943d3a1c67737b2846bb996489f3666", "class_name": "RelatedNodeInfo"}}, "text": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "start_char_idx": 1274, "end_char_idx": 1376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a490ddf-a10b-4641-8938-cb01dd03f681": {"__data__": {"id_": "8a490ddf-a10b-4641-8938-cb01dd03f681", "embedding": null, "metadata": {"window": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24b85c5c-3c6c-4ccf-a403-44de862098b8", "node_type": "1", "metadata": {"window": "As I mentioned earlier, there were two discrete items included in our prior year third quarter results: a $60 million  \npre-tax charge related to the bankruptcy of Shopko and a pre -tax benefit of approximately $17 million related to \nthe reversal of accrued New York State Opioid Stewardship Act charges.  If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations. ", "original_text": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ff57cab9b2abdf592f6bc4fef48b59954c717435ebbd4f05e672e16bf2a5ce1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ffa0adb-082b-4f7f-a303-f26093681c93", "node_type": "1", "metadata": {"window": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "original_text": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n"}, "hash": "c5da89bbd1d867985bb845349c4d02e83c33056389c2de5c689d21484e1324c2", "class_name": "RelatedNodeInfo"}}, "text": "On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "start_char_idx": 1376, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ffa0adb-082b-4f7f-a303-f26093681c93": {"__data__": {"id_": "9ffa0adb-082b-4f7f-a303-f26093681c93", "embedding": null, "metadata": {"window": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "original_text": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a490ddf-a10b-4641-8938-cb01dd03f681", "node_type": "1", "metadata": {"window": "If you adjust for these two prior year \nitems, the segment adjusted oper ating profit was up 3.5% year -over-year in the quarter.  \n \n Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "original_text": "On a year -to-date basis, the segment adjusted operating profit is up 7%. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d612d96aa3f19f1a7e192e05fcd1b69b6ff41f7d3727e9c14d26236b57886fa6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8a3001e4-b94d-4ad1-bbdd-16b73d496938", "node_type": "1", "metadata": {"window": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "original_text": "For the third quarter, brand price activity trended in line with our ex pectations. "}, "hash": "ead135fb3c79230737222216e8b95aaca6ded648abb087e726b778621ae7b13b", "class_name": "RelatedNodeInfo"}}, "text": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "start_char_idx": 1450, "end_char_idx": 1739, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8a3001e4-b94d-4ad1-bbdd-16b73d496938": {"__data__": {"id_": "8a3001e4-b94d-4ad1-bbdd-16b73d496938", "embedding": null, "metadata": {"window": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "original_text": "For the third quarter, brand price activity trended in line with our ex pectations. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ffa0adb-082b-4f7f-a303-f26093681c93", "node_type": "1", "metadata": {"window": "Also, as a reminder, this is the final quarter in which we are lapping the effects of the lost Shopko earnings, which \nwas approximately $8 million per quarter in terms of operating profit.  The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "original_text": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "32c5ea1ae6f5bfb7c114ae03f4177d19442e8938a23a49397bd9a3edcbba6a0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "59c62317-c987-4bc9-9ae3-6b9ba97e3c32", "node_type": "1", "metadata": {"window": "On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "original_text": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n"}, "hash": "c13480276cc1552cb136e3ce00d268a5647beb6dd00a8deef84157d01458db94", "class_name": "RelatedNodeInfo"}}, "text": "For the third quarter, brand price activity trended in line with our ex pectations. ", "start_char_idx": 1739, "end_char_idx": 1823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "59c62317-c987-4bc9-9ae3-6b9ba97e3c32": {"__data__": {"id_": "59c62317-c987-4bc9-9ae3-6b9ba97e3c32", "embedding": null, "metadata": {"window": "On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "original_text": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8a3001e4-b94d-4ad1-bbdd-16b73d496938", "node_type": "1", "metadata": {"window": "The segmen t adjusted operating margin rate \nwas 140 basis points, an increase of 6 basis points.  \n \n On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "original_text": "For the third quarter, brand price activity trended in line with our ex pectations. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8e3427979dbd3469d76d9730c854bb00ce382f974c6f7609017b8663cb4415a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae130a12-56f9-47da-8843-69fc5dbd0806", "node_type": "1", "metadata": {"window": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "original_text": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. "}, "hash": "161989052276c6c281e438f2d7314ebd8d3a7b3a840152f73871af83a090c4b8", "class_name": "RelatedNodeInfo"}}, "text": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "start_char_idx": 1823, "end_char_idx": 2025, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae130a12-56f9-47da-8843-69fc5dbd0806": {"__data__": {"id_": "ae130a12-56f9-47da-8843-69fc5dbd0806", "embedding": null, "metadata": {"window": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "original_text": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "59c62317-c987-4bc9-9ae3-6b9ba97e3c32", "node_type": "1", "metadata": {"window": "On a year -to-date basis, the segment adjusted operating profit is up 7%.  If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "original_text": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "41d8e70f7a88b694c67f056710238970eb4db45fe3d6807fa8e3ad8c80ad54a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23441e52-44e0-4aca-99b6-87554cff3158", "node_type": "1", "metadata": {"window": "For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "original_text": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n"}, "hash": "e2cbc0b1060150f567788af5ffb4e0b62409c743284f62c4c94991031cdbbc7a", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "start_char_idx": 2025, "end_char_idx": 2274, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23441e52-44e0-4aca-99b6-87554cff3158": {"__data__": {"id_": "23441e52-44e0-4aca-99b6-87554cff3158", "embedding": null, "metadata": {"window": "For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "original_text": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae130a12-56f9-47da-8843-69fc5dbd0806", "node_type": "1", "metadata": {"window": "If you adjust for the prior year impact of \nthe $60 million pre -tax charge related to the bankrup tcy of Shopko and the prior year earnings contribution of \napproximately $24 million from three quarters of Shopko results, segment adjusted operating profit increased 5% \nyear-to-date.  \n \n For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "original_text": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e95ee009fb3a018e5a70d8a588408a085678247000bba297eef9bb591ba45f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ba450eef-f988-4aa4-8d90-b9506732f14e", "node_type": "1", "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "original_text": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. "}, "hash": "b045eba397fc454625dd69f0e9bdfef001d48ea76c0c7d87b36e3d253a3bb611", "class_name": "RelatedNodeInfo"}}, "text": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "start_char_idx": 2274, "end_char_idx": 2544, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ba450eef-f988-4aa4-8d90-b9506732f14e": {"__data__": {"id_": "ba450eef-f988-4aa4-8d90-b9506732f14e", "embedding": null, "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "original_text": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23441e52-44e0-4aca-99b6-87554cff3158", "node_type": "1", "metadata": {"window": "For the third quarter, brand price activity trended in line with our ex pectations.  Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "original_text": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b6c81d4918a8590d979883099a62359cb71935912566a2c61df24cf724d45ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5befd3e-7a70-43a8-8128-49fcaa30ce8f", "node_type": "1", "metadata": {"window": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "original_text": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. "}, "hash": "aa6328117267fd9212d1eb31e8aee1565129928370a5675230e76c6d05f53afd", "class_name": "RelatedNodeInfo"}}, "text": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "start_char_idx": 2544, "end_char_idx": 2663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5befd3e-7a70-43a8-8128-49fcaa30ce8f": {"__data__": {"id_": "b5befd3e-7a70-43a8-8128-49fcaa30ce8f", "embedding": null, "metadata": {"window": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "original_text": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ba450eef-f988-4aa4-8d90-b9506732f14e", "node_type": "1", "metadata": {"window": "Additionally, based on \nmanufacturer price actions taken in January, we are maintaining our full year fiscal 2020 assumption of brand \nprice increases to be in the mid -single -digit percent range.  \n \n I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "original_text": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ef5aee7727ec9609ad3753e9541567875e44abbb6ee140d867d0afa3ad06b426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e5a024-aed3-46c9-880b-3d8ba57e8899", "node_type": "1", "metadata": {"window": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "original_text": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. "}, "hash": "1ff10dbcd9bdb9520c1be800016a4fc2bb2900c1e0b9977ec58d2bd7021329f1", "class_name": "RelatedNodeInfo"}}, "text": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "start_char_idx": 2663, "end_char_idx": 2792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e5a024-aed3-46c9-880b-3d8ba57e8899": {"__data__": {"id_": "79e5a024-aed3-46c9-880b-3d8ba57e8899", "embedding": null, "metadata": {"window": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "original_text": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5befd3e-7a70-43a8-8128-49fcaa30ce8f", "node_type": "1", "metadata": {"window": "I would remind you that our branded pharmaceutica l contracts are primarily fixed fee -for-service rate in nature and \nas a result, our compensation with branded manufacturers is less impacted by price increases when compared to \nseveral years ago.  To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "original_text": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "87c07824a83da9ce79224b61675a4121d62635b0864e0a654c9bfc29bb266ae7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "07861af3-e06f-499b-ad23-90c6ebf76ccf", "node_type": "1", "metadata": {"window": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "original_text": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n"}, "hash": "cf1fec0354c70dcfe83a76fc67a5f2db89a824a24ba500d59d18502ee0f4f87f", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "start_char_idx": 2792, "end_char_idx": 3008, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "07861af3-e06f-499b-ad23-90c6ebf76ccf": {"__data__": {"id_": "07861af3-e06f-499b-ad23-90c6ebf76ccf", "embedding": null, "metadata": {"window": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "original_text": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e5a024-aed3-46c9-880b-3d8ba57e8899", "node_type": "1", "metadata": {"window": "To wrap up this segment, given the underlying strength in th e quarter and the year -to-date \nperformance, we have confidence that segment adjusted operating profit growth will be on the high end of the \npreviously provided range of 3% to 5% growth for fiscal 2020.  \n \n Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "original_text": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "349a87e95ec447dee2b5cf0ee3e600c4ea88801288caef8dcadb358ff7b610de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed4b902-dad5-4b46-b4b6-0be887d6cfb6", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. "}, "hash": "c1d3935e042830ba99c48041f121ca041305b987e64a47cfbec9c2b4a9e00289", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "start_char_idx": 3008, "end_char_idx": 3133, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed4b902-dad5-4b46-b4b6-0be887d6cfb6": {"__data__": {"id_": "fed4b902-dad5-4b46-b4b6-0be887d6cfb6", "embedding": null, "metadata": {"window": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "07861af3-e06f-499b-ad23-90c6ebf76ccf", "node_type": "1", "metadata": {"window": "Next, European Pharmaceutical Solutions; revenues wer e $6.9 billion for the quarter, which was flat year -over-\nyear.  On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "original_text": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7325d8505de4cca7147b41ecaab2cc49e099737bd223da665174baac0af1110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "22c18147-d05e-4f80-9bd2-ce8db5f5232a", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n"}, "hash": "7b4d9083397ca22134387a9c8cb89ed065266573fb69e7639c6f6c7c908f6375", "class_name": "RelatedNodeInfo"}}, "text": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "start_char_idx": 3133, "end_char_idx": 3385, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "22c18147-d05e-4f80-9bd2-ce8db5f5232a": {"__data__": {"id_": "22c18147-d05e-4f80-9bd2-ce8db5f5232a", "embedding": null, "metadata": {"window": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed4b902-dad5-4b46-b4b6-0be887d6cfb6", "node_type": "1", "metadata": {"window": "On an FX -adjusted basis, revenues increased 3%, driven primarily by market growth in the pharmaceutical \ndistribution business.  Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "original_text": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb20b006f427dd5107c2cbc8a413f45dbe430f05180ea692113aac8f9cd2d216", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f077a5c1-6597-4231-9a83-69e4c536d82f", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. "}, "hash": "1a13ff3b417a1985122be1c3f6b6e77390eeb784263fa1dcd3e377d7a637a5cc", "class_name": "RelatedNodeInfo"}}, "text": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "start_char_idx": 3385, "end_char_idx": 3493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f077a5c1-6597-4231-9a83-69e4c536d82f": {"__data__": {"id_": "f077a5c1-6597-4231-9a83-69e4c536d82f", "embedding": null, "metadata": {"window": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "22c18147-d05e-4f80-9bd2-ce8db5f5232a", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit was up 16% to $80 million, drive n in part by lower \noperating expenses as a result of actions previously taken to rationalize store footprint and streamline back office \nfunctions.  The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "07eab8162555f8afb64baabb7dec9f5ff36dc4c77fa25050a252cdfbefac2c21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734f93e5-2f04-4f4a-8ff0-187c3e81cb49", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Year -to-date, \nthe segment adjusted operating profit  growth is 18%. "}, "hash": "91eff0793a542f7344cfad71f9e538c6f41c150beb348efd365737256b155f46", "class_name": "RelatedNodeInfo"}}, "text": "The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "start_char_idx": 3493, "end_char_idx": 3590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "734f93e5-2f04-4f4a-8ff0-187c3e81cb49": {"__data__": {"id_": "734f93e5-2f04-4f4a-8ff0-187c3e81cb49", "embedding": null, "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f077a5c1-6597-4231-9a83-69e4c536d82f", "node_type": "1", "metadata": {"window": "The segment adjusted operating margin rate was 116 basis points on a constant currency basis, an \nincrease of 16 points.  \n \n Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51140d13f95080b616c06b4fb800b0bda9418b27db8ab20b8e6b1d77dd7401ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "30aaeac0-3197-4a4c-8989-bf472c5572a1", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n "}, "hash": "64e161cc10a6210a1433f693cfd2f8a48f7339e18b254c7cd04d0f60d721b384", "class_name": "RelatedNodeInfo"}}, "text": "Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "start_char_idx": 3590, "end_char_idx": 3660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "30aaeac0-3197-4a4c-8989-bf472c5572a1": {"__data__": {"id_": "30aaeac0-3197-4a4c-8989-bf472c5572a1", "embedding": null, "metadata": {"window": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d", "node_type": "4", "metadata": {"page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c574bf5f87e036e6c538b52dd5c910a99100217ca0699d4eed31896340d44c0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734f93e5-2f04-4f4a-8ff0-187c3e81cb49", "node_type": "1", "metadata": {"window": "Moving now to Medical -Surgical Solutions, revenues were $2.1 billion for the quarter, which was up 6%, driven by \norganic growth led by the primary care business, including higher pharmaceutical volumes and an earlier start to \nthe influenza seas on.  Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "Year -to-date, \nthe segment adjusted operating profit  growth is 18%. ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3db72334ce84f0267a7262c6af178613fcfee3b9d2daf41af950778c574aa47f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "original_text": "McKesson Corp.  "}, "hash": "22baff04447a1d542f3bb0e7a97e9fa8fc9f4c9017325c24ed9b7b6eecc590ec", "class_name": "RelatedNodeInfo"}}, "text": "As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "start_char_idx": 3660, "end_char_idx": 3869, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4": {"__data__": {"id_": "d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "30aaeac0-3197-4a4c-8989-bf472c5572a1", "node_type": "1", "metadata": {"window": "Segment adjusted operating profit for the quarter was up 8% to $184 million, driven by \norganic growth.  \n \n The segment adjusted operating margin rate was 859 basis points, an increase of 14 basis points.  Year -to-date, \nthe segment adjusted operating profit  growth is 18%.  As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "original_text": "As a result of the organic growth in the segment year -to-\ndate, we now anticipate that the segment adjusted operating profit for fiscal 2020 will increase by a low -double -\ndigit percent year -over-year.  \n ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dced41f23eb368fa1a1ba339853983fe0bb0d7581ae91db17fcb69a2bc29c6d1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8940e8fc-f6a4-436b-a1a6-344cbc4ece08", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business. "}, "hash": "ea8ee9f8c5d71cba5be6956944b0554ad8c300c72cbf5167ff4fb72b2588d1f2", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8940e8fc-f6a4-436b-a1a6-344cbc4ece08": {"__data__": {"id_": "8940e8fc-f6a4-436b-a1a6-344cbc4ece08", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4de018761353ffdb2a6223cdab44dfed5b9cc75ddf8ac11a0082bd20d0058b79", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "original_text": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n"}, "hash": "8e791eadb91c03877dec82937c68ea927d05fa6ea79a351342a84f60075dc033", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business. ", "start_char_idx": 16, "end_char_idx": 359, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5": {"__data__": {"id_": "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "original_text": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8940e8fc-f6a4-436b-a1a6-344cbc4ece08", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "33eed1a5bcc8a0387831799d361443ec248f4e7c9e18c1c7f1a2d0251d6132bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "original_text": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. "}, "hash": "813e76628334d7915a10b18b649111e8e6095a9a0b1312110119b693d322383a", "class_name": "RelatedNodeInfo"}}, "text": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n", "start_char_idx": 359, "end_char_idx": 606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9": {"__data__": {"id_": "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "original_text": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "original_text": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "54affca04a6f841fcc1a4d232b8f8efcff60b0685dc9b8c6badc981fd23db8da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n", "original_text": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n"}, "hash": "097cd9a4e080eba0be16952839a73d26f48a2c2bb7d26148aae77db9b694522e", "class_name": "RelatedNodeInfo"}}, "text": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "start_char_idx": 606, "end_char_idx": 737, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf": {"__data__": {"id_": "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n", "original_text": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "original_text": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b2ae22cff0d1bb8570e77b10a6d67e1495b7ebca8faab71a619939b18b778d78", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4923a773-07b5-44fc-96f6-6d5861b4d140", "node_type": "1", "metadata": {"window": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "original_text": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. "}, "hash": "6395bafacc6434b373e3e7a70c46bc6389e2e8fd38c4be4b1b3d7fcdd3057857", "class_name": "RelatedNodeInfo"}}, "text": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "start_char_idx": 737, "end_char_idx": 906, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4923a773-07b5-44fc-96f6-6d5861b4d140": {"__data__": {"id_": "4923a773-07b5-44fc-96f6-6d5861b4d140", "embedding": null, "metadata": {"window": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "original_text": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n", "original_text": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "46627c2419ee0a6c351b0637cafb0377f70a5cdc66dc0d2ce627fefa0789d31e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a88e6803-8cae-4f38-8e4e-9b962c2795bc", "node_type": "1", "metadata": {"window": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "original_text": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner. "}, "hash": "84cdca9ca132f48664003419190577cb620c84d6fefc76cf32bd9b30c3f5ec8a", "class_name": "RelatedNodeInfo"}}, "text": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "start_char_idx": 906, "end_char_idx": 1090, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a88e6803-8cae-4f38-8e4e-9b962c2795bc": {"__data__": {"id_": "a88e6803-8cae-4f38-8e4e-9b962c2795bc", "embedding": null, "metadata": {"window": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "original_text": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4923a773-07b5-44fc-96f6-6d5861b4d140", "node_type": "1", "metadata": {"window": "Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "original_text": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c7f78075147b730e4f90f253455db3d351f9caadfcb49c651342cf561b89a981", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6ef4340-2a0d-411f-a2a9-7017b879bd8d", "node_type": "1", "metadata": {"window": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "original_text": "I direct you to today's filing for additional information.  \n \n"}, "hash": "706a15dd449d49846ea47b2a21e1779e6e02ed85a4bf83c3278ab28c3f155547", "class_name": "RelatedNodeInfo"}}, "text": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "start_char_idx": 1090, "end_char_idx": 1179, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6ef4340-2a0d-411f-a2a9-7017b879bd8d": {"__data__": {"id_": "a6ef4340-2a0d-411f-a2a9-7017b879bd8d", "embedding": null, "metadata": {"window": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "original_text": "I direct you to today's filing for additional information.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a88e6803-8cae-4f38-8e4e-9b962c2795bc", "node_type": "1", "metadata": {"window": "Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter.  As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "original_text": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ba12c047831dd5575534e8f139b550f2a91112a1755ded8f35c176682dcbe439", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39636ac3-7925-44f8-807e-7f2de9afd743", "node_type": "1", "metadata": {"window": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "original_text": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. "}, "hash": "db1cc089bcaeb25d5a4656da2840457ef62ed0cccacb890f1ba23bdc7492d9f5", "class_name": "RelatedNodeInfo"}}, "text": "I direct you to today's filing for additional information.  \n \n", "start_char_idx": 1179, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39636ac3-7925-44f8-807e-7f2de9afd743": {"__data__": {"id_": "39636ac3-7925-44f8-807e-7f2de9afd743", "embedding": null, "metadata": {"window": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "original_text": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6ef4340-2a0d-411f-a2a9-7017b879bd8d", "node_type": "1", "metadata": {"window": "As  a reminder, our equity investment ownership in Change Healthcare was approximately \n58.5% in our fiscal third quarter 2020 as compared to 70% in the prior year.  \n \n As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "original_text": "I direct you to today's filing for additional information.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "492a71b6d12af4851e0f78ee4f10ef1492c9cc25507a4a0d640ed684799918a4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "764eaee9-cfce-4812-a32a-b6047b1d44b5", "node_type": "1", "metadata": {"window": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "original_text": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. "}, "hash": "0f6c5bff57aa3e0e576fa670a5beab810cd7a4004e6c611879673ca7617c63b8", "class_name": "RelatedNodeInfo"}}, "text": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "start_char_idx": 1242, "end_char_idx": 1474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "764eaee9-cfce-4812-a32a-b6047b1d44b5": {"__data__": {"id_": "764eaee9-cfce-4812-a32a-b6047b1d44b5", "embedding": null, "metadata": {"window": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "original_text": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39636ac3-7925-44f8-807e-7f2de9afd743", "node_type": "1", "metadata": {"window": "As Brian mentioned earlier, registration statements were filed this morning with the SEC, disc losing our intention \nto exit our investment in Change Healthcare via an exchange offer.  This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "original_text": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72bff029bc0d7addd9437009252ceaf3927f4f8dbfb71a25850e211d73ded169", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76d53e28-9073-467c-a16e-0eb65ab094c6", "node_type": "1", "metadata": {"window": "I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "original_text": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n"}, "hash": "11adb7f74531bae9f265517bb45dd576bd4a3fe7b39b235fa644fe167537d7ec", "class_name": "RelatedNodeInfo"}}, "text": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "start_char_idx": 1474, "end_char_idx": 1606, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76d53e28-9073-467c-a16e-0eb65ab094c6": {"__data__": {"id_": "76d53e28-9073-467c-a16e-0eb65ab094c6", "embedding": null, "metadata": {"window": "I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "original_text": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "764eaee9-cfce-4812-a32a-b6047b1d44b5", "node_type": "1", "metadata": {"window": "This is the next step in the process to exit our \ninvestment in a tax -efficient manner.  I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "original_text": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "af716226d8635222f21aa8177810b95f02d188e58b7cd744676a6a43889c77a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a76f092-c9f2-41ee-a4b1-565e80fba1c3", "node_type": "1", "metadata": {"window": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "original_text": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. "}, "hash": "ac7633791286c6a9703c8b66b4e4e6ae752ca1eda9ccd950317b7d4a19e42c40", "class_name": "RelatedNodeInfo"}}, "text": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "start_char_idx": 1606, "end_char_idx": 1717, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a76f092-c9f2-41ee-a4b1-565e80fba1c3": {"__data__": {"id_": "7a76f092-c9f2-41ee-a4b1-565e80fba1c3", "embedding": null, "metadata": {"window": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "original_text": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76d53e28-9073-467c-a16e-0eb65ab094c6", "node_type": "1", "metadata": {"window": "I direct you to today's filing for additional information.  \n \n Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "original_text": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "503fef643b8853cc42347994b2e22be3667f63ca00c4d635d7c86f3453b43fc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "828c5cf3-e433-4bd5-ada4-b10f4ae36638", "node_type": "1", "metadata": {"window": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "original_text": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n"}, "hash": "6f1dc4ce2f47a10d37391701cb5e769bb060cd88d395833f3b4b651c3f6ab0ab", "class_name": "RelatedNodeInfo"}}, "text": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "start_char_idx": 1717, "end_char_idx": 1945, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "828c5cf3-e433-4bd5-ada4-b10f4ae36638": {"__data__": {"id_": "828c5cf3-e433-4bd5-ada4-b10f4ae36638", "embedding": null, "metadata": {"window": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "original_text": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a76f092-c9f2-41ee-a4b1-565e80fba1c3", "node_type": "1", "metadata": {"window": "Next, McKesson record ed $178 million in adjusted corporate expenses, which was an increase of 29% year -over-\nyear, driven primarily by planned technology investments, which included investments in data and analytic \ncapabilities.  For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "original_text": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "360491f4840fc2e731bada16d7b2b19262946ddb41a3577acbb28a7aef91cb0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc", "node_type": "1", "metadata": {"window": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "original_text": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n"}, "hash": "15b0cd2f50e4a31cc315649527864fa43fb7853125a0ccb223a85d836c71f58d", "class_name": "RelatedNodeInfo"}}, "text": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "start_char_idx": 1945, "end_char_idx": 2134, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc": {"__data__": {"id_": "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc", "embedding": null, "metadata": {"window": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "original_text": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "828c5cf3-e433-4bd5-ada4-b10f4ae36638", "node_type": "1", "metadata": {"window": "For the third quarter, we reported net opioid -related adjusted operating expenses of $36 million and, \nyear-to-date, $108 million.  For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "original_text": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aacf61775edb0591eddaad3fcdaa27acd77157096b2e613981c23ac5fcfc31da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e814365a-cf87-4e62-bdf2-27a6b001000e", "node_type": "1", "metadata": {"window": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "original_text": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. "}, "hash": "92eb78495b6dc63b6cb6540b8403d450b981b8d0e1ad41c405a7115c4617c945", "class_name": "RelatedNodeInfo"}}, "text": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "start_char_idx": 2134, "end_char_idx": 2460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e814365a-cf87-4e62-bdf2-27a6b001000e": {"__data__": {"id_": "e814365a-cf87-4e62-bdf2-27a6b001000e", "embedding": null, "metadata": {"window": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "original_text": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc", "node_type": "1", "metadata": {"window": "For fiscal 2020, we continue to anticipate that opioid -related costs will approximately \nbe $150 million.  \n \n We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "original_text": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bedeab16becd29c22f6f4f7b1cfc6ef23a15469814425cecf64618fedb178bd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d21b476-e84d-40c7-8e07-bc1df6b4db26", "node_type": "1", "metadata": {"window": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "original_text": "We feel really good abo ut \nour steady execution throughout fiscal 2020. "}, "hash": "3649f02277e31679662af06a168fa85c81361a267f06d3c2da960dde2b40a692", "class_name": "RelatedNodeInfo"}}, "text": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "start_char_idx": 2460, "end_char_idx": 2546, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d21b476-e84d-40c7-8e07-bc1df6b4db26": {"__data__": {"id_": "1d21b476-e84d-40c7-8e07-bc1df6b4db26", "embedding": null, "metadata": {"window": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "original_text": "We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e814365a-cf87-4e62-bdf2-27a6b001000e", "node_type": "1", "metadata": {"window": "We continue to make solid progress against our cost savings programs,  which include a focus on our core \noperating expenses, by leveraging the scale of our enterprise and the continued transformation of back office \nfunctions.  We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "original_text": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ea186321346c45e9f5a074aac9ce1078141a9c7dd159e2971d2c2e3f34e7507", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5015f498-7bdb-4b2f-895b-1eb560254d89", "node_type": "1", "metadata": {"window": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10. ", "original_text": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n"}, "hash": "983ad37e6c6a453015ac2d869583c4ff3968963115c788eb9640bc4ab90e58df", "class_name": "RelatedNodeInfo"}}, "text": "We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "start_char_idx": 2546, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5015f498-7bdb-4b2f-895b-1eb560254d89": {"__data__": {"id_": "5015f498-7bdb-4b2f-895b-1eb560254d89", "embedding": null, "metadata": {"window": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10. ", "original_text": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d21b476-e84d-40c7-8e07-bc1df6b4db26", "node_type": "1", "metadata": {"window": "We remain on track with our previously announced annual pre -tax savings of $400 million to $500 \nmillion, which is anticipated to be substantially delivered by the end of fiscal 2021.  \n \n As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "original_text": "We feel really good abo ut \nour steady execution throughout fiscal 2020. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c41c06ca97e386ca20c1b21d8826084e51b3e3f681c13f3389f5d02aadf80ae2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3670b3b9-5590-4458-8a60-5c4279bbcedd", "node_type": "1", "metadata": {"window": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n", "original_text": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n"}, "hash": "abaf347395646ef0439f8ec26712bcec788e7ef6a23f69f51fb872208f52206d", "class_name": "RelatedNodeInfo"}}, "text": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "start_char_idx": 2619, "end_char_idx": 3217, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3670b3b9-5590-4458-8a60-5c4279bbcedd": {"__data__": {"id_": "3670b3b9-5590-4458-8a60-5c4279bbcedd", "embedding": null, "metadata": {"window": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n", "original_text": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5015f498-7bdb-4b2f-895b-1eb560254d89", "node_type": "1", "metadata": {"window": "As we've discussed, a portion of these savings will be reinvested back into the business, in line with our growth \ninitiatives, and the remaining will flow to the bottom lin e. As a result of our performance year -to-date, we now \nanticipate adjusted corporate expenses to be in the range of $660 million to $700 million.  \n \n Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10. ", "original_text": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "497274e26b80fd4b0caaa585a704b03fd6d628bcac8c953b757c75a79f6b43b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0c87db11-0056-4b82-804b-16f244e990f2", "node_type": "1", "metadata": {"window": "We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations. ", "original_text": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n"}, "hash": "c91175f0776a73b08c9ab2d87eecb1c9a2b6b3171203c244a6697af56cc625dc", "class_name": "RelatedNodeInfo"}}, "text": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "start_char_idx": 3217, "end_char_idx": 3556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0c87db11-0056-4b82-804b-16f244e990f2": {"__data__": {"id_": "0c87db11-0056-4b82-804b-16f244e990f2", "embedding": null, "metadata": {"window": "We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations. ", "original_text": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3670b3b9-5590-4458-8a60-5c4279bbcedd", "node_type": "1", "metadata": {"window": "Now that I've wrapped up our results, let me discuss our updated fiscal 2020 outlook.  We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n", "original_text": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8d81449997b195207384fcfd845c30a4549f45d48bebe2c611a76c2c4ef94b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5ac47a27-70e3-420f-a760-184773eb0d82", "node_type": "1", "metadata": {"window": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "original_text": "Turning, now, to cash, which can be found on slide 10. "}, "hash": "2efb8370b7d0df2e241fbcaae275a75c0813e93c696e05f5bbe2957957bc6b1c", "class_name": "RelatedNodeInfo"}}, "text": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "start_char_idx": 3556, "end_char_idx": 3643, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5ac47a27-70e3-420f-a760-184773eb0d82": {"__data__": {"id_": "5ac47a27-70e3-420f-a760-184773eb0d82", "embedding": null, "metadata": {"window": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "original_text": "Turning, now, to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0c87db11-0056-4b82-804b-16f244e990f2", "node_type": "1", "metadata": {"window": "We feel really good abo ut \nour steady execution throughout fiscal 2020.  The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations. ", "original_text": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "241160631fcfe7abc90ed6578c3a1a72105db98ef130e10ad388696c261478bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3a1e6b18-9cb3-400c-8130-0237b470afd6", "node_type": "1", "metadata": {"window": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "original_text": "We ended the quarter with a cash balance of $2.1 billion. \n"}, "hash": "33ff88f8ec098d2459a9e0f558bd4f80cc0600904a38d20c1ec5d7171fb82fb1", "class_name": "RelatedNodeInfo"}}, "text": "Turning, now, to cash, which can be found on slide 10. ", "start_char_idx": 3643, "end_char_idx": 3698, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3a1e6b18-9cb3-400c-8130-0237b470afd6": {"__data__": {"id_": "3a1e6b18-9cb3-400c-8130-0237b470afd6", "embedding": null, "metadata": {"window": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "original_text": "We ended the quarter with a cash balance of $2.1 billion. \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5ac47a27-70e3-420f-a760-184773eb0d82", "node_type": "1", "metadata": {"window": "The recent narrowing and increase to our fiscal 2020 adjusted \nearnings per diluted share to a range of $14.60 to $14.80 reflects the following: solid core performance in our US \nPharmaceutical and Specialty So lutions segment, driven by continued strength across our differentiated portfolio \nof specialty businesses; organic growth in our Medical -Surgical segment; improved second half performance in \nour European segment as compared to the prior year; lower corpora te expenses than originally anticipated; and, \na lower share count as a result of share repurchase activity year -to-date.  \n \n This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "original_text": "Turning, now, to cash, which can be found on slide 10. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fbff84cd1ae9db82378a6c3b5b4ad88184bc861d9fb7aea5ae5ff97b5093eb25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d", "node_type": "1", "metadata": {"window": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "In the quarter, McKesson used $121 million in cash flow from operations. "}, "hash": "038eef57b31ef61421ee98d4ff25e1a982dcc89c7824490da8ca370884e95bd5", "class_name": "RelatedNodeInfo"}}, "text": "We ended the quarter with a cash balance of $2.1 billion. \n", "start_char_idx": 3698, "end_char_idx": 3757, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d": {"__data__": {"id_": "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d", "embedding": null, "metadata": {"window": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "In the quarter, McKesson used $121 million in cash flow from operations. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3a1e6b18-9cb3-400c-8130-0237b470afd6", "node_type": "1", "metadata": {"window": "This solid performance was partially mitigated by continued planned investments in strategic initiatives, including \nincremental second  half investment in our differentiated oncology and manufacturer services businesses; \ninvestment in our technology products; and, investment in technology infrastructure, including data and analytics. \n We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "original_text": "We ended the quarter with a cash balance of $2.1 billion. \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6e42db7c84b9f80f4408d31a4359fb7e6ba1dc75fdf6bfa48506dffc74fdff9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71195d66-4360-4c68-aa2f-9d248705a566", "node_type": "1", "metadata": {"window": "Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n"}, "hash": "ee3913a0860c18194c40482c1f7800be05bf45e2b6a39686a8f95f610d4338b0", "class_name": "RelatedNodeInfo"}}, "text": "In the quarter, McKesson used $121 million in cash flow from operations. ", "start_char_idx": 3757, "end_char_idx": 3830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71195d66-4360-4c68-aa2f-9d248705a566": {"__data__": {"id_": "71195d66-4360-4c68-aa2f-9d248705a566", "embedding": null, "metadata": {"window": "Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d", "node_type": "1", "metadata": {"window": "We remain confident that we are well positioned to exec ute in our fourth quarter.  \n \n Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "In the quarter, McKesson used $121 million in cash flow from operations. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec4d321ffcf5d3ed6d63fb15b9d66e57ccf49602e3f038e5ef8574450217ae21", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0e396e3-e950-4a93-b5a2-ca91df50c827", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. "}, "hash": "045361f0b2dc552537225280889e369e50ca84b13171b88680b8e2b97e5e9729", "class_name": "RelatedNodeInfo"}}, "text": "After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "start_char_idx": 3830, "end_char_idx": 3951, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0e396e3-e950-4a93-b5a2-ca91df50c827": {"__data__": {"id_": "d0e396e3-e950-4a93-b5a2-ca91df50c827", "embedding": null, "metadata": {"window": "We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71195d66-4360-4c68-aa2f-9d248705a566", "node_type": "1", "metadata": {"window": "Turning, now, to cash, which can be found on slide 10.  We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5eb15d29790f1f1bab1e2d90513fce613cdf4b3886e54e47dae06a53ae742e70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "045ece9a-a56f-42ac-a275-9fbb02aa6a32", "node_type": "1", "metadata": {"window": "In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "It is  not uncommon to experience net use of cash "}, "hash": "9ab19c14a0bda38463ab40853ef9cc55334bd9fa87f7859238652ac5edfe81e8", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "start_char_idx": 3951, "end_char_idx": 4128, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "045ece9a-a56f-42ac-a275-9fbb02aa6a32": {"__data__": {"id_": "045ece9a-a56f-42ac-a275-9fbb02aa6a32", "embedding": null, "metadata": {"window": "In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "It is  not uncommon to experience net use of cash ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd", "node_type": "4", "metadata": {"page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73e9379df110c59c3c296be4c76386e46ad99c885ab5a35fc7a433cb3e938bea", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0e396e3-e950-4a93-b5a2-ca91df50c827", "node_type": "1", "metadata": {"window": "We ended the quarter with a cash balance of $2.1 billion. \n In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter. ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a74806af4099dcbf1abaceda17f095a9ada0fa19a0c982f3e82f38356a2646a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6220d97-f3e3-4476-a7b8-4168008e3bcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock. ", "original_text": "McKesson Corp.  "}, "hash": "5cfe191c2aafe6b76ef81b4bc07dffa873ff677c3d7c9920bea73a6a875b18c8", "class_name": "RelatedNodeInfo"}}, "text": "It is  not uncommon to experience net use of cash ", "start_char_idx": 4128, "end_char_idx": 4178, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6220d97-f3e3-4476-a7b8-4168008e3bcd": {"__data__": {"id_": "f6220d97-f3e3-4476-a7b8-4168008e3bcd", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "045ece9a-a56f-42ac-a275-9fbb02aa6a32", "node_type": "1", "metadata": {"window": "In the quarter, McKesson used $121 million in cash flow from operations.  After deducting $154 million in internal \ncapital investments, McKesson had negative free cash flow of $275 million.  \n \n I would remind you that our working capital metrics and resulting cash flow may be impacted by timing, including \nthe day of the week that marks the close of the given quarter.  It is  not uncommon to experience net use of cash ", "original_text": "It is  not uncommon to experience net use of cash ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c65a92d6f0fdb1435d8ff3d31e8de52dc164c6a8aaa5a1b1b532e115da75de89", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f759ef81-8c94-4bb9-bae6-50dd8480a3de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season. "}, "hash": "66304b367b0a84260ae7655aa1b2cd856448c33cebe9bd742fb6e0d31845869c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f759ef81-8c94-4bb9-bae6-50dd8480a3de": {"__data__": {"id_": "f759ef81-8c94-4bb9-bae6-50dd8480a3de", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6220d97-f3e3-4476-a7b8-4168008e3bcd", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "996529d4632342a799040607f07e2c0af0482ea42f342e2d565a37c7fd0c72a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cea36626-5b03-4fc4-92f4-8e10213d70f4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "original_text": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n"}, "hash": "7080a9f4fa1dacd838c21b95a0439a70bbdb883f1dd87da9b5663fabef7f7110", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season. ", "start_char_idx": 16, "end_char_idx": 281, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cea36626-5b03-4fc4-92f4-8e10213d70f4": {"__data__": {"id_": "cea36626-5b03-4fc4-92f4-8e10213d70f4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "original_text": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f759ef81-8c94-4bb9-bae6-50dd8480a3de", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cef5546e015dc567c420ed3b418d39bb8e0c2eafe8f0ad618400f87afbe8e4f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ed9e29ee-e3f2-494e-9119-1b524a033d72", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "original_text": "During the quarter, we repurchased approximately $500 million of common stock. "}, "hash": "f2e4a2e7cdba85f9576f77dd085b40a69d0aebad82fbd2e6a58447bd8e46aa1e", "class_name": "RelatedNodeInfo"}}, "text": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n", "start_char_idx": 281, "end_char_idx": 395, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ed9e29ee-e3f2-494e-9119-1b524a033d72": {"__data__": {"id_": "ed9e29ee-e3f2-494e-9119-1b524a033d72", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "original_text": "During the quarter, we repurchased approximately $500 million of common stock. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cea36626-5b03-4fc4-92f4-8e10213d70f4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "original_text": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d1935626361d9aa86582ecb177bddc2def5f9c866faddab09993c2cfd2f6af6a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7db2c06-bbd8-43da-8338-c58a96b2f424", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "original_text": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. "}, "hash": "8afdc3a2259473cbf59a3925317bca182a233d0dbbcff1e05d8966a6ba3a2e3e", "class_name": "RelatedNodeInfo"}}, "text": "During the quarter, we repurchased approximately $500 million of common stock. ", "start_char_idx": 395, "end_char_idx": 474, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7db2c06-bbd8-43da-8338-c58a96b2f424": {"__data__": {"id_": "f7db2c06-bbd8-43da-8338-c58a96b2f424", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "original_text": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ed9e29ee-e3f2-494e-9119-1b524a033d72", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "original_text": "During the quarter, we repurchased approximately $500 million of common stock. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecdd43388dd5c019dd3bd0d153cf52b6f3679d3c8103188d943dc01fdc1c6204", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb13e694-e17c-417a-b15e-2872476b874b", "node_type": "1", "metadata": {"window": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "original_text": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. "}, "hash": "4858556dc3da6c51a0f25a5d58622aa17d5a3d223498996d45f5a527168fa745", "class_name": "RelatedNodeInfo"}}, "text": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "start_char_idx": 474, "end_char_idx": 586, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb13e694-e17c-417a-b15e-2872476b874b": {"__data__": {"id_": "eb13e694-e17c-417a-b15e-2872476b874b", "embedding": null, "metadata": {"window": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "original_text": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7db2c06-bbd8-43da-8338-c58a96b2f424", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "original_text": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d0e9dd7f46dea4ba0b2aa1426ffa99d3bf35ba0c860974de6db697b1e6cbc784", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4b382532-e5b4-4adf-8597-1492976992ff", "node_type": "1", "metadata": {"window": "During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "original_text": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n"}, "hash": "247a7d7025cdec3e8f1980878789be35e708a3e4cbfb3086312964f7db7f42af", "class_name": "RelatedNodeInfo"}}, "text": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "start_char_idx": 586, "end_char_idx": 682, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4b382532-e5b4-4adf-8597-1492976992ff": {"__data__": {"id_": "4b382532-e5b4-4adf-8597-1492976992ff", "embedding": null, "metadata": {"window": "During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "original_text": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb13e694-e17c-417a-b15e-2872476b874b", "node_type": "1", "metadata": {"window": "In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "original_text": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c042f2c6666112d1c898cf1cd0517bd2b3bd92a1feef95094190db56c3a3e056", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dd8fe1f0-c710-49c7-9c95-23e51415f0e9", "node_type": "1", "metadata": {"window": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "original_text": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. "}, "hash": "de2cc35edb7644fe3423af7df083df4d7450695c0e8828967f494da951402fc0", "class_name": "RelatedNodeInfo"}}, "text": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "start_char_idx": 682, "end_char_idx": 792, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dd8fe1f0-c710-49c7-9c95-23e51415f0e9": {"__data__": {"id_": "dd8fe1f0-c710-49c7-9c95-23e51415f0e9", "embedding": null, "metadata": {"window": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "original_text": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4b382532-e5b4-4adf-8597-1492976992ff", "node_type": "1", "metadata": {"window": "During the quarter, we repurchased approximately $500 million of common stock.  We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "original_text": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "310ebe90f9bda4fced9497a1720abcfe93ed0c986d641735a1f5828c1c50b2b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5", "node_type": "1", "metadata": {"window": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "original_text": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n"}, "hash": "8f5cfa932087b93e684481c4faf07b23e26ea9b2b3c005b53a2925ab18e075c5", "class_name": "RelatedNodeInfo"}}, "text": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "start_char_idx": 792, "end_char_idx": 912, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5": {"__data__": {"id_": "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5", "embedding": null, "metadata": {"window": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "original_text": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dd8fe1f0-c710-49c7-9c95-23e51415f0e9", "node_type": "1", "metadata": {"window": "We've now repurchased \napproximately $1.9 billion in common stock for the first nine months of the fiscal year.  The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "original_text": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eee6ff967cd3f5d4552729a2194c4abc37fee4b3b3f946ad800d598c24909f43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8", "node_type": "1", "metadata": {"window": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. "}, "hash": "f63af646d37a741a2060918e919d7d12a155fa13a8df3402924af4704056abb9", "class_name": "RelatedNodeInfo"}}, "text": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "start_char_idx": 912, "end_char_idx": 1101, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8": {"__data__": {"id_": "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8", "embedding": null, "metadata": {"window": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5", "node_type": "1", "metadata": {"window": "The repurchase of our \ncommon stock underpins our belief that McKesson  shares are undervalued.  Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "original_text": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "197cb4d564fab4c85d98b36ab8e05195ab4bacd89528902d20216e0be133c254", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "71b4b3f9-74fe-4873-ad8a-fa426117bc13", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n"}, "hash": "6991e5094deff76d4c9450b5bd319d3eedb951fb391e79c1733449e18453739b", "class_name": "RelatedNodeInfo"}}, "text": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "start_char_idx": 1101, "end_char_idx": 1228, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "71b4b3f9-74fe-4873-ad8a-fa426117bc13": {"__data__": {"id_": "71b4b3f9-74fe-4873-ad8a-fa426117bc13", "embedding": null, "metadata": {"window": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8", "node_type": "1", "metadata": {"window": "Combined with the confidence in our \nexecution and our outlook, we view this as a prudent use of capital.  \n \n For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions. ", "original_text": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0f07ce5cff1969ddc7aec7f7117263499b0f8df08a649bca20b1cd821cc98c77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e800dc3c-88b9-4eeb-813d-387467f9c46d", "node_type": "1", "metadata": {"window": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n ", "original_text": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n"}, "hash": "e5f9841e43e63a2c5ebdd4bbbdcb73bce92e19ec565dd01730106003afda7665", "class_name": "RelatedNodeInfo"}}, "text": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "start_char_idx": 1228, "end_char_idx": 1480, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e800dc3c-88b9-4eeb-813d-387467f9c46d": {"__data__": {"id_": "e800dc3c-88b9-4eeb-813d-387467f9c46d", "embedding": null, "metadata": {"window": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n ", "original_text": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "71b4b3f9-74fe-4873-ad8a-fa426117bc13", "node_type": "1", "metadata": {"window": "For the first nine months of the fiscal year, McKesson paid $97 million for acquisition and $222 million in \ndividends.  We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "original_text": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ab9637caa4607c30a7860005dc8fb9df377078b774a869ab206c401a012446e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e50ab97e-e560-4f56-abfb-30b67e8327db", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "With that, I'll turn the call over to the operator for your questions. "}, "hash": "a5943e7f58e9ab7253e98388dfacf8c07c85a954a12f0e74c44114a6f3cca092", "class_name": "RelatedNodeInfo"}}, "text": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "start_char_idx": 1480, "end_char_idx": 1728, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e50ab97e-e560-4f56-abfb-30b67e8327db": {"__data__": {"id_": "e50ab97e-e560-4f56-abfb-30b67e8327db", "embedding": null, "metadata": {"window": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e800dc3c-88b9-4eeb-813d-387467f9c46d", "node_type": "1", "metadata": {"window": "We now  expect internal capital investment to be in the range of $500 million to $600 million, and we \ncontinue to anticipate free cash flow in the range of $2.8 billion to $3 billion.  \n \n In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n ", "original_text": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9bf9930097049cafb63e8768bba4eca4d824a61f82901df48aaa980e71155ee1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0878bc9-cd3b-48db-b3e8-0939bacccb8e", "node_type": "1", "metadata": {"window": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. "}, "hash": "01ecf5ab34364132deb5e7724a9abec8308b63c9a90d4cfc32a999a1b0560483", "class_name": "RelatedNodeInfo"}}, "text": "With that, I'll turn the call over to the operator for your questions. ", "start_char_idx": 1728, "end_char_idx": 1799, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0878bc9-cd3b-48db-b3e8-0939bacccb8e": {"__data__": {"id_": "b0878bc9-cd3b-48db-b3e8-0939bacccb8e", "embedding": null, "metadata": {"window": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e50ab97e-e560-4f56-abfb-30b67e8327db", "node_type": "1", "metadata": {"window": "In closing, we are pleased with the solid operational results of our fiscal th ird quarter and our performance year -\nto-date.  We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "original_text": "With that, I'll turn the call over to the operator for your questions. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a43034a0e59a8094275b551412b6defb26e1afc9325b8185bb025d60d5f1010e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c72e871-2ca3-4588-a274-4678ef501f58", "node_type": "1", "metadata": {"window": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n ", "original_text": "Operator?  \n "}, "hash": "3eeda05a718c4345c7fd233e4d7602b84788f51444045758583ada37dc53f6de", "class_name": "RelatedNodeInfo"}}, "text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "start_char_idx": 1799, "end_char_idx": 1944, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c72e871-2ca3-4588-a274-4678ef501f58": {"__data__": {"id_": "7c72e871-2ca3-4588-a274-4678ef501f58", "embedding": null, "metadata": {"window": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n ", "original_text": "Operator?  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0878bc9-cd3b-48db-b3e8-0939bacccb8e", "node_type": "1", "metadata": {"window": "We will build on our third quarter performance and we remain confident in our business as we focus on a \nstrong finish to the year, which is reflected in our expected adjusted earnings per diluted share range of  $14.60 to \n$14.80 for fiscal 2020.  \n \n As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "original_text": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4d8917070f2a179ff732c370b7fce94af0246ce440b622bd56fce4c72445341", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d354dd42-7bea-4cf7-8a21-f9e80013c92e", "node_type": "1", "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. "}, "hash": "4e2d98deb25632dcf5154c00c652a5f5c42e7b93b6e4580427de213cfdaf7030", "class_name": "RelatedNodeInfo"}}, "text": "Operator?  \n ", "start_char_idx": 1944, "end_char_idx": 1957, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d354dd42-7bea-4cf7-8a21-f9e80013c92e": {"__data__": {"id_": "d354dd42-7bea-4cf7-8a21-f9e80013c92e", "embedding": null, "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c72e871-2ca3-4588-a274-4678ef501f58", "node_type": "1", "metadata": {"window": "As I look at our performance over the past several quarters and our outlook for the remainder of fiscal 2020, it \nclearly demonstrates focus and execution against our strategy as well as continued steady improvement in ou r \nfinancial results.  \n \n With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n ", "original_text": "Operator?  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "925cbcbb41f7ce17b9f743fb8dd40c8ae2d20d76a541aee2502ed77dc3524442", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7e44c3f3-b322-4f4b-888f-808343121ff6", "node_type": "1", "metadata": {"window": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n"}, "hash": "a247edfd09d04d71d60131d458815611e7d81394d28f082b4c120cbd6b29ce12", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "start_char_idx": 1957, "end_char_idx": 2286, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7e44c3f3-b322-4f4b-888f-808343121ff6": {"__data__": {"id_": "7e44c3f3-b322-4f4b-888f-808343121ff6", "embedding": null, "metadata": {"window": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d354dd42-7bea-4cf7-8a21-f9e80013c92e", "node_type": "1", "metadata": {"window": "With that, I'll turn the call over to the operator for your questions.  In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d62c6e2e6191c057acf2bd14da02626166a22224747da4603d6c0766daf6129", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20565ee-21f9-45a1-9b2d-297fbd4bad17", "node_type": "1", "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Your line is open.  \n "}, "hash": "3b53bbaf4442ec3053a5e6ba016165ca8cec9667710f82624ca8f0a1a932521a", "class_name": "RelatedNodeInfo"}}, "text": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "start_char_idx": 2286, "end_char_idx": 2375, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20565ee-21f9-45a1-9b2d-297fbd4bad17": {"__data__": {"id_": "c20565ee-21f9-45a1-9b2d-297fbd4bad17", "embedding": null, "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Your line is open.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7e44c3f3-b322-4f4b-888f-808343121ff6", "node_type": "1", "metadata": {"window": "In the interest of time, I ask you to limit yourself \nto just one question and a brief follow -up to allow others an opportunity to participate.  Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah. ", "original_text": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b8eb5b1467048a3d1b93cbd784a5b08f7d1c28f4dc95abf91e6cec9d4108f34e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "bde5733ffc9080a4cbd92435e8dd6be414b1babb70a2357a0f8ab0c6291e5cd4", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 2375, "end_char_idx": 2397, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc": {"__data__": {"id_": "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20565ee-21f9-45a1-9b2d-297fbd4bad17", "node_type": "1", "metadata": {"window": "Operator?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question. ", "original_text": "Your line is open.  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2169249927767eb7a0068329b04d95c124fa65afac0f4743be7813fb16cf08ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eff013ec-06b2-4fca-a201-14f02990da77", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated? ", "original_text": "LLC  Q \nYeah. "}, "hash": "987c6b6de5a6cf62e861695eef4d2b443cc1f4a4480510e1090ac2d91a4e142a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 2397, "end_char_idx": 2706, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eff013ec-06b2-4fca-a201-14f02990da77": {"__data__": {"id_": "eff013ec-06b2-4fca-a201-14f02990da77", "embedding": null, "metadata": {"window": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated? ", "original_text": "LLC  Q \nYeah. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nQUESTION AND ANSWER SECTION  \n  \nOperator : Thank you.  [Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f9bec8dbed3abd76b792f54d12c1ff40d562d60c4d74382c43ce576160df18b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b5c7e6c3-1f77-4346-a3fb-b983e5073497", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "original_text": "Thanks for taking the question. "}, "hash": "bde8e69881ca5dcae1aa01692e5ba168ebad44a7a293521a45f3bca52a64c265", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah. ", "start_char_idx": 2706, "end_char_idx": 2720, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b5c7e6c3-1f77-4346-a3fb-b983e5073497": {"__data__": {"id_": "b5c7e6c3-1f77-4346-a3fb-b983e5073497", "embedding": null, "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "original_text": "Thanks for taking the question. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eff013ec-06b2-4fca-a201-14f02990da77", "node_type": "1", "metadata": {"window": "[Operator Instructions] And our first question will come from Charles Rhyee with Cowen. \n Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated? ", "original_text": "LLC  Q \nYeah. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da8a9d84e131111b1eeb05e4d56a64c74c48b939d6e17a076ccfa537ad6a1ef1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "11c9deb7-f056-4afe-8b89-35e5b4862260", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "original_text": "Maybe, Brian, we  could start with just on opioids, real quickly. "}, "hash": "a8db808abea3b1f7fe046c861ebfa0b98cc9310a70be3088b5fc964580a07bd8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for taking the question. ", "start_char_idx": 2720, "end_char_idx": 2752, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "11c9deb7-f056-4afe-8b89-35e5b4862260": {"__data__": {"id_": "11c9deb7-f056-4afe-8b89-35e5b4862260", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "original_text": "Maybe, Brian, we  could start with just on opioids, real quickly. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b5c7e6c3-1f77-4346-a3fb-b983e5073497", "node_type": "1", "metadata": {"window": "Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "original_text": "Thanks for taking the question. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a24bf52dd46563887d5134eeac2be7749e26ebeccfea4cd550b8d402e7851582", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6615aaf-dd52-4efa-b8c3-784181d6ccd7", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "original_text": "What are the \nremaining points that are being negotiated? "}, "hash": "b2def9cc3a90ab796d2148a3cf0a627e0e1ed0bdd8c70d49d2a62743d9b229c3", "class_name": "RelatedNodeInfo"}}, "text": "Maybe, Brian, we  could start with just on opioids, real quickly. ", "start_char_idx": 2752, "end_char_idx": 2818, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6615aaf-dd52-4efa-b8c3-784181d6ccd7": {"__data__": {"id_": "f6615aaf-dd52-4efa-b8c3-784181d6ccd7", "embedding": null, "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "original_text": "What are the \nremaining points that are being negotiated? ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "11c9deb7-f056-4afe-8b89-35e5b4862260", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "original_text": "Maybe, Brian, we  could start with just on opioids, real quickly. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b57838969a09d71735cb363c2885e73c689c73d07b8fd5ccf547e4098d7a4354", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4623f08-6ccc-490d-9b2d-cb49a01d139f", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "original_text": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. "}, "hash": "124791ca2de2aabaa470a08ce32c0087aceee2ab7c8bc30925a271a74c85fce3", "class_name": "RelatedNodeInfo"}}, "text": "What are the \nremaining points that are being negotiated? ", "start_char_idx": 2818, "end_char_idx": 2876, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4623f08-6ccc-490d-9b2d-cb49a01d139f": {"__data__": {"id_": "c4623f08-6ccc-490d-9b2d-cb49a01d139f", "embedding": null, "metadata": {"window": "Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "original_text": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6615aaf-dd52-4efa-b8c3-784181d6ccd7", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah.  Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "original_text": "What are the \nremaining points that are being negotiated? ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94e64a1e15856df825990bc1522abae1ed24a458da6b7dc86bc75f1c25b2dee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab", "node_type": "1", "metadata": {"window": "Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "original_text": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. "}, "hash": "63b45afb53d2907080953ccd797aaf5403a04d26db8a4a0f30fc665825f54544", "class_name": "RelatedNodeInfo"}}, "text": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "start_char_idx": 2876, "end_char_idx": 3004, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab": {"__data__": {"id_": "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab", "embedding": null, "metadata": {"window": "Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "original_text": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4623f08-6ccc-490d-9b2d-cb49a01d139f", "node_type": "1", "metadata": {"window": "Thanks for taking the question.  Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "original_text": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9823dd9a62146de6cec841572cbb75218b67b99052942526f757e64be01f6bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3ce55e8e-199e-47b3-a008-4610ffa6ab86", "node_type": "1", "metadata": {"window": "What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n"}, "hash": "0a7cd6baa7407a585848a726b30cb7b506e67a6dcf869dc1cdf9199ee0c38c41", "class_name": "RelatedNodeInfo"}}, "text": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "start_char_idx": 3004, "end_char_idx": 3103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3ce55e8e-199e-47b3-a008-4610ffa6ab86": {"__data__": {"id_": "3ce55e8e-199e-47b3-a008-4610ffa6ab86", "embedding": null, "metadata": {"window": "What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab", "node_type": "1", "metadata": {"window": "Maybe, Brian, we  could start with just on opioids, real quickly.  What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "original_text": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps. ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fa03527990194b7dca01c5e46c52ac7247f9bdb744e083231c221d030feb8622", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28334526-9b98-4d91-a66b-80c6e07359e2", "node_type": "1", "metadata": {"window": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? "}, "hash": "1fc21b6234109ee99e1b610fd57af5fdcba2a3cbf3de41e32ef96cee397699c8", "class_name": "RelatedNodeInfo"}}, "text": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "start_char_idx": 3103, "end_char_idx": 3263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28334526-9b98-4d91-a66b-80c6e07359e2": {"__data__": {"id_": "28334526-9b98-4d91-a66b-80c6e07359e2", "embedding": null, "metadata": {"window": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3ce55e8e-199e-47b3-a008-4610ffa6ab86", "node_type": "1", "metadata": {"window": "What are the \nremaining points that are being negotiated?  You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2df716cbfb1218f5e22248edbdead57ade29d0b01f60b095db57f390b8356ae8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7c880145-9e52-419a-9139-66fefcc0d15c", "node_type": "1", "metadata": {"window": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n "}, "hash": "54b3cb9a362c2b3f9d6e202ab59880f9946f7d4eaa2bd07dbdf7a812bd4d448a", "class_name": "RelatedNodeInfo"}}, "text": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "start_char_idx": 3263, "end_char_idx": 3676, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7c880145-9e52-419a-9139-66fefcc0d15c": {"__data__": {"id_": "7c880145-9e52-419a-9139-66fefcc0d15c", "embedding": null, "metadata": {"window": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28334526-9b98-4d91-a66b-80c6e07359e2", "node_type": "1", "metadata": {"window": "You kind of said that the negotiations are going well or it seems to be \nprogressing and some of the points are being resolved.  Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem? ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ecc503d7a878aa2248e9d8a426ffb7fab5376f7748b04764d6b5ce48a9f5fc3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1858fe23-6034-4043-ab60-068fd05d6c88", "node_type": "1", "metadata": {"window": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "2bfdf52edcc02b9c436fc2cd2fe165ac3412a357591030b81da9ca3a7497c278", "class_name": "RelatedNodeInfo"}}, "text": "Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "start_char_idx": 3676, "end_char_idx": 3764, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1858fe23-6034-4043-ab60-068fd05d6c88": {"__data__": {"id_": "1858fe23-6034-4043-ab60-068fd05d6c88", "embedding": null, "metadata": {"window": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7c880145-9e52-419a-9139-66fefcc0d15c", "node_type": "1", "metadata": {"window": "Maybe you can give us a  sense of what are some of the \nremaining kind of sticking points perhaps.  And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4997022521a15ab1e034be3feec02e1a11abacc0e7edf28bee2629f64dfd0dbe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27be2fe9-5ada-405d-b99c-4ae10007b93a", "node_type": "1", "metadata": {"window": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A "}, "hash": "7d94661bbbdb139ab6cb8296b1b1796b24fcb7128b3a6e84012228f33505dddb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3764, "end_char_idx": 4105, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27be2fe9-5ada-405d-b99c-4ae10007b93a": {"__data__": {"id_": "27be2fe9-5ada-405d-b99c-4ae10007b93a", "embedding": null, "metadata": {"window": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9", "node_type": "4", "metadata": {"page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6671515eeaf31b432b223378eef875feb8a9631fadfc3091c94a34694216e28b", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1858fe23-6034-4043-ab60-068fd05d6c88", "node_type": "1", "metadata": {"window": "And if I understand correctly, the framework is being discussed among \n\u2013 or is being led by four state attorney generals (sic) [attorneys general] (31:55).  \n \n During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3befd6336bcef87013b3ca2296affc63714eaa8c76e12e3bb3a88ad6c6fea034", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "18b4c702-a1e2-45a3-8047-8c242fc171d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs. ", "original_text": "McKesson Corp.  "}, "hash": "06257c03dbeded9c9c5d50140ad35f293d5ce8c9410e48b19f3add497074b59a", "class_name": "RelatedNodeInfo"}}, "text": "A ", "start_char_idx": 4105, "end_char_idx": 4107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "18b4c702-a1e2-45a3-8047-8c242fc171d1": {"__data__": {"id_": "18b4c702-a1e2-45a3-8047-8c242fc171d1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27be2fe9-5ada-405d-b99c-4ae10007b93a", "node_type": "1", "metadata": {"window": "During these kind of discu ssions, are the other constituents, let's say, the other states or some of the bigger \nmunicipalities that are in this lawsuit or part of this multi -district litigation, are they able to sort of see the progress \nas well and understand what is being kind of negotiated so that when we get to maybe a final framework, the \nprocess for them to review and to accept is kind of in tandem?  Or is this kind of being done in kind of a closed \nsession and then opened up later?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A ", "original_text": "A ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c7b268f467625f12912e0d5627611f3fce41f6010f328069a0f9505aa82968a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "537bdb29-b92b-4d05-914a-8b9ef412f126", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles. "}, "hash": "ea9905bb03d1afe9a8897c1c2878ac6fdfda06c4bb5e98a65cad46734d7db659", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "537bdb29-b92b-4d05-914a-8b9ef412f126": {"__data__": {"id_": "537bdb29-b92b-4d05-914a-8b9ef412f126", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "18b4c702-a1e2-45a3-8047-8c242fc171d1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "071f7289042f7df4c4802fe802be430f8442d51b4387505dc8a74cc12d63fdcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "original_text": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n"}, "hash": "e576390a9da1d21956c1faae2ad3ad343c246d1f7cbbb54184da4566ea04d0fe", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles. ", "start_char_idx": 16, "end_char_idx": 218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686": {"__data__": {"id_": "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "original_text": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "537bdb29-b92b-4d05-914a-8b9ef412f126", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a760b42d270b83de7a5b1a4cdf7b43cfc00cb0735b79ef0e5df15807f0f2345", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af21af63-0494-4425-be67-03432ec7c351", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "original_text": "We do continue to be in constructive dialogue with the AGs. "}, "hash": "ac3ca7600b3315bcca67ffb7cda48a00003b430b17f0222317c46bce7c74420b", "class_name": "RelatedNodeInfo"}}, "text": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n", "start_char_idx": 218, "end_char_idx": 413, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af21af63-0494-4425-be67-03432ec7c351": {"__data__": {"id_": "af21af63-0494-4425-be67-03432ec7c351", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "original_text": "We do continue to be in constructive dialogue with the AGs. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "original_text": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a005a527d0334cebd6271628cb9fb26beaab402d6bf277add0b576b66183cf85", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8f39e64-a79d-4986-8119-54e1156a76a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n", "original_text": "The AGs have broadened their group and they \ncontinue to talk amongst themselves. "}, "hash": "303ea0dbb8f245ac557eefdbe79756df842087f24fc9efe16bca43a9d79967bf", "class_name": "RelatedNodeInfo"}}, "text": "We do continue to be in constructive dialogue with the AGs. ", "start_char_idx": 413, "end_char_idx": 473, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8f39e64-a79d-4986-8119-54e1156a76a6": {"__data__": {"id_": "f8f39e64-a79d-4986-8119-54e1156a76a6", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n", "original_text": "The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af21af63-0494-4425-be67-03432ec7c351", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "original_text": "We do continue to be in constructive dialogue with the AGs. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdc521ddba3fe17bfadc80f3b3d7595d1ac6107209eabda32dc533fdd297cb1c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "03c3c982-71cb-420d-a14e-d1f4b723043e", "node_type": "1", "metadata": {"window": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous. ", "original_text": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n"}, "hash": "01d2679d3b80c6c101cc6aed9907e733acbf8ae83533d60b4b4c7559f4b4ebd1", "class_name": "RelatedNodeInfo"}}, "text": "The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "start_char_idx": 473, "end_char_idx": 555, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "03c3c982-71cb-420d-a14e-d1f4b723043e": {"__data__": {"id_": "03c3c982-71cb-420d-a14e-d1f4b723043e", "embedding": null, "metadata": {"window": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous. ", "original_text": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8f39e64-a79d-4986-8119-54e1156a76a6", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n", "original_text": "The AGs have broadened their group and they \ncontinue to talk amongst themselves. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4ec7a545463d819cbe1a25734acc37bcaf9d4e797b5c09a58de829b141310a14", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f117cd3-3831-445d-aa35-d4b0edfcdef0", "node_type": "1", "metadata": {"window": "We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "original_text": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. "}, "hash": "1e29c6f2160c73543493fa857c64a6a58aa7b09dc42b954fed6d760075450c3d", "class_name": "RelatedNodeInfo"}}, "text": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "start_char_idx": 555, "end_char_idx": 760, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f117cd3-3831-445d-aa35-d4b0edfcdef0": {"__data__": {"id_": "1f117cd3-3831-445d-aa35-d4b0edfcdef0", "embedding": null, "metadata": {"window": "We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "original_text": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "03c3c982-71cb-420d-a14e-d1f4b723043e", "node_type": "1", "metadata": {"window": "And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous. ", "original_text": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "adc741a424b2afdc559bc64c2c0676954788302131511e91b59695093af62168", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2", "node_type": "1", "metadata": {"window": "The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "original_text": "So, there's a lot of work that is ongoing. \n"}, "hash": "c09c796980ff3da2adc765c725bbd39db087181fd1dcfb400c7bfe26e0cd5466", "class_name": "RelatedNodeInfo"}}, "text": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "start_char_idx": 760, "end_char_idx": 947, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2": {"__data__": {"id_": "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2", "embedding": null, "metadata": {"window": "The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "original_text": "So, there's a lot of work that is ongoing. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f117cd3-3831-445d-aa35-d4b0edfcdef0", "node_type": "1", "metadata": {"window": "We do continue to be in constructive dialogue with the AGs.  The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "original_text": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4dd29bcbbd5685bfb1f9b9e84fdbf01deb01f33aae98e5bf27e444d1add08c0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cce68de8-ac56-4c1f-af77-18b299828f30", "node_type": "1", "metadata": {"window": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing. ", "original_text": "The discussions are really continuous. "}, "hash": "414dcc49650298be0583a175fd729bbb2ffe7137f1bb410d7024c4b750e90e73", "class_name": "RelatedNodeInfo"}}, "text": "So, there's a lot of work that is ongoing. \n", "start_char_idx": 947, "end_char_idx": 991, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cce68de8-ac56-4c1f-af77-18b299828f30": {"__data__": {"id_": "cce68de8-ac56-4c1f-af77-18b299828f30", "embedding": null, "metadata": {"window": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing. ", "original_text": "The discussions are really continuous. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2", "node_type": "1", "metadata": {"window": "The AGs have broadened their group and they \ncontinue to talk amongst themselves.  The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "original_text": "So, there's a lot of work that is ongoing. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "45eefe53b171194e77af011220138428bfcc6b6a316fe5577947ea3106090805", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77b8acc7-283c-440c-8ab9-39d19d5967f4", "node_type": "1", "metadata": {"window": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "original_text": "It'd be too early for me to try to project a timeline or where the finish line \nmight be. "}, "hash": "e575bd33ce3197f3e507621cb9f16b49edb7da051c784201502a14fa76019fa9", "class_name": "RelatedNodeInfo"}}, "text": "The discussions are really continuous. ", "start_char_idx": 991, "end_char_idx": 1030, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77b8acc7-283c-440c-8ab9-39d19d5967f4": {"__data__": {"id_": "77b8acc7-283c-440c-8ab9-39d19d5967f4", "embedding": null, "metadata": {"window": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "original_text": "It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cce68de8-ac56-4c1f-af77-18b299828f30", "node_type": "1", "metadata": {"window": "The good news from my perspective is the basic framework that we've laid \nout is still the framework that's being d iscussed and the details for the many component parts of that are \nprogressing well.  \n \n There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing. ", "original_text": "The discussions are really continuous. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d30ec89aa24f146b728ac74bfcb81f9c5d64024571ebb00ba81d9c2973e24f16", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e", "node_type": "1", "metadata": {"window": "So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I am pleased that the framework that we've been negotiating continu es to be the framework. "}, "hash": "f343352d1182a40db93084c4c21bc55e64079b650c4e5b9ac0b9623e42ae094d", "class_name": "RelatedNodeInfo"}}, "text": "It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "start_char_idx": 1030, "end_char_idx": 1120, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e": {"__data__": {"id_": "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e", "embedding": null, "metadata": {"window": "So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77b8acc7-283c-440c-8ab9-39d19d5967f4", "node_type": "1", "metadata": {"window": "There is still a long way to go with regard to ultimately getting as broad of AG support as we can and then AGs \nthemselves going to their subdivisions and extending that b road support.  So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "original_text": "It'd be too early for me to try to project a timeline or where the finish line \nmight be. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "efe25920f8780cb51c82532bfba97ecbdfcfc8b4647db3309fcf10426699011a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fed0063b-ae8f-465a-86ef-545deb87d65c", "node_type": "1", "metadata": {"window": "The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "The \ndetails are progressing. "}, "hash": "7e3f4a95d6a4402ea4c69bb34dc99e32a1cbbc87d2da253c9d1781ee65b59842", "class_name": "RelatedNodeInfo"}}, "text": "But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "start_char_idx": 1120, "end_char_idx": 1216, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fed0063b-ae8f-465a-86ef-545deb87d65c": {"__data__": {"id_": "fed0063b-ae8f-465a-86ef-545deb87d65c", "embedding": null, "metadata": {"window": "The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "The \ndetails are progressing. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e", "node_type": "1", "metadata": {"window": "So, there's a lot of work that is ongoing. \n The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "But I am pleased that the framework that we've been negotiating continu es to be the framework. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4282d6fff8ee7083ab7acd2acc1868d8615ad7326b31d7d6f9daa5b3521192b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "163236cb-8b96-4d61-bd98-c364657b9a7b", "node_type": "1", "metadata": {"window": "It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "original_text": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n "}, "hash": "40fd40eafbc9d085b6834184a1ef064e6e4558f9f6e949d8800812f6b7e557a2", "class_name": "RelatedNodeInfo"}}, "text": "The \ndetails are progressing. ", "start_char_idx": 1216, "end_char_idx": 1246, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "163236cb-8b96-4d61-bd98-c364657b9a7b": {"__data__": {"id_": "163236cb-8b96-4d61-bd98-c364657b9a7b", "embedding": null, "metadata": {"window": "It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "original_text": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fed0063b-ae8f-465a-86ef-545deb87d65c", "node_type": "1", "metadata": {"window": "The discussions are really continuous.  It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat. ", "original_text": "The \ndetails are progressing. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7982f794c1d2a8c12c174d96001353401cce1f69aac11f37596f4e2f933fc6f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2446827d-558e-4a39-b145-6a7bd19c14a9", "node_type": "1", "metadata": {"window": "But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "686b4efbf25a797f1146fc81e5c17699e30fed44e3658a321bd5baf1ea041c1f", "class_name": "RelatedNodeInfo"}}, "text": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "start_char_idx": 1246, "end_char_idx": 1378, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2446827d-558e-4a39-b145-6a7bd19c14a9": {"__data__": {"id_": "2446827d-558e-4a39-b145-6a7bd19c14a9", "embedding": null, "metadata": {"window": "But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "163236cb-8b96-4d61-bd98-c364657b9a7b", "node_type": "1", "metadata": {"window": "It'd be too early for me to try to project a timeline or where the finish line \nmight be.  But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "original_text": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00619367dff1569327519b576cb8b5ca6426a16a0619dbd2effdcdb240dc803b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c078654e-2641-40b1-8adb-fa65feee04d5", "node_type": "1", "metadata": {"window": "The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "original_text": "LLC  Q \nGreat. "}, "hash": "7babbb8f8b8558dc007fc9a3f379752b2a4e4426d7d8976014f2fd55fe02daa3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1378, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c078654e-2641-40b1-8adb-fa65feee04d5": {"__data__": {"id_": "c078654e-2641-40b1-8adb-fa65feee04d5", "embedding": null, "metadata": {"window": "The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "original_text": "LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2446827d-558e-4a39-b145-6a7bd19c14a9", "node_type": "1", "metadata": {"window": "But I am pleased that the framework that we've been negotiating continu es to be the framework.  The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6006c94a91928394514c1c500d2bd6b5afe61d36545d15e178c4adc9109cb479", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5078eb6-d92e-435f-a75e-70a46b603376", "node_type": "1", "metadata": {"window": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n ", "original_text": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. "}, "hash": "d69edc0fc198f6316349479e9731c22b7f2a1febeb00254ed5a1a2afa8363e89", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 1687, "end_char_idx": 1702, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5078eb6-d92e-435f-a75e-70a46b603376": {"__data__": {"id_": "f5078eb6-d92e-435f-a75e-70a46b603376", "embedding": null, "metadata": {"window": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n ", "original_text": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c078654e-2641-40b1-8adb-fa65feee04d5", "node_type": "1", "metadata": {"window": "The \ndetails are progressing.  And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "original_text": "LLC  Q \nGreat. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6c4b89055df358096aee9983a84542205b935ff85aecbec15c84f7eb01054a31", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ca75a93-d5d2-4b5d-802e-eb80a99969b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It seems like a lot of things are moving in the right direction. "}, "hash": "38a19aa37a66685da0c7ca6ef4a37c96306f432689cb679fb93d06509dbd757c", "class_name": "RelatedNodeInfo"}}, "text": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "start_char_idx": 1702, "end_char_idx": 1842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ca75a93-d5d2-4b5d-802e-eb80a99969b0": {"__data__": {"id_": "8ca75a93-d5d2-4b5d-802e-eb80a99969b0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It seems like a lot of things are moving in the right direction. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5078eb6-d92e-435f-a75e-70a46b603376", "node_type": "1", "metadata": {"window": "And I think as we get through the coming months, we'll begin to assess what the various \nAG and sub -municipality positions are.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n ", "original_text": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cd38b209252de0e1844ceab644bd98abcd620afcedb7b7ab82db71cd6afed5f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02f7c31a-3509-41fb-a373-fda5b877168a", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments. ", "original_text": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? "}, "hash": "f27d3d2526ecf96f64104336853568f9510d92c17da9c7274797aa373e3b392d", "class_name": "RelatedNodeInfo"}}, "text": "It seems like a lot of things are moving in the right direction. ", "start_char_idx": 1842, "end_char_idx": 1907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02f7c31a-3509-41fb-a373-fda5b877168a": {"__data__": {"id_": "02f7c31a-3509-41fb-a373-fda5b877168a", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments. ", "original_text": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ca75a93-d5d2-4b5d-802e-eb80a99969b0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It seems like a lot of things are moving in the right direction. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "696e9eaed0f2474fb0bdcd57494574a09a75ac2faaf4a5dfbae117afd467451a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7efa958a-edbd-44fa-99bf-0b42967e63b3", "node_type": "1", "metadata": {"window": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "original_text": "Thank you.  \n "}, "hash": "2c09b88f51fe4ba3d6b95a290d9b2ebab93e44abdf37610e74c358ce091e69c1", "class_name": "RelatedNodeInfo"}}, "text": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "start_char_idx": 1907, "end_char_idx": 2006, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7efa958a-edbd-44fa-99bf-0b42967e63b3": {"__data__": {"id_": "7efa958a-edbd-44fa-99bf-0b42967e63b3", "embedding": null, "metadata": {"window": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02f7c31a-3509-41fb-a373-fda5b877168a", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments. ", "original_text": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here? ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b93e757d506d65bd32a3bc003525873315385fbdcd18376d5bd706c9632a88cd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1f415be2-3d32-4ea1-b7c4-e29ec731165e", "node_type": "1", "metadata": {"window": "It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "e1d8c81b1a104f4623792eae257f613efaefeef00758aca09981de44580364da", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2006, "end_char_idx": 2020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1f415be2-3d32-4ea1-b7c4-e29ec731165e": {"__data__": {"id_": "1f415be2-3d32-4ea1-b7c4-e29ec731165e", "embedding": null, "metadata": {"window": "It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7efa958a-edbd-44fa-99bf-0b42967e63b3", "node_type": "1", "metadata": {"window": "And if I could have a fol low-up just on the core business, obviously, you increased your outlook on the core \npharmaceutical segment here.  It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80059d19b3f9fb00d26110a40e17757a61e6ab633262a824facf79cdf8b1a03c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99d2a2f0-4d67-4587-b613-5aa51618f675", "node_type": "1", "metadata": {"window": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "original_text": "A \nMaybe I'll start and then Britt might want to offer a few comments. "}, "hash": "d488b05ef67235f1b2b69258db3fbd8bd95b6fbef270c5957dd49bcd86fe9fe4", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 2020, "end_char_idx": 2361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99d2a2f0-4d67-4587-b613-5aa51618f675": {"__data__": {"id_": "99d2a2f0-4d67-4587-b613-5aa51618f675", "embedding": null, "metadata": {"window": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "original_text": "A \nMaybe I'll start and then Britt might want to offer a few comments. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1f415be2-3d32-4ea1-b7c4-e29ec731165e", "node_type": "1", "metadata": {"window": "It seems like a lot of things are moving in the right direction.  Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "944785c10a7dde6c9c0681c417be006647783c82479a7858add672e733bd6007", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83a961b4-3435-4ab0-ac95-ce45659d8caf", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "original_text": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. "}, "hash": "be3bda018dd667ffbcb4cce069d10f29b6afcae895f8aa66ce53d7719da14d6d", "class_name": "RelatedNodeInfo"}}, "text": "A \nMaybe I'll start and then Britt might want to offer a few comments. ", "start_char_idx": 2361, "end_char_idx": 2432, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83a961b4-3435-4ab0-ac95-ce45659d8caf": {"__data__": {"id_": "83a961b4-3435-4ab0-ac95-ce45659d8caf", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "original_text": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99d2a2f0-4d67-4587-b613-5aa51618f675", "node_type": "1", "metadata": {"window": "Is there anything you'd \npoint to specifically that is kind of driving the impr oved outlook here?  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "original_text": "A \nMaybe I'll start and then Britt might want to offer a few comments. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57aff886f2fc66a8f451278dbf0541db4da57db165fa4e8dce5b3910df9b1fba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a8729388-e619-4179-9330-da803fbb1d99", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "original_text": "The \ngeneric market is continuing to behave in a way that we had forecast. "}, "hash": "3ac254837382f00bb11efdb018c14da4c5fb3f81a5936aec1919d9037c797fb2", "class_name": "RelatedNodeInfo"}}, "text": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "start_char_idx": 2432, "end_char_idx": 2590, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a8729388-e619-4179-9330-da803fbb1d99": {"__data__": {"id_": "a8729388-e619-4179-9330-da803fbb1d99", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "original_text": "The \ngeneric market is continuing to behave in a way that we had forecast. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83a961b4-3435-4ab0-ac95-ce45659d8caf", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "original_text": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8a7134a8021e3ed0320cd72bfb202fb3419f833354c282a96b340fe88b1e878e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39078449-47ba-4c56-a200-5ff5e4d32a8a", "node_type": "1", "metadata": {"window": "A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "original_text": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n"}, "hash": "8a7875b4bb83deeb2f63687ba86e8fb1920d64ce15bc2ffd0e35e59186db47e7", "class_name": "RelatedNodeInfo"}}, "text": "The \ngeneric market is continuing to behave in a way that we had forecast. ", "start_char_idx": 2590, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39078449-47ba-4c56-a200-5ff5e4d32a8a": {"__data__": {"id_": "39078449-47ba-4c56-a200-5ff5e4d32a8a", "embedding": null, "metadata": {"window": "A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "original_text": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a8729388-e619-4179-9330-da803fbb1d99", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "original_text": "The \ngeneric market is continuing to behave in a way that we had forecast. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "885733a0d76499ce010499d785e920ef89bdb630425e9e291d69024cd8dfc426", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185", "node_type": "1", "metadata": {"window": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "original_text": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n"}, "hash": "c9c285baf4b7a0f3b216d33971831f21b929c14d98abc29c8396a258c6609daf", "class_name": "RelatedNodeInfo"}}, "text": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "start_char_idx": 2665, "end_char_idx": 2768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185": {"__data__": {"id_": "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185", "embedding": null, "metadata": {"window": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "original_text": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39078449-47ba-4c56-a200-5ff5e4d32a8a", "node_type": "1", "metadata": {"window": "A \nMaybe I'll start and then Britt might want to offer a few comments.  I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "original_text": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "137a4591400e436785d9026a80a38286e7a95b953c3f7729bf3c0a5ee5195689", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9923d52f-db5c-475f-ae09-963bfd2a19fd", "node_type": "1", "metadata": {"window": "The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "original_text": "And we think that the competitive \u2013 the sell side in the generics market remains stable. "}, "hash": "aaf3741b2aa8d75cadbe27fa9c90a62d59e198a3a74747d21fff6194798f7699", "class_name": "RelatedNodeInfo"}}, "text": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "start_char_idx": 2768, "end_char_idx": 2885, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9923d52f-db5c-475f-ae09-963bfd2a19fd": {"__data__": {"id_": "9923d52f-db5c-475f-ae09-963bfd2a19fd", "embedding": null, "metadata": {"window": "The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "original_text": "And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185", "node_type": "1", "metadata": {"window": "I mean, I think if you think about the general \nkind of industry fundamentals, the brand  price inflation has been in line with where we thought it would be.  The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "original_text": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "00b1c10289c3c384d7187c49e8a1b02416eac6909c07b90527bad834fbb7462b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d9209479-341c-4ff1-b4c0-bfdc1ea4535f", "node_type": "1", "metadata": {"window": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n"}, "hash": "c1f4d862b2a580b3ff87648ff2c63a5bd22e59425564d2ab1d0d43a36ffe17e4", "class_name": "RelatedNodeInfo"}}, "text": "And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "start_char_idx": 2885, "end_char_idx": 2974, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d9209479-341c-4ff1-b4c0-bfdc1ea4535f": {"__data__": {"id_": "d9209479-341c-4ff1-b4c0-bfdc1ea4535f", "embedding": null, "metadata": {"window": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9923d52f-db5c-475f-ae09-963bfd2a19fd", "node_type": "1", "metadata": {"window": "The \ngeneric market is continuing to behave in a way that we had forecast.  And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "original_text": "And we think that the competitive \u2013 the sell side in the generics market remains stable. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "524290be1b6a5a4eaf222906fcc22df5ece8d62284f67736e43190bd8f0acd63", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2950c40-7674-4dac-a891-b818b6478063", "node_type": "1", "metadata": {"window": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add. ", "original_text": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. "}, "hash": "b27b577ff3ca7569a3cefa0c691101711ee35092fd1c32c6354ae3e006b6a0b9", "class_name": "RelatedNodeInfo"}}, "text": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "start_char_idx": 2974, "end_char_idx": 3043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2950c40-7674-4dac-a891-b818b6478063": {"__data__": {"id_": "f2950c40-7674-4dac-a891-b818b6478063", "embedding": null, "metadata": {"window": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add. ", "original_text": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d9209479-341c-4ff1-b4c0-bfdc1ea4535f", "node_type": "1", "metadata": {"window": "And by that I mean our scaled sourcing \nentity continues to produce in line with our anticipation.  \n \n We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8958130fe67ff2e1b97e9af0a86b34b9353439ee00d3e096f0566b4c2ab49af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "97925442-ced9-486b-9c80-57513b05a298", "node_type": "1", "metadata": {"window": "And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here. ", "original_text": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n "}, "hash": "6081373219f9fb587a7a091ac4e503de181341d0bc87051f5490f274e7a5a38d", "class_name": "RelatedNodeInfo"}}, "text": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "start_char_idx": 3043, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "97925442-ced9-486b-9c80-57513b05a298": {"__data__": {"id_": "97925442-ced9-486b-9c80-57513b05a298", "embedding": null, "metadata": {"window": "And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here. ", "original_text": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2950c40-7674-4dac-a891-b818b6478063", "node_type": "1", "metadata": {"window": "We are going i n the market with a very disciplined approach reflective of the transition our industry has been in. \n And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add. ", "original_text": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "51a71eb3fda6a1146772aa624c3bdbc97addbfed422876a57094ff6cb0b36d3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2d400cda-3f48-4a68-b4fd-1e275f0458aa", "node_type": "1", "metadata": {"window": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "5cfd041ba0347211f3b4295727d4304ff33ab114ff3f7ff3676b7953914946d6", "class_name": "RelatedNodeInfo"}}, "text": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "start_char_idx": 3196, "end_char_idx": 3339, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2d400cda-3f48-4a68-b4fd-1e275f0458aa": {"__data__": {"id_": "2d400cda-3f48-4a68-b4fd-1e275f0458aa", "embedding": null, "metadata": {"window": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "97925442-ced9-486b-9c80-57513b05a298", "node_type": "1", "metadata": {"window": "And we think that the competitive \u2013 the sell side in the generics market remains stable.  I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here. ", "original_text": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "03e75aeb3906275d60a921da969aae7d264c0acf30ba19aedd6ef482756fdf6c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f35fecc-6026-4e14-927e-552f63cc571c", "node_type": "1", "metadata": {"window": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "original_text": "A \nMaybe I might just add. "}, "hash": "ad41d0712cf5558c6d94a02f4415ae2510f03e1358d971c295b5428c04ddd58c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3339, "end_char_idx": 3699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f35fecc-6026-4e14-927e-552f63cc571c": {"__data__": {"id_": "7f35fecc-6026-4e14-927e-552f63cc571c", "embedding": null, "metadata": {"window": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "original_text": "A \nMaybe I might just add. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2d400cda-3f48-4a68-b4fd-1e275f0458aa", "node_type": "1", "metadata": {"window": "I mean it's competitive and \nthere's pressures, but it's stable.  \n \n I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80035a4a29b456fdf5f2f2e380553b3a997d8503362875f7a5b5c8f0a392a0b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "289032ac-87d0-45cd-9c2e-eaf501e9ddc7", "node_type": "1", "metadata": {"window": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "original_text": "I think, Brian, you hit on it here. "}, "hash": "689734797ab3eb68b21ea3ef3313cec23fedcaad67c638e7ba1a4cbca0973d10", "class_name": "RelatedNodeInfo"}}, "text": "A \nMaybe I might just add. ", "start_char_idx": 3699, "end_char_idx": 3726, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "289032ac-87d0-45cd-9c2e-eaf501e9ddc7": {"__data__": {"id_": "289032ac-87d0-45cd-9c2e-eaf501e9ddc7", "embedding": null, "metadata": {"window": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "original_text": "I think, Brian, you hit on it here. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f35fecc-6026-4e14-927e-552f63cc571c", "node_type": "1", "metadata": {"window": "I think we're seeing the benefits of a lot of the work and planning that we've been \u2013 the last several quarters, \nwe've been executing and implementing.  And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "original_text": "A \nMaybe I might just add. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "852332df6e221dff4ce2cc7068bb1d38df5d22033ed7fd0d745c5d5add77ce05", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f494131a-7a83-40d5-8bef-abe375896952", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. "}, "hash": "97667ffa3cba899cf9511bbe9be0a98dbf77a5569389aaf8ddc9c15413210c74", "class_name": "RelatedNodeInfo"}}, "text": "I think, Brian, you hit on it here. ", "start_char_idx": 3726, "end_char_idx": 3762, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f494131a-7a83-40d5-8bef-abe375896952": {"__data__": {"id_": "f494131a-7a83-40d5-8bef-abe375896952", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "289032ac-87d0-45cd-9c2e-eaf501e9ddc7", "node_type": "1", "metadata": {"window": "And so combining that I think with the market fundamentals and our \nreally good positions in specialty is driving the results that you see.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "original_text": "I think, Brian, you hit on it here. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3f6a0f51caf66b4408912f9524058638b4ba5788e4f4611767cb769e352c5fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "74e85b4a-33a9-4af6-b5bf-b86a48de7317", "node_type": "1", "metadata": {"window": "A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n"}, "hash": "0818ff164d80111f1fbd52e1cc37ec02f35622cca6021c577cc25127bb44e997", "class_name": "RelatedNodeInfo"}}, "text": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "start_char_idx": 3762, "end_char_idx": 3924, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "74e85b4a-33a9-4af6-b5bf-b86a48de7317": {"__data__": {"id_": "74e85b4a-33a9-4af6-b5bf-b86a48de7317", "embedding": null, "metadata": {"window": "A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f494131a-7a83-40d5-8bef-abe375896952", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "original_text": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8e96125528af1aad0bebfb18202fdf13f05fde32ccea0a5a8e885cde65fff30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "06f36781-0bdc-4cbe-8017-a8cb2029b4c2", "node_type": "1", "metadata": {"window": "I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n ", "original_text": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n "}, "hash": "84fcb3f76e026ba8af8648564d7d3ed5daec85e880eaf297a8be4f68ae19095d", "class_name": "RelatedNodeInfo"}}, "text": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "start_char_idx": 3924, "end_char_idx": 4062, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "06f36781-0bdc-4cbe-8017-a8cb2029b4c2": {"__data__": {"id_": "06f36781-0bdc-4cbe-8017-a8cb2029b4c2", "embedding": null, "metadata": {"window": "I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n ", "original_text": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "74e85b4a-33a9-4af6-b5bf-b86a48de7317", "node_type": "1", "metadata": {"window": "A \nMaybe I might just add.  I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay. ", "original_text": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f571d6f9388299d8007340d095a43d3725c0cc8d2f82c123d7384c5fee8ce305", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "32eb1574-1dff-414c-86b1-fb61ed653fb9", "node_type": "1", "metadata": {"window": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. "}, "hash": "1ed55bacb02f0796e2a98606211714a45082872e131fb9fca0936dafc618e8ed", "class_name": "RelatedNodeInfo"}}, "text": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "start_char_idx": 4062, "end_char_idx": 4253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "32eb1574-1dff-414c-86b1-fb61ed653fb9": {"__data__": {"id_": "32eb1574-1dff-414c-86b1-fb61ed653fb9", "embedding": null, "metadata": {"window": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "06f36781-0bdc-4cbe-8017-a8cb2029b4c2", "node_type": "1", "metadata": {"window": "I think, Brian, you hit on it here.  The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n ", "original_text": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9c0486166781634dd4a707d7b57a5b2665360885b80130fbc4440ef6b3202452", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0ba4dd2d-df84-4629-add6-e95b616d9f59", "node_type": "1", "metadata": {"window": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nOkay. "}, "hash": "e0b875f7e2e1b55cb2b51b4f07d218251b1009783cd3e062b6cfb931350cb422", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "start_char_idx": 1378, "end_char_idx": 1687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0ba4dd2d-df84-4629-add6-e95b616d9f59": {"__data__": {"id_": "0ba4dd2d-df84-4629-add6-e95b616d9f59", "embedding": null, "metadata": {"window": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "32eb1574-1dff-414c-86b1-fb61ed653fb9", "node_type": "1", "metadata": {"window": "The focus and our execution against our differentiated \nassets, particula rly specialty and you talked a lot about that, I think is really driving a lot of this.  And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2d92c97c1088f94504b61b77e7c41445c09dba11be721ff0f97a540d529b3084", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "78c9c329-453a-42e3-b8c0-cd69f6d62904", "node_type": "1", "metadata": {"window": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n "}, "hash": "49f50629d8cb689b567752c9b769b002f26f7e3278dd63ed68ee8c81a87bd0ce", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nOkay. ", "start_char_idx": 4562, "end_char_idx": 4576, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "78c9c329-453a-42e3-b8c0-cd69f6d62904": {"__data__": {"id_": "78c9c329-453a-42e3-b8c0-cd69f6d62904", "embedding": null, "metadata": {"window": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0ba4dd2d-df84-4629-add6-e95b616d9f59", "node_type": "1", "metadata": {"window": "And then, I would \njust reiterate that our cost programs are really driving not only in our corporate line, but also across our segment. \n And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "LLC  Q \nOkay. ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "873395f8e9d4125b7496d98a5415cfec8d74bbfc514b90627e477257ac90f0ca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b671f24d-7b15-4e16-b183-927693eeaeac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "841a55b73c5dd7b186250e4cf18b090427fa147482ef129d8c7658d413394b50", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2006, "end_char_idx": 2020, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b671f24d-7b15-4e16-b183-927693eeaeac": {"__data__": {"id_": "b671f24d-7b15-4e16-b183-927693eeaeac", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "862e1938-6d97-499c-a474-4304eea1cef2", "node_type": "4", "metadata": {"page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d3d0febdd6075b130ad3ffe5b3677711e9ef5531f1bd5cc8c30f88697136950", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "78c9c329-453a-42e3-b8c0-cd69f6d62904", "node_type": "1", "metadata": {"window": "And so, that focus is not only o n our core set of differentiated assets, but just the discipline and focus around cost \nacross not only our corporate segments, but our business segments.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Thank you.  \n ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b09786bc75b79654699be0d39a141e39079bf7b298a686cec8e1d67623058680", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "aa171cf7-4e46-42e4-9107-b8063abf23ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "McKesson Corp.  "}, "hash": "631ba60b5e7c3fee67521dc44633e0b8d7bd5d03442e1893f2c3f137d168a99e", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1378, "end_char_idx": 1649, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "aa171cf7-4e46-42e4-9107-b8063abf23ab": {"__data__": {"id_": "aa171cf7-4e46-42e4-9107-b8063abf23ab", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b671f24d-7b15-4e16-b183-927693eeaeac", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nCharles Rhyee  \nAnalyst, Cowen & Co.  LLC  Q \nOkay.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7dda32eec37520c73522aeb33ace73abf2fbc45137d338849c093c1becea647a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "85ef0847-1a5b-4831-80f7-c2015b67981d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9fee26886c011c26be40c90029f51446ab9cf8e836369ee84003060c6aaf6888", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "85ef0847-1a5b-4831-80f7-c2015b67981d": {"__data__": {"id_": "85ef0847-1a5b-4831-80f7-c2015b67981d", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "aa171cf7-4e46-42e4-9107-b8063abf23ab", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "656fcd7da56a5125777901b8563e4884821d6e5d8012667cb7817b70c277a1c9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d3c2969c-d078-441f-9c55-e7d3286e6d36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "original_text": "A \nThank you, Charles.  \n "}, "hash": "89a00a92bf546e46f4dc7c7146cbc76d7be582e1324c70358d59f520d8723974", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d3c2969c-d078-441f-9c55-e7d3286e6d36": {"__data__": {"id_": "d3c2969c-d078-441f-9c55-e7d3286e6d36", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "original_text": "A \nThank you, Charles.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "85ef0847-1a5b-4831-80f7-c2015b67981d", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7b96a358dce7db1d669bc23ced703b802ecd1d17d78313b664cd7dc60c543ad2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "922d802d-8aa3-48bb-a5d6-16ff463a85c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n "}, "hash": "95f184af7b9212adb4fceb22a2f984dd6ea22d5ba11799b60446531d1360aceb", "class_name": "RelatedNodeInfo"}}, "text": "A \nThank you, Charles.  \n ", "start_char_idx": 250, "end_char_idx": 276, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "922d802d-8aa3-48bb-a5d6-16ff463a85c3": {"__data__": {"id_": "922d802d-8aa3-48bb-a5d6-16ff463a85c3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d3c2969c-d078-441f-9c55-e7d3286e6d36", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "original_text": "A \nThank you, Charles.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0403acf54c03914b12c4b80386ecf88658cf974fcb00cf0a2cc1b768504ada47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1373e821-346f-4a68-bfa4-41de03aa617e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. "}, "hash": "82ba0add4a7dfa92a0e3f3fd00714c1aaf282c61cff3ba019917af71d8b71f7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "start_char_idx": 276, "end_char_idx": 613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1373e821-346f-4a68-bfa4-41de03aa617e": {"__data__": {"id_": "1373e821-346f-4a68-bfa4-41de03aa617e", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "922d802d-8aa3-48bb-a5d6-16ff463a85c3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bdcba1dab25732cac259c9cc681bd7b5f46678a0c71ee92f2524aa586869ba7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "499232bb-750f-4665-ae12-288b1d7e460a", "node_type": "1", "metadata": {"window": "A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n ", "original_text": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. "}, "hash": "2fa3f027782c86791bafe62010361987700f54ccb5bdcadc942480be8b26d54d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "start_char_idx": 613, "end_char_idx": 983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "499232bb-750f-4665-ae12-288b1d7e460a": {"__data__": {"id_": "499232bb-750f-4665-ae12-288b1d7e460a", "embedding": null, "metadata": {"window": "A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n ", "original_text": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1373e821-346f-4a68-bfa4-41de03aa617e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bf6b59ae6a63e1f7c31c612e01185ce2058966a0fe3241cfeabf20b303c47f5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "27bf8026-d1a0-4afc-9a31-df8fdef6c0da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? "}, "hash": "06038566a088b058cc279102d630402f0f8d1a8bd9eedf445361ed818a886aa3", "class_name": "RelatedNodeInfo"}}, "text": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "start_char_idx": 983, "end_char_idx": 1123, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "27bf8026-d1a0-4afc-9a31-df8fdef6c0da": {"__data__": {"id_": "27bf8026-d1a0-4afc-9a31-df8fdef6c0da", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "499232bb-750f-4665-ae12-288b1d7e460a", "node_type": "1", "metadata": {"window": "A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n ", "original_text": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2db2da7b69a6a3a51416c6de8fa02504ad55bbb51b4a96abf74d3a0a36140f57", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cd7ac18-fcee-4c12-a54a-8ce656dd862f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? "}, "hash": "ea7ed7bf5fe9dee81a3bef9c01c4e6b621afe14c70f6bc6c9cb30b6040d74647", "class_name": "RelatedNodeInfo"}}, "text": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "start_char_idx": 1123, "end_char_idx": 1255, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cd7ac18-fcee-4c12-a54a-8ce656dd862f": {"__data__": {"id_": "9cd7ac18-fcee-4c12-a54a-8ce656dd862f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "27bf8026-d1a0-4afc-9a31-df8fdef6c0da", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically? ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e2d1ccc2418db400a0b61fc5780826cefabfa79c86619f5daa8ff70d58bab0a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e86e9163-3963-4433-8b75-6f7bd51baaee", "node_type": "1", "metadata": {"window": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses. ", "original_text": "Thanks.  \n "}, "hash": "881debecc07c87c839a5a76f803082d5feec24fedcf3cd1c435dc637ca1b31fc", "class_name": "RelatedNodeInfo"}}, "text": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "start_char_idx": 1255, "end_char_idx": 1417, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e86e9163-3963-4433-8b75-6f7bd51baaee": {"__data__": {"id_": "e86e9163-3963-4433-8b75-6f7bd51baaee", "embedding": null, "metadata": {"window": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cd7ac18-fcee-4c12-a54a-8ce656dd862f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nHi, good morning, and congrats on a good quarter.  So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah. ", "original_text": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well? ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9509f7e73578dc2d25e02db1f6c2fe21e0706edf7e54350292231040fe761220", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3fccc0f2-aa0a-486d-9a65-69717afbb848", "node_type": "1", "metadata": {"window": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "caf838b41e2d51bbf84a0cdb5b67ba4a7cb34c0b4cf07677addd62dedda71e8c", "class_name": "RelatedNodeInfo"}}, "text": "Thanks.  \n ", "start_char_idx": 1417, "end_char_idx": 1428, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3fccc0f2-aa0a-486d-9a65-69717afbb848": {"__data__": {"id_": "3fccc0f2-aa0a-486d-9a65-69717afbb848", "embedding": null, "metadata": {"window": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e86e9163-3963-4433-8b75-6f7bd51baaee", "node_type": "1", "metadata": {"window": "So, I guess the question for me as I think about it, Brian, you \ntalked about the execution and how you guys seem really positive about it.  So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses. ", "original_text": "Thanks.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4b341ece04e4575bcae6fa2721b86c5d8377ac01bebdfb0114f049be5e432f5b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a", "node_type": "1", "metadata": {"window": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general. ", "original_text": "A \nYeah. "}, "hash": "5eed3b16fb697f4692dd5cd60c0b585fa151f40f2db82f0771ae9001b3a67874", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1428, "end_char_idx": 1769, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a": {"__data__": {"id_": "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a", "embedding": null, "metadata": {"window": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3fccc0f2-aa0a-486d-9a65-69717afbb848", "node_type": "1", "metadata": {"window": "So, how do you think about the \nrunway remaining in specialty as we head into fiscal 2021 without going into guidance specifically?  And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f628ce0a1db65896a4e9cb4372e776335e457730c11bf1265f37fc98eda13543", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94912769-d28e-441e-b7d7-6e5a3a8394b0", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "original_text": "I mean, we're really pleased with our specialty businesses. "}, "hash": "7e9901b74a91a59b70335844a4eff8fe56e3f4874ccd15e7d926658dcfe380ac", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 1769, "end_char_idx": 1778, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94912769-d28e-441e-b7d7-6e5a3a8394b0": {"__data__": {"id_": "94912769-d28e-441e-b7d7-6e5a3a8394b0", "embedding": null, "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "original_text": "I mean, we're really pleased with our specialty businesses. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a", "node_type": "1", "metadata": {"window": "And just how \nyou're looking a t the volume outlook from the key accounts because it sounds like that's a volume driver that's \nbeen driving some upside as well?  Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general. ", "original_text": "A \nYeah. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f66eaa4137a25c2ec97496533113d016b3e2128346e933c9145a16584a3f5b30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments. ", "original_text": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. "}, "hash": "180be3f11369680c183f5cc4ebda0536944a6ebb74184ba22e931ebc1c2f129a", "class_name": "RelatedNodeInfo"}}, "text": "I mean, we're really pleased with our specialty businesses. ", "start_char_idx": 1778, "end_char_idx": 1838, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c": {"__data__": {"id_": "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments. ", "original_text": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94912769-d28e-441e-b7d7-6e5a3a8394b0", "node_type": "1", "metadata": {"window": "Thanks.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "original_text": "I mean, we're really pleased with our specialty businesses. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bb0fa6484b5908ba7ca68722d095e7b46906e1b14542d9c1d9d13c6131e343a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f82211b0-2418-4ac1-b01a-3ed1a461f53f", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "original_text": "And clearly, we \nbenefit there from the growth that these products have just in general. "}, "hash": "d40a2db87ba48c8242c53dd32111c9b15638ee0909c1118a64aa5c6cf0ff782f", "class_name": "RelatedNodeInfo"}}, "text": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "start_char_idx": 1838, "end_char_idx": 1983, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f82211b0-2418-4ac1-b01a-3ed1a461f53f": {"__data__": {"id_": "f82211b0-2418-4ac1-b01a-3ed1a461f53f", "embedding": null, "metadata": {"window": "A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "original_text": "And clearly, we \nbenefit there from the growth that these products have just in general. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments. ", "original_text": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae25ccbc7d3a51d6d3cbfef50d8edf2f7e736cceaef8fe60c2e17a62c2ec8bdf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f497cb3-0e38-4927-91fd-cbf12895fc6b", "node_type": "1", "metadata": {"window": "I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings. ", "original_text": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. "}, "hash": "dbbc3381dce7862b7c1514e2adbaba8af57aace9312d88185ef49e20852a83c2", "class_name": "RelatedNodeInfo"}}, "text": "And clearly, we \nbenefit there from the growth that these products have just in general. ", "start_char_idx": 1983, "end_char_idx": 2072, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f497cb3-0e38-4927-91fd-cbf12895fc6b": {"__data__": {"id_": "4f497cb3-0e38-4927-91fd-cbf12895fc6b", "embedding": null, "metadata": {"window": "I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings. ", "original_text": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f82211b0-2418-4ac1-b01a-3ed1a461f53f", "node_type": "1", "metadata": {"window": "A \nYeah.  I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "original_text": "And clearly, we \nbenefit there from the growth that these products have just in general. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7e1619bb5389a4b5ee82918f680bb58c5781b00afa426f32df492ec3b8888f74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d1e9a38f-eea1-4249-9bcf-6981c4626c8a", "node_type": "1", "metadata": {"window": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n", "original_text": "And as you know, we've got established scaled \nchannels across both of these segments. "}, "hash": "eeaa7c56d194b008b11f1683215b04ddef4d36b20b4821b322fa23788a6b6e3e", "class_name": "RelatedNodeInfo"}}, "text": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "start_char_idx": 2072, "end_char_idx": 2183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d1e9a38f-eea1-4249-9bcf-6981c4626c8a": {"__data__": {"id_": "d1e9a38f-eea1-4249-9bcf-6981c4626c8a", "embedding": null, "metadata": {"window": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n", "original_text": "And as you know, we've got established scaled \nchannels across both of these segments. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f497cb3-0e38-4927-91fd-cbf12895fc6b", "node_type": "1", "metadata": {"window": "I mean, we're really pleased with our specialty businesses.  We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings. ", "original_text": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e2c2647c6a33f632483be03d882cbf3cf903a06e61f311eb38988038ed9f32fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "107909fc-5832-44f2-b39f-7728d5a68e1a", "node_type": "1", "metadata": {"window": "And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "original_text": "And then, if you think about the community setting, oncology we  have a \nclear leading stake. "}, "hash": "81aca060358cae2dd168169219bb483342030cdd2b04e39a6c19ae037b5350df", "class_name": "RelatedNodeInfo"}}, "text": "And as you know, we've got established scaled \nchannels across both of these segments. ", "start_char_idx": 2183, "end_char_idx": 2270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "107909fc-5832-44f2-b39f-7728d5a68e1a": {"__data__": {"id_": "107909fc-5832-44f2-b39f-7728d5a68e1a", "embedding": null, "metadata": {"window": "And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "original_text": "And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d1e9a38f-eea1-4249-9bcf-6981c4626c8a", "node_type": "1", "metadata": {"window": "We talked a few weeks ago about the \"core,\" \nthe distribution of these products to hospitals and retail pharmacies as being our biggest segment.  And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n", "original_text": "And as you know, we've got established scaled \nchannels across both of these segments. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ac751fd5114ce56c1d498050064056fef04e1ca8f7c57d3f71dfb9a5a6e08f41", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a7fecc35-5d82-4c4e-b837-984620879911", "node_type": "1", "metadata": {"window": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "original_text": "We're a leader in many of the other multi -specialty settings. "}, "hash": "4f7fd81b94cd7d61514f0feff3b5464d4108133820702713ec0cfb2d1390d7fd", "class_name": "RelatedNodeInfo"}}, "text": "And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "start_char_idx": 2270, "end_char_idx": 2364, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a7fecc35-5d82-4c4e-b837-984620879911": {"__data__": {"id_": "a7fecc35-5d82-4c4e-b837-984620879911", "embedding": null, "metadata": {"window": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "original_text": "We're a leader in many of the other multi -specialty settings. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "107909fc-5832-44f2-b39f-7728d5a68e1a", "node_type": "1", "metadata": {"window": "And clearly, we \nbenefit there from the growth that these products have just in general.  An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "original_text": "And then, if you think about the community setting, oncology we  have a \nclear leading stake. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c984e4db3501a2e55a5431d0bb0ce893049d65881d5add96c76920952cfab4c8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5010fac3-d5f2-4013-bde0-74fe0920d4ed", "node_type": "1", "metadata": {"window": "And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology. ", "original_text": "They're going to benefit from that \nsame pipeline.  \n \n"}, "hash": "e9f158dd08b93a6a098d40167ad7d157e3b4806934c2e060f4f85823d8aa1de5", "class_name": "RelatedNodeInfo"}}, "text": "We're a leader in many of the other multi -specialty settings. ", "start_char_idx": 2364, "end_char_idx": 2427, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5010fac3-d5f2-4013-bde0-74fe0920d4ed": {"__data__": {"id_": "5010fac3-d5f2-4013-bde0-74fe0920d4ed", "embedding": null, "metadata": {"window": "And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology. ", "original_text": "They're going to benefit from that \nsame pipeline.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a7fecc35-5d82-4c4e-b837-984620879911", "node_type": "1", "metadata": {"window": "An d the pipeline, if you look at the pipeline \nof the innovative products coming, they tend to look that way.  And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "original_text": "We're a leader in many of the other multi -specialty settings. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7875cefb69f02f800f623868b2bc9a3a3fb5ccbe51fecfdb9d00c7fe4d833afc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "05aa294a-8a18-4dc1-9a66-8d5987a77a0d", "node_type": "1", "metadata": {"window": "And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong. ", "original_text": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. "}, "hash": "9627b39fb5b70cbba3b2af99ba6575da80720dc3caf660a53166418f108753f8", "class_name": "RelatedNodeInfo"}}, "text": "They're going to benefit from that \nsame pipeline.  \n \n", "start_char_idx": 2427, "end_char_idx": 2482, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "05aa294a-8a18-4dc1-9a66-8d5987a77a0d": {"__data__": {"id_": "05aa294a-8a18-4dc1-9a66-8d5987a77a0d", "embedding": null, "metadata": {"window": "And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong. ", "original_text": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5010fac3-d5f2-4013-bde0-74fe0920d4ed", "node_type": "1", "metadata": {"window": "And as you know, we've got established scaled \nchannels across both of these segments.  And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology. ", "original_text": "They're going to benefit from that \nsame pipeline.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ed8327909f08f37c5033d0cf8fb14cfde0e6d6432de5c4aa87124806619b8dac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4f40c597-ddcb-44b1-81cd-acda1f2d0f94", "node_type": "1", "metadata": {"window": "We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence. ", "original_text": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n"}, "hash": "b04b62065b983d706ce438b61fe1c5faf0d07251dffaba64e75726b3ccbaca65", "class_name": "RelatedNodeInfo"}}, "text": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "start_char_idx": 2482, "end_char_idx": 2766, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4f40c597-ddcb-44b1-81cd-acda1f2d0f94": {"__data__": {"id_": "4f40c597-ddcb-44b1-81cd-acda1f2d0f94", "embedding": null, "metadata": {"window": "We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence. ", "original_text": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "05aa294a-8a18-4dc1-9a66-8d5987a77a0d", "node_type": "1", "metadata": {"window": "And then, if you think about the community setting, oncology we  have a \nclear leading stake.  We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong. ", "original_text": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb48adc5fc797e871ce27873e7f2e0597eb4eb7038db9c74fd3474ebbb223d5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68f7f8e2-d8fc-4c8d-923d-2de016a587da", "node_type": "1", "metadata": {"window": "They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "original_text": "And then, our US oncology business, we have particular depth and strength in oncology. "}, "hash": "c2d9dd98d4c187abd53500d243c2f32f8f9f2abbac8d8056292a628dc0ad261e", "class_name": "RelatedNodeInfo"}}, "text": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "start_char_idx": 2766, "end_char_idx": 2875, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68f7f8e2-d8fc-4c8d-923d-2de016a587da": {"__data__": {"id_": "68f7f8e2-d8fc-4c8d-923d-2de016a587da", "embedding": null, "metadata": {"window": "They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "original_text": "And then, our US oncology business, we have particular depth and strength in oncology. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4f40c597-ddcb-44b1-81cd-acda1f2d0f94", "node_type": "1", "metadata": {"window": "We're a leader in many of the other multi -specialty settings.  They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence. ", "original_text": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c3f17fefaff305521aa4d64bfef401e4511ef7f947a64b51d7d06f75303ebedd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d464d2b3-948d-4970-a50d-724ee1a3ed6e", "node_type": "1", "metadata": {"window": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "original_text": "And if you look at the \npipeline there, that continues to be strong. "}, "hash": "cfefd79614be4f0e2b44650de7d3d45b2bbe1bb3e1d43d6c6ca5b13848fc45cc", "class_name": "RelatedNodeInfo"}}, "text": "And then, our US oncology business, we have particular depth and strength in oncology. ", "start_char_idx": 2875, "end_char_idx": 2962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d464d2b3-948d-4970-a50d-724ee1a3ed6e": {"__data__": {"id_": "d464d2b3-948d-4970-a50d-724ee1a3ed6e", "embedding": null, "metadata": {"window": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "original_text": "And if you look at the \npipeline there, that continues to be strong. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68f7f8e2-d8fc-4c8d-923d-2de016a587da", "node_type": "1", "metadata": {"window": "They're going to benefit from that \nsame pipeline.  \n \n And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "original_text": "And then, our US oncology business, we have particular depth and strength in oncology. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "12c6704fca246f1207ea16409279f83bd6b133d6f68b566196b9668075a67c72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44913343-8779-4965-88a8-71f2e1707003", "node_type": "1", "metadata": {"window": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "original_text": "So, I would say, all of those things are what are giving us our \nconfidence. "}, "hash": "b5a7fa539fc08d1cff63babda12987469cd58f5a6833e3258a99a046f4cf8765", "class_name": "RelatedNodeInfo"}}, "text": "And if you look at the \npipeline there, that continues to be strong. ", "start_char_idx": 2962, "end_char_idx": 3031, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44913343-8779-4965-88a8-71f2e1707003": {"__data__": {"id_": "44913343-8779-4965-88a8-71f2e1707003", "embedding": null, "metadata": {"window": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "original_text": "So, I would say, all of those things are what are giving us our \nconfidence. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d464d2b3-948d-4970-a50d-724ee1a3ed6e", "node_type": "1", "metadata": {"window": "And I also think if you step up from a more macro view, if you think about the challenges that the cost of \nhealthc are represent in this country, we have a fundamental belief that to get at access, cost and quality care \nneeds to continue to shift into the community based settings.  So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "original_text": "And if you look at the \npipeline there, that continues to be strong. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "465bf50bf516008456a211b8970fa19a139150032b41a3af89e2054f7fd698e9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b8f8a27d-6745-4851-8fac-3ddbebdffee1", "node_type": "1", "metadata": {"window": "And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n "}, "hash": "1131fe42b8360c7ebb4ceabec49f45469566ffdf34092978fe2dfab7cd3995f4", "class_name": "RelatedNodeInfo"}}, "text": "So, I would say, all of those things are what are giving us our \nconfidence. ", "start_char_idx": 3031, "end_char_idx": 3108, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b8f8a27d-6745-4851-8fac-3ddbebdffee1": {"__data__": {"id_": "b8f8a27d-6745-4851-8fac-3ddbebdffee1", "embedding": null, "metadata": {"window": "And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44913343-8779-4965-88a8-71f2e1707003", "node_type": "1", "metadata": {"window": "So, that's where our community provider business, I \nthink, from a macro standpoint is wel l positioned.  \n \n And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "original_text": "So, I would say, all of those things are what are giving us our \nconfidence. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f6ca06777cf4640e1eb47441ae5d67f42479735e4d282c39d55c67a429d70abb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b0add6ae-83e7-449e-ba71-e654147038a9", "node_type": "1", "metadata": {"window": "And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. "}, "hash": "16fc37105896957505ca8a9c1b0d7eec47b4e9b049b5c590473eeffe9f801bea", "class_name": "RelatedNodeInfo"}}, "text": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "start_char_idx": 3108, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b0add6ae-83e7-449e-ba71-e654147038a9": {"__data__": {"id_": "b0add6ae-83e7-449e-ba71-e654147038a9", "embedding": null, "metadata": {"window": "And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b8f8a27d-6745-4851-8fac-3ddbebdffee1", "node_type": "1", "metadata": {"window": "And then, our US oncology business, we have particular depth and strength in oncology.  And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "81884395cd725f624db4abb442f333e0bfa1b1e894e7dbfb0526e8d72efc9f09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4bcef189-1bb0-4506-bdd0-8432d9f1a482", "node_type": "1", "metadata": {"window": "So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n "}, "hash": "d430f871f199a9ac2fc9b6af0a915f27eb805074eb09b4ddf6cdc68a4ef59240", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "start_char_idx": 3261, "end_char_idx": 3687, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4bcef189-1bb0-4506-bdd0-8432d9f1a482": {"__data__": {"id_": "4bcef189-1bb0-4506-bdd0-8432d9f1a482", "embedding": null, "metadata": {"window": "So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b0add6ae-83e7-449e-ba71-e654147038a9", "node_type": "1", "metadata": {"window": "And if you look at the \npipeline there, that continues to be strong.  So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "42f96aa3d75f766341c47d699c31b83d9e78864242e4c857e187f0ecb2f7e909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac9e391-2315-49e5-9592-584dd2c5fb4b", "node_type": "1", "metadata": {"window": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "db77f47e003917d1efac9f26e25633824d32ba3c293f9f87989257df79891347", "class_name": "RelatedNodeInfo"}}, "text": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "start_char_idx": 3687, "end_char_idx": 3834, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac9e391-2315-49e5-9592-584dd2c5fb4b": {"__data__": {"id_": "8ac9e391-2315-49e5-9592-584dd2c5fb4b", "embedding": null, "metadata": {"window": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4bcef189-1bb0-4506-bdd0-8432d9f1a482", "node_type": "1", "metadata": {"window": "So, I would say, all of those things are what are giving us our \nconfidence.  But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52066ecd7cbee29f3372d93c190bbb6c7c60b75fefd30b50da56614b1949778a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eb1d164c-db36-4cc0-816e-b07427fd084b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. "}, "hash": "f0e7705fe271fbea348afbacf0d5f874573885fbdac77488447a63e95d35e9aa", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3834, "end_char_idx": 4194, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eb1d164c-db36-4cc0-816e-b07427fd084b": {"__data__": {"id_": "eb1d164c-db36-4cc0-816e-b07427fd084b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac9e391-2315-49e5-9592-584dd2c5fb4b", "node_type": "1", "metadata": {"window": "But at the  bottom \u2013 at the end of the day, it's really the execution of the business to let you capitalize \non those macro trends and opportunities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6811ca652a8d178f93de06ecb6f52597c2d438b4a4ae878b9e0f28e685713a4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "874c26e4-625d-4d8d-a216-09df3a2216e9", "node_type": "1", "metadata": {"window": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and "}, "hash": "2b6d388c24dc3df3b74061fe04cbef288e74bbc3656be146cc5b747b816c5bbe", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "start_char_idx": 4194, "end_char_idx": 4313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "874c26e4-625d-4d8d-a216-09df3a2216e9": {"__data__": {"id_": "874c26e4-625d-4d8d-a216-09df3a2216e9", "embedding": null, "metadata": {"window": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5", "node_type": "4", "metadata": {"page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3df3d1203467d979d1483dbb9b24b0059ed8dae5d0a4bfd36c81be19ca2b9015", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eb1d164c-db36-4cc0-816e-b07427fd084b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nI guess my follow -up, Britt, you mentioned the cost cuts and the opport unities that you've found there.  So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021. ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ce29f244546f7b4b633d61a443b81d6e1cf8b0fa6c654b13c7f4bbefabcdc01", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "792ca380-fac8-4716-8adb-07aeed6db45b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "original_text": "McKesson Corp.  "}, "hash": "26205b66a6cf38a09717b4dcd9b9a0f180d12a0d3b9e992e7ad2b2a91bb226b0", "class_name": "RelatedNodeInfo"}}, "text": "So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "start_char_idx": 4313, "end_char_idx": 4542, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "792ca380-fac8-4716-8adb-07aeed6db45b": {"__data__": {"id_": "792ca380-fac8-4716-8adb-07aeed6db45b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "874c26e4-625d-4d8d-a216-09df3a2216e9", "node_type": "1", "metadata": {"window": "So, do you \nthink there's a lot of runway left as we think about cost opportunities both on the corporate side and also on the \noperation side?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, our cost program, Brian, what we talked about we would capture these cost savings at the end of fiscal \n2021.  So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "original_text": "So, we're still making progress not only in leveraging the scale of our enterprise across all of our business \nunits, but some of the  things that we've talked about previously in terms of back office function transformation and ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "69989db3d76df16f59752ef5c2ebc1697fcf39c6a0c766488d3f05382d8838a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e879e79a-a400-40a2-8aac-ac8e73bc997b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n"}, "hash": "5806d6ac98d15c101aff63ee756f7928c6c648c56adb417bfc215070d70e216c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e879e79a-a400-40a2-8aac-ac8e73bc997b": {"__data__": {"id_": "e879e79a-a400-40a2-8aac-ac8e73bc997b", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "792ca380-fac8-4716-8adb-07aeed6db45b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "afe9b5a4c48ef5b9343d9ac1fc063a8ba54fa5328793c601193434250491d40c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49922953-162a-4795-a15d-865f00f77376", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n ", "original_text": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021. "}, "hash": "b042b5153018ec4099ebb4d19d3b20877db1ce06b2cf6041190cdeccf6f83643", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n", "start_char_idx": 16, "end_char_idx": 340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49922953-162a-4795-a15d-865f00f77376": {"__data__": {"id_": "49922953-162a-4795-a15d-865f00f77376", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n ", "original_text": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e879e79a-a400-40a2-8aac-ac8e73bc997b", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2c84ec50a35593e7dca5f070d72221984acff3ff68c6bea6529c3fae852a227f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "45278803-e4cd-491e-ab46-959f51f61b28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n "}, "hash": "e0066683926da5ce36ae298d1f36f2d2fab16c2f93ccc0b211b98c8c78aa8dc9", "class_name": "RelatedNodeInfo"}}, "text": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021. ", "start_char_idx": 340, "end_char_idx": 468, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "45278803-e4cd-491e-ab46-959f51f61b28": {"__data__": {"id_": "45278803-e4cd-491e-ab46-959f51f61b28", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49922953-162a-4795-a15d-865f00f77376", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n ", "original_text": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f78b36b30249135b4c9070b0a1f2d9b1f07eb6fd035d45863d1115f392bc5b8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "58516f36-faa6-4750-81c2-f57c31d94fff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. "}, "hash": "febe45b4551100d7840d841420b9a44d82a4dff67f5cb339b780d759a8240a78", "class_name": "RelatedNodeInfo"}}, "text": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "start_char_idx": 468, "end_char_idx": 654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "58516f36-faa6-4750-81c2-f57c31d94fff": {"__data__": {"id_": "58516f36-faa6-4750-81c2-f57c31d94fff", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "45278803-e4cd-491e-ab46-959f51f61b28", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "82555e1d95d10c0655dd34f5d64f6dcf2b6ea87ce4756aff38a521460b837e45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a3ab2d56-4035-4651-9165-974b3f814100", "node_type": "1", "metadata": {"window": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "original_text": "Thanks, guys.  \n "}, "hash": "ed3318b2f533d3e855c119619cfee5de9b048d14caec5a480334abab9cf28580", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "start_char_idx": 654, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a3ab2d56-4035-4651-9165-974b3f814100": {"__data__": {"id_": "a3ab2d56-4035-4651-9165-974b3f814100", "embedding": null, "metadata": {"window": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "original_text": "Thanks, guys.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "58516f36-faa6-4750-81c2-f57c31d94fff", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f4bce4dec28c4dec8df0dffa300d8a35830becf62c1d1c9e5749c6c9f75894ed", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0e98a3db-95fb-4953-9199-cef8992d8752", "node_type": "1", "metadata": {"window": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "cb59e4dbb70cc36ca1ce15ca7ba76cb1fb6172af21a00d3d8dcd1c4e8017b983", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, guys.  \n ", "start_char_idx": 982, "end_char_idx": 999, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0e98a3db-95fb-4953-9199-cef8992d8752": {"__data__": {"id_": "0e98a3db-95fb-4953-9199-cef8992d8752", "embedding": null, "metadata": {"window": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a3ab2d56-4035-4651-9165-974b3f814100", "node_type": "1", "metadata": {"window": "So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "original_text": "Thanks, guys.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cca3514adc061be05d91360ce93a23eec558e236010f5ca437aebb8b866e9a5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a6f4187-74eb-4afc-81cf-76df14289826", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. "}, "hash": "59b5b5a0423e696b8a23830f8978b9f4137d3808d56541c8af8b256f422aea10", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 999, "end_char_idx": 1340, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a6f4187-74eb-4afc-81cf-76df14289826": {"__data__": {"id_": "0a6f4187-74eb-4afc-81cf-76df14289826", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0e98a3db-95fb-4953-9199-cef8992d8752", "node_type": "1", "metadata": {"window": "However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c02d0b944c65fffab9a08f9c60a0ae4cb7452a82daf335653c3f9e5d8fc1a59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "26024142-e50f-4c63-b6bd-995b1ea6331f", "node_type": "1", "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n ", "original_text": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. "}, "hash": "93483a6c8263a7f50c7dc96920b645ba454295f2dc9bdaf6952140d3b4c4cbef", "class_name": "RelatedNodeInfo"}}, "text": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "start_char_idx": 1340, "end_char_idx": 1440, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "26024142-e50f-4c63-b6bd-995b1ea6331f": {"__data__": {"id_": "26024142-e50f-4c63-b6bd-995b1ea6331f", "embedding": null, "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n ", "original_text": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a6f4187-74eb-4afc-81cf-76df14289826", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "original_text": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f305db01686c64df47491f693f7c0e80f5748a8f4e6a9af4576f7ec96a0356b3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6ac0a699-efa8-4b1f-820a-806b4782f617", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "It's a part of the way we think \nabout how we manage and run the business.  \n "}, "hash": "cf32342d86f01f5374feaddd880193e61e40049afb621f3d9bed6f4881756ac8", "class_name": "RelatedNodeInfo"}}, "text": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "start_char_idx": 1440, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6ac0a699-efa8-4b1f-820a-806b4782f617": {"__data__": {"id_": "6ac0a699-efa8-4b1f-820a-806b4782f617", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "It's a part of the way we think \nabout how we manage and run the business.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "26024142-e50f-4c63-b6bd-995b1ea6331f", "node_type": "1", "metadata": {"window": "Thanks, guys.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n ", "original_text": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8da4a76c9aaef4001aff635fea62ffb8353d349f9de3ccfafb431109a5108ebb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34ed8821-0310-45d0-bbc6-06c10c5e66a5", "node_type": "1", "metadata": {"window": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. "}, "hash": "963516790b3a0960eef136c05747af8030e72634c9c88d12798cd9a0e90e214d", "class_name": "RelatedNodeInfo"}}, "text": "It's a part of the way we think \nabout how we manage and run the business.  \n ", "start_char_idx": 1541, "end_char_idx": 1619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34ed8821-0310-45d0-bbc6-06c10c5e66a5": {"__data__": {"id_": "34ed8821-0310-45d0-bbc6-06c10c5e66a5", "embedding": null, "metadata": {"window": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6ac0a699-efa8-4b1f-820a-806b4782f617", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "original_text": "It's a part of the way we think \nabout how we manage and run the business.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2fb8a7b301d0d01f5b6d20d186417d9c7c4cbaee621d49748f66c3332ca4bff2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bac0d47-5370-4620-83f1-6eae30386112", "node_type": "1", "metadata": {"window": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "T hank you.  \n "}, "hash": "cb20ec13e22c67d5525c5612c3e9792b003fd08103818ce7a74c41f918909682", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "start_char_idx": 654, "end_char_idx": 982, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bac0d47-5370-4620-83f1-6eae30386112": {"__data__": {"id_": "2bac0d47-5370-4620-83f1-6eae30386112", "embedding": null, "metadata": {"window": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "T hank you.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34ed8821-0310-45d0-bbc6-06c10c5e66a5", "node_type": "1", "metadata": {"window": "A \nI mean efficiency is a core part of the way you have to run a business  like this at this scale.  So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b85bc2a1e1c54a83dd4e15ffe6f852534df16296af5d5e45bc1aeb322e8d1b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2254ffd-77bf-4e43-88c2-852851710bae", "node_type": "1", "metadata": {"window": "It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n "}, "hash": "c299882cce5b710ae62f95dee4bc775bc4c0667f75e25e9b085e5f766c77c598", "class_name": "RelatedNodeInfo"}}, "text": "T hank you.  \n ", "start_char_idx": 1947, "end_char_idx": 1962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2254ffd-77bf-4e43-88c2-852851710bae": {"__data__": {"id_": "b2254ffd-77bf-4e43-88c2-852851710bae", "embedding": null, "metadata": {"window": "It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bac0d47-5370-4620-83f1-6eae30386112", "node_type": "1", "metadata": {"window": "So, it is a program \nthat we implemented a few years ago, but most importantly to me it's a mindset.  It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat. ", "original_text": "T hank you.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8d1e2829d9c0807ff2f8e068366da97b8ff87be62fd948c776538a10a96aaa80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "13347dab-1b85-4a19-9e05-3240219d7d93", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "5441773db67ed3c035c3ed8d267b3d1d8bdeb0205c293dd91976f0b2cdc91f33", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "start_char_idx": 1962, "end_char_idx": 2300, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "13347dab-1b85-4a19-9e05-3240219d7d93": {"__data__": {"id_": "13347dab-1b85-4a19-9e05-3240219d7d93", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2254ffd-77bf-4e43-88c2-852851710bae", "node_type": "1", "metadata": {"window": "It's a part of the way we think \nabout how we manage and run the business.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0e6534edc4dc31b9f806d5309df5fadf9632aa0663e056d14ad8672a58fbb9b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "79e9fea0-d404-41d3-be82-d75f90dc827e", "node_type": "1", "metadata": {"window": "T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "original_text": "LLC  Q \nGreat. "}, "hash": "6d26fa6dc8f01eef83c9e1556c74e0297bdde6010aae84e7ce337f312f02fbf9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 2300, "end_char_idx": 2619, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "79e9fea0-d404-41d3-be82-d75f90dc827e": {"__data__": {"id_": "79e9fea0-d404-41d3-be82-d75f90dc827e", "embedding": null, "metadata": {"window": "T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "original_text": "LLC  Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "13347dab-1b85-4a19-9e05-3240219d7d93", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian G. Tanquilut  \nAnalyst, Jefferies LLC  Q \nGot it.  T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "06a8b2b893cae4d89cbaff5adbc3261964f959e1e047e99a7688a1012d1fb9d6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9ada613-ec47-40d3-bd47-cbab7de5e9b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt. ", "original_text": "Thanks for the questions. "}, "hash": "fbe783ee38ca497308856ac3cceb41a3bf4df201439bf165902962fd036952e4", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nGreat. ", "start_char_idx": 2619, "end_char_idx": 2634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9ada613-ec47-40d3-bd47-cbab7de5e9b8": {"__data__": {"id_": "b9ada613-ec47-40d3-bd47-cbab7de5e9b8", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt. ", "original_text": "Thanks for the questions. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "79e9fea0-d404-41d3-be82-d75f90dc827e", "node_type": "1", "metadata": {"window": "T hank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "original_text": "LLC  Q \nGreat. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0544b0e48a1466eac95c6c13133dbc2aa7cf21fce4a435dec0fc7c683a630d4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "db297077-ff8c-4e6c-aad4-a251a24eb7e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "original_text": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. "}, "hash": "9581d2451e95c9a1467610232d47512e015ea07c709cf8273f22a064dee3e33d", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the questions. ", "start_char_idx": 2634, "end_char_idx": 2660, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "db297077-ff8c-4e6c-aad4-a251a24eb7e1": {"__data__": {"id_": "db297077-ff8c-4e6c-aad4-a251a24eb7e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "original_text": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9ada613-ec47-40d3-bd47-cbab7de5e9b8", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Robert Jones with Goldman Sachs.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt. ", "original_text": "Thanks for the questions. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "05a425a397f29c577c2319971eeefd5e99f2a275668689b2a06366fb0c16c72d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b6314490-afce-4db1-b48c-04dd9e0cbc73", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n ", "original_text": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. "}, "hash": "7757fc32e6045f86766bb5d11c5a786b9bae3d869162f137d84082b2375d1fd1", "class_name": "RelatedNodeInfo"}}, "text": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "start_char_idx": 2660, "end_char_idx": 2749, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b6314490-afce-4db1-b48c-04dd9e0cbc73": {"__data__": {"id_": "b6314490-afce-4db1-b48c-04dd9e0cbc73", "embedding": null, "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n ", "original_text": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "db297077-ff8c-4e6c-aad4-a251a24eb7e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "original_text": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cf42f474f3d15c5c462a66ae61b08414390d9f1230f8bcd5476cf47d5a803c6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c6c6d19-b984-449b-97ca-708c0b314d16", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know there's a number of moving pieces, Britt. "}, "hash": "26a8b39ebed6b8bbc83a1e9c04237e0e60cf154c61d1104929d3e1d45130603d", "class_name": "RelatedNodeInfo"}}, "text": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "start_char_idx": 2749, "end_char_idx": 2907, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c6c6d19-b984-449b-97ca-708c0b314d16": {"__data__": {"id_": "6c6c6d19-b984-449b-97ca-708c0b314d16", "embedding": null, "metadata": {"window": "Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know there's a number of moving pieces, Britt. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b6314490-afce-4db1-b48c-04dd9e0cbc73", "node_type": "1", "metadata": {"window": "LLC  Q \nGreat.  Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n ", "original_text": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "210e3905243d1874bc5a4c83402f299f7dc40c54cff74ce029162eeb10dff4b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b2c883a-d71c-46b3-b559-5d1685555bc8", "node_type": "1", "metadata": {"window": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob. ", "original_text": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. "}, "hash": "e90fbf371f6fb2acd2eb561162366a444a40290f80e56dc9c242a10efdac2bfa", "class_name": "RelatedNodeInfo"}}, "text": "I know there's a number of moving pieces, Britt. ", "start_char_idx": 2907, "end_char_idx": 2956, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b2c883a-d71c-46b3-b559-5d1685555bc8": {"__data__": {"id_": "5b2c883a-d71c-46b3-b559-5d1685555bc8", "embedding": null, "metadata": {"window": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob. ", "original_text": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c6c6d19-b984-449b-97ca-708c0b314d16", "node_type": "1", "metadata": {"window": "Thanks for the questions.  I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "I know there's a number of moving pieces, Britt. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "805019c6ad239982f2778cbde29ab158269d3588308468af255a8c239fb99a4f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7", "node_type": "1", "metadata": {"window": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied. ", "original_text": "So, just want to make sure we had the moving \npieces there correctly.  \n "}, "hash": "06ce310f1fb0210dc3c34aa89047d13ef5eb0d1b4ff4274f2b4c9fd673b24e77", "class_name": "RelatedNodeInfo"}}, "text": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "start_char_idx": 2956, "end_char_idx": 3261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7": {"__data__": {"id_": "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7", "embedding": null, "metadata": {"window": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied. ", "original_text": "So, just want to make sure we had the moving \npieces there correctly.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b2c883a-d71c-46b3-b559-5d1685555bc8", "node_type": "1", "metadata": {"window": "I guess just to go back to the segment guidance and specifically the US Pharma \nsegment.  It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob. ", "original_text": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e1044f4d306c5ce80f56f6d05dacac3cd28c4441dbee34a605c5dfa2bd07a56", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efd44c8b-c9fe-452b-9956-97010041a70f", "node_type": "1", "metadata": {"window": "I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "1baf11a2b349efe565e3b7162dac696aa0f717a7be75c7fb02badb823ebfdc68", "class_name": "RelatedNodeInfo"}}, "text": "So, just want to make sure we had the moving \npieces there correctly.  \n ", "start_char_idx": 3261, "end_char_idx": 3334, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efd44c8b-c9fe-452b-9956-97010041a70f": {"__data__": {"id_": "efd44c8b-c9fe-452b-9956-97010041a70f", "embedding": null, "metadata": {"window": "I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7", "node_type": "1", "metadata": {"window": "It seems  like if I look at what's implied with 4Q, at the high end it seems like you're kind of calling for \nyear-over-year flat EBIT there in that segment.  I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied. ", "original_text": "So, just want to make sure we had the moving \npieces there correctly.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "328b69e274700b6234fcc9b1c2ca43460b9b824a6eeb5b4eb37aad0224cb4c2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5459581d-a3fd-43db-86af-41647cdbc619", "node_type": "1", "metadata": {"window": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n", "original_text": "A \nYeah, sure, Bob. "}, "hash": "259e94cc08e86a0df027f9ec80b332ecf01c7ab6cb309fbd1663754e7531e305", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3334, "end_char_idx": 3694, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5459581d-a3fd-43db-86af-41647cdbc619": {"__data__": {"id_": "5459581d-a3fd-43db-86af-41647cdbc619", "embedding": null, "metadata": {"window": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n", "original_text": "A \nYeah, sure, Bob. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efd44c8b-c9fe-452b-9956-97010041a70f", "node_type": "1", "metadata": {"window": "I know there's a number of moving pieces, Britt.  But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1913515cd1e6967e83fb9321a3b8595edbda6c6c46cc12fa6b9b28be3a9021b6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20487140-c2cb-4059-951f-913739aa3b29", "node_type": "1", "metadata": {"window": "So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "original_text": "You're right about the implied. "}, "hash": "0bcc255e377d882cc0af349bcda4e1c1e35be33a75834cfea57243ee97b577ad", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, sure, Bob. ", "start_char_idx": 3694, "end_char_idx": 3714, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20487140-c2cb-4059-951f-913739aa3b29": {"__data__": {"id_": "20487140-c2cb-4059-951f-913739aa3b29", "embedding": null, "metadata": {"window": "So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "original_text": "You're right about the implied. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5459581d-a3fd-43db-86af-41647cdbc619", "node_type": "1", "metadata": {"window": "But maybe could \nyou just help us think about what the major  swing factors are in 4Q because you guys highlighted the business \nthere, in particular, specialty seems to be performing well and there's some momentum, but it seems like 4Q \nyou're implying at least that things could potentially slow a bit.  So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n", "original_text": "A \nYeah, sure, Bob. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a23fef4dc7e0cfe2fd526b7e232642af5c7acb90cc345cd950349d938357c61", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a9cb4ac4-e79c-461b-bdba-94605ed127ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "original_text": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. "}, "hash": "29b89962c36387cd19c58257d600ddbdcdad69e2cb8904ee280229a1277ccc4b", "class_name": "RelatedNodeInfo"}}, "text": "You're right about the implied. ", "start_char_idx": 3714, "end_char_idx": 3746, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a9cb4ac4-e79c-461b-bdba-94605ed127ae": {"__data__": {"id_": "a9cb4ac4-e79c-461b-bdba-94605ed127ae", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "original_text": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20487140-c2cb-4059-951f-913739aa3b29", "node_type": "1", "metadata": {"window": "So, just want to make sure we had the moving \npieces there correctly.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "original_text": "You're right about the implied. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c101a12a5b247a00f9b1c42eda5caa5d028937c3b4da8f88d752638e3ffc1466", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ae85804-eee6-40e1-a6b7-1b2799663b2a", "node_type": "1", "metadata": {"window": "A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "We've seen that historically.  \n \n"}, "hash": "d5b5e6c36b29e6fecbdf82b3cd532265473e226fa25a10663315e957644341c9", "class_name": "RelatedNodeInfo"}}, "text": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "start_char_idx": 3746, "end_char_idx": 4012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ae85804-eee6-40e1-a6b7-1b2799663b2a": {"__data__": {"id_": "9ae85804-eee6-40e1-a6b7-1b2799663b2a", "embedding": null, "metadata": {"window": "A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "We've seen that historically.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a9cb4ac4-e79c-461b-bdba-94605ed127ae", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "original_text": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a9cfcab5204d26260facfad8d403eee34e758821bd29236f5307646daf02669f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370", "node_type": "1", "metadata": {"window": "You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. "}, "hash": "ad3b991bf9a639bc99eab79a2f74f63a2a2f13be3ffbce1ab54d5a0a27587b12", "class_name": "RelatedNodeInfo"}}, "text": "We've seen that historically.  \n \n", "start_char_idx": 4012, "end_char_idx": 4046, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370": {"__data__": {"id_": "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370", "embedding": null, "metadata": {"window": "You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ae85804-eee6-40e1-a6b7-1b2799663b2a", "node_type": "1", "metadata": {"window": "A \nYeah, sure, Bob.  You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "We've seen that historically.  \n \n", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fb57b3df80d058e973f2ab3ee8009f01e79905b7fd1b822e98e350e1ebb9e67c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b", "node_type": "1", "metadata": {"window": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. "}, "hash": "f814fec793d398eb21009ac2888c868db477ba3eba4fae0c5ff07308391f4f4c", "class_name": "RelatedNodeInfo"}}, "text": "I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "start_char_idx": 4046, "end_char_idx": 4183, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b": {"__data__": {"id_": "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b", "embedding": null, "metadata": {"window": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370", "node_type": "1", "metadata": {"window": "You're right about the implied.  What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93f935462a9141560adf950eee2213ae2d4228a185fc6df3213e892d77d906cb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b094c53a-4119-4ab1-9ba1-2a387ee5ab34", "node_type": "1", "metadata": {"window": "We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n "}, "hash": "b88cc8f58c15985f254334e6eea695bf6dac587d46fe27cd767883e567482347", "class_name": "RelatedNodeInfo"}}, "text": "I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "start_char_idx": 4183, "end_char_idx": 4394, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b094c53a-4119-4ab1-9ba1-2a387ee5ab34": {"__data__": {"id_": "b094c53a-4119-4ab1-9ba1-2a387ee5ab34", "embedding": null, "metadata": {"window": "We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081", "node_type": "4", "metadata": {"page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd063cec33e1896c54b36b51028891ae7dfee75171c5a26da3f5a0c130662499", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b", "node_type": "1", "metadata": {"window": "What I would just go back to and point out is that I've talked  about \nin a business the size of ours with customers that are growing and you have mix that is changing in terms of \ncustomer and product mix, we are going to see fluctuations from quarter -to-quarter.  We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics. ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a09ad387436ad7bde4a218687bdd3194a5abc7b43646826f6e24b06afa31a00c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5cc71b01-8152-46c1-8059-6c7286116457", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year. ", "original_text": "McKesson Corp.  "}, "hash": "50db6746ce37faaf233be47f35a199d1cf4fc2fd88a53dfed1ff035287220bca", "class_name": "RelatedNodeInfo"}}, "text": "But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "start_char_idx": 4394, "end_char_idx": 4556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5cc71b01-8152-46c1-8059-6c7286116457": {"__data__": {"id_": "5cc71b01-8152-46c1-8059-6c7286116457", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b094c53a-4119-4ab1-9ba1-2a387ee5ab34", "node_type": "1", "metadata": {"window": "We've seen that historically.  \n \n I think we're seeing that  a little bit more this year as some of our larger retail national customers are growing a \nlittle bit faster.  I think what we're pleased with though, as Brian talked about, there is some stability in the pricing \nenvironment, particularly with branded prici ng, certainly continue to make good progress against generics.  But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "original_text": "But \nwhat you should expect, as I talked about at the beginning, is that we are going to see some items that are going \nto fluctuate from quarter -to-quarter.  \n ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35ec2b5bb214603a5c711ddebb069749fdd07110ed6871652ff7a73e257013f2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6252d7e-8400-4ad8-a2f9-434d874a3690", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul. "}, "hash": "464ebce8dad5bce342709377a23445d013e8c8da1cdae032114a975945ceb31f", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6252d7e-8400-4ad8-a2f9-434d874a3690": {"__data__": {"id_": "a6252d7e-8400-4ad8-a2f9-434d874a3690", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5cc71b01-8152-46c1-8059-6c7286116457", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0af4c6c87114a14c1103420268522d8af0a300f729317a4d20211589bb53011b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b70896e7-41a7-430d-8080-656fba9fe054", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "original_text": "We look at our business on \nan annual basis. "}, "hash": "c7e2b0496135bde736b57dc341c016d9c9f9fa40159607983a2860e07a9d94d7", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul. ", "start_char_idx": 16, "end_char_idx": 263, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b70896e7-41a7-430d-8080-656fba9fe054": {"__data__": {"id_": "b70896e7-41a7-430d-8080-656fba9fe054", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "original_text": "We look at our business on \nan annual basis. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6252d7e-8400-4ad8-a2f9-434d874a3690", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d439ce5ae3e8018ee55f6de64747d6a96d35a6791099c4fe100492e32418c8f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And these items do tend to balance out over the course of the year. "}, "hash": "d1d8a705a688deddb98cb5fcde828d2d0132bee7a7e126cf04c73c1c0b9a5eaa", "class_name": "RelatedNodeInfo"}}, "text": "We look at our business on \nan annual basis. ", "start_char_idx": 263, "end_char_idx": 308, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3": {"__data__": {"id_": "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And these items do tend to balance out over the course of the year. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b70896e7-41a7-430d-8080-656fba9fe054", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "original_text": "We look at our business on \nan annual basis. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "401211bb1d3707acf451f9e83819baf486f6c59a954b4f26a652e27ca0ae743e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4f46f62-e0b3-45c5-a935-c0f9b9215425", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair. ", "original_text": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. "}, "hash": "534688813950b568ca2f39fe80f21c9022bd5e01a18f5e3e2d3975558de8062b", "class_name": "RelatedNodeInfo"}}, "text": "And these items do tend to balance out over the course of the year. ", "start_char_idx": 308, "end_char_idx": 376, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4f46f62-e0b3-45c5-a935-c0f9b9215425": {"__data__": {"id_": "f4f46f62-e0b3-45c5-a935-c0f9b9215425", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair. ", "original_text": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "original_text": "And these items do tend to balance out over the course of the year. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "23badf618414a949d08190321188bfef7bad3d3976361e377735abe80d4ae3bc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82", "node_type": "1", "metadata": {"window": "We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "original_text": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n "}, "hash": "49d59d63e151031b9de425e89a6594599d9a5864d776490702f0cd25ee38d92b", "class_name": "RelatedNodeInfo"}}, "text": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "start_char_idx": 376, "end_char_idx": 668, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82": {"__data__": {"id_": "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82", "embedding": null, "metadata": {"window": "We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "original_text": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4f46f62-e0b3-45c5-a935-c0f9b9215425", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair. ", "original_text": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53b49cb80ca5cd7c3624f6b4549a6bc3b98d72bdb4f85728ff5370b834ab231c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5fc36a86-b882-4631-862d-dfa8902ed3c9", "node_type": "1", "metadata": {"window": "And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. "}, "hash": "3b9f5bbad382f7dc36605a9bac5fe2105f45bd412e534cce49846c10a6e7ee46", "class_name": "RelatedNodeInfo"}}, "text": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "start_char_idx": 668, "end_char_idx": 797, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5fc36a86-b882-4631-862d-dfa8902ed3c9": {"__data__": {"id_": "5fc36a86-b882-4631-862d-dfa8902ed3c9", "embedding": null, "metadata": {"window": "And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82", "node_type": "1", "metadata": {"window": "We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "original_text": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91b48f95134307de05deb391335395b686e3d68809786dca3add4d1eb1e22b77", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "34f97fbf-f68a-408c-98ba-b74777ac6ff0", "node_type": "1", "metadata": {"window": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "original_text": "LLC  Q \nNo, that's fair. "}, "hash": "6372001ef6ca6d136fbd0bdf20548ea195eb4766136ece718682f181fa79844f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "start_char_idx": 797, "end_char_idx": 1116, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "34f97fbf-f68a-408c-98ba-b74777ac6ff0": {"__data__": {"id_": "34f97fbf-f68a-408c-98ba-b74777ac6ff0", "embedding": null, "metadata": {"window": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "original_text": "LLC  Q \nNo, that's fair. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5fc36a86-b882-4631-862d-dfa8902ed3c9", "node_type": "1", "metadata": {"window": "And these items do tend to balance out over the course of the year.  We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bd05238d5438ffbd1d5747833969a3de62cea82365e49b53c999857286d8dd54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebb56970-5e9d-4909-853c-ee869950ddc7", "node_type": "1", "metadata": {"window": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind. ", "original_text": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. "}, "hash": "3d743768538615cf1b57ca1dff4499ad24412e5badf6ea7b420d972902768128", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nNo, that's fair. ", "start_char_idx": 1116, "end_char_idx": 1141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebb56970-5e9d-4909-853c-ee869950ddc7": {"__data__": {"id_": "ebb56970-5e9d-4909-853c-ee869950ddc7", "embedding": null, "metadata": {"window": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind. ", "original_text": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "34f97fbf-f68a-408c-98ba-b74777ac6ff0", "node_type": "1", "metadata": {"window": "We were very pleased that \nwe started the year with being able to guide back to growth in this segme nt and we're very pleased that given the \nmomentum and the execution that Brian talked about, particularly in our specialty business, so we could raise that \nguidance today to the upper end.  So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "original_text": "LLC  Q \nNo, that's fair. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c19d7273cf5f2a0587978f0165477e0a9929a4ed6e82f9639b7a1851d4ea23f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f77af948-1c36-4058-9e44-4ab030be7c85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "original_text": "And so I \nknow we'll get more detail i n May. "}, "hash": "fa518c8631f51ec292aaa8ac77f2df8d22034c4317c3433da49da33d3525f870", "class_name": "RelatedNodeInfo"}}, "text": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "start_char_idx": 1141, "end_char_idx": 1232, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f77af948-1c36-4058-9e44-4ab030be7c85": {"__data__": {"id_": "f77af948-1c36-4058-9e44-4ab030be7c85", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "original_text": "And so I \nknow we'll get more detail i n May. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebb56970-5e9d-4909-853c-ee869950ddc7", "node_type": "1", "metadata": {"window": "So, we're making good progress, but I think you should expect to co ntinue to \nsee some fluctuation in our quarterly results.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind. ", "original_text": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6e85994295366983b7b843e45e4aafc79267e2982fa19fc5138bfac80514f30", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "61856695-56ae-4a29-95a6-c24d78c4bc5d", "node_type": "1", "metadata": {"window": "LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds. ", "original_text": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. "}, "hash": "69fcfd67066f0f4a93cd064f2e006c01a576ebdfcd44f842818846d7df8157b8", "class_name": "RelatedNodeInfo"}}, "text": "And so I \nknow we'll get more detail i n May. ", "start_char_idx": 1232, "end_char_idx": 1278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "61856695-56ae-4a29-95a6-c24d78c4bc5d": {"__data__": {"id_": "61856695-56ae-4a29-95a6-c24d78c4bc5d", "embedding": null, "metadata": {"window": "LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds. ", "original_text": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f77af948-1c36-4058-9e44-4ab030be7c85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRobert P. Jones  \nAnalyst, Goldman Sachs & Co.  LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "original_text": "And so I \nknow we'll get more detail i n May. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a30a4b74d133fc609a82176c74027fa6d946bde58b9f611acc432caee755c55d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1665c421-687e-4e9f-ae44-bdacf3a97309", "node_type": "1", "metadata": {"window": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "original_text": "You guys have highlighted the VA is not a material headwind. "}, "hash": "865afdd797d1d9fc6439b2345424f9b37ea3306c8c6f45d707aac01ba0f342be", "class_name": "RelatedNodeInfo"}}, "text": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "start_char_idx": 1278, "end_char_idx": 1391, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1665c421-687e-4e9f-ae44-bdacf3a97309": {"__data__": {"id_": "1665c421-687e-4e9f-ae44-bdacf3a97309", "embedding": null, "metadata": {"window": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "original_text": "You guys have highlighted the VA is not a material headwind. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "61856695-56ae-4a29-95a6-c24d78c4bc5d", "node_type": "1", "metadata": {"window": "LLC  Q \nNo, that's fair.  And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds. ", "original_text": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3a71f5e329fed6333bf9f42170738e8d020f4c6f636a7bbb5dccd6946747c2b5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "771d07bc-d309-429c-8593-c19b8fb9b6d9", "node_type": "1", "metadata": {"window": "And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. "}, "hash": "9b84cc9b0d6f22d3c8a157f581747c098e0e29d6e555a176ace90c689cbf12a7", "class_name": "RelatedNodeInfo"}}, "text": "You guys have highlighted the VA is not a material headwind. ", "start_char_idx": 1391, "end_char_idx": 1452, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "771d07bc-d309-429c-8593-c19b8fb9b6d9": {"__data__": {"id_": "771d07bc-d309-429c-8593-c19b8fb9b6d9", "embedding": null, "metadata": {"window": "And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1665c421-687e-4e9f-ae44-bdacf3a97309", "node_type": "1", "metadata": {"window": "And then I guess, Brian, you opened the door to a little bit of preliminary 2021 thoughts.  And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "original_text": "You guys have highlighted the VA is not a material headwind. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "496f25c27badef07e9405c3cd2e92c23c2d7447d8477a7f8e4ee0ce2452ad672", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0dab892d-7109-4230-9c17-0c10c9741a63", "node_type": "1", "metadata": {"window": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "original_text": "All seem pretty neutral to tailwinds. "}, "hash": "d05bb36f9652e08b6087bbb4eb41a75b0e89dcfa768a94ed50e5461641facb91", "class_name": "RelatedNodeInfo"}}, "text": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "start_char_idx": 1452, "end_char_idx": 1541, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0dab892d-7109-4230-9c17-0c10c9741a63": {"__data__": {"id_": "0dab892d-7109-4230-9c17-0c10c9741a63", "embedding": null, "metadata": {"window": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "original_text": "All seem pretty neutral to tailwinds. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "771d07bc-d309-429c-8593-c19b8fb9b6d9", "node_type": "1", "metadata": {"window": "And so I \nknow we'll get more detail i n May.  But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5e20c7e92f7b8444cb5a3b5e7be824487f83184a2f69f6e90180b0f56d9ced6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "408c5946-b07f-4dc1-ab1d-091b980ccae3", "node_type": "1", "metadata": {"window": "You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "original_text": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n "}, "hash": "919609fc050f1f46d9b3ba46a5de11a4bbc048fba2aa506fac52d8abaee014e8", "class_name": "RelatedNodeInfo"}}, "text": "All seem pretty neutral to tailwinds. ", "start_char_idx": 1541, "end_char_idx": 1579, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "408c5946-b07f-4dc1-ab1d-091b980ccae3": {"__data__": {"id_": "408c5946-b07f-4dc1-ab1d-091b980ccae3", "embedding": null, "metadata": {"window": "You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "original_text": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0dab892d-7109-4230-9c17-0c10c9741a63", "node_type": "1", "metadata": {"window": "But if I heard you correctly, it sounds like core drivers playing out in line this \nyear with your expectations.  You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "original_text": "All seem pretty neutral to tailwinds. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9150e5b369043f26e929517c1ef2b909b56b2a358c78e5d6dc4a531a168bd9a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2b12a39-2531-4280-a052-ef2cbf03f5cd", "node_type": "1", "metadata": {"window": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "29b8a31f76c48bec4956895d4e0ccc9d051690385283b8212fad206e46ecffd0", "class_name": "RelatedNodeInfo"}}, "text": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "start_char_idx": 1579, "end_char_idx": 1711, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2b12a39-2531-4280-a052-ef2cbf03f5cd": {"__data__": {"id_": "f2b12a39-2531-4280-a052-ef2cbf03f5cd", "embedding": null, "metadata": {"window": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "408c5946-b07f-4dc1-ab1d-091b980ccae3", "node_type": "1", "metadata": {"window": "You guys have highlighted the VA is not a material headwind.  It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "original_text": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "946c7c42952fdaaa168be68c2f6ecbe7ba870cad67c74ec6105b27600972aa7a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28", "node_type": "1", "metadata": {"window": "All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight. ", "original_text": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. "}, "hash": "38064c192dad7a39d275ac9a1653698e146311ee315aec9c96d9396b954d8e32", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 1711, "end_char_idx": 2052, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28": {"__data__": {"id_": "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28", "embedding": null, "metadata": {"window": "All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight. ", "original_text": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2b12a39-2531-4280-a052-ef2cbf03f5cd", "node_type": "1", "metadata": {"window": "It sounds like cost \nsavings will continue, could be a benefit from capital a llocation.  All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "71231983e915e927077269cf21a07a14f68adf373747aab462a5b42eea100a52", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76390cb2-dff3-4644-844a-d66ae0f0af25", "node_type": "1", "metadata": {"window": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "original_text": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. "}, "hash": "239c29a3720032a298ad2432aabcec9b84f7e4b239924383758fd75c10002ab0", "class_name": "RelatedNodeInfo"}}, "text": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "start_char_idx": 2052, "end_char_idx": 2165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76390cb2-dff3-4644-844a-d66ae0f0af25": {"__data__": {"id_": "76390cb2-dff3-4644-844a-d66ae0f0af25", "embedding": null, "metadata": {"window": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "original_text": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28", "node_type": "1", "metadata": {"window": "All seem pretty neutral to tailwinds.  Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight. ", "original_text": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7bd8fdb630177b904cef0d5a53119124ad3fae7392011b78bdf61e6c2e1e3e58", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "original_text": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. "}, "hash": "32ef703da404f62d08af4df87b62968458a8e706b81c8bbda818b99b096fce97", "class_name": "RelatedNodeInfo"}}, "text": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "start_char_idx": 2165, "end_char_idx": 2301, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b": {"__data__": {"id_": "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "original_text": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76390cb2-dff3-4644-844a-d66ae0f0af25", "node_type": "1", "metadata": {"window": "Is there any \nmajor headwinds you would have us start to contemplate as we start to think about framing 2021 more \nspecifically?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "original_text": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4978b96426d116738f06a299f03f6ded7248c7bd8af93a6a22dadb85b799ad48", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb", "node_type": "1", "metadata": {"window": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "original_text": "I would suspect we'll hear some commentary tonight. "}, "hash": "4b9f04fa4bf35ffcd90491c7d93a756e5d9f3450f9eafed7e1a84c75443e2089", "class_name": "RelatedNodeInfo"}}, "text": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "start_char_idx": 2301, "end_char_idx": 2424, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb": {"__data__": {"id_": "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb", "embedding": null, "metadata": {"window": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "original_text": "I would suspect we'll hear some commentary tonight. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "original_text": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "49221c827f0f89d1a3b5d09a91b094e9d6b90d9c4e1ea2f989883f78e9d6df0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4", "node_type": "1", "metadata": {"window": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "original_text": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. "}, "hash": "1868b480ae55ebdee008677456fb0e4f56d5a27def683977a34eb70fb8bf1a49", "class_name": "RelatedNodeInfo"}}, "text": "I would suspect we'll hear some commentary tonight. ", "start_char_idx": 2424, "end_char_idx": 2476, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4": {"__data__": {"id_": "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4", "embedding": null, "metadata": {"window": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "original_text": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb", "node_type": "1", "metadata": {"window": "A \nWell, look, as we come to May, we will try to be very thoughtful and share with you our view of the thinking.  If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "original_text": "I would suspect we'll hear some commentary tonight. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f3553b4557051bfc134db9f5ae280ff6268f406d7abafdc015039a546212da81", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b15f0657-6496-4da3-bb26-c40112607f4e", "node_type": "1", "metadata": {"window": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind. ", "original_text": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n"}, "hash": "dc8d8b3373a207dd2952b4bf43f56b00eff14e155e887ebcadf4c1b408229d7a", "class_name": "RelatedNodeInfo"}}, "text": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "start_char_idx": 2476, "end_char_idx": 2697, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b15f0657-6496-4da3-bb26-c40112607f4e": {"__data__": {"id_": "b15f0657-6496-4da3-bb26-c40112607f4e", "embedding": null, "metadata": {"window": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind. ", "original_text": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4", "node_type": "1", "metadata": {"window": "If I \nthink about what could materialize as headwinds, I mean the policy arena has been dynamic, well, probably for \nmost of my career.  But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "original_text": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "330b2bf8e9174c51a6df4e03e52353ed57cf884728ed8217efeccdcbf34d207b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e7d4e2c-ae28-4ede-9196-bad98da61ea1", "node_type": "1", "metadata": {"window": "I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n ", "original_text": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. "}, "hash": "95401d4b728846e7dd0a8696563912d25baf62a9ee49945cafbd13f6456b60f7", "class_name": "RelatedNodeInfo"}}, "text": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "start_char_idx": 2697, "end_char_idx": 2801, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e7d4e2c-ae28-4ede-9196-bad98da61ea1": {"__data__": {"id_": "6e7d4e2c-ae28-4ede-9196-bad98da61ea1", "embedding": null, "metadata": {"window": "I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n ", "original_text": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b15f0657-6496-4da3-bb26-c40112607f4e", "node_type": "1", "metadata": {"window": "But certainly for my tenure as CEO and yet while the clouds always seem to be gathering, \nnothing has really materialized.  I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind. ", "original_text": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "93aa970f09694baa669a217e2cbb3c3a2aca63e252abb9028c2a56115a1f5f64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3b22e94d-282e-49d3-8fd8-104eef50c869", "node_type": "1", "metadata": {"window": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. "}, "hash": "19c592bd416ecdb27eeb73a91d19bba686f37848935e67f44ccb947d7e3c227a", "class_name": "RelatedNodeInfo"}}, "text": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "start_char_idx": 2801, "end_char_idx": 3019, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3b22e94d-282e-49d3-8fd8-104eef50c869": {"__data__": {"id_": "3b22e94d-282e-49d3-8fd8-104eef50c869", "embedding": null, "metadata": {"window": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e7d4e2c-ae28-4ede-9196-bad98da61ea1", "node_type": "1", "metadata": {"window": "I would suspect we'll hear some commentary tonight.  I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n ", "original_text": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1a799d4f7fd0dc995ca782c875e39fdb71c56061dc420ea57a12b91db36e52bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0854f6a0-7380-466c-b21b-2d0af6a98d02", "node_type": "1", "metadata": {"window": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n ", "original_text": "So, I mean, those are the two things that first pop to mind. "}, "hash": "30ae7069b49974ed8b3cbcf8e0a15fcd79882f40477a684037252f791c45d661", "class_name": "RelatedNodeInfo"}}, "text": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "start_char_idx": 3019, "end_char_idx": 3289, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0854f6a0-7380-466c-b21b-2d0af6a98d02": {"__data__": {"id_": "0854f6a0-7380-466c-b21b-2d0af6a98d02", "embedding": null, "metadata": {"window": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n ", "original_text": "So, I mean, those are the two things that first pop to mind. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3b22e94d-282e-49d3-8fd8-104eef50c869", "node_type": "1", "metadata": {"window": "I think as we come into the \nface of election year, we'll be evaluating not only the policy proposals , but the politics that's around that sort of set \nof framework for the likelihood of any of that really getting done.  But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4434f0ee0bd55be20729745eab2bff415cde212fdfd26511436c1a899443913b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "969a6c96-3f6e-4c93-902a-e1dcb3280f8c", "node_type": "1", "metadata": {"window": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "Anything  you want \nto add, Britt?  \n "}, "hash": "4c0c7a3cfad21691304604cfada2a42b4b001236b9c8422663d0d035312bbd8a", "class_name": "RelatedNodeInfo"}}, "text": "So, I mean, those are the two things that first pop to mind. ", "start_char_idx": 3289, "end_char_idx": 3350, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "969a6c96-3f6e-4c93-902a-e1dcb3280f8c": {"__data__": {"id_": "969a6c96-3f6e-4c93-902a-e1dcb3280f8c", "embedding": null, "metadata": {"window": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "Anything  you want \nto add, Britt?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0854f6a0-7380-466c-b21b-2d0af6a98d02", "node_type": "1", "metadata": {"window": "But to me that's a normal part of being in \nhealthcare and a normal part of being in this business.  \n \n I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n ", "original_text": "So, I mean, those are the two things that first pop to mind. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6e9896efe5447fc23165ef3f21a5543e2a6c2ac9e91e26954d74f6a45780e998", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "be36b1fc-d932-4d9b-94df-17d1c03c8ce2", "node_type": "1", "metadata": {"window": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "8a7fe50b0c5c30e86376333e0df6f1b132059fe17edb9b9ec890c6cef418f782", "class_name": "RelatedNodeInfo"}}, "text": "Anything  you want \nto add, Britt?  \n ", "start_char_idx": 3350, "end_char_idx": 3388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "be36b1fc-d932-4d9b-94df-17d1c03c8ce2": {"__data__": {"id_": "be36b1fc-d932-4d9b-94df-17d1c03c8ce2", "embedding": null, "metadata": {"window": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "969a6c96-3f6e-4c93-902a-e1dcb3280f8c", "node_type": "1", "metadata": {"window": "I think our European business is comin g off of a good quarter, but our experience there particularly in NHS has \nbeen challenges around having good line of sight into how the reimbursement mechanisms really play out.  And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "original_text": "Anything  you want \nto add, Britt?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "40994bb8cef345ef5e6fbecebc169d2286d597bc8ee64cdcac9f773840fd4783", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "408f8421-d2a8-4c92-8fc6-7b0d58426bce", "node_type": "1", "metadata": {"window": "So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning. ", "original_text": "A \nNo, I think you've captured them correctly, Brian.  \n "}, "hash": "d59972409c3114c7912ca7be09006c526599b8c66e136446556dd3ff2dc7b111", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3388, "end_char_idx": 3748, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "408f8421-d2a8-4c92-8fc6-7b0d58426bce": {"__data__": {"id_": "408f8421-d2a8-4c92-8fc6-7b0d58426bce", "embedding": null, "metadata": {"window": "So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning. ", "original_text": "A \nNo, I think you've captured them correctly, Brian.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "be36b1fc-d932-4d9b-94df-17d1c03c8ce2", "node_type": "1", "metadata": {"window": "And so \nwhile we're encouraged that we have a five -year macro agreement with NH S for the pharmacy community there, I \nthink underneath the nuances of the timing and the different mechanisms that make up that framework, we'll have \nto continue to monitor and evaluate.  So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "36d88bc887961f1d3f6252f4bfb187fa7211f0487b4e58440543fcd5955b4fdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072", "node_type": "1", "metadata": {"window": "Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n "}, "hash": "88eb7f49b7ffe3813b98a170edec99d4ba51331903bb5fb3ee620fd522048cca", "class_name": "RelatedNodeInfo"}}, "text": "A \nNo, I think you've captured them correctly, Brian.  \n ", "start_char_idx": 3748, "end_char_idx": 3805, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072": {"__data__": {"id_": "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072", "embedding": null, "metadata": {"window": "Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "408f8421-d2a8-4c92-8fc6-7b0d58426bce", "node_type": "1", "metadata": {"window": "So, I mean, those are the two things that first pop to mind.  Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning. ", "original_text": "A \nNo, I think you've captured them correctly, Brian.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f4703e3a3c7d00f276d4e23941e35d8e8d15808a42abc96b5ebeb26a13aecc3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1d3ccebc-799b-4161-babb-5cc5ae1495ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. "}, "hash": "0e34f8fe417e2ed7f8a8813476365a8af9e936e3829b4c1981bca03396c2aac5", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "start_char_idx": 3805, "end_char_idx": 4135, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1d3ccebc-799b-4161-babb-5cc5ae1495ea": {"__data__": {"id_": "1d3ccebc-799b-4161-babb-5cc5ae1495ea", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072", "node_type": "1", "metadata": {"window": "Anything  you want \nto add, Britt?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1e40fa8442039fbc2bdf245ba7d5af25595dcaf1d8aa0a234e4a9b6d2f38f60e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f5a23d90-54c2-42e3-9426-fc925b55f5c4", "node_type": "1", "metadata": {"window": "A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "original_text": "Good morning. "}, "hash": "20cd21f5417719e713a584074dd8b1a1558b163e4b6e319812c83e2c8dd8d5f3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "start_char_idx": 4135, "end_char_idx": 4463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f5a23d90-54c2-42e3-9426-fc925b55f5c4": {"__data__": {"id_": "f5a23d90-54c2-42e3-9426-fc925b55f5c4", "embedding": null, "metadata": {"window": "A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1d3ccebc-799b-4161-babb-5cc5ae1495ea", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ae153ca5b574ac36e107804aeda8803dba3031d5783373aabe5039155c54b754", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16713678-05f7-423a-8ad6-41f6f6eef755", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "original_text": "Brian, I just want to follow up on that last point as you talk about the policy arena. "}, "hash": "ef84e6abd16c8da72692c83e526bc19430422fee9f11ff45babc1b809416b067", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 4463, "end_char_idx": 4477, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16713678-05f7-423a-8ad6-41f6f6eef755": {"__data__": {"id_": "16713678-05f7-423a-8ad6-41f6f6eef755", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "original_text": "Brian, I just want to follow up on that last point as you talk about the policy arena. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f5a23d90-54c2-42e3-9426-fc925b55f5c4", "node_type": "1", "metadata": {"window": "A \nNo, I think you've captured them correctly, Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "original_text": "Good morning. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d24712e311410908add4b2e954ba86acc99958c7b3612b56bfeb57f7851a2a1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2db397e-89e1-47b0-bc8f-367a234ac7d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. "}, "hash": "4205553f4dd21ebea54ca3b6268302147bdfbcbf21e1f6c134ea72b9c8ab8c80", "class_name": "RelatedNodeInfo"}}, "text": "Brian, I just want to follow up on that last point as you talk about the policy arena. ", "start_char_idx": 4477, "end_char_idx": 4564, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2db397e-89e1-47b0-bc8f-367a234ac7d3": {"__data__": {"id_": "e2db397e-89e1-47b0-bc8f-367a234ac7d3", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16713678-05f7-423a-8ad6-41f6f6eef755", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Lisa Gill with JPMorgan.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "original_text": "Brian, I just want to follow up on that last point as you talk about the policy arena. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30c93b5e59b63c955a7b963b122aaac461c27233d07b3616d47deb754c6fb110", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c98f13a0-cc75-442e-aae2-4796c737f963", "node_type": "1", "metadata": {"window": "Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What are your thoughts around IPI \nand what i t could mean to your specialty business? "}, "hash": "68d9aaa811c516851163bb0d6b6e2f0554ea5e7b3672f210b85aa0f02ca09b5d", "class_name": "RelatedNodeInfo"}}, "text": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "start_char_idx": 4564, "end_char_idx": 4654, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c98f13a0-cc75-442e-aae2-4796c737f963": {"__data__": {"id_": "c98f13a0-cc75-442e-aae2-4796c737f963", "embedding": null, "metadata": {"window": "Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2db397e-89e1-47b0-bc8f-367a234ac7d3", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nHi.  Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty. ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5ad979b4a79b023bfb32dc0910b67d911fea821eb5029561af686af6995aeb66", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2b16850-e11a-483e-982d-d0978fda0d16", "node_type": "1", "metadata": {"window": "Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n "}, "hash": "f35b0465c7b7f6a19659460995f1a1f0f29c5b9e9d956e792e39e6210fc0b8af", "class_name": "RelatedNodeInfo"}}, "text": "What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "start_char_idx": 4654, "end_char_idx": 4741, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2b16850-e11a-483e-982d-d0978fda0d16": {"__data__": {"id_": "b2b16850-e11a-483e-982d-d0978fda0d16", "embedding": null, "metadata": {"window": "Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c98f13a0-cc75-442e-aae2-4796c737f963", "node_type": "1", "metadata": {"window": "Good morning.  Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "What are your thoughts around IPI \nand what i t could mean to your specialty business? ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e0fe23fdb9c49614251a08038b54c3fef1f5c6fa25cca7a341f5a60196461416", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "247277fe-b7a1-46a5-a492-10019692e4e7", "node_type": "1", "metadata": {"window": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "ec9bebbaf07b493a87bfff10cd4f1f19d594f456218ad06f513d0fcac6b1778b", "class_name": "RelatedNodeInfo"}}, "text": "And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "start_char_idx": 4741, "end_char_idx": 4914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "247277fe-b7a1-46a5-a492-10019692e4e7": {"__data__": {"id_": "247277fe-b7a1-46a5-a492-10019692e4e7", "embedding": null, "metadata": {"window": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "1510173a-ecd3-4f24-a812-98c86bfd459d", "node_type": "4", "metadata": {"page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25a1c58e3d24f09b4d2e715102c6701701b2e0b73252925d2862a0f1a946fe53", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2b16850-e11a-483e-982d-d0978fda0d16", "node_type": "1", "metadata": {"window": "Brian, I just want to follow up on that last point as you talk about the policy arena.  Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "56db19664a74d40d6945e4a32ace7b349d257fd0d6444f25620acd95f13cadba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "907e31c8-16e1-40c8-8d43-44b78d08cc6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa. ", "original_text": "McKesson Corp.  "}, "hash": "404af3f8316e7e897a6354935d00c5f788b1cb77e91e82a33b0e49d06a89c83f", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 797, "end_char_idx": 1068, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "907e31c8-16e1-40c8-8d43-44b78d08cc6e": {"__data__": {"id_": "907e31c8-16e1-40c8-8d43-44b78d08cc6e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "247277fe-b7a1-46a5-a492-10019692e4e7", "node_type": "1", "metadata": {"window": "Clearly, \nspecialty has been a growth area, you've talked the whole call about specialty.  What are your thoughts around IPI \nand what i t could mean to your specialty business?  And then, secondly, as we think about the European markets, \nwhat have you learned from the European markets where it is a fixed -cost environment versus here in the US?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d5841147a85b88d6b19259d0377f204bab2a317a4e2f57c48d9caef925efeb8e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "952a12b9-d6a3-459f-a711-fff5da9100fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.  "}, "hash": "3d8d2327a9843c380d7fd1ae841f082d52ec8aeffc60ef71fbc907ee5be9dfc7", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "952a12b9-d6a3-459f-a711-fff5da9100fb": {"__data__": {"id_": "952a12b9-d6a3-459f-a711-fff5da9100fb", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "907e31c8-16e1-40c8-8d43-44b78d08cc6e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b10ff417b4f89261198226b34b908d761b9942a4df4660b595c99fe953e1b0e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6a321ed-635f-4133-a19c-ddae2dfb619a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "original_text": "A \nGreat. "}, "hash": "8497768f4f30313c621a6c969a0d35b09085ef60c4e47b932d48882f72116ef5", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6a321ed-635f-4133-a19c-ddae2dfb619a": {"__data__": {"id_": "c6a321ed-635f-4133-a19c-ddae2dfb619a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "original_text": "A \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "952a12b9-d6a3-459f-a711-fff5da9100fb", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e39dc0a93e00972242f63e3618234ff6e3b3e26b13477fed56c021c579ac59f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "939dac22-ec6d-4927-907d-79b03d4417a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "original_text": "Thanks, Lisa. "}, "hash": "6595d5b6a6f5549eca67f728ac42ecdfe0fe8e0f0106c70b23e4acb981b327c7", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat. ", "start_char_idx": 251, "end_char_idx": 261, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "939dac22-ec6d-4927-907d-79b03d4417a5": {"__data__": {"id_": "939dac22-ec6d-4927-907d-79b03d4417a5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "original_text": "Thanks, Lisa. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6a321ed-635f-4133-a19c-ddae2dfb619a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "original_text": "A \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c6358f90c2f0e668dd77a51b5f97e8cf421fcc2466fc80f6ba8d1c063927829d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54b748c3-9afe-44c4-b36a-895d4706cd48", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum. ", "original_text": "I'll take the IPI business first \u2013 the question first. "}, "hash": "b26ba5a9bc9eb811fba5ea2056e2588cdeb5f2026a02953de9ea45f2ccff3871", "class_name": "RelatedNodeInfo"}}, "text": "Thanks, Lisa. ", "start_char_idx": 261, "end_char_idx": 275, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54b748c3-9afe-44c4-b36a-895d4706cd48": {"__data__": {"id_": "54b748c3-9afe-44c4-b36a-895d4706cd48", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum. ", "original_text": "I'll take the IPI business first \u2013 the question first. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "939dac22-ec6d-4927-907d-79b03d4417a5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "original_text": "Thanks, Lisa. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "53009d5184e59279b0a72b2a968cbf230a76c1a3ba24d4b064fe084861dbe0ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "80e05c75-a236-497e-aba1-40e5a2fcfe18", "node_type": "1", "metadata": {"window": "A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "original_text": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. "}, "hash": "a6f9262642f628f22958f5402feb9c7832e02449db0126873c8631889e734828", "class_name": "RelatedNodeInfo"}}, "text": "I'll take the IPI business first \u2013 the question first. ", "start_char_idx": 275, "end_char_idx": 330, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "80e05c75-a236-497e-aba1-40e5a2fcfe18": {"__data__": {"id_": "80e05c75-a236-497e-aba1-40e5a2fcfe18", "embedding": null, "metadata": {"window": "A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "original_text": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54b748c3-9afe-44c4-b36a-895d4706cd48", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum. ", "original_text": "I'll take the IPI business first \u2013 the question first. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b398d4799b14454e66fdb2388d6546b2a8059916c1c26a63d6aed208b12e3182", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4360a740-2efe-41b7-9ec4-c161b1679329", "node_type": "1", "metadata": {"window": "Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "original_text": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n"}, "hash": "8c99364f4c726df17d3d96046ea935a30314881eb6ed2a5985a094cc3887e66e", "class_name": "RelatedNodeInfo"}}, "text": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "start_char_idx": 330, "end_char_idx": 514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4360a740-2efe-41b7-9ec4-c161b1679329": {"__data__": {"id_": "4360a740-2efe-41b7-9ec4-c161b1679329", "embedding": null, "metadata": {"window": "Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "original_text": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "80e05c75-a236-497e-aba1-40e5a2fcfe18", "node_type": "1", "metadata": {"window": "A \nGreat.  Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "original_text": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c90c5e9574ea8c7e5ff1720297b9926f119f29fd89bb6bf4590aa8270bad6d17", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dc9b3723-83af-49be-a3b2-f35dd84c6e99", "node_type": "1", "metadata": {"window": "I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n", "original_text": "So, the proposals have really been very wide in the spectrum. "}, "hash": "78948caa4e10d7067936c86950a4a0fa0b347dfd0e3f5fcdd61f117e959f857e", "class_name": "RelatedNodeInfo"}}, "text": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "start_char_idx": 514, "end_char_idx": 751, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dc9b3723-83af-49be-a3b2-f35dd84c6e99": {"__data__": {"id_": "dc9b3723-83af-49be-a3b2-f35dd84c6e99", "embedding": null, "metadata": {"window": "I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n", "original_text": "So, the proposals have really been very wide in the spectrum. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4360a740-2efe-41b7-9ec4-c161b1679329", "node_type": "1", "metadata": {"window": "Thanks, Lisa.  I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "original_text": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4a2190f9d7397738e558e325d47197e5d8b8b3ff919fdb3c4d74af801bd50061", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8e5d658b-613b-4c87-9d08-57014b8fed89", "node_type": "1", "metadata": {"window": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "original_text": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. "}, "hash": "a99acad2c8c6bcf276669fc2e1533fa752d8847ac67eea74ff77e990e42ab017", "class_name": "RelatedNodeInfo"}}, "text": "So, the proposals have really been very wide in the spectrum. ", "start_char_idx": 751, "end_char_idx": 813, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8e5d658b-613b-4c87-9d08-57014b8fed89": {"__data__": {"id_": "8e5d658b-613b-4c87-9d08-57014b8fed89", "embedding": null, "metadata": {"window": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "original_text": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dc9b3723-83af-49be-a3b2-f35dd84c6e99", "node_type": "1", "metadata": {"window": "I'll take the IPI business first \u2013 the question first.  So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n", "original_text": "So, the proposals have really been very wide in the spectrum. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "846f5a68302e69fe4833ffdd686440a295be34d61bd658ebcd1d76c9d1108d8c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f4ce8af9-7674-4627-bda8-41476dfbccda", "node_type": "1", "metadata": {"window": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "original_text": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. "}, "hash": "0a09ebde632c909d9702b7a234ac1a4cb01aa296f61f1f7d16413535718b7802", "class_name": "RelatedNodeInfo"}}, "text": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "start_char_idx": 813, "end_char_idx": 1078, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f4ce8af9-7674-4627-bda8-41476dfbccda": {"__data__": {"id_": "f4ce8af9-7674-4627-bda8-41476dfbccda", "embedding": null, "metadata": {"window": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "original_text": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8e5d658b-613b-4c87-9d08-57014b8fed89", "node_type": "1", "metadata": {"window": "So, IPI is, I guess there's been a lot of \ndifferent constructs around getting to Part B. There's been discussions of caps or limiting ASP rates, future caps  \non allowable inflation.  IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "original_text": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8705a92c319953635a1d056463f3812ea0779855fba837bc8202b4f6a5003651", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "272f8d13-d546-47ff-91ae-f8e32bd30c21", "node_type": "1", "metadata": {"window": "So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "original_text": "So, it kind of hits all \nthe three macro principles.  \n \n"}, "hash": "394404bdcad6f06a2c24deb2e3ed6958fc222a25fe9333bb546f38bf77603367", "class_name": "RelatedNodeInfo"}}, "text": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "start_char_idx": 1078, "end_char_idx": 1182, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "272f8d13-d546-47ff-91ae-f8e32bd30c21": {"__data__": {"id_": "272f8d13-d546-47ff-91ae-f8e32bd30c21", "embedding": null, "metadata": {"window": "So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "original_text": "So, it kind of hits all \nthe three macro principles.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f4ce8af9-7674-4627-bda8-41476dfbccda", "node_type": "1", "metadata": {"window": "IPI would be a proposal to index what the US pays based on a basket of internationally \nreferenced prices for various products, and I think there's even been some debate or discussion around MFN or \nmost favored nation type clauses.  \n \n So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "original_text": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "588df152300d28cd4bbeaa9ccd19678bf65751552c3ec5327bfd2727786c813c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a51d6c7-5b32-4525-a603-717d087ef74f", "node_type": "1", "metadata": {"window": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "original_text": "And so anything \u2013 any reform that  were to happen in our view should move care into the community. "}, "hash": "e883c67618941e562d14eed594b4fc291e963efc45496e042a8f21d43078696e", "class_name": "RelatedNodeInfo"}}, "text": "So, it kind of hits all \nthe three macro principles.  \n \n", "start_char_idx": 1182, "end_char_idx": 1239, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a51d6c7-5b32-4525-a603-717d087ef74f": {"__data__": {"id_": "9a51d6c7-5b32-4525-a603-717d087ef74f", "embedding": null, "metadata": {"window": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "original_text": "And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "272f8d13-d546-47ff-91ae-f8e32bd30c21", "node_type": "1", "metadata": {"window": "So, the proposals have really been very wide in the spectrum.  And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "original_text": "So, it kind of hits all \nthe three macro principles.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "97e66256a1cc8a0507259326fbd336dbb7bdcc35411ed4cd6be19b9198aac57c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "095f701d-43b5-41a0-a7cf-0b3820847784", "node_type": "1", "metadata": {"window": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "original_text": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. "}, "hash": "7af3af33f50063f64c0ded89d75fbbc54fb19e4fefa60166104c50fe81895a82", "class_name": "RelatedNodeInfo"}}, "text": "And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "start_char_idx": 1239, "end_char_idx": 1338, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "095f701d-43b5-41a0-a7cf-0b3820847784": {"__data__": {"id_": "095f701d-43b5-41a0-a7cf-0b3820847784", "embedding": null, "metadata": {"window": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "original_text": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a51d6c7-5b32-4525-a603-717d087ef74f", "node_type": "1", "metadata": {"window": "And without commenting on any of them \nspecifically, I would say first and foremost, we think any reform in Part B should be constructed and we work with \nindustry, the government and our partner s to advocate for this in a way that pushes care into the community.  It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "original_text": "And so anything \u2013 any reform that  were to happen in our view should move care into the community. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "65e3d87fcaee96b83bde266ae2cc8e1762d4f45fc772cbed8d036189ed4e7d20", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "de8cb963-2d9f-41e4-b107-efb4eba786fc", "node_type": "1", "metadata": {"window": "So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely. ", "original_text": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. "}, "hash": "681e91e8f425d32702e50e4e542c0b70d25481cfea6fb3c035e10e8fc1ce3707", "class_name": "RelatedNodeInfo"}}, "text": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "start_char_idx": 1338, "end_char_idx": 1463, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "de8cb963-2d9f-41e4-b107-efb4eba786fc": {"__data__": {"id_": "de8cb963-2d9f-41e4-b107-efb4eba786fc", "embedding": null, "metadata": {"window": "So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely. ", "original_text": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "095f701d-43b5-41a0-a7cf-0b3820847784", "node_type": "1", "metadata": {"window": "It's \nclearly the low -cost, high -access setting and we believe it has extremely high quality as well.  So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "original_text": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a40f06625e27ebf4db572133441a0ab9fb668ba6c914a0f6ed88aa04a71498a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "49ca42ad-a794-4dd3-97dc-121a9b5f7759", "node_type": "1", "metadata": {"window": "And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "original_text": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n"}, "hash": "3fc10738d050700a15a3259362a175be611cd37e1ca5b2e11db1abdde9320414", "class_name": "RelatedNodeInfo"}}, "text": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "start_char_idx": 1463, "end_char_idx": 1671, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "49ca42ad-a794-4dd3-97dc-121a9b5f7759": {"__data__": {"id_": "49ca42ad-a794-4dd3-97dc-121a9b5f7759", "embedding": null, "metadata": {"window": "And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "original_text": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "de8cb963-2d9f-41e4-b107-efb4eba786fc", "node_type": "1", "metadata": {"window": "So, it kind of hits all \nthe three macro principles.  \n \n And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely. ", "original_text": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a44d8491daee59a57afc51c69f38ee0374870e4c79b5c366508252d70cac4c94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "20aedfba-e4f3-461e-8c2d-01f29c937f20", "node_type": "1", "metadata": {"window": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. "}, "hash": "ae630d0d1b683d900ffefd6c698443c18aaf7d77e7d5dcd0bbaa258662e95e1d", "class_name": "RelatedNodeInfo"}}, "text": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "start_char_idx": 1671, "end_char_idx": 1754, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "20aedfba-e4f3-461e-8c2d-01f29c937f20": {"__data__": {"id_": "20aedfba-e4f3-461e-8c2d-01f29c937f20", "embedding": null, "metadata": {"window": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "49ca42ad-a794-4dd3-97dc-121a9b5f7759", "node_type": "1", "metadata": {"window": "And so anything \u2013 any reform that  were to happen in our view should move care into the community.  Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "original_text": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "685320a42105fa8b575e68a5df46aa33a932ed86206d94ed3af96934e8524661", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8d5fa321-8486-4ee5-ae15-27c389cd3f2c", "node_type": "1", "metadata": {"window": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "original_text": "So, we continue to watch this very closely. "}, "hash": "4121ab2bda38476e05c924a8cd04c76815df7e63da30f5be17605f8a23233175", "class_name": "RelatedNodeInfo"}}, "text": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "start_char_idx": 1754, "end_char_idx": 1914, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8d5fa321-8486-4ee5-ae15-27c389cd3f2c": {"__data__": {"id_": "8d5fa321-8486-4ee5-ae15-27c389cd3f2c", "embedding": null, "metadata": {"window": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "original_text": "So, we continue to watch this very closely. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "20aedfba-e4f3-461e-8c2d-01f29c937f20", "node_type": "1", "metadata": {"window": "Anything \nthat \u2013 what move the opposite way would be counterproductive, really, for the US spend on healthcare, in \ngeneral.  Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "original_text": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9486a396127b59eb85f948c15755abf76986a3df0e3d94e8b5ff6796cc6e07f5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2750933-3b35-4ddd-b2bb-78ef873bc3d6", "node_type": "1", "metadata": {"window": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before. ", "original_text": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n "}, "hash": "ccd21bb250f17120c291057bd52a487175d43124c2938ffe2c26d734696aa4d5", "class_name": "RelatedNodeInfo"}}, "text": "So, we continue to watch this very closely. ", "start_char_idx": 1914, "end_char_idx": 1958, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2750933-3b35-4ddd-b2bb-78ef873bc3d6": {"__data__": {"id_": "e2750933-3b35-4ddd-b2bb-78ef873bc3d6", "embedding": null, "metadata": {"window": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before. ", "original_text": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8d5fa321-8486-4ee5-ae15-27c389cd3f2c", "node_type": "1", "metadata": {"window": "Now, relative to IPI, if something were to occur, the way I think ab out this is in most instances in our core \npharma distribution, in our community provider setting, this is an implication to our customer.  And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "original_text": "So, we continue to watch this very closely. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b75380b9ccb5e11461b9f49979f369485b0b688a265951b70674d5254f6dc64", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9cdf51d2-52da-41ad-9b01-c50517ab756a", "node_type": "1", "metadata": {"window": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. "}, "hash": "ecad9a033accfbedd563d7b5d8ec06e286bd261b6c17bb528e3c26837d32270c", "class_name": "RelatedNodeInfo"}}, "text": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "start_char_idx": 1958, "end_char_idx": 2220, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9cdf51d2-52da-41ad-9b01-c50517ab756a": {"__data__": {"id_": "9cdf51d2-52da-41ad-9b01-c50517ab756a", "embedding": null, "metadata": {"window": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2750933-3b35-4ddd-b2bb-78ef873bc3d6", "node_type": "1", "metadata": {"window": "And so, it will be a \nsecondary effect, really, from a wholesaler perspective.  \n \n The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before. ", "original_text": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52fd1305c8111f61ad5588c1eb3396940663e1b57ae6133d81696a0ba003bee6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "734f614f-8a29-444d-a1e7-db6685942582", "node_type": "1", "metadata": {"window": "So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. "}, "hash": "5c0ebb81f1597b25df0d2fa4aafb9e00a94015dbfed3558c986f3b8dc9a44154", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "start_char_idx": 2220, "end_char_idx": 2551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "734f614f-8a29-444d-a1e7-db6685942582": {"__data__": {"id_": "734f614f-8a29-444d-a1e7-db6685942582", "embedding": null, "metadata": {"window": "So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9cdf51d2-52da-41ad-9b01-c50517ab756a", "node_type": "1", "metadata": {"window": "The one place we would have some exposu re would be in The US Oncology Network, where I remind you \nthrough our partnership we share in the practice economics.  So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7c89ee2cb348b9a376b613f3954ba39d7a860507a749eeb2ea66ef520099fdca", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "54a00d97-5371-45da-9a93-8d4672989ff2", "node_type": "1", "metadata": {"window": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa. ", "original_text": "And you said it's consistent with what you've said before. "}, "hash": "67d455bb97257bf695131a3d2fd0f52601d1314c4244010cd1bc81ebeb7891fc", "class_name": "RelatedNodeInfo"}}, "text": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "start_char_idx": 2551, "end_char_idx": 2675, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "54a00d97-5371-45da-9a93-8d4672989ff2": {"__data__": {"id_": "54a00d97-5371-45da-9a93-8d4672989ff2", "embedding": null, "metadata": {"window": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa. ", "original_text": "And you said it's consistent with what you've said before. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "734f614f-8a29-444d-a1e7-db6685942582", "node_type": "1", "metadata": {"window": "So, we continue to watch this very closely.  I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dab42ef6bb78f1fc7d3bc1d74f1183a7220eb02f0d2a1b40ef5358e13cc9f4ac", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83616195-07fa-4d80-a055-b3630e254146", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "original_text": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n "}, "hash": "3c71178b9ccc115def9cabaced6cea8f83249669b99acaf766ece78a02e2dfb7", "class_name": "RelatedNodeInfo"}}, "text": "And you said it's consistent with what you've said before. ", "start_char_idx": 2675, "end_char_idx": 2734, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83616195-07fa-4d80-a055-b3630e254146": {"__data__": {"id_": "83616195-07fa-4d80-a055-b3630e254146", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "original_text": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "54a00d97-5371-45da-9a93-8d4672989ff2", "node_type": "1", "metadata": {"window": "I'm not \nsure there's been a proposal that's had more commentary and more aligned commentary t o kind of come out \nagainst it, because of the impact, potentially, to patients and patient access and cost of care, but I suppose we'll \nsee what we hear tonight.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa. ", "original_text": "And you said it's consistent with what you've said before. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "140e68a32b8cb9261bf766cb290caadd236d811df5af3632e6a05545007337fd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5c9defa-9c96-40ea-93b0-873b7110161c", "node_type": "1", "metadata": {"window": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "758cbfd2d90d7fea0d1dc43a4d5241b7b3b73752c2ba615aa0867d5137e06efa", "class_name": "RelatedNodeInfo"}}, "text": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "start_char_idx": 2734, "end_char_idx": 2814, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5c9defa-9c96-40ea-93b0-873b7110161c": {"__data__": {"id_": "a5c9defa-9c96-40ea-93b0-873b7110161c", "embedding": null, "metadata": {"window": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83616195-07fa-4d80-a055-b3630e254146", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nLisa C. Gill  \nAnalyst, JPMorgan Securities LLC  Q \nGreat.  And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "original_text": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f389ae9a9a2a82c08936ec47aaf74b3200e00edd4e7fede5b092815c24f3b9fe", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a49bb762-dea7-4c5a-9786-f64a4e78b160", "node_type": "1", "metadata": {"window": "And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "original_text": "A \nSure, Lisa. "}, "hash": "68c5758d96ae70cbcee56d63943c2f548932effc61a76b30b606bbb860f7cf51", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 2814, "end_char_idx": 3174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a49bb762-dea7-4c5a-9786-f64a4e78b160": {"__data__": {"id_": "a49bb762-dea7-4c5a-9786-f64a4e78b160", "embedding": null, "metadata": {"window": "And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "original_text": "A \nSure, Lisa. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5c9defa-9c96-40ea-93b0-873b7110161c", "node_type": "1", "metadata": {"window": "And then, just my follow -up, I just \u2013 Britt, you talked about the Change exit as being one of the key \ncomponents to 2021.  And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c57aeb0957031674b75eb687fdba3eb8241200b384a7586c3aaa5764b7b2c912", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f9c6bdb0-4564-4d67-afb8-92eada705ef6", "node_type": "1", "metadata": {"window": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n ", "original_text": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. "}, "hash": "ba09239f1b66d7f46a563544be8e7c5f740aeca20fd496073721ae78c43c32b9", "class_name": "RelatedNodeInfo"}}, "text": "A \nSure, Lisa. ", "start_char_idx": 3174, "end_char_idx": 3189, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f9c6bdb0-4564-4d67-afb8-92eada705ef6": {"__data__": {"id_": "f9c6bdb0-4564-4d67-afb8-92eada705ef6", "embedding": null, "metadata": {"window": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n ", "original_text": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a49bb762-dea7-4c5a-9786-f64a4e78b160", "node_type": "1", "metadata": {"window": "And you said it's consistent with what you've said before.  Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "original_text": "A \nSure, Lisa. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b826ac73b7c12b619b92fe969ce262eafb9653d8cc7d84c1fa29a7012122e44", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "182a9263-3bfb-49b3-8663-90101c1ab82a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I would \nreiterate that language today.  \n "}, "hash": "28051af161f84d0bd86a8bbf172492d4627534f766f1d991fcc13cd51953fd59", "class_name": "RelatedNodeInfo"}}, "text": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "start_char_idx": 3189, "end_char_idx": 3399, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "182a9263-3bfb-49b3-8663-90101c1ab82a": {"__data__": {"id_": "182a9263-3bfb-49b3-8663-90101c1ab82a", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I would \nreiterate that language today.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f9c6bdb0-4564-4d67-afb8-92eada705ef6", "node_type": "1", "metadata": {"window": "Can you just remind us what \nyou've said before on the timeline of the exit?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n ", "original_text": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bae7a1fdfcd6cfd4e85ed32bee473f42b8398798f8565609fdc44adedec87d45", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e", "node_type": "1", "metadata": {"window": "A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. "}, "hash": "cbf6b4d3e947562fb59fa49e361aa4b5b39f15959527aee24ae42a714e931c0c", "class_name": "RelatedNodeInfo"}}, "text": "So, I would \nreiterate that language today.  \n ", "start_char_idx": 3399, "end_char_idx": 3446, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e": {"__data__": {"id_": "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e", "embedding": null, "metadata": {"window": "A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "182a9263-3bfb-49b3-8663-90101c1ab82a", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I would \nreiterate that language today.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f3ec4f220ad084b01a3a69407189213c7fa36caee8426348c60236c7537001f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043", "node_type": "1", "metadata": {"window": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative. ", "original_text": "Your line is \nopen.  \n "}, "hash": "8b76c5d79a755bfc1317d06bd15b5f2c12e2dcf4b247cec5e7b03e5d59ff9287", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "start_char_idx": 3446, "end_char_idx": 3819, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043": {"__data__": {"id_": "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043", "embedding": null, "metadata": {"window": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative. ", "original_text": "Your line is \nopen.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e", "node_type": "1", "metadata": {"window": "A \nSure, Lisa.  So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "34262a5f7a195448d2d1f1a3fc083bebe580df6c222f592b0b9d8158fa3834af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7", "node_type": "1", "metadata": {"window": "So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "cf4852200cc94ecf4a575a16c4046162e62df5003ea2c58329bcd6ad0abf22f3", "class_name": "RelatedNodeInfo"}}, "text": "Your line is \nopen.  \n ", "start_char_idx": 3819, "end_char_idx": 3842, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7": {"__data__": {"id_": "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7", "embedding": null, "metadata": {"window": "So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043", "node_type": "1", "metadata": {"window": "So, what we've said previously, dating back to our Q2 earnings call, from that point in time we'd expect \nto exit our transaction in 6 to 12 months, although that it could be before the end of our fiscal 2020.  So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative. ", "original_text": "Your line is \nopen.  \n ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c523b364d26e2748a224a6b7b2a3ffc3e8b199337f64d04384fe2f2aed1cd3a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2951060d-c620-49d7-b071-8b8476c321db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "LLC  Q \nYeah, hi, good  morning. "}, "hash": "4ceb8ccc6c6cc8728d24b6998eb95bd2eddffb72a32a062335bf569d17028fc8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 3842, "end_char_idx": 4166, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2951060d-c620-49d7-b071-8b8476c321db": {"__data__": {"id_": "2951060d-c620-49d7-b071-8b8476c321db", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "LLC  Q \nYeah, hi, good  morning. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7", "node_type": "1", "metadata": {"window": "So, I would \nreiterate that language today.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0b4cda9f02caa5dbd1ce6564a6ab84fe20ae77cecd73a5f5bea69cac98db07d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "cbfa4b3e-8403-415a-b330-4b06cdb94ce0", "node_type": "1", "metadata": {"window": "Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I have a follow -up question on the cost cutting initiative. "}, "hash": "e187208d2c283d6bf4065ad07941e0c4a4a17f430c984def2f1b86eeb6b9163d", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nYeah, hi, good  morning. ", "start_char_idx": 4166, "end_char_idx": 4199, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "cbfa4b3e-8403-415a-b330-4b06cdb94ce0": {"__data__": {"id_": "cbfa4b3e-8403-415a-b330-4b06cdb94ce0", "embedding": null, "metadata": {"window": "Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I have a follow -up question on the cost cutting initiative. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2951060d-c620-49d7-b071-8b8476c321db", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Ricky Goldswater (sic) [Ricky Goldwasser] (47:15) with Morgan Stanley.  Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "LLC  Q \nYeah, hi, good  morning. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "611d55e81d787cfe262885e525075afbc3041db6bc0b7889dbfc679acad14c25", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "92f79018-f9f5-454c-91a1-416ee0bd0b1d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I think you reduced your \ncorporate expense guidance by about $45 million. "}, "hash": "2b56742f067e55ab90065eb22cfa21c03202955093fc8e28418c139de8ecfe8b", "class_name": "RelatedNodeInfo"}}, "text": "I have a follow -up question on the cost cutting initiative. ", "start_char_idx": 4199, "end_char_idx": 4260, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "92f79018-f9f5-454c-91a1-416ee0bd0b1d": {"__data__": {"id_": "92f79018-f9f5-454c-91a1-416ee0bd0b1d", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I think you reduced your \ncorporate expense guidance by about $45 million. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "cbfa4b3e-8403-415a-b330-4b06cdb94ce0", "node_type": "1", "metadata": {"window": "Your line is \nopen.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I have a follow -up question on the cost cutting initiative. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be731283ae93935489ac48d6fd594e856b0bbb7da56da3b34a045164cef26b7c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f73af628-dae8-4670-9c7e-49cd41e3bf6f", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "Part of it is flow -through of cost savings to the bottom line and "}, "hash": "3e1bed7c991323741741d1f6c324c94efdeb3247e2feb11acd845319084804ac", "class_name": "RelatedNodeInfo"}}, "text": "I think you reduced your \ncorporate expense guidance by about $45 million. ", "start_char_idx": 4260, "end_char_idx": 4335, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f73af628-dae8-4670-9c7e-49cd41e3bf6f": {"__data__": {"id_": "f73af628-dae8-4670-9c7e-49cd41e3bf6f", "embedding": null, "metadata": {"window": "LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "Part of it is flow -through of cost savings to the bottom line and ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "54883497-6044-4c3b-acfe-65b40ed873b0", "node_type": "4", "metadata": {"page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cae129817ac1d00c8fe70de143075bd6a9377a22d6680d90d77bdf49eb662543", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "92f79018-f9f5-454c-91a1-416ee0bd0b1d", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "I think you reduced your \ncorporate expense guidance by about $45 million. ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b1cba8782a9de781867301f70bf57483ed5c33e3c4f538ccd6450a178e3d403a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8c108cd7-5abe-417a-b5eb-016b7d970dee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "original_text": "McKesson Corp.  "}, "hash": "39bc1c74c9e21613d46b6e2c72c285d42b59f551419a313f3f4dd5f830592670", "class_name": "RelatedNodeInfo"}}, "text": "Part of it is flow -through of cost savings to the bottom line and ", "start_char_idx": 4335, "end_char_idx": 4402, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8c108cd7-5abe-417a-b5eb-016b7d970dee": {"__data__": {"id_": "8c108cd7-5abe-417a-b5eb-016b7d970dee", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f73af628-dae8-4670-9c7e-49cd41e3bf6f", "node_type": "1", "metadata": {"window": "LLC  Q \nYeah, hi, good  morning.  I have a follow -up question on the cost cutting initiative.  I think you reduced your \ncorporate expense guidance by about $45 million.  Part of it is flow -through of cost savings to the bottom line and ", "original_text": "Part of it is flow -through of cost savings to the bottom line and ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "88cbf98c8271d2604dd2d779e3b36d0865be45af0ea0c8c2dcfd95a45f3e2ac3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a485c554-5068-4b1c-84ad-817b4bed427a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments. "}, "hash": "32754900f3570b61ff53538a5d30768b053c097bcca0b6e4cd6b294803d8dacc", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a485c554-5068-4b1c-84ad-817b4bed427a": {"__data__": {"id_": "a485c554-5068-4b1c-84ad-817b4bed427a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8c108cd7-5abe-417a-b5eb-016b7d970dee", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0576665486c3ba46bb24985614a7801dcb74f51b40a85307e59a09693259dcfb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7a311813-98ab-4f0c-9b35-2c1c688c27f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky. ", "original_text": "By our calculation , it's about $0.18 to the EPS. "}, "hash": "64093b9263faa8670560beeed252b73074f5b5fcba9084d2792bbfe4443deded", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments. ", "start_char_idx": 16, "end_char_idx": 209, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7a311813-98ab-4f0c-9b35-2c1c688c27f1": {"__data__": {"id_": "7a311813-98ab-4f0c-9b35-2c1c688c27f1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky. ", "original_text": "By our calculation , it's about $0.18 to the EPS. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a485c554-5068-4b1c-84ad-817b4bed427a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c831a4d90acecdf70639f9ca7b8cac53c4be5bdd12fea318968fbe5ffabf2a09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efeaf1f5-74de-4520-8234-28f9d7cd49e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "original_text": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n "}, "hash": "63c9f315aa9a948baac843d375fd63be01efe10e86b8cc3f6f261ed89547a496", "class_name": "RelatedNodeInfo"}}, "text": "By our calculation , it's about $0.18 to the EPS. ", "start_char_idx": 209, "end_char_idx": 259, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efeaf1f5-74de-4520-8234-28f9d7cd49e4": {"__data__": {"id_": "efeaf1f5-74de-4520-8234-28f9d7cd49e4", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "original_text": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7a311813-98ab-4f0c-9b35-2c1c688c27f1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky. ", "original_text": "By our calculation , it's about $0.18 to the EPS. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d175b6ed99546a5ae4fa6fd88bfc62c7ab691c23122c912bc8e56a7e79be6dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23dbebbc-4660-4a2f-a1d7-c10bd9655886", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  "}, "hash": "848b5044d161781735ce2caefa5409e28a784ed7e267ff4d07a4bed0cce1afeb", "class_name": "RelatedNodeInfo"}}, "text": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "start_char_idx": 259, "end_char_idx": 409, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23dbebbc-4660-4a2f-a1d7-c10bd9655886": {"__data__": {"id_": "23dbebbc-4660-4a2f-a1d7-c10bd9655886", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efeaf1f5-74de-4520-8234-28f9d7cd49e4", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "original_text": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aef8e2addf7d91329d3a7d1b626532bfa9141f0a1377f9c9507a4353869f16af", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "786a24d8-c50e-46d6-a170-b66c35d140d4", "node_type": "1", "metadata": {"window": "By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "original_text": "A \nYeah, let me answer that, Ricky. "}, "hash": "be674b5cead4f4fb5db2a0dd432b2ab4e7aa41ef715bf074d2580d4eb4f16d2d", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "start_char_idx": 409, "end_char_idx": 770, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "786a24d8-c50e-46d6-a170-b66c35d140d4": {"__data__": {"id_": "786a24d8-c50e-46d6-a170-b66c35d140d4", "embedding": null, "metadata": {"window": "By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "original_text": "A \nYeah, let me answer that, Ricky. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23dbebbc-4660-4a2f-a1d7-c10bd9655886", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0dee7166e9710e8b5f7a9bb66f811e04d4dd690a25ccbfbebc5f0260c9c35f71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7", "node_type": "1", "metadata": {"window": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "original_text": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n"}, "hash": "5b36737122498b55f9aebf199ea6e0a538792acddca24c7cb9ad1a369d1871cf", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, let me answer that, Ricky. ", "start_char_idx": 770, "end_char_idx": 806, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7": {"__data__": {"id_": "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7", "embedding": null, "metadata": {"window": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "original_text": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "786a24d8-c50e-46d6-a170-b66c35d140d4", "node_type": "1", "metadata": {"window": "By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "original_text": "A \nYeah, let me answer that, Ricky. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bbc601d303cade2b659c6b5d69eae250a6b09e73ce565735845a7c579cd335f6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "351ee781-ca26-4489-bfde-20b17498e0a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out. ", "original_text": "So, the cost pr ograms are ongoing.  \n \n"}, "hash": "270c3330d913a7325d0ed20a55f3e7989df937f2ebd9d498d1733779ee277acc", "class_name": "RelatedNodeInfo"}}, "text": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "start_char_idx": 806, "end_char_idx": 1005, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "351ee781-ca26-4489-bfde-20b17498e0a0": {"__data__": {"id_": "351ee781-ca26-4489-bfde-20b17498e0a0", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out. ", "original_text": "So, the cost pr ograms are ongoing.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7", "node_type": "1", "metadata": {"window": "So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "original_text": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ce1ffca4c5ab6e5bd1b6110fe1b35440db2adfb54ad7121fd9557091d2374a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "422df89b-387f-4762-a910-57742912377a", "node_type": "1", "metadata": {"window": "A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "original_text": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. "}, "hash": "0ed949114300d673a3b7ec4bca870714b1134e28298f07e27fa0cdc474efa2d3", "class_name": "RelatedNodeInfo"}}, "text": "So, the cost pr ograms are ongoing.  \n \n", "start_char_idx": 1005, "end_char_idx": 1045, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "422df89b-387f-4762-a910-57742912377a": {"__data__": {"id_": "422df89b-387f-4762-a910-57742912377a", "embedding": null, "metadata": {"window": "A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "original_text": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "351ee781-ca26-4489-bfde-20b17498e0a0", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesso n Corp.   A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out. ", "original_text": "So, the cost pr ograms are ongoing.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c2e666db636fbd8b2b2d6e3708b8e72636a45a3dc8a5df2cd2b116902270d05e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f55171c1-f3b0-4fed-ba42-89abf5fb1894", "node_type": "1", "metadata": {"window": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "original_text": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n"}, "hash": "a1b9e5505b35fb3f167d60703d65b24a756a161eeb28fe1975930c32e28bba0f", "class_name": "RelatedNodeInfo"}}, "text": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "start_char_idx": 1045, "end_char_idx": 1249, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f55171c1-f3b0-4fed-ba42-89abf5fb1894": {"__data__": {"id_": "f55171c1-f3b0-4fed-ba42-89abf5fb1894", "embedding": null, "metadata": {"window": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "original_text": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "422df89b-387f-4762-a910-57742912377a", "node_type": "1", "metadata": {"window": "A \nYeah, let me answer that, Ricky.  Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "original_text": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c48ef51b854fbe9284311ed0d0922c324d04a0cf6cfc5f6750c8d1e2d57d9693", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "baae808c-8101-4048-a1e8-5d31a7ef81c6", "node_type": "1", "metadata": {"window": "So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I don't think you can necessarily take our performance this quarter and just run it out. "}, "hash": "9128a1195263904d8cd8c7713f034dd7bf70a489a6089fd2e735740946df32ab", "class_name": "RelatedNodeInfo"}}, "text": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "start_char_idx": 1249, "end_char_idx": 1357, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "baae808c-8101-4048-a1e8-5d31a7ef81c6": {"__data__": {"id_": "baae808c-8101-4048-a1e8-5d31a7ef81c6", "embedding": null, "metadata": {"window": "So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I don't think you can necessarily take our performance this quarter and just run it out. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f55171c1-f3b0-4fed-ba42-89abf5fb1894", "node_type": "1", "metadata": {"window": "Certainly, we are pleased with the progress that we're making against our cost \ninitiatives, and I'd reiterate that we expect to generate $400 million to $500 million of savings by the end of 2021. \n So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "original_text": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0cd8532515f6547c69ce4eaaa0b1f59f4e6776eba91da74eaa5e32d0bb08dc70", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e", "node_type": "1", "metadata": {"window": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. "}, "hash": "63dac686ef0bbb60b9e44a712662907f52c5e7a40e160549dc86877920772879", "class_name": "RelatedNodeInfo"}}, "text": "So, I don't think you can necessarily take our performance this quarter and just run it out. ", "start_char_idx": 1357, "end_char_idx": 1450, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e": {"__data__": {"id_": "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e", "embedding": null, "metadata": {"window": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "baae808c-8101-4048-a1e8-5d31a7ef81c6", "node_type": "1", "metadata": {"window": "So, the cost pr ograms are ongoing.  \n \n As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "original_text": "So, I don't think you can necessarily take our performance this quarter and just run it out. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3cc29e7678ca30e0ab8583f562ee0ff092e38ef518f78b4921d37cc5c4f0b351", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "65649958-a5f5-421b-aecb-3718a7449643", "node_type": "1", "metadata": {"window": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "original_text": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n "}, "hash": "02e13612ff91232daf270f6491a61469ad72b49926006122bad72fbc0b2557af", "class_name": "RelatedNodeInfo"}}, "text": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "start_char_idx": 1450, "end_char_idx": 1613, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "65649958-a5f5-421b-aecb-3718a7449643": {"__data__": {"id_": "65649958-a5f5-421b-aecb-3718a7449643", "embedding": null, "metadata": {"window": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "original_text": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e", "node_type": "1", "metadata": {"window": "As I called out at the beginning of the year, there were some additional investments that we were going to be \nmaking, particularly in the areas of information security management and data and analytics.  We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay. ", "original_text": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c791ac5d950c89b34ef12358662e0bb7ff62914d561a369e401b92290baa0c35", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0f13e637-ba92-4137-91e4-bf15d767c1a2", "node_type": "1", "metadata": {"window": "So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. "}, "hash": "447185b4d051ec4895eedad9739cd9f13384c8f329e50cc6a2db1ddf4c4273bf", "class_name": "RelatedNodeInfo"}}, "text": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "start_char_idx": 1613, "end_char_idx": 1829, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0f13e637-ba92-4137-91e4-bf15d767c1a2": {"__data__": {"id_": "0f13e637-ba92-4137-91e4-bf15d767c1a2", "embedding": null, "metadata": {"window": "So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "65649958-a5f5-421b-aecb-3718a7449643", "node_type": "1", "metadata": {"window": "We are continuing to \nmake those investments, but we're seeing good efficiency across the organization.  \n \n So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "original_text": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e9f22f5b8737a542439c1b1e84fbee2da45917631e7ef3e69979e40754d83ae", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "740a091f-0af6-44d8-89f3-3cc0218a23eb", "node_type": "1", "metadata": {"window": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact? ", "original_text": "LLC  Q \nOkay. "}, "hash": "8fdfac40856610587b32d16292a27f897e94c2cfff6370cea6a6fce2880a641c", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "start_char_idx": 1829, "end_char_idx": 2153, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "740a091f-0af6-44d8-89f3-3cc0218a23eb": {"__data__": {"id_": "740a091f-0af6-44d8-89f3-3cc0218a23eb", "embedding": null, "metadata": {"window": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact? ", "original_text": "LLC  Q \nOkay. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0f13e637-ba92-4137-91e4-bf15d767c1a2", "node_type": "1", "metadata": {"window": "So, I don't think you can necessarily take our performance this quarter and just run it out.  We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b9f726457aa4769609f92215e1b9d65540c1c7b33b019a2b06e00bd3b3a6cf09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0a5f2b96-8e81-4dd9-b042-72693d92cb33", "node_type": "1", "metadata": {"window": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive? ", "original_text": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. "}, "hash": "7f1c59283beb2976164db41f6a66f4665690e769f8a3160a34df75d76429f9ab", "class_name": "RelatedNodeInfo"}}, "text": "LLC  Q \nOkay. ", "start_char_idx": 2153, "end_char_idx": 2167, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0a5f2b96-8e81-4dd9-b042-72693d92cb33": {"__data__": {"id_": "0a5f2b96-8e81-4dd9-b042-72693d92cb33", "embedding": null, "metadata": {"window": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive? ", "original_text": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "740a091f-0af6-44d8-89f3-3cc0218a23eb", "node_type": "1", "metadata": {"window": "We're continuing to \nmake investments in the business, but we're also continuing along getti ng the efficiencies from scale in some of \nthe back office functions.  So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact? ", "original_text": "LLC  Q \nOkay. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfcb696b7368ee1078134cb0ffff7b2d32b880e1b097203b62e26ca1bf725b71", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n ", "original_text": "But can you \njust remind us directionally kind of like the mechanics? "}, "hash": "284e89e12a6a1f693a2d509563debf8f351c7fee9d73844220cfe8d21531e3f3", "class_name": "RelatedNodeInfo"}}, "text": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "start_char_idx": 2167, "end_char_idx": 2266, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2": {"__data__": {"id_": "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n ", "original_text": "But can you \njust remind us directionally kind of like the mechanics? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0a5f2b96-8e81-4dd9-b042-72693d92cb33", "node_type": "1", "metadata": {"window": "So, what we wanted to do today was to update our guidance based on some of the \nbenefits that we've seen in performance and execution, but we're continuing to make investments along as we \ngenerate those savings.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive? ", "original_text": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "669c3d4da0696fd1578803864637f03c8d394f4f79e19263e1262f676c38975c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "820f29c9-3a64-41ce-8167-f432cf1c1b14", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "original_text": "Should we expect Change \u2013 what should we expect in \nterms of impact? "}, "hash": "ca4dce8ea8556f9dfdf855cb869e79cb5c7eb07eab58eeb139a4393c6d54f1c0", "class_name": "RelatedNodeInfo"}}, "text": "But can you \njust remind us directionally kind of like the mechanics? ", "start_char_idx": 2266, "end_char_idx": 2336, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "820f29c9-3a64-41ce-8167-f432cf1c1b14": {"__data__": {"id_": "820f29c9-3a64-41ce-8167-f432cf1c1b14", "embedding": null, "metadata": {"window": "LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "original_text": "Should we expect Change \u2013 what should we expect in \nterms of impact? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nRicky R. Goldwasser  \nAnalyst, Morgan Stanley & Co.  LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n ", "original_text": "But can you \njust remind us directionally kind of like the mechanics? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "22ab8e81b0b7d24bcb547a6c686fc3ace1008f03d786cceaad4a1f7dc02d1f4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7", "node_type": "1", "metadata": {"window": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah. ", "original_text": "Would it be neutral to EPS, accretive or dilutive? "}, "hash": "2291ebf1e3316df18cd7b936b21df3ddfcabdcf29d4b3215936c1bfcc20eea24", "class_name": "RelatedNodeInfo"}}, "text": "Should we expect Change \u2013 what should we expect in \nterms of impact? ", "start_char_idx": 2336, "end_char_idx": 2405, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7": {"__data__": {"id_": "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7", "embedding": null, "metadata": {"window": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah. ", "original_text": "Would it be neutral to EPS, accretive or dilutive? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "820f29c9-3a64-41ce-8167-f432cf1c1b14", "node_type": "1", "metadata": {"window": "LLC  Q \nOkay.  And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "original_text": "Should we expect Change \u2013 what should we expect in \nterms of impact? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "549e1c45bb65c3abbb06d40f5cec7b2d89aa09f226ef49137a263605252b713f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "44dd30c8-01e7-4e51-ab37-755406c559f9", "node_type": "1", "metadata": {"window": "But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit. ", "original_text": "And same, how should we think about just \ndirectionally the impact to cash?  \n "}, "hash": "21d08ca6d19358bb70eeda046d35dad784083e1c33064dc7b1612010af6c2e01", "class_name": "RelatedNodeInfo"}}, "text": "Would it be neutral to EPS, accretive or dilutive? ", "start_char_idx": 2405, "end_char_idx": 2456, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "44dd30c8-01e7-4e51-ab37-755406c559f9": {"__data__": {"id_": "44dd30c8-01e7-4e51-ab37-755406c559f9", "embedding": null, "metadata": {"window": "But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit. ", "original_text": "And same, how should we think about just \ndirectionally the impact to cash?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7", "node_type": "1", "metadata": {"window": "And then, one follow -up on Change, I mean, obviously I understand that the exit is tax efficient.  But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah. ", "original_text": "Would it be neutral to EPS, accretive or dilutive? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "920cfc3f31cc7c998c2519aca3601235dfdb7eebba6987ac07e08e45d57a64ba", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2683f5a8-45d5-42b3-8935-dba1703e09d2", "node_type": "1", "metadata": {"window": "Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  "}, "hash": "bcd26242927e9c0488af75616af4b1b8f3e0132645fb7068f81599a89633a30d", "class_name": "RelatedNodeInfo"}}, "text": "And same, how should we think about just \ndirectionally the impact to cash?  \n ", "start_char_idx": 2456, "end_char_idx": 2535, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2683f5a8-45d5-42b3-8935-dba1703e09d2": {"__data__": {"id_": "2683f5a8-45d5-42b3-8935-dba1703e09d2", "embedding": null, "metadata": {"window": "Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "44dd30c8-01e7-4e51-ab37-755406c559f9", "node_type": "1", "metadata": {"window": "But can you \njust remind us directionally kind of like the mechanics?  Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit. ", "original_text": "And same, how should we think about just \ndirectionally the impact to cash?  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "de5c2bbdd68f83944edb411d193694d819495c5e96e71b2561cef4584eded869", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8399d6e8-70ec-447e-a913-d4e6471cf0b4", "node_type": "1", "metadata": {"window": "Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that. ", "original_text": "A \nYeah. "}, "hash": "342996b860e1130f676d68a58b84c7f4eb0e85cbc966dfa40a77924d6a8d6625", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "start_char_idx": 2535, "end_char_idx": 2896, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8399d6e8-70ec-447e-a913-d4e6471cf0b4": {"__data__": {"id_": "8399d6e8-70ec-447e-a913-d4e6471cf0b4", "embedding": null, "metadata": {"window": "Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2683f5a8-45d5-42b3-8935-dba1703e09d2", "node_type": "1", "metadata": {"window": "Should we expect Change \u2013 what should we expect in \nterms of impact?  Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0a767be5cd3a9dd71b9a9e28f447969e7120440980487ae412949a3b410142d5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32", "node_type": "1", "metadata": {"window": "And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "original_text": "So, let me just remind you that today is a filing that is another step along our exit. "}, "hash": "b9bf0fa04adc344a08c9d194b739b3bc49bac9419fd6e60d04431466e08c3ba5", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah. ", "start_char_idx": 2896, "end_char_idx": 2905, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32": {"__data__": {"id_": "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32", "embedding": null, "metadata": {"window": "And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "original_text": "So, let me just remind you that today is a filing that is another step along our exit. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8399d6e8-70ec-447e-a913-d4e6471cf0b4", "node_type": "1", "metadata": {"window": "Would it be neutral to EPS, accretive or dilutive?  And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that. ", "original_text": "A \nYeah. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c7366de232ae2efbad428c933aceae1c7774f3f24c7e7ebe553358787b22e43", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9674d575-81ec-4c10-91ca-ac6c22dc28fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "original_text": "We have nothing that is \nincluded in our FY 2020 guidance related to Change. "}, "hash": "cc69261ab88a1353141cacbd1a23ff76d65345d3cf821dc028342dda45c80b2f", "class_name": "RelatedNodeInfo"}}, "text": "So, let me just remind you that today is a filing that is another step along our exit. ", "start_char_idx": 2905, "end_char_idx": 2992, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9674d575-81ec-4c10-91ca-ac6c22dc28fd": {"__data__": {"id_": "9674d575-81ec-4c10-91ca-ac6c22dc28fd", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "original_text": "We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32", "node_type": "1", "metadata": {"window": "And same, how should we think about just \ndirectionally the impact to cash?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "original_text": "So, let me just remind you that today is a filing that is another step along our exit. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ec4fbc4ec00c7d789929b7e58e5341d66338b39e277c188b2bde87f141ce1e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2c7c26d-dc90-4889-b798-d43c91625aec", "node_type": "1", "metadata": {"window": "A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "original_text": "So, there's no additional information that I can provide yo u \non that. "}, "hash": "0bc9e881bb7217b43504689932b002f68e8cad7ad30da5e1ed0738ea4a26b2a4", "class_name": "RelatedNodeInfo"}}, "text": "We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "start_char_idx": 2992, "end_char_idx": 3069, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2c7c26d-dc90-4889-b798-d43c91625aec": {"__data__": {"id_": "a2c7c26d-dc90-4889-b798-d43c91625aec", "embedding": null, "metadata": {"window": "A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "original_text": "So, there's no additional information that I can provide yo u \non that. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9674d575-81ec-4c10-91ca-ac6c22dc28fd", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial  Officer, McKesson Corp.   A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "original_text": "We have nothing that is \nincluded in our FY 2020 guidance related to Change. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "309917a40e88afc231fe79a25076ec727a67c53b53a583e6bad30a4efcb9bc28", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f0b05edd-597e-4c29-aa5b-c6a65bdb998d", "node_type": "1", "metadata": {"window": "So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side. ", "original_text": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n "}, "hash": "4585e233e39133693d7858ca6dd2e275179354f5fe788c305a935743879054b0", "class_name": "RelatedNodeInfo"}}, "text": "So, there's no additional information that I can provide yo u \non that. ", "start_char_idx": 3069, "end_char_idx": 3141, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f0b05edd-597e-4c29-aa5b-c6a65bdb998d": {"__data__": {"id_": "f0b05edd-597e-4c29-aa5b-c6a65bdb998d", "embedding": null, "metadata": {"window": "So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side. ", "original_text": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2c7c26d-dc90-4889-b798-d43c91625aec", "node_type": "1", "metadata": {"window": "A \nYeah.  So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "original_text": "So, there's no additional information that I can provide yo u \non that. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2313ac051eee2473c504f939d317e904a6a1829b1b6e702d1c5bdc15dc938ccd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "76fe6634-dc0a-460c-9b1f-608708e03334", "node_type": "1", "metadata": {"window": "We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n "}, "hash": "cf8c1d7c98ad17400773855248d22376c6d98f1f20f8e399777fe498cb8341d4", "class_name": "RelatedNodeInfo"}}, "text": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "start_char_idx": 3141, "end_char_idx": 3244, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "76fe6634-dc0a-460c-9b1f-608708e03334": {"__data__": {"id_": "76fe6634-dc0a-460c-9b1f-608708e03334", "embedding": null, "metadata": {"window": "We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f0b05edd-597e-4c29-aa5b-c6a65bdb998d", "node_type": "1", "metadata": {"window": "So, let me just remind you that today is a filing that is another step along our exit.  We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side. ", "original_text": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e3abe711968dc481bf6c5d602d92e20cab54024e36367229e64f0ebc9bee8c10", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d", "node_type": "1", "metadata": {"window": "So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. "}, "hash": "4e353a360f49bb7e98436757deb570dfafa7f95cf9db2afe0f12d379f0b2b056", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "start_char_idx": 3244, "end_char_idx": 3583, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d": {"__data__": {"id_": "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d", "embedding": null, "metadata": {"window": "So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "76fe6634-dc0a-460c-9b1f-608708e03334", "node_type": "1", "metadata": {"window": "We have nothing that is \nincluded in our FY 2020 guidance related to Change.  So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6a7ed5864852429cb7d3752ae1e3f2fb4d68444aac4dd8ac484ed10a81b21939", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2a22c804-5ca6-4257-b516-32f7fbc1ee47", "node_type": "1", "metadata": {"window": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual? ", "original_text": "Just maybe broader long -term picture on the specialty side. "}, "hash": "3c7f596032004e812d4a1e588280c14d282cd12f85f223ce5c003da950b05408", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "start_char_idx": 3583, "end_char_idx": 3932, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2a22c804-5ca6-4257-b516-32f7fbc1ee47": {"__data__": {"id_": "2a22c804-5ca6-4257-b516-32f7fbc1ee47", "embedding": null, "metadata": {"window": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual? ", "original_text": "Just maybe broader long -term picture on the specialty side. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d", "node_type": "1", "metadata": {"window": "So, there's no additional information that I can provide yo u \non that.  And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "43623d07aafc5a9930f559f6e1046096decb9d703365c86deda8b007ebbebbb6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e18924fb-964f-4f23-9182-0a65f26fda23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n ", "original_text": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? "}, "hash": "e243e7add57bef6270acd7656279ac02bf8c5bf25c8c3f47e4600ed205352c48", "class_name": "RelatedNodeInfo"}}, "text": "Just maybe broader long -term picture on the specialty side. ", "start_char_idx": 3932, "end_char_idx": 3993, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e18924fb-964f-4f23-9182-0a65f26fda23": {"__data__": {"id_": "e18924fb-964f-4f23-9182-0a65f26fda23", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n ", "original_text": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2a22c804-5ca6-4257-b516-32f7fbc1ee47", "node_type": "1", "metadata": {"window": "And in terms of when we exit, depending on \u2013 regardless of how we exit, there'll be no cash impact.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual? ", "original_text": "Just maybe broader long -term picture on the specialty side. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4f7b345ac0823bf2be9cb379d075b78f66ad809358d67c708aa60f9034122a4c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b928815e-38c2-40d4-b637-d35d45b8dd96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? "}, "hash": "3bb1c09c10417b1552793f7a4f98b5f932908968c7d31898c6c68449f1ea074b", "class_name": "RelatedNodeInfo"}}, "text": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "start_char_idx": 3993, "end_char_idx": 4169, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b928815e-38c2-40d4-b637-d35d45b8dd96": {"__data__": {"id_": "b928815e-38c2-40d4-b637-d35d45b8dd96", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e18924fb-964f-4f23-9182-0a65f26fda23", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Elizabeth Anderson with Evercore.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n ", "original_text": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a20e41920fb81501428122b90ea071e933dada7d9d468c4a2f0adb9a74f3be06", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539", "node_type": "1", "metadata": {"window": "Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "original_text": "Is it something gradual? "}, "hash": "cd5a20ce0f59c2911d5d8a81200f9790d66e45f228309af8a31ae3335faafd91", "class_name": "RelatedNodeInfo"}}, "text": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "start_char_idx": 4169, "end_char_idx": 4294, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539": {"__data__": {"id_": "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539", "embedding": null, "metadata": {"window": "Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "original_text": "Is it something gradual? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b928815e-38c2-40d4-b637-d35d45b8dd96", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nHi, good morning, guys.  Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b594ed9c4d5d311372f60759bc9b1479a728c7032a7dc09ce3b1064b1096c908", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b904e35-7106-41ed-b0b7-53596872ea2a", "node_type": "1", "metadata": {"window": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "I'm just sort of looking for like a longer -term \nvision of that.  \n "}, "hash": "3ccd304ce4ffd85fb39549a3b14f2e9f10bde5440cfec6158868528955c3c24c", "class_name": "RelatedNodeInfo"}}, "text": "Is it something gradual? ", "start_char_idx": 4294, "end_char_idx": 4319, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b904e35-7106-41ed-b0b7-53596872ea2a": {"__data__": {"id_": "9b904e35-7106-41ed-b0b7-53596872ea2a", "embedding": null, "metadata": {"window": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "I'm just sort of looking for like a longer -term \nvision of that.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539", "node_type": "1", "metadata": {"window": "Just maybe broader long -term picture on the specialty side.  How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "original_text": "Is it something gradual? ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "674e5c206b3498134fc651caf3047bb4aac1b86bb63de2066d9a5fccd073cc0b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f268ceb1-f566-4a1c-ac0f-8955cded8732", "node_type": "1", "metadata": {"window": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "5fc5879f9238230e4ebb9e07cfde00ed8d06f420c82aa8a8c6e5aeba8dd61d02", "class_name": "RelatedNodeInfo"}}, "text": "I'm just sort of looking for like a longer -term \nvision of that.  \n ", "start_char_idx": 4319, "end_char_idx": 4388, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f268ceb1-f566-4a1c-ac0f-8955cded8732": {"__data__": {"id_": "f268ceb1-f566-4a1c-ac0f-8955cded8732", "embedding": null, "metadata": {"window": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b904e35-7106-41ed-b0b7-53596872ea2a", "node_type": "1", "metadata": {"window": "How do we think about like \nthe ramp -up in sort of additional specialty services you're providing, particularly on the US oncology side, but \nmaybe also in the core business?  And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "I'm just sort of looking for like a longer -term \nvision of that.  \n ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0afbeb96624f2a66e6ad666c6036a8aa4842f0d9c543d77e92e3d53cc42fad3d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a4e9e66a-6c71-48ed-9788-0129f1c4971d", "node_type": "1", "metadata": {"window": "Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "A \nYeah, it's a great question and it's obviously an area that we have some excitement about. "}, "hash": "f31ceb80c1fe18591c279c45dafef3a748063380019c2cf43625b9f056a2d2ae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 4388, "end_char_idx": 4729, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a4e9e66a-6c71-48ed-9788-0129f1c4971d": {"__data__": {"id_": "a4e9e66a-6c71-48ed-9788-0129f1c4971d", "embedding": null, "metadata": {"window": "Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f268ceb1-f566-4a1c-ac0f-8955cded8732", "node_type": "1", "metadata": {"window": "And sort of, are there sort of key moments that cause either providers or other \ncustomers to sort of take up that services?  Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6d29ebbe18c3df97512ac58eac95f4e5d63d4a849fdfc8ceacc079862fac2a72", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c6d3ef4e-7745-421f-ab09-a30e19763ff9", "node_type": "1", "metadata": {"window": "I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through "}, "hash": "25ab81e179b1742a22a3314a3c6cf8916400520610223cd173f7d274431b66f1", "class_name": "RelatedNodeInfo"}}, "text": "A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "start_char_idx": 4729, "end_char_idx": 4823, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c6d3ef4e-7745-421f-ab09-a30e19763ff9": {"__data__": {"id_": "c6d3ef4e-7745-421f-ab09-a30e19763ff9", "embedding": null, "metadata": {"window": "I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "9499270a-7af5-4ef0-8315-eb13e53c8613", "node_type": "4", "metadata": {"page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b4f71f47487f3aaf5db81f94250af6fedf2c33ac6190875f635fb6769cf1ced0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a4e9e66a-6c71-48ed-9788-0129f1c4971d", "node_type": "1", "metadata": {"window": "Is it something gradual?  I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "A \nYeah, it's a great question and it's obviously an area that we have some excitement about. ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e5dc28084bb4621af1cd660251ca7cf4eb7c49d8c117f9c9b1ddf6d0e23deb4d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bccc890-e091-4c5c-85ba-cc6aa9e42c46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system. ", "original_text": "McKesson Corp.  "}, "hash": "50606045d459d659305709e7e6dde0c213a45eb23e0253f40c99016bdca43ae9", "class_name": "RelatedNodeInfo"}}, "text": "And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "start_char_idx": 4823, "end_char_idx": 4954, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bccc890-e091-4c5c-85ba-cc6aa9e42c46": {"__data__": {"id_": "2bccc890-e091-4c5c-85ba-cc6aa9e42c46", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c6d3ef4e-7745-421f-ab09-a30e19763ff9", "node_type": "1", "metadata": {"window": "I'm just sort of looking for like a longer -term \nvision of that.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nYeah, it's a great question and it's obviously an area that we have some excitement about.  And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "original_text": "And we have spent, \nreally, a good part of the last 10 or 15 years building out some through internal development and some through ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "edeaccdf841e7bf53fcd1d022c6c0b689ce63924408c64b41692c7a445b25bcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ae91e9a6-edd5-4026-9c46-e87d9f9ce009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n"}, "hash": "22f54eb571c6adfad1dcd7e99f4fd642e9162fd00b587d63440038a522a1916c", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ae91e9a6-edd5-4026-9c46-e87d9f9ce009": {"__data__": {"id_": "ae91e9a6-edd5-4026-9c46-e87d9f9ce009", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bccc890-e091-4c5c-85ba-cc6aa9e42c46", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f8c1fc54c81af54759186f091300a71854b6e7e851aa435620205297cb69ffcf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e423da95-2d38-4c85-9d9a-57d83eb9da49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "original_text": "So, the first good news in that is that the patient gets the best outcome. "}, "hash": "ad78cc7a2e79a6abe23beb5e9215eddea3ff9a81899038433815d7a3c963ba56", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n", "start_char_idx": 16, "end_char_idx": 572, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e423da95-2d38-4c85-9d9a-57d83eb9da49": {"__data__": {"id_": "e423da95-2d38-4c85-9d9a-57d83eb9da49", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "original_text": "So, the first good news in that is that the patient gets the best outcome. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ae91e9a6-edd5-4026-9c46-e87d9f9ce009", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3543f1bb4240ee6b9441ead8aae30e36e514a828cec5b0b448ee3c2c48684663", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "300084a9-a3a3-49be-a286-f6f217452209", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "original_text": "We think it's good for the patient and it's \ngood for the healthcare system. "}, "hash": "16e9f0270133156fcf55152582b628e5e410343898558783f270667df6f30fb4", "class_name": "RelatedNodeInfo"}}, "text": "So, the first good news in that is that the patient gets the best outcome. ", "start_char_idx": 572, "end_char_idx": 647, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "300084a9-a3a3-49be-a286-f6f217452209": {"__data__": {"id_": "300084a9-a3a3-49be-a286-f6f217452209", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "original_text": "We think it's good for the patient and it's \ngood for the healthcare system. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e423da95-2d38-4c85-9d9a-57d83eb9da49", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "original_text": "So, the first good news in that is that the patient gets the best outcome. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "73cddbd8b50cdbcebe66235a539363fffaa41a429f803f78bcc3cbb3ba739f2a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "original_text": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. "}, "hash": "0ef8894ef79256b818278821de417b7e7819e6e6242ac19b52f80bf87e8ee599", "class_name": "RelatedNodeInfo"}}, "text": "We think it's good for the patient and it's \ngood for the healthcare system. ", "start_char_idx": 647, "end_char_idx": 724, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27": {"__data__": {"id_": "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "original_text": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "300084a9-a3a3-49be-a286-f6f217452209", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "original_text": "We think it's good for the patient and it's \ngood for the healthcare system. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f7341898a6f2d65f94963ac974977b9a0764d0b8e1519fe69f00deacceadd5f8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ee24867b-d2fe-4b67-9910-de21e313856e", "node_type": "1", "metadata": {"window": "So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "original_text": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. "}, "hash": "97df489200a4fe84f0891af521faf8b681d68809581c064c1c8899082608a2e5", "class_name": "RelatedNodeInfo"}}, "text": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "start_char_idx": 724, "end_char_idx": 830, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ee24867b-d2fe-4b67-9910-de21e313856e": {"__data__": {"id_": "ee24867b-d2fe-4b67-9910-de21e313856e", "embedding": null, "metadata": {"window": "So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "original_text": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "original_text": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "67840d19aaa50c330542c95cebc79fc219301eb13c321988b40ccc751d2f0ad9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "827243a2-24a1-456c-844d-5d77a9c6fc57", "node_type": "1", "metadata": {"window": "We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "original_text": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n"}, "hash": "fce4ac5f4d3a71948d38eff919574f8c7446c501e8c4c2958665d1199122cf22", "class_name": "RelatedNodeInfo"}}, "text": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "start_char_idx": 830, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "827243a2-24a1-456c-844d-5d77a9c6fc57": {"__data__": {"id_": "827243a2-24a1-456c-844d-5d77a9c6fc57", "embedding": null, "metadata": {"window": "We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "original_text": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ee24867b-d2fe-4b67-9910-de21e313856e", "node_type": "1", "metadata": {"window": "So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "original_text": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ca4eacd1e86efedd22b46283bf2d462ca08cf907bbdbfcec57786029f833ef00", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2c907959-a6f8-41fd-908f-dd317b67cee1", "node_type": "1", "metadata": {"window": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "original_text": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. "}, "hash": "c9b2228937d36ef95c4ef81e39a8e7eed912396a2cb5d62c2d69e6e40a5dedcf", "class_name": "RelatedNodeInfo"}}, "text": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "start_char_idx": 943, "end_char_idx": 1225, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2c907959-a6f8-41fd-908f-dd317b67cee1": {"__data__": {"id_": "2c907959-a6f8-41fd-908f-dd317b67cee1", "embedding": null, "metadata": {"window": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "original_text": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "827243a2-24a1-456c-844d-5d77a9c6fc57", "node_type": "1", "metadata": {"window": "We think it's good for the patient and it's \ngood for the healthcare system.  Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "original_text": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9ac4e3cb2d6a9cf1cf13bd6e81a40ab544e12282bfe025c274c758de7c19a5dc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "28031336-03e8-4383-b7f9-d57dea2dca1a", "node_type": "1", "metadata": {"window": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "original_text": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. "}, "hash": "da04093b2023c9b9acc87616f8f645085cf5da5e5373e7bf0f9d19477d27e6fc", "class_name": "RelatedNodeInfo"}}, "text": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "start_char_idx": 1225, "end_char_idx": 1514, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "28031336-03e8-4383-b7f9-d57dea2dca1a": {"__data__": {"id_": "28031336-03e8-4383-b7f9-d57dea2dca1a", "embedding": null, "metadata": {"window": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "original_text": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2c907959-a6f8-41fd-908f-dd317b67cee1", "node_type": "1", "metadata": {"window": "Obviously, f or our biopharma partners, that can result in more patients benefiting \nfrom their products.  That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "original_text": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "52512c9c87051a45b62f079cd4b4bf43d1f49ec88e93e1ba5371bbaac725733a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "483ebc3f-2308-49f4-ae35-4d2d920046f0", "node_type": "1", "metadata": {"window": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful. ", "original_text": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n"}, "hash": "57d46b1840f7fce78e1108c098b2bc8e33e732c38f442b8afb5a757bec089575", "class_name": "RelatedNodeInfo"}}, "text": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "start_char_idx": 1514, "end_char_idx": 1663, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "483ebc3f-2308-49f4-ae35-4d2d920046f0": {"__data__": {"id_": "483ebc3f-2308-49f4-ae35-4d2d920046f0", "embedding": null, "metadata": {"window": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful. ", "original_text": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "28031336-03e8-4383-b7f9-d57dea2dca1a", "node_type": "1", "metadata": {"window": "That has obvious benefit to them and that's a service, therefore, they're quite interested in \npaying us for it.  So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "original_text": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5416c6a639d90dc0fef7b358f8f4ebce17886abddc9ca3647f7fdd6e58396dcc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "205bd97f-70d9-4232-8045-c5a76c9567e1", "node_type": "1", "metadata": {"window": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n ", "original_text": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n "}, "hash": "8ca3c3c5a458703f5db135e705ef9f6a47388f6eb47770c69429552f3af64b58", "class_name": "RelatedNodeInfo"}}, "text": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "start_char_idx": 1663, "end_char_idx": 1789, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "205bd97f-70d9-4232-8045-c5a76c9567e1": {"__data__": {"id_": "205bd97f-70d9-4232-8045-c5a76c9567e1", "embedding": null, "metadata": {"window": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n ", "original_text": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "483ebc3f-2308-49f4-ae35-4d2d920046f0", "node_type": "1", "metadata": {"window": "So, as we think about building off of really our 20 -year experience in this marketplace, building off \nof the sets of assets that we've acquired for the commercialization of these products, there's opportunities to both \nrefine and deepen and develop the tools we offer today.  \n \n A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful. ", "original_text": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5f4557ded4b4baec5fa64fbeb3809d951c3e34e76b8c9e5e6b4d6c3202841be", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4faa18bd-3f04-44a4-8098-07ddb6027989", "node_type": "1", "metadata": {"window": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. "}, "hash": "bb8a7e5a786755f46825b30a03245b49b9a588c942476abcc319c65af9385e44", "class_name": "RelatedNodeInfo"}}, "text": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "start_char_idx": 1789, "end_char_idx": 2073, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4faa18bd-3f04-44a4-8098-07ddb6027989": {"__data__": {"id_": "4faa18bd-3f04-44a4-8098-07ddb6027989", "embedding": null, "metadata": {"window": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "205bd97f-70d9-4232-8045-c5a76c9567e1", "node_type": "1", "metadata": {"window": "A few weeks ago, I shared an exa mple of a program like that we're calling Access for More Patients, which \nfundamentally is getting at the same issue, but it's doing it in a more automated, efficient way that lets us get more \n\u2013 find more patients and get them on those therapies faster.  As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n ", "original_text": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8bea01df2242378b6b01d9fd3358aa3c191695eaa5e52801468112b8d50fdce6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b", "node_type": "1", "metadata": {"window": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That's really helpful. "}, "hash": "ea41f4cb36c6cdd54298b962356fbb3669898198bde7ceb3276596525d5c8575", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "start_char_idx": 2073, "end_char_idx": 2407, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b": {"__data__": {"id_": "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b", "embedding": null, "metadata": {"window": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That's really helpful. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4faa18bd-3f04-44a4-8098-07ddb6027989", "node_type": "1", "metadata": {"window": "As  we look at that as a core, we think there are \nopportunities to expand downstream and to get earlier -stage services to support pharmaceuticals.  And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5abb3627fd203bba795d75b3c84e6b3b4ef71119d2a5d3f47bc624772a0b0011", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ce8e4918-6270-407c-adbc-64eeb85cbf09", "node_type": "1", "metadata": {"window": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "Thank you.  \n "}, "hash": "ca4868a39318aa60c4a59be766c1c07a001091129629f007cd59bc477ed32c48", "class_name": "RelatedNodeInfo"}}, "text": "That's really helpful. ", "start_char_idx": 2407, "end_char_idx": 2430, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ce8e4918-6270-407c-adbc-64eeb85cbf09": {"__data__": {"id_": "ce8e4918-6270-407c-adbc-64eeb85cbf09", "embedding": null, "metadata": {"window": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b", "node_type": "1", "metadata": {"window": "And as we \nthink about some of our provider segments, there's opportunity to do some integration with providers d ownstream. \n So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "original_text": "That's really helpful. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "203edd5cec645dff0df6b45a57df491ce1c772b4974a426f2d7fac0f7e31012a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "91aa5270-01b7-47e7-abb5-236784f64b14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n "}, "hash": "f96e580f46b9fd78e0e5c7a550638726786170953201cefe32ecc7d4ad353d2f", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2430, "end_char_idx": 2444, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "91aa5270-01b7-47e7-abb5-236784f64b14": {"__data__": {"id_": "91aa5270-01b7-47e7-abb5-236784f64b14", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ce8e4918-6270-407c-adbc-64eeb85cbf09", "node_type": "1", "metadata": {"window": "So, this is an area that we think, as you look at the pipeline, as you look at the products, as you look at what's \nhappening in terms of in the clinical trial space and the fragmentation of populations, that there's going to continue \nto be a goo d opportunity here for McKesson.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks. ", "original_text": "Thank you.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "974a13638081be13b6310dff0f32f07332d701f69317672dcf51d927269c2271", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "47ed7284-e789-4604-86da-8d451f156ba0", "node_type": "1", "metadata": {"window": "That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  "}, "hash": "d3eae77a5f7ff03b8cc20c2b2f98e93523e5162b7cfc6bd5e3afcadf619185b3", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "start_char_idx": 2444, "end_char_idx": 2775, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "47ed7284-e789-4604-86da-8d451f156ba0": {"__data__": {"id_": "47ed7284-e789-4604-86da-8d451f156ba0", "embedding": null, "metadata": {"window": "That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "91aa5270-01b7-47e7-abb5-236784f64b14", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nElizabeth Anderson  \nAnalyst, Evercore Group LLC  Q \nPerfect.  That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b75878168950b013b3d56c580a1dde1eae7d7c453bab6254de2a87af2a832090", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7414504b-5b5b-4c96-9e79-b4699a329725", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers. ", "original_text": "Q \nThanks. "}, "hash": "b4ac4c4c1e04cf2cd7274e7e5820a14a9af04b4fee4c6f82308e41c63d66f3b6", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "start_char_idx": 2775, "end_char_idx": 3107, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7414504b-5b5b-4c96-9e79-b4699a329725": {"__data__": {"id_": "7414504b-5b5b-4c96-9e79-b4699a329725", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers. ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "47ed7284-e789-4604-86da-8d451f156ba0", "node_type": "1", "metadata": {"window": "That's really helpful.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8076ef5bd6ab31cc1c6750a51f29107ee8cce5c3f086dede629fa77f3c8ad084", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b61262ce-0946-454d-ba59-4f10361658ce", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "original_text": "Good morning. "}, "hash": "30bf1abe8f52c1b9fffee8c576416944399321c89b22294ba36be1f0a3402faf", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks. ", "start_char_idx": 3107, "end_char_idx": 3118, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b61262ce-0946-454d-ba59-4f10361658ce": {"__data__": {"id_": "b61262ce-0946-454d-ba59-4f10361658ce", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7414504b-5b5b-4c96-9e79-b4699a329725", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers. ", "original_text": "Q \nThanks. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e66fd822bc0c6df1afb8cb12c272ea1790cd47f0f69d238bbc99ea53606d29e7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c090daf5-9e66-4135-8049-289a618afcaa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "original_text": "So, maybe I'd just focus on the Med -Surg segment for a second. "}, "hash": "a2f6c2486214a1ec5125f452b85f4959990951d81b3c9f1d08b3dffe8058b80e", "class_name": "RelatedNodeInfo"}}, "text": "Good morning. ", "start_char_idx": 3118, "end_char_idx": 3132, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c090daf5-9e66-4135-8049-289a618afcaa": {"__data__": {"id_": "c090daf5-9e66-4135-8049-289a618afcaa", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "original_text": "So, maybe I'd just focus on the Med -Surg segment for a second. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b61262ce-0946-454d-ba59-4f10361658ce", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Eric Coldwell with Baird.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "original_text": "Good morning. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa9faba766d41b1f633e3cf9dbd720ec3df3ff9642b04c8e1d52b156991b7f38", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7f2084a2-ca63-4ad2-9562-40beb9a066ab", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting. ", "original_text": "You've mentioned the \nearly flu season consistent with peers. "}, "hash": "298be4536281c89d54bf39c9e57061a4371ba182ebd054a3a7917e90bdc112bf", "class_name": "RelatedNodeInfo"}}, "text": "So, maybe I'd just focus on the Med -Surg segment for a second. ", "start_char_idx": 3132, "end_char_idx": 3196, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7f2084a2-ca63-4ad2-9562-40beb9a066ab": {"__data__": {"id_": "7f2084a2-ca63-4ad2-9562-40beb9a066ab", "embedding": null, "metadata": {"window": "Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting. ", "original_text": "You've mentioned the \nearly flu season consistent with peers. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c090daf5-9e66-4135-8049-289a618afcaa", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric White Coldwell  \nAnalyst, Robert W. Baird & Co., Inc.   Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "original_text": "So, maybe I'd just focus on the Med -Surg segment for a second. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "50ff03d7c8bfe2c257f234353655f8c64ba3f2dc5afeb9a95cffa5348956974f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "75ade40f-fa78-4f99-8481-b05fbe3e5e53", "node_type": "1", "metadata": {"window": "Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n ", "original_text": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. "}, "hash": "09563b02d8901cd34fd80e5f54448c5a40299ff5e2327141a276949262179685", "class_name": "RelatedNodeInfo"}}, "text": "You've mentioned the \nearly flu season consistent with peers. ", "start_char_idx": 3196, "end_char_idx": 3258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "75ade40f-fa78-4f99-8481-b05fbe3e5e53": {"__data__": {"id_": "75ade40f-fa78-4f99-8481-b05fbe3e5e53", "embedding": null, "metadata": {"window": "Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n ", "original_text": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7f2084a2-ca63-4ad2-9562-40beb9a066ab", "node_type": "1", "metadata": {"window": "Q \nThanks.  Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting. ", "original_text": "You've mentioned the \nearly flu season consistent with peers. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "135e4110242cf9e8fff262bcce86447bc295955a1ca7a6c2187b81e39f4081a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ade6fe83-d661-407b-9ace-f453f2446e4d", "node_type": "1", "metadata": {"window": "So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. "}, "hash": "8a7b263db3956bda428d6897b41b179d2d6f32f4e8b4102ff3ad4b200574f96f", "class_name": "RelatedNodeInfo"}}, "text": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "start_char_idx": 3258, "end_char_idx": 3372, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ade6fe83-d661-407b-9ace-f453f2446e4d": {"__data__": {"id_": "ade6fe83-d661-407b-9ace-f453f2446e4d", "embedding": null, "metadata": {"window": "So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "75ade40f-fa78-4f99-8481-b05fbe3e5e53", "node_type": "1", "metadata": {"window": "Good morning.  So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n ", "original_text": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6cd1506c804a4aeddfa8c585a56c88b64a6d5728d1326dabd0eaf63ff07c5b23", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ac38b28-df2c-4578-8a83-d29a7a78dfa2", "node_type": "1", "metadata": {"window": "You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric. ", "original_text": "Just any answers on coronavirus \nimpact so far would be interesting. "}, "hash": "0053604ec591d027a51c99c06c9af1e7b33cf5a647e07ead04113e258ea1e234", "class_name": "RelatedNodeInfo"}}, "text": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "start_char_idx": 3372, "end_char_idx": 3644, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ac38b28-df2c-4578-8a83-d29a7a78dfa2": {"__data__": {"id_": "8ac38b28-df2c-4578-8a83-d29a7a78dfa2", "embedding": null, "metadata": {"window": "You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric. ", "original_text": "Just any answers on coronavirus \nimpact so far would be interesting. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ade6fe83-d661-407b-9ace-f453f2446e4d", "node_type": "1", "metadata": {"window": "So, maybe I'd just focus on the Med -Surg segment for a second.  You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "26f0f1c7c1cb285cfbb158527386dd0bb5434f33997954b924ba9d1491bf365a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b9085612-c533-4769-8e79-47f2b61ab6ac", "node_type": "1", "metadata": {"window": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt. ", "original_text": "Thanks so much.  \n "}, "hash": "e0dd577012c0eb08ef1c0f6ec1104f5b92dc10038dbab903af0a8938795ac281", "class_name": "RelatedNodeInfo"}}, "text": "Just any answers on coronavirus \nimpact so far would be interesting. ", "start_char_idx": 3644, "end_char_idx": 3713, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b9085612-c533-4769-8e79-47f2b61ab6ac": {"__data__": {"id_": "b9085612-c533-4769-8e79-47f2b61ab6ac", "embedding": null, "metadata": {"window": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt. ", "original_text": "Thanks so much.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ac38b28-df2c-4578-8a83-d29a7a78dfa2", "node_type": "1", "metadata": {"window": "You've mentioned the \nearly flu season consistent with peers.  I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric. ", "original_text": "Just any answers on coronavirus \nimpact so far would be interesting. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "72a89c0ffbc880eea842d546ff70a073762043fb585c58862344dd0673517fd7", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "449be7d3-d35b-4a8c-81fa-378c63ba4bbf", "node_type": "1", "metadata": {"window": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "9aafdecd14bf95aafb17fac389bbf1688521f5dc069bd1926b0fe6fd1d708eb5", "class_name": "RelatedNodeInfo"}}, "text": "Thanks so much.  \n ", "start_char_idx": 3713, "end_char_idx": 3732, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "449be7d3-d35b-4a8c-81fa-378c63ba4bbf": {"__data__": {"id_": "449be7d3-d35b-4a8c-81fa-378c63ba4bbf", "embedding": null, "metadata": {"window": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b9085612-c533-4769-8e79-47f2b61ab6ac", "node_type": "1", "metadata": {"window": "I'm curious, if you could carve out for us what you think the incremental \nbenefit of early flu was or heavy flu.  And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt. ", "original_text": "Thanks so much.  \n ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c5a1fb77dbbd4369aa8feb8b08a5074c756105b89ff95c184b92292a020e85e5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "68910868-73d1-40cf-93f4-424a9728366c", "node_type": "1", "metadata": {"window": "Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "original_text": "A \nGood morning, Eric. "}, "hash": "44097053b6fef9e22321742e5f3b5a7209b80d1e5389d8a54478933d3218bdfb", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 3732, "end_char_idx": 4092, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "68910868-73d1-40cf-93f4-424a9728366c": {"__data__": {"id_": "68910868-73d1-40cf-93f4-424a9728366c", "embedding": null, "metadata": {"window": "Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "original_text": "A \nGood morning, Eric. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "449be7d3-d35b-4a8c-81fa-378c63ba4bbf", "node_type": "1", "metadata": {"window": "And t hen, I know it's probably a bit early and maybe an evolving situation, but \ncoronavirus, any issues with sourcing out of the Asia -Pac region or pricing changes, demand changes in the US \nas maybe some facilities pre -stock certain gloves, gowns, masks, et cet era.  Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "db2ec9f1ceba2343e80ed2995e44481ca24286e823939d49e657be8b98871d6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5d4997ed-9cfa-4c80-a34f-089b163d2be1", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business. ", "original_text": "This is Britt. "}, "hash": "622249550cd17ce06b5cf01751c01998a842bef50600f0f088a111c5afe3f853", "class_name": "RelatedNodeInfo"}}, "text": "A \nGood morning, Eric. ", "start_char_idx": 4092, "end_char_idx": 4115, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5d4997ed-9cfa-4c80-a34f-089b163d2be1": {"__data__": {"id_": "5d4997ed-9cfa-4c80-a34f-089b163d2be1", "embedding": null, "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business. ", "original_text": "This is Britt. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "68910868-73d1-40cf-93f4-424a9728366c", "node_type": "1", "metadata": {"window": "Just any answers on coronavirus \nimpact so far would be interesting.  Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "original_text": "A \nGood morning, Eric. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "84eb43ba77281fa0d43a100f4d48990d7cbe2f8670c218e53dbf8bb28733024c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "original_text": "I'll take the first one and let Brian comm ent on the second. "}, "hash": "1f07a96f73a07517ad6c8451382342572f791c77521a7b3fe0f6a6db36406037", "class_name": "RelatedNodeInfo"}}, "text": "This is Britt. ", "start_char_idx": 4115, "end_char_idx": 4130, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9": {"__data__": {"id_": "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "original_text": "I'll take the first one and let Brian comm ent on the second. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5d4997ed-9cfa-4c80-a34f-089b163d2be1", "node_type": "1", "metadata": {"window": "Thanks so much.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business. ", "original_text": "This is Britt. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d6c1dc887a987dfc4415a18bd2e71dbec6cd3bea3cfc2165b4f7ae6bb24397a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd50eb44-4c33-42fc-9b59-0cc0a4155396", "node_type": "1", "metadata": {"window": "A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n", "original_text": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. "}, "hash": "1b5c1f81e69671ec9d0ae1248305ef4f61bad13e1344590b3d796d3fe6d0d543", "class_name": "RelatedNodeInfo"}}, "text": "I'll take the first one and let Brian comm ent on the second. ", "start_char_idx": 4130, "end_char_idx": 4192, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd50eb44-4c33-42fc-9b59-0cc0a4155396": {"__data__": {"id_": "fd50eb44-4c33-42fc-9b59-0cc0a4155396", "embedding": null, "metadata": {"window": "A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n", "original_text": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.   A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "original_text": "I'll take the first one and let Brian comm ent on the second. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "effa1ebbf9e8a57c517a72fc8c1a33875c84372e237b8640fc1ddc981fc23e13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bc3e2cda-5265-40fb-b865-0aad14f9b2a5", "node_type": "1", "metadata": {"window": "This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "original_text": "We had good organic growth \nreally across our business, but primarily in our primary care business. "}, "hash": "172eb410037b197d09b8a2c6a1d8de06ffd87c160abe280c6e380df37c27bf10", "class_name": "RelatedNodeInfo"}}, "text": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "start_char_idx": 4192, "end_char_idx": 4293, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bc3e2cda-5265-40fb-b865-0aad14f9b2a5": {"__data__": {"id_": "bc3e2cda-5265-40fb-b865-0aad14f9b2a5", "embedding": null, "metadata": {"window": "This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "original_text": "We had good organic growth \nreally across our business, but primarily in our primary care business. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd50eb44-4c33-42fc-9b59-0cc0a4155396", "node_type": "1", "metadata": {"window": "A \nGood morning, Eric.  This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n", "original_text": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e9b3733485319a611400cd737e3898e546e6d043d0198ed9ca0aaa75a083c47", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4ea59e98-cdbe-4689-b35d-d7ef2ad25543", "node_type": "1", "metadata": {"window": "I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "original_text": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers. "}, "hash": "9a3308acd32c96c899aebd8efc8d52edcae906c12e6e355d0931d84527cdb22f", "class_name": "RelatedNodeInfo"}}, "text": "We had good organic growth \nreally across our business, but primarily in our primary care business. ", "start_char_idx": 4293, "end_char_idx": 4393, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4ea59e98-cdbe-4689-b35d-d7ef2ad25543": {"__data__": {"id_": "4ea59e98-cdbe-4689-b35d-d7ef2ad25543", "embedding": null, "metadata": {"window": "I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "original_text": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bc3e2cda-5265-40fb-b865-0aad14f9b2a5", "node_type": "1", "metadata": {"window": "This is Britt.  I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "original_text": "We had good organic growth \nreally across our business, but primarily in our primary care business. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1b482a9062cca060af7f123355be4792c835a0b41d859cff953000cc32ecb5b0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bef86e86-f9f1-44c0-ab70-81d4dc2918b6", "node_type": "1", "metadata": {"window": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did see some modest impact from early flu season.  \n \n"}, "hash": "98d947389255deb1cda9138869ca85801731776895161f4bdd2dcfe344246270", "class_name": "RelatedNodeInfo"}}, "text": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "start_char_idx": 4393, "end_char_idx": 4470, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bef86e86-f9f1-44c0-ab70-81d4dc2918b6": {"__data__": {"id_": "bef86e86-f9f1-44c0-ab70-81d4dc2918b6", "embedding": null, "metadata": {"window": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did see some modest impact from early flu season.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4ea59e98-cdbe-4689-b35d-d7ef2ad25543", "node_type": "1", "metadata": {"window": "I'll take the first one and let Brian comm ent on the second.  As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "original_text": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2365ea8512cc91fb85f024aeef8071c2e08c02471cb20735ad8146f044a04610", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "99be23b1-4127-4716-a184-c7fbe88e5451", "node_type": "1", "metadata": {"window": "We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. "}, "hash": "5778c08407a52e3636c40a366ae5a3d14a8d50958efdba0571a6d1aee7ca0bc9", "class_name": "RelatedNodeInfo"}}, "text": "We did see some modest impact from early flu season.  \n \n", "start_char_idx": 4470, "end_char_idx": 4527, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "99be23b1-4127-4716-a184-c7fbe88e5451": {"__data__": {"id_": "99be23b1-4127-4716-a184-c7fbe88e5451", "embedding": null, "metadata": {"window": "We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bef86e86-f9f1-44c0-ab70-81d4dc2918b6", "node_type": "1", "metadata": {"window": "As I talked about in \nmy remarks, we're really pleased with the performance of the medical business.  We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did see some modest impact from early flu season.  \n \n", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "30c761405327b87a00aa4b9970ed32f58d979051020ee103ccde61ca2c76fa1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d", "node_type": "1", "metadata": {"window": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. "}, "hash": "2d2ca11cb25ca0cb91b99fd899582b89449c4c412fedc6f5f6665d38ccb76fec", "class_name": "RelatedNodeInfo"}}, "text": "I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "start_char_idx": 4527, "end_char_idx": 4650, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d": {"__data__": {"id_": "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d", "embedding": null, "metadata": {"window": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "99be23b1-4127-4716-a184-c7fbe88e5451", "node_type": "1", "metadata": {"window": "We had good organic growth \nreally across our business, but primarily in our primary care business.  And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92f9170116c52dcbb84169bb75abf9545c7f9f2e86e9ff3d12d0902972b233a2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8bf1f6e3-ca93-47b6-b262-82964cff6117", "node_type": "1", "metadata": {"window": "We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  "}, "hash": "95e5ff7abce5cbdb0413a46521fc935e87d106ff30b79e39c404476565049fdc", "class_name": "RelatedNodeInfo"}}, "text": "We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "start_char_idx": 4650, "end_char_idx": 4756, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8bf1f6e3-ca93-47b6-b262-82964cff6117": {"__data__": {"id_": "8bf1f6e3-ca93-47b6-b262-82964cff6117", "embedding": null, "metadata": {"window": "We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "fcf436d0-8977-4423-ae40-830e59ee55f9", "node_type": "4", "metadata": {"page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5d2a64b6a023fd5b5185fd1c58d88168ff6d67ea14f636b6bdc74930bdfc9f59", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d", "node_type": "1", "metadata": {"window": "And I also called out higher pharmaceu tical \nvolumes as one of the drivers.  We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated. ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "990b10cf736acc3e520976b60f606bfff9e536916ae8ff79760f23d764c2b159", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0adf2d6a-1ae7-4f61-9afb-0561964d0904", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time. ", "original_text": "McKesson Corp.  "}, "hash": "cd9b2034fd8bdb7d0f410cd9e6e1ba4a56e0b2b07796f55c49d0abcfe9de2156", "class_name": "RelatedNodeInfo"}}, "text": "But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "start_char_idx": 4756, "end_char_idx": 4962, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0adf2d6a-1ae7-4f61-9afb-0561964d0904": {"__data__": {"id_": "0adf2d6a-1ae7-4f61-9afb-0561964d0904", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8bf1f6e3-ca93-47b6-b262-82964cff6117", "node_type": "1", "metadata": {"window": "We did see some modest impact from early flu season.  \n \n I would remind you though that typically the flu season has a larger impact on our fourth quarter than our third \nquarter.  We did plan the year for a normal flu seaso n. So, we saw a little earlier start than we had anticipated.  But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "original_text": "But \nagain, I would just remind you that the strong core organic growth across our primary care business, which was \ninclusive of higher pharmaceutical volumes, was really the driver for the perfo rmance.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "fddb93496f651ad2273ff80b606e9f8294cc12565c39caafb5b456f6b8e9e5b1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ef46d05a-b76d-406d-8d4e-13132fcf369f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "dcd431634c744f7b9da0b2255b971d6a127abde018b5656cbba1211813a47147", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ef46d05a-b76d-406d-8d4e-13132fcf369f": {"__data__": {"id_": "ef46d05a-b76d-406d-8d4e-13132fcf369f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0adf2d6a-1ae7-4f61-9afb-0561964d0904", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5891a9c514d6ff9437363fc4ddb83ce175d282c4850f21ab38327621e103cda5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "829cbd28-7cd6-434b-80a5-f2cd7e4d7081", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start. ", "original_text": "A \nI'll take the coronavirus. "}, "hash": "11324a4390ecdfb24b215d554e33b4ce71aa36461714ebe90049c49f9723b547", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 16, "end_char_idx": 250, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "829cbd28-7cd6-434b-80a5-f2cd7e4d7081": {"__data__": {"id_": "829cbd28-7cd6-434b-80a5-f2cd7e4d7081", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start. ", "original_text": "A \nI'll take the coronavirus. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ef46d05a-b76d-406d-8d4e-13132fcf369f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "92b621fc23981f29639101f9e869f473dd727cfb0fccecd7a745bd89b18885f9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a50a9f7c-a97b-4813-8ee2-25be289b79b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity. ", "original_text": "Maybe before that, we've been around this business for a long time. "}, "hash": "33e0a4bf458a4e231d2f1c71ebef3c1c724d66742505002a9b90c0cb406c8e8c", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll take the coronavirus. ", "start_char_idx": 250, "end_char_idx": 280, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a50a9f7c-a97b-4813-8ee2-25be289b79b5": {"__data__": {"id_": "a50a9f7c-a97b-4813-8ee2-25be289b79b5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity. ", "original_text": "Maybe before that, we've been around this business for a long time. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "829cbd28-7cd6-434b-80a5-f2cd7e4d7081", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start. ", "original_text": "A \nI'll take the coronavirus. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f363b8be592d62e86ec667799ed4385b519566c71ae19f9b5ba5082b99efd31f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "808608fc-c58a-4a5a-b4e8-5df612cabce9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now. ", "original_text": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. "}, "hash": "f39622aade6ec7e44cbea32ae8f9cc0158c142af275c16b67241d79cae9aa53b", "class_name": "RelatedNodeInfo"}}, "text": "Maybe before that, we've been around this business for a long time. ", "start_char_idx": 280, "end_char_idx": 348, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "808608fc-c58a-4a5a-b4e8-5df612cabce9": {"__data__": {"id_": "808608fc-c58a-4a5a-b4e8-5df612cabce9", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now. ", "original_text": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a50a9f7c-a97b-4813-8ee2-25be289b79b5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity. ", "original_text": "Maybe before that, we've been around this business for a long time. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5f6f197c0987663285a20ff4e30ed219ee31eb8a148e607acc20614b8e497a94", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9ca020e3-3e05-4ad3-995c-b9005596c153", "node_type": "1", "metadata": {"window": "A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "original_text": "And so, I think it's fair to say, we have seen an early start. "}, "hash": "1e5e64e423e152cc99061e3aab626640db7abf087be37da3b86987bf28dcd2e8", "class_name": "RelatedNodeInfo"}}, "text": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "start_char_idx": 348, "end_char_idx": 493, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9ca020e3-3e05-4ad3-995c-b9005596c153": {"__data__": {"id_": "9ca020e3-3e05-4ad3-995c-b9005596c153", "embedding": null, "metadata": {"window": "A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "original_text": "And so, I think it's fair to say, we have seen an early start. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "808608fc-c58a-4a5a-b4e8-5df612cabce9", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now. ", "original_text": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e914edd338727d6363335efad35975c313a3aeedf6f30380b48057ed0c1f43ad", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "33e25f73-7b51-4f7b-ac43-caca18302646", "node_type": "1", "metadata": {"window": "Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "original_text": "Ultimately, how that plays out will depend on \nthe duration and the severity. "}, "hash": "4dbf49a457bf6ddb10a692837938cbeb22e1723b03738566193be8c670e761f2", "class_name": "RelatedNodeInfo"}}, "text": "And so, I think it's fair to say, we have seen an early start. ", "start_char_idx": 493, "end_char_idx": 556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "33e25f73-7b51-4f7b-ac43-caca18302646": {"__data__": {"id_": "33e25f73-7b51-4f7b-ac43-caca18302646", "embedding": null, "metadata": {"window": "Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "original_text": "Ultimately, how that plays out will depend on \nthe duration and the severity. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9ca020e3-3e05-4ad3-995c-b9005596c153", "node_type": "1", "metadata": {"window": "A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "original_text": "And so, I think it's fair to say, we have seen an early start. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "da8cf5c138bb7be1227fa552664981b04addefbf4c07ebe5ff5dc734cf1b1e0d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e421efaa-a891-404c-93d2-b6c021e4add9", "node_type": "1", "metadata": {"window": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem. ", "original_text": "And it's probably hard to predict that right now. "}, "hash": "eaae7a40633733f1744510a2addbbe4ea1bf520b2b90ad3fb5dea11a85ce62d3", "class_name": "RelatedNodeInfo"}}, "text": "Ultimately, how that plays out will depend on \nthe duration and the severity. ", "start_char_idx": 556, "end_char_idx": 634, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e421efaa-a891-404c-93d2-b6c021e4add9": {"__data__": {"id_": "e421efaa-a891-404c-93d2-b6c021e4add9", "embedding": null, "metadata": {"window": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem. ", "original_text": "And it's probably hard to predict that right now. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "33e25f73-7b51-4f7b-ac43-caca18302646", "node_type": "1", "metadata": {"window": "Maybe before that, we've been around this business for a long time.  And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "original_text": "Ultimately, how that plays out will depend on \nthe duration and the severity. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "dfef616c8f880e793153dad95b14d68c147fe520a928fcb830334cfc1ebbc203", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "16827b63-223d-44de-97cd-99a85916ba23", "node_type": "1", "metadata": {"window": "And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely. ", "original_text": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n"}, "hash": "8792e0e11dddc79064daced76feedadb464caa210ca334d8073259d7575e5ede", "class_name": "RelatedNodeInfo"}}, "text": "And it's probably hard to predict that right now. ", "start_char_idx": 634, "end_char_idx": 684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "16827b63-223d-44de-97cd-99a85916ba23": {"__data__": {"id_": "16827b63-223d-44de-97cd-99a85916ba23", "embedding": null, "metadata": {"window": "And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely. ", "original_text": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e421efaa-a891-404c-93d2-b6c021e4add9", "node_type": "1", "metadata": {"window": "And we chart every \nyear what the flu season, influenza season looked like in the US and every season has its own cycle or rhythm, if \nyou will.  And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem. ", "original_text": "And it's probably hard to predict that right now. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5b336859da04abb147ef71976b9a18e20cc6c46d8a39098c0ac723eca9d58daa", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd6413ce-d32c-4bfc-8116-0578fe028981", "node_type": "1", "metadata": {"window": "Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts. ", "original_text": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. "}, "hash": "98912dfe0aec3a2b2c67ef2214510da0ba04960ce51baefed32ab0da1ca74ad9", "class_name": "RelatedNodeInfo"}}, "text": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "start_char_idx": 684, "end_char_idx": 900, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd6413ce-d32c-4bfc-8116-0578fe028981": {"__data__": {"id_": "fd6413ce-d32c-4bfc-8116-0578fe028981", "embedding": null, "metadata": {"window": "Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts. ", "original_text": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "16827b63-223d-44de-97cd-99a85916ba23", "node_type": "1", "metadata": {"window": "And so, I think it's fair to say, we have seen an early start.  Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely. ", "original_text": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ebd8ab7736d480e3f2ca3e0441b569d995e066b714ebcf8d80664c515611d0b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c49858b4-3039-4e31-a22e-0083516ba4f9", "node_type": "1", "metadata": {"window": "And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them. ", "original_text": "So, we try to jump on these things early and get ahead of \nthem. "}, "hash": "bcae9e343fcc89eb768be086c3d0cea7e4beb743ba66df6f78047da6218bdd01", "class_name": "RelatedNodeInfo"}}, "text": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "start_char_idx": 900, "end_char_idx": 1059, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c49858b4-3039-4e31-a22e-0083516ba4f9": {"__data__": {"id_": "c49858b4-3039-4e31-a22e-0083516ba4f9", "embedding": null, "metadata": {"window": "And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them. ", "original_text": "So, we try to jump on these things early and get ahead of \nthem. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd6413ce-d32c-4bfc-8116-0578fe028981", "node_type": "1", "metadata": {"window": "Ultimately, how that plays out will depend on \nthe duration and the severity.  And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts. ", "original_text": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "57d0d16c7f5c47800f1f992fa4455a317b8e87276cdbc310d4ca5b907ef9ac9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "da691378-ef70-46ed-b9e0-b7714b794b02", "node_type": "1", "metadata": {"window": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "original_text": "And so, we're monitoring this very, very closely. "}, "hash": "8ea1a1859e121fb4c0ab9ce392373f008e962dbda2430976289ca07c41334fb0", "class_name": "RelatedNodeInfo"}}, "text": "So, we try to jump on these things early and get ahead of \nthem. ", "start_char_idx": 1059, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "da691378-ef70-46ed-b9e0-b7714b794b02": {"__data__": {"id_": "da691378-ef70-46ed-b9e0-b7714b794b02", "embedding": null, "metadata": {"window": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "original_text": "And so, we're monitoring this very, very closely. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c49858b4-3039-4e31-a22e-0083516ba4f9", "node_type": "1", "metadata": {"window": "And it's probably hard to predict that right now.  Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them. ", "original_text": "So, we try to jump on these things early and get ahead of \nthem. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8f62257824490654ca0d0f4e4f897f252815566ab5a242136790aa7556592de9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4765a2da-85ba-44a3-a094-8801b508c5a1", "node_type": "1", "metadata": {"window": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "original_text": "I would remind everybody that we don't manufacture these \nproducts. "}, "hash": "0d28e6e273cee70b84653fbcc48b4b0b5662f864d09bbc108ec05f05d6116188", "class_name": "RelatedNodeInfo"}}, "text": "And so, we're monitoring this very, very closely. ", "start_char_idx": 1124, "end_char_idx": 1174, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4765a2da-85ba-44a3-a094-8801b508c5a1": {"__data__": {"id_": "4765a2da-85ba-44a3-a094-8801b508c5a1", "embedding": null, "metadata": {"window": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "original_text": "I would remind everybody that we don't manufacture these \nproducts. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "da691378-ef70-46ed-b9e0-b7714b794b02", "node_type": "1", "metadata": {"window": "Relativ e to coronavirus, I guess let \nme start by first saying our thoughts and sympathies go out to those, particularly in China, but really Asia that are \nobviously dealing with this in a very real -time way.  \n \n We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "original_text": "And so, we're monitoring this very, very closely. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9907568ba76ed9dcd101c5ac8c127394d5e736f9265c574ec7f6368b47778016", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "866df582-8f2e-4957-a34b-0acdc58575b2", "node_type": "1", "metadata": {"window": "So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "original_text": "We procure them, we sell them and we distribute them. "}, "hash": "a4b4beade0317261ed8e2cae1ecd17589ec2fb181320d91e3c74229b0ce859f8", "class_name": "RelatedNodeInfo"}}, "text": "I would remind everybody that we don't manufacture these \nproducts. ", "start_char_idx": 1174, "end_char_idx": 1242, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "866df582-8f2e-4957-a34b-0acdc58575b2": {"__data__": {"id_": "866df582-8f2e-4957-a34b-0acdc58575b2", "embedding": null, "metadata": {"window": "So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "original_text": "We procure them, we sell them and we distribute them. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4765a2da-85ba-44a3-a094-8801b508c5a1", "node_type": "1", "metadata": {"window": "We at McKesson have really been working across industr y partners, peers, trade associations, government \nagencies for the better part of three or four weeks.  So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "original_text": "I would remind everybody that we don't manufacture these \nproducts. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e931f66b05fc34f2c17eb0e5c53d65066bc33c1537877a01057276a3de77779", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "efe4629d-cec0-49c3-a656-0558a821e06f", "node_type": "1", "metadata": {"window": "And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "original_text": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n"}, "hash": "42511da9e8485bce1421091e6aac5374c1c2d64a25381f2bf4235278a9d570dc", "class_name": "RelatedNodeInfo"}}, "text": "We procure them, we sell them and we distribute them. ", "start_char_idx": 1242, "end_char_idx": 1296, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "efe4629d-cec0-49c3-a656-0558a821e06f": {"__data__": {"id_": "efe4629d-cec0-49c3-a656-0558a821e06f", "embedding": null, "metadata": {"window": "And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "original_text": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "866df582-8f2e-4957-a34b-0acdc58575b2", "node_type": "1", "metadata": {"window": "So, we try to jump on these things early and get ahead of \nthem.  And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "original_text": "We procure them, we sell them and we distribute them. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9e8a16e35f8f5bef19130078f2579fb7e2bd2a70e18e2b500ecaed52412f1274", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5", "node_type": "1", "metadata": {"window": "I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "original_text": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. "}, "hash": "a27311ee8547608aa27653cd5ae5c43b4af235b5a5bd2afc9b3107353bbaffb7", "class_name": "RelatedNodeInfo"}}, "text": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "start_char_idx": 1296, "end_char_idx": 1460, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5": {"__data__": {"id_": "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5", "embedding": null, "metadata": {"window": "I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "original_text": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "efe4629d-cec0-49c3-a656-0558a821e06f", "node_type": "1", "metadata": {"window": "And so, we're monitoring this very, very closely.  I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "original_text": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0c16e4799f26d25582d82b77d01530a88dc11381dca9176afc705a685394dc7b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "525e5693-90ba-4c9f-bbb2-415fdc390271", "node_type": "1", "metadata": {"window": "We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "original_text": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n"}, "hash": "4c4388c7be429e2813be8d124a957c9d4b56375744f6ff505670eab5c4b76278", "class_name": "RelatedNodeInfo"}}, "text": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "start_char_idx": 1460, "end_char_idx": 1577, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "525e5693-90ba-4c9f-bbb2-415fdc390271": {"__data__": {"id_": "525e5693-90ba-4c9f-bbb2-415fdc390271", "embedding": null, "metadata": {"window": "We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "original_text": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5", "node_type": "1", "metadata": {"window": "I would remind everybody that we don't manufacture these \nproducts.  We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "original_text": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "91e260f7447475d346004fd64ee2e8cf1e059ac6b401b5eb86e1ee8fa3a76447", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "0824275f-4d1b-48d3-a319-85ca3db84021", "node_type": "1", "metadata": {"window": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. "}, "hash": "e6f67bf90950e06e0c090522a3abd17611f7f8424a7555685ba4aa163223f3ee", "class_name": "RelatedNodeInfo"}}, "text": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "start_char_idx": 1577, "end_char_idx": 1853, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "0824275f-4d1b-48d3-a319-85ca3db84021": {"__data__": {"id_": "0824275f-4d1b-48d3-a319-85ca3db84021", "embedding": null, "metadata": {"window": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "525e5693-90ba-4c9f-bbb2-415fdc390271", "node_type": "1", "metadata": {"window": "We procure them, we sell them and we distribute them.  And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "original_text": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b60acf315f23105e37edce99dba9e8f91b8807ebcc59917f1df9eaed5f8b3ed8", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e81d6b20-f384-40ce-99c8-7b74bda282ad", "node_type": "1", "metadata": {"window": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question. ", "original_text": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n "}, "hash": "0c3e84bdccc8c365adf4f63f0a45326e7ea62a392bd6d930e23aed8ad7db0359", "class_name": "RelatedNodeInfo"}}, "text": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "start_char_idx": 1853, "end_char_idx": 2041, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e81d6b20-f384-40ce-99c8-7b74bda282ad": {"__data__": {"id_": "e81d6b20-f384-40ce-99c8-7b74bda282ad", "embedding": null, "metadata": {"window": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question. ", "original_text": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "0824275f-4d1b-48d3-a319-85ca3db84021", "node_type": "1", "metadata": {"window": "And we do have a domestic supplier base, \nalthough the majority of the products, the masks and the disinfectants and the gowns are sourced from Asia or \nChina.  \n \n I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "original_text": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bac531393c18261a8a5827b373a4d539eeea0d9d1ab6076926bc08b023370a74", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "287b0305-e7d0-44c0-8e18-93f9ad06a55a", "node_type": "1", "metadata": {"window": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n "}, "hash": "3b53a2646acef2ee42296eb21bb17207878e7cf141f3b2f96493e6b6d7cc374c", "class_name": "RelatedNodeInfo"}}, "text": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "start_char_idx": 2041, "end_char_idx": 2208, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "287b0305-e7d0-44c0-8e18-93f9ad06a55a": {"__data__": {"id_": "287b0305-e7d0-44c0-8e18-93f9ad06a55a", "embedding": null, "metadata": {"window": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e81d6b20-f384-40ce-99c8-7b74bda282ad", "node_type": "1", "metadata": {"window": "I guess fortuna tely or unfortunately, depending on your perspective, we've had some experience with SARS and \nH1N1.  And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question. ", "original_text": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5e96e833afe4b0ec4fb027cda689d987146ddc50754fa127b3a6e5156bd7dcbb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d0198e2e-49a6-4f16-8576-b8c3ee36d799", "node_type": "1", "metadata": {"window": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  "}, "hash": "8e28fd73aa8739e942fce2d4692091afebe57ca06f23699cf1e7ad5f3fa2d6d8", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "start_char_idx": 2208, "end_char_idx": 2551, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d0198e2e-49a6-4f16-8576-b8c3ee36d799": {"__data__": {"id_": "d0198e2e-49a6-4f16-8576-b8c3ee36d799", "embedding": null, "metadata": {"window": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "287b0305-e7d0-44c0-8e18-93f9ad06a55a", "node_type": "1", "metadata": {"window": "And so, what we're doing is implementing the protocols, the monitoring capabilities that we've built up \nthrough these prior experiences and working in close  coordination with government agencies and industry \npartners to make sure we can keep good continuity of supply.  \n \n Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "be0264b7c3b2ed2365f52cb808728d8feae574df36c1bff07bd002a8476c2cdd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2536282-da0e-4217-996e-acdd53f797e9", "node_type": "1", "metadata": {"window": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "original_text": "Q \nThanks so much for taking the question. "}, "hash": "b94774eebf674e74478b49902b45a95977ff4ddbe0765bdc6d9abee30986e8ca", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "start_char_idx": 2551, "end_char_idx": 2872, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2536282-da0e-4217-996e-acdd53f797e9": {"__data__": {"id_": "e2536282-da0e-4217-996e-acdd53f797e9", "embedding": null, "metadata": {"window": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "original_text": "Q \nThanks so much for taking the question. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d0198e2e-49a6-4f16-8576-b8c3ee36d799", "node_type": "1", "metadata": {"window": "Now, what that ultimately looks like depends really on how does the virus continue to proliferate, does it stay \ncontained in a region, and so those are things that we just have to watch.  But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "28bd9d104fb3b789a9f67935fcab96c2fe2457ff663752569c3e077170599930", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a6979613-7cdc-4f18-b8aa-de405f56620f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "original_text": "I guess a lot of the key topics have been asked. "}, "hash": "665f9163f1b58a7a38cb9b6aa429b15267d5a62267ae6482c1f412a9fcdf3b47", "class_name": "RelatedNodeInfo"}}, "text": "Q \nThanks so much for taking the question. ", "start_char_idx": 2872, "end_char_idx": 2915, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a6979613-7cdc-4f18-b8aa-de405f56620f": {"__data__": {"id_": "a6979613-7cdc-4f18-b8aa-de405f56620f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "original_text": "I guess a lot of the key topics have been asked. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2536282-da0e-4217-996e-acdd53f797e9", "node_type": "1", "metadata": {"window": "But we wake up every day thinking \nabout the markets that we serve and how we make sure we have product available for our customers that operate \nin those markets.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "original_text": "Q \nThanks so much for taking the question. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8de12b49f32120470f84035b4e18e81826a66d80f0da25b5877b5bc180d851bd", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2dd1f7cc-a76f-446f-904a-d090bc223e0f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n"}, "hash": "25ff13fadb921bf24e0254e78b6497807deac4757f7b05aeda19e244de3908c2", "class_name": "RelatedNodeInfo"}}, "text": "I guess a lot of the key topics have been asked. ", "start_char_idx": 2915, "end_char_idx": 2964, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2dd1f7cc-a76f-446f-904a-d090bc223e0f": {"__data__": {"id_": "2dd1f7cc-a76f-446f-904a-d090bc223e0f", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a6979613-7cdc-4f18-b8aa-de405f56620f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Michael Cherny with  BofA Securities.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "original_text": "I guess a lot of the key topics have been asked. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9b6e3242f875c3460295affd65754296e2336f1bc7e315c7e67e4e6b3db66d62", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "563f1b73-bd64-4d5f-80a0-40eb07415831", "node_type": "1", "metadata": {"window": "Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? "}, "hash": "0144a1ef1d001b5850070a0469a0bf735ef5502f248ae1b47bee0e225e251493", "class_name": "RelatedNodeInfo"}}, "text": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "start_char_idx": 2964, "end_char_idx": 3201, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "563f1b73-bd64-4d5f-80a0-40eb07415831": {"__data__": {"id_": "563f1b73-bd64-4d5f-80a0-40eb07415831", "embedding": null, "metadata": {"window": "Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2dd1f7cc-a76f-446f-904a-d090bc223e0f", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nMichael Cherny  \nAnalyst, BofA Securities, Inc.   Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "original_text": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6ddced4341bfbd833edad0bdf1bad8cb28433e9aba629e2b14c7531369c3cc09", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ebe1dafb-0a7c-4146-a32a-d99738947bf0", "node_type": "1", "metadata": {"window": "I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "original_text": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n "}, "hash": "e090243289c6b14d40aaf2394af5a63389817608d6eebe74f73a623a25928cc6", "class_name": "RelatedNodeInfo"}}, "text": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "start_char_idx": 3201, "end_char_idx": 3495, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ebe1dafb-0a7c-4146-a32a-d99738947bf0": {"__data__": {"id_": "ebe1dafb-0a7c-4146-a32a-d99738947bf0", "embedding": null, "metadata": {"window": "I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "original_text": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "563f1b73-bd64-4d5f-80a0-40eb07415831", "node_type": "1", "metadata": {"window": "Q \nThanks so much for taking the question.  I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question. ", "original_text": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth? ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a6f54b705f8000062f793f272f3ea51139907315b8a4fa15533f1187698da737", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1", "node_type": "1", "metadata": {"window": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  "}, "hash": "9621b3361bbce106c3e6b69f6d8b8b3a7d2b7425be2ff2bad925a144b02d60fa", "class_name": "RelatedNodeInfo"}}, "text": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "start_char_idx": 3495, "end_char_idx": 3683, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1": {"__data__": {"id_": "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1", "embedding": null, "metadata": {"window": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ebe1dafb-0a7c-4146-a32a-d99738947bf0", "node_type": "1", "metadata": {"window": "I guess a lot of the key topics have been asked.  The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "original_text": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "55089905a7bf6149cadb82a962d33fc1f45f87a9dac0c67df9cb62f53a0bb82d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9c121c78-3197-4259-8bd6-6e894b54fbba", "node_type": "1", "metadata": {"window": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "A \nGreat question. "}, "hash": "40631811955534f2021be89fa2ce30812177b3babe1094fe5fa03c1840126506", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "start_char_idx": 3683, "end_char_idx": 4024, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9c121c78-3197-4259-8bd6-6e894b54fbba": {"__data__": {"id_": "9c121c78-3197-4259-8bd6-6e894b54fbba", "embedding": null, "metadata": {"window": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "A \nGreat question. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1", "node_type": "1", "metadata": {"window": "The one thing that did \nstand out, you highlighted the recent success on the transaction side, medical really rocking it, pretty low so far \nfrom an acquisition perspective, at least, in terms of your historical spend year -to-date.  \n \n As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "86acbbaebff330b06228673b83bc20dd3f1db2dc0205f73efc1296ab5eed47c4", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a21d7908-3b86-4d66-9381-08342178ccf3", "node_type": "1", "metadata": {"window": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. "}, "hash": "4e0786e252a781d9eb3e19539567d55a8e162f0daee49218bb02f28b8af4d6b5", "class_name": "RelatedNodeInfo"}}, "text": "A \nGreat question. ", "start_char_idx": 4024, "end_char_idx": 4043, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a21d7908-3b86-4d66-9381-08342178ccf3": {"__data__": {"id_": "a21d7908-3b86-4d66-9381-08342178ccf3", "embedding": null, "metadata": {"window": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9c121c78-3197-4259-8bd6-6e894b54fbba", "node_type": "1", "metadata": {"window": "As you're heading into fiscal 2021, as you're getting rid of the Change position on the balance sheet and the \nownership  stake, as you think forward of the portfolio, are there any macro trends that you think would drive some \nareas for opportunities for you to go and drive inorganic growth?  Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "A \nGreat question. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c69a4eca4c9582d905927c1aab56cd599de6a7e56da9a208f362194053bc0ce9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "5b7420e2-0a73-4aba-b234-9d41614fe889", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate "}, "hash": "228617fb7fece7eb05c8f2154bbac57887b889a76c770aba0b2c4aaa3ef818d4", "class_name": "RelatedNodeInfo"}}, "text": "I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "start_char_idx": 4043, "end_char_idx": 4368, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "5b7420e2-0a73-4aba-b234-9d41614fe889": {"__data__": {"id_": "5b7420e2-0a73-4aba-b234-9d41614fe889", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3", "node_type": "4", "metadata": {"page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6909c2a05470f0d63398bb1292f0dc181958afc9b5eb15ed1b909b35790c2fd0", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a21d7908-3b86-4d66-9381-08342178ccf3", "node_type": "1", "metadata": {"window": "Or anything from a broader picture perspective \nwhere your customers are really askin g you to pursue an area that you may not be in or in as strong as you would \nlike to be right now?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat. ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7eaed1ab09e3e34921b2737a8e42939095edda9087f1547afd6593698d9b6a1e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ecaf43c6-2498-45b8-800b-4297f15de201", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "original_text": "McKesson Corp.  "}, "hash": "d81977791242f2ac7b3a768a1715fa41a9b857f4ab5575f95a101aee0e19f122", "class_name": "RelatedNodeInfo"}}, "text": "And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "start_char_idx": 4368, "end_char_idx": 4481, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ecaf43c6-2498-45b8-800b-4297f15de201": {"__data__": {"id_": "ecaf43c6-2498-45b8-800b-4297f15de201", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "5b7420e2-0a73-4aba-b234-9d41614fe889", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nGreat question.  I think we probably \u2013 if you look back over the past few years, we came  through a cycle of pretty \nheavy M&A as we really bolstered some of the capabilities and assets that we thought surrounded our specialty \nbiopharma manufacturer value prop and our oncology business or ecosystem, however, you want to think about \nthat.  And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "original_text": "And as  we've done the work to integrate those and it's a lot of work to integrate these things and to integrate ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad498a0c1f2bc0deb1e59d8903233f41a07149ba9aea386ac4434c74d7cd7449", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "defa66c3-f5d3-4c67-93af-2745f4ba7e1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies. "}, "hash": "f12739489c7e1d13108b69d1a7812428bb99f1ce89da7de33fca4d2c8fd5e1aa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "defa66c3-f5d3-4c67-93af-2745f4ba7e1a": {"__data__": {"id_": "defa66c3-f5d3-4c67-93af-2745f4ba7e1a", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ecaf43c6-2498-45b8-800b-4297f15de201", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2e4b026eff3ce8b1cb50eabe3fec72c4204762fb958d8156cf0308ec01497714", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth. ", "original_text": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n"}, "hash": "0724a80f184323c0a93cb53290cb23d2f8c1b459d47c54ac235ae8e7ff5753bd", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies. ", "start_char_idx": 16, "end_char_idx": 251, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25": {"__data__": {"id_": "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth. ", "original_text": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "defa66c3-f5d3-4c67-93af-2745f4ba7e1a", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f85e0d3b640141fba1d348c278df40af941d4ff8a35f023dbcdbefc0bc3585a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b2042e6f-9da3-4a88-9ada-78f55962c06f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "original_text": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. "}, "hash": "457de4818371df51c169666a635b4f63a0c8ab1e460cc5ac840e6816943edfeb", "class_name": "RelatedNodeInfo"}}, "text": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n", "start_char_idx": 251, "end_char_idx": 361, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b2042e6f-9da3-4a88-9ada-78f55962c06f": {"__data__": {"id_": "b2042e6f-9da3-4a88-9ada-78f55962c06f", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "original_text": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth. ", "original_text": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "209fa18081355d498dfcd601948d9bda6e844a3466ecf1e0f8f0c73fb7e321ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2612b332-abd1-4f03-ade5-c958e4a64e8e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n", "original_text": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n"}, "hash": "f65bd9e23f9cbb40f2331309537f5dba5d0fca4c0e7ac9ccd453dab9eb4e1177", "class_name": "RelatedNodeInfo"}}, "text": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "start_char_idx": 361, "end_char_idx": 533, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2612b332-abd1-4f03-ade5-c958e4a64e8e": {"__data__": {"id_": "2612b332-abd1-4f03-ade5-c958e4a64e8e", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n", "original_text": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b2042e6f-9da3-4a88-9ada-78f55962c06f", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "original_text": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1f7dd4ed09308e01654e6ce7f02e8e2554405ae2f39a91afe4e55b9ce2f2d387", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "50841597-9b34-4fa8-89f1-e6367f260fd5", "node_type": "1", "metadata": {"window": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments. ", "original_text": "And then, the second area we'd look for is growth. "}, "hash": "95e39f2a6be1ca2730a33efd2c16081ac5b26528b84876fe8866b05e8694d8b2", "class_name": "RelatedNodeInfo"}}, "text": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "start_char_idx": 533, "end_char_idx": 699, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "50841597-9b34-4fa8-89f1-e6367f260fd5": {"__data__": {"id_": "50841597-9b34-4fa8-89f1-e6367f260fd5", "embedding": null, "metadata": {"window": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments. ", "original_text": "And then, the second area we'd look for is growth. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2612b332-abd1-4f03-ade5-c958e4a64e8e", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n", "original_text": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ec945c7985e154e6021cd371641eee4b37a9996a3f71bb9cb5037f9f80f107e6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f8735ca3-bf26-4689-8ba0-da071dd45d3d", "node_type": "1", "metadata": {"window": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "original_text": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. "}, "hash": "44d45d035cedc3716f3eb7026edcccc43793d33535160e41c46890bfa4745376", "class_name": "RelatedNodeInfo"}}, "text": "And then, the second area we'd look for is growth. ", "start_char_idx": 699, "end_char_idx": 750, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f8735ca3-bf26-4689-8ba0-da071dd45d3d": {"__data__": {"id_": "f8735ca3-bf26-4689-8ba0-da071dd45d3d", "embedding": null, "metadata": {"window": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "original_text": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "50841597-9b34-4fa8-89f1-e6367f260fd5", "node_type": "1", "metadata": {"window": "And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments. ", "original_text": "And then, the second area we'd look for is growth. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "18e8c63491bb67f66322ae8f25b864e813b0fde40276d1111a1f76ddea001cdc", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f2d12c19-1282-42e1-aca0-9138a2d54c8a", "node_type": "1", "metadata": {"window": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "original_text": "A nd I think that that's what you should expect from us.  \n \n"}, "hash": "362be46179bc9b68f76d9cc27c44bc57cb4d0d6e21d4963b47030a7ab17cd488", "class_name": "RelatedNodeInfo"}}, "text": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "start_char_idx": 750, "end_char_idx": 850, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f2d12c19-1282-42e1-aca0-9138a2d54c8a": {"__data__": {"id_": "f2d12c19-1282-42e1-aca0-9138a2d54c8a", "embedding": null, "metadata": {"window": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "original_text": "A nd I think that that's what you should expect from us.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f8735ca3-bf26-4689-8ba0-da071dd45d3d", "node_type": "1", "metadata": {"window": "And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects.  So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "original_text": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2ba8cbad9798f53c0d668890915f08f1a43ada32cf1c4e6dbf2362d5b289eef0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "eac03119-1d2d-44ec-a23a-5ce58e06b9f3", "node_type": "1", "metadata": {"window": "And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we like growth investments. "}, "hash": "8cbec7cdb3981bfa3fbc53555589d8e319bb9ecc721b0a4ba420f804422160ba", "class_name": "RelatedNodeInfo"}}, "text": "A nd I think that that's what you should expect from us.  \n \n", "start_char_idx": 850, "end_char_idx": 911, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "eac03119-1d2d-44ec-a23a-5ce58e06b9f3": {"__data__": {"id_": "eac03119-1d2d-44ec-a23a-5ce58e06b9f3", "embedding": null, "metadata": {"window": "And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we like growth investments. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f2d12c19-1282-42e1-aca0-9138a2d54c8a", "node_type": "1", "metadata": {"window": "So, when I think about capital deployment, we've \nobviously got to deploy capital to be invested in efficiency and compliant and safe, secure always on environment. \n And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "original_text": "A nd I think that that's what you should expect from us.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8ab6c4dad5f6efa5403d8c94a7147cc6e04190ec96802a4fc6d3e993a33bf5a9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "963e761f-2f04-486d-acf0-713e8cd142ec", "node_type": "1", "metadata": {"window": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. "}, "hash": "8538ab008cb09b2ba75f4a6593fca6a895331b180265a6285dce40116bec36b5", "class_name": "RelatedNodeInfo"}}, "text": "So, we like growth investments. ", "start_char_idx": 911, "end_char_idx": 943, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "963e761f-2f04-486d-acf0-713e8cd142ec": {"__data__": {"id_": "963e761f-2f04-486d-acf0-713e8cd142ec", "embedding": null, "metadata": {"window": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "eac03119-1d2d-44ec-a23a-5ce58e06b9f3", "node_type": "1", "metadata": {"window": "And then, the second area we'd look for is growth.  But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "original_text": "So, we like growth investments. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "882f55e15a562bbbe01f6a95974a5bd73a9ad9e8445684cd9d4e4de7fe292ecb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c20c6b96-7fc7-4382-9f82-a70584f16443", "node_type": "1", "metadata": {"window": "A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question. ", "original_text": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n "}, "hash": "c97214ed05a4b84ea113aec31ff17c7ccf72a66b8855ef2fa2f783abe575afa4", "class_name": "RelatedNodeInfo"}}, "text": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "start_char_idx": 943, "end_char_idx": 1218, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c20c6b96-7fc7-4382-9f82-a70584f16443": {"__data__": {"id_": "c20c6b96-7fc7-4382-9f82-a70584f16443", "embedding": null, "metadata": {"window": "A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question. ", "original_text": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "963e761f-2f04-486d-acf0-713e8cd142ec", "node_type": "1", "metadata": {"window": "But those growth investments, meaning M&A investments, \nhave to be closely aligned to the strategy.  A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "original_text": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "f9389fc0405ca84dac23f220efeb247153b3020650ecc9cdca1e7f2dd92895eb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836", "node_type": "1", "metadata": {"window": "So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n "}, "hash": "2e329dd283e0b61f2ea325df90a0bff10eca49d18ff832a69792a0d49a464b50", "class_name": "RelatedNodeInfo"}}, "text": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "start_char_idx": 1218, "end_char_idx": 1540, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836": {"__data__": {"id_": "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836", "embedding": null, "metadata": {"window": "So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c20c6b96-7fc7-4382-9f82-a70584f16443", "node_type": "1", "metadata": {"window": "A nd I think that that's what you should expect from us.  \n \n So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question. ", "original_text": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5107acac668859c65b4ae5685a7e66c05781f08f6de7e262a7b03f885ae359ec", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b470c5d3-1f72-4baf-8c93-497c46a0ceb7", "node_type": "1", "metadata": {"window": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. "}, "hash": "3be97a5a6100f4b4ce2bcb4fde02c469582d68881e320f2d747538c02c8b68e0", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "start_char_idx": 1540, "end_char_idx": 1881, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b470c5d3-1f72-4baf-8c93-497c46a0ceb7": {"__data__": {"id_": "b470c5d3-1f72-4baf-8c93-497c46a0ceb7", "embedding": null, "metadata": {"window": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836", "node_type": "1", "metadata": {"window": "So, we like growth investments.  We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1ffd6a6583f7b093b6eae63ffbdd00712901fead08e3590dda7d6e40c2bb86c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a1c08e5-cdbf-4731-936a-d977ed333d37", "node_type": "1", "metadata": {"window": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n", "original_text": "Thanks for the question. "}, "hash": "30c842032668f5296c31920f601b61a3da89ca4a1565ac4439cdddcb51c664de", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "start_char_idx": 1881, "end_char_idx": 2206, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a1c08e5-cdbf-4731-936a-d977ed333d37": {"__data__": {"id_": "4a1c08e5-cdbf-4731-936a-d977ed333d37", "embedding": null, "metadata": {"window": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n", "original_text": "Thanks for the question. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b470c5d3-1f72-4baf-8c93-497c46a0ceb7", "node_type": "1", "metadata": {"window": "We like growth capital, either extend our capabilities or add scale to the places \nthat we have capabilities; although, we always have to balance \u2013 obviously, strategy c an't be based on M&A, \nbecause it takes a buyer and a seller and it takes a price that you can agree on.  So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "574c5432bb5e966b201ab3e1e5cd1d6570a054414e29df1577cdc909fe121f98", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ec004370-b16d-46f0-9fec-f30cca13ee85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "original_text": "So, wanted to ask about the generics business. "}, "hash": "66fca6edde19a2beffb107592c6eda6e185e4a8d6ba65a5cdfe04292e627e2d8", "class_name": "RelatedNodeInfo"}}, "text": "Thanks for the question. ", "start_char_idx": 2206, "end_char_idx": 2231, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ec004370-b16d-46f0-9fec-f30cca13ee85": {"__data__": {"id_": "ec004370-b16d-46f0-9fec-f30cca13ee85", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "original_text": "So, wanted to ask about the generics business. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a1c08e5-cdbf-4731-936a-d977ed333d37", "node_type": "1", "metadata": {"window": "So, as we've looked at the \nmarket and looked at those trade -offs obviously the past 12 months or so, we've been favoring to deploy our \ncapital to buy ba ck our shares, because we think those are great investments, but we continue to be very active in \nlooking for areas we can inorganically help support the growth.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n", "original_text": "Thanks for the question. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "98b7f2529eedd9122abb19566c867feb340ca8dcdcdb3d494252706dc62c48b9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bd68a4cb-32fa-44b0-9853-cb01858d80e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "original_text": "I mean, you guys have been very \nclear that gross profit is growing here. "}, "hash": "5faa268bce7f42f64b9b49579e38e2af7dd3479b9cdc6d5ef3a92e1ca140f545", "class_name": "RelatedNodeInfo"}}, "text": "So, wanted to ask about the generics business. ", "start_char_idx": 2231, "end_char_idx": 2278, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bd68a4cb-32fa-44b0-9853-cb01858d80e1": {"__data__": {"id_": "bd68a4cb-32fa-44b0-9853-cb01858d80e1", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "original_text": "I mean, you guys have been very \nclear that gross profit is growing here. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ec004370-b16d-46f0-9fec-f30cca13ee85", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Stephen Baxter with Wolfe Research.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "original_text": "So, wanted to ask about the generics business. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2bc5f912a9f852bb0baa36cde07b4ca6e2ef3a100b22c41c1b4493caa262cc6e", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c5c8ac45-6747-4155-8df1-b55f7c1917aa", "node_type": "1", "metadata": {"window": "Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "original_text": "And that appears to be a pretty different result than the rest of the industry. \n"}, "hash": "6bc4a97c45f54bce6a9fde23c97769cb0225fa118b3b7702bfb08b039d8ebb5a", "class_name": "RelatedNodeInfo"}}, "text": "I mean, you guys have been very \nclear that gross profit is growing here. ", "start_char_idx": 2278, "end_char_idx": 2352, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c5c8ac45-6747-4155-8df1-b55f7c1917aa": {"__data__": {"id_": "c5c8ac45-6747-4155-8df1-b55f7c1917aa", "embedding": null, "metadata": {"window": "Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "original_text": "And that appears to be a pretty different result than the rest of the industry. \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bd68a4cb-32fa-44b0-9853-cb01858d80e1", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nStephen Baxter  \nAnalyst, Wolfe Research LLC  Q \nHi.  Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "original_text": "I mean, you guys have been very \nclear that gross profit is growing here. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4aa0fd062bae0e288b9c364d74306102d058ef4ef641e239aeb9411ca09088df", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "b1ea3200-8e0a-440d-a1dd-f35de316e542", "node_type": "1", "metadata": {"window": "So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "original_text": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n"}, "hash": "b5d09d16cfc8522906fde213df0ca24c21d6a6be2c5ba353084bdfa06780056c", "class_name": "RelatedNodeInfo"}}, "text": "And that appears to be a pretty different result than the rest of the industry. \n", "start_char_idx": 2352, "end_char_idx": 2433, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "b1ea3200-8e0a-440d-a1dd-f35de316e542": {"__data__": {"id_": "b1ea3200-8e0a-440d-a1dd-f35de316e542", "embedding": null, "metadata": {"window": "So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "original_text": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c5c8ac45-6747-4155-8df1-b55f7c1917aa", "node_type": "1", "metadata": {"window": "Thanks for the question.  So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "original_text": "And that appears to be a pretty different result than the rest of the industry. \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9375c1b7680cb15c1cd72342e8abc2c1a9381b8f3dcc3f11deb05a5943e91cc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "64726c32-5fa6-4dff-90b0-4d6a5d10b022", "node_type": "1", "metadata": {"window": "I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n ", "original_text": "So, I was hoping to better understand what's driving your growth here in bigger picture terms. "}, "hash": "7c4a1fc87d47bb5b3bbe648f1c00bb813c359d334cd2176a1e01fa8f565c2587", "class_name": "RelatedNodeInfo"}}, "text": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "start_char_idx": 2433, "end_char_idx": 2528, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "64726c32-5fa6-4dff-90b0-4d6a5d10b022": {"__data__": {"id_": "64726c32-5fa6-4dff-90b0-4d6a5d10b022", "embedding": null, "metadata": {"window": "I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n ", "original_text": "So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "b1ea3200-8e0a-440d-a1dd-f35de316e542", "node_type": "1", "metadata": {"window": "So, wanted to ask about the generics business.  I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "original_text": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "995c73791a73b8a76d5de76d4ba787ca903e97f3bac62680f68242035ddad62f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c17b148e-9795-43ac-8f9d-891064202b09", "node_type": "1", "metadata": {"window": "And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "original_text": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? "}, "hash": "55c660f02f72ef871f44e3e58dd9066eb4e8e304bef0cdc31c85a4a1251beb18", "class_name": "RelatedNodeInfo"}}, "text": "So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "start_char_idx": 2528, "end_char_idx": 2623, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c17b148e-9795-43ac-8f9d-891064202b09": {"__data__": {"id_": "c17b148e-9795-43ac-8f9d-891064202b09", "embedding": null, "metadata": {"window": "And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "original_text": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "64726c32-5fa6-4dff-90b0-4d6a5d10b022", "node_type": "1", "metadata": {"window": "I mean, you guys have been very \nclear that gross profit is growing here.  And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n ", "original_text": "So, I was hoping to better understand what's driving your growth here in bigger picture terms. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "25c2ae0c1671ea23b71526269b42e0258c34cc787c08690669652098a33f086d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c", "node_type": "1", "metadata": {"window": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning. ", "original_text": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. "}, "hash": "597253b55615c554f729d069dc4cfa88611680f976953e40ffaa72e5531d3d78", "class_name": "RelatedNodeInfo"}}, "text": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "start_char_idx": 2623, "end_char_idx": 2736, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c": {"__data__": {"id_": "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c", "embedding": null, "metadata": {"window": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning. ", "original_text": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c17b148e-9795-43ac-8f9d-891064202b09", "node_type": "1", "metadata": {"window": "And that appears to be a pretty different result than the rest of the industry. \n So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "original_text": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins? ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4526c89218540fdd0bcc09ef8b0655c70179566eed277ddd76ab26a6fc061004", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17b2c6cb-5630-4f7a-8c07-94db71d1a60b", "node_type": "1", "metadata": {"window": "So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on. ", "original_text": "Thank you.  \n "}, "hash": "9f23b6f4a581a51353d0125ab8f1fc3b54250ef81823a0379ab603b31d538510", "class_name": "RelatedNodeInfo"}}, "text": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "start_char_idx": 2736, "end_char_idx": 2878, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17b2c6cb-5630-4f7a-8c07-94db71d1a60b": {"__data__": {"id_": "17b2c6cb-5630-4f7a-8c07-94db71d1a60b", "embedding": null, "metadata": {"window": "So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c", "node_type": "1", "metadata": {"window": "So, from a macro point of view, it looks to us like the broader market is relatively flat.  \n \n So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning. ", "original_text": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e181188ae946592567fd9809092fac8146d387cd6941564e834119e73dd886a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3710b61d-d460-41c2-9feb-5f3250578315", "node_type": "1", "metadata": {"window": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  "}, "hash": "8a987c249b4878abcdcb9d81e77ceec871c2df12cdb52c7cc9b7469bb4ae6ce8", "class_name": "RelatedNodeInfo"}}, "text": "Thank you.  \n ", "start_char_idx": 2878, "end_char_idx": 2892, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3710b61d-d460-41c2-9feb-5f3250578315": {"__data__": {"id_": "3710b61d-d460-41c2-9feb-5f3250578315", "embedding": null, "metadata": {"window": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17b2c6cb-5630-4f7a-8c07-94db71d1a60b", "node_type": "1", "metadata": {"window": "So, I was hoping to better understand what's driving your growth here in bigger picture terms.  Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on. ", "original_text": "Thank you.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "676cbd43339377e59f87fa2fe3d9dcf973bb1d1c9672b23e7f41dc82afe8a7ea", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4a8a010-db67-4ab4-a22f-2659d90f6709", "node_type": "1", "metadata": {"window": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation. ", "original_text": "A \nGood morning. "}, "hash": "d2fd427b4022dc50773b2ea10b7a021c3515fb742b900f4019d72f0ececfc639", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "start_char_idx": 2892, "end_char_idx": 3253, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4a8a010-db67-4ab4-a22f-2659d90f6709": {"__data__": {"id_": "d4a8a010-db67-4ab4-a22f-2659d90f6709", "embedding": null, "metadata": {"window": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation. ", "original_text": "A \nGood morning. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3710b61d-d460-41c2-9feb-5f3250578315", "node_type": "1", "metadata": {"window": "Are you growing \ngeneric revenue against the backdrop of stable margins, st able revenue with improving margins?  Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f43154ac0665a58bdd33e789865de3c2e4ae961c3ea6df91aff0d5d9d4b4fc5", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody. ", "original_text": "I'll start and certainly Brian can add on. "}, "hash": "448ddcbb3ce05d8b7fe5a78e36e08aa4de574e9e9a57f84d2c9f73822ac8bafa", "class_name": "RelatedNodeInfo"}}, "text": "A \nGood morning. ", "start_char_idx": 3253, "end_char_idx": 3270, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461": {"__data__": {"id_": "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461", "embedding": null, "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody. ", "original_text": "I'll start and certainly Brian can add on. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4a8a010-db67-4ab4-a22f-2659d90f6709", "node_type": "1", "metadata": {"window": "Really any color \nyou can add on how you're achieving this result so we can better assess sustainability going forward would be \nappreciated.  Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation. ", "original_text": "A \nGood morning. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "19b05e8c36b142d0804e03bcbdc3ac5508c0f3fa03ef73efa6c0435aa64e8474", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "89fd4b1b-37ee-4a01-8e4b-7078b259bac2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n", "original_text": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. "}, "hash": "08c8f6a3754da154c4019b0106764b70de4c5f4f891c37c423d6a850318c6de0", "class_name": "RelatedNodeInfo"}}, "text": "I'll start and certainly Brian can add on. ", "start_char_idx": 3270, "end_char_idx": 3313, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "89fd4b1b-37ee-4a01-8e4b-7078b259bac2": {"__data__": {"id_": "89fd4b1b-37ee-4a01-8e4b-7078b259bac2", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n", "original_text": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461", "node_type": "1", "metadata": {"window": "Thank you.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody. ", "original_text": "I'll start and certainly Brian can add on. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "096c1e22d910aed3f7cfb0f6c7361b01eb1979d94a5c412cd9ff028c411b0dab", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17b8ff01-4f25-4c1e-ac70-4a8347c94808", "node_type": "1", "metadata": {"window": "A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment. ", "original_text": "First of all, we have a scaled and \nefficient sourcing operation. "}, "hash": "a16691c210389a62c29d08f33669a7f79e27d8227de18370fedf76c502510f87", "class_name": "RelatedNodeInfo"}}, "text": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "start_char_idx": 3313, "end_char_idx": 3451, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17b8ff01-4f25-4c1e-ac70-4a8347c94808": {"__data__": {"id_": "17b8ff01-4f25-4c1e-ac70-4a8347c94808", "embedding": null, "metadata": {"window": "A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment. ", "original_text": "First of all, we have a scaled and \nefficient sourcing operation. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "89fd4b1b-37ee-4a01-8e4b-7078b259bac2", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Offic er, McKesson Corp.   A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n", "original_text": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b805e233bbf2859af96551ba690441806efdfbf969431cf801e26fdce460452f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "463e723d-979f-4492-a653-30862917733d", "node_type": "1", "metadata": {"window": "I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "original_text": "We think we source as well as anybody. "}, "hash": "17725d12b2188e52860026fbb937de924af1f62a5d0e08af332022cf44a63229", "class_name": "RelatedNodeInfo"}}, "text": "First of all, we have a scaled and \nefficient sourcing operation. ", "start_char_idx": 3451, "end_char_idx": 3517, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "463e723d-979f-4492-a653-30862917733d": {"__data__": {"id_": "463e723d-979f-4492-a653-30862917733d", "embedding": null, "metadata": {"window": "I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "original_text": "We think we source as well as anybody. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17b8ff01-4f25-4c1e-ac70-4a8347c94808", "node_type": "1", "metadata": {"window": "A \nGood morning.  I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment. ", "original_text": "First of all, we have a scaled and \nefficient sourcing operation. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "8eeaa5e6fc651ca811695fce36520706b1bfd428a368085a7804f865252d0f50", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2bbb2678-bcbd-4986-888b-4b63facc5a38", "node_type": "1", "metadata": {"window": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units. ", "original_text": "And we continue to find opportunities from a \nsourcing perspective.  \n \n"}, "hash": "26329afe9921237863a586ef84333a58a3196331646c1529ee64d2ec33cd5759", "class_name": "RelatedNodeInfo"}}, "text": "We think we source as well as anybody. ", "start_char_idx": 3517, "end_char_idx": 3556, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2bbb2678-bcbd-4986-888b-4b63facc5a38": {"__data__": {"id_": "2bbb2678-bcbd-4986-888b-4b63facc5a38", "embedding": null, "metadata": {"window": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units. ", "original_text": "And we continue to find opportunities from a \nsourcing perspective.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "463e723d-979f-4492-a653-30862917733d", "node_type": "1", "metadata": {"window": "I'll start and certainly Brian can add on.  As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "original_text": "We think we source as well as anybody. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "80fe1c9f4162408ab1cc427c1b351acc3b93729fa38de5d3ea1c0b8f4591e909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d02987d7-6595-424a-8b0c-af089b299a72", "node_type": "1", "metadata": {"window": "First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "original_text": "We continue to be disciplined in a stable, yet competitive environment. "}, "hash": "23283850e44903d6d74f8a596b0f93ad030befefab717717bedec8e7582a6d83", "class_name": "RelatedNodeInfo"}}, "text": "And we continue to find opportunities from a \nsourcing perspective.  \n \n", "start_char_idx": 3556, "end_char_idx": 3628, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d02987d7-6595-424a-8b0c-af089b299a72": {"__data__": {"id_": "d02987d7-6595-424a-8b0c-af089b299a72", "embedding": null, "metadata": {"window": "First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "original_text": "We continue to be disciplined in a stable, yet competitive environment. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2bbb2678-bcbd-4986-888b-4b63facc5a38", "node_type": "1", "metadata": {"window": "As we've talked about previously, we're really pleased with \na couple of dimensions that lead to \u2013 that are around our generics business.  First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units. ", "original_text": "And we continue to find opportunities from a \nsourcing perspective.  \n \n", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "68cc9f48058b00cee63d39cb8e16b8a6f37b4788990e197ef4a995448f9dbd3c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "10acac68-9ebd-4946-8fbb-b239fb017bec", "node_type": "1", "metadata": {"window": "We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "original_text": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. "}, "hash": "ca007234827bcc57d686085a6b56783ff5a69a31d263d8d01e37d49673571b91", "class_name": "RelatedNodeInfo"}}, "text": "We continue to be disciplined in a stable, yet competitive environment. ", "start_char_idx": 3628, "end_char_idx": 3700, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "10acac68-9ebd-4946-8fbb-b239fb017bec": {"__data__": {"id_": "10acac68-9ebd-4946-8fbb-b239fb017bec", "embedding": null, "metadata": {"window": "We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "original_text": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d02987d7-6595-424a-8b0c-af089b299a72", "node_type": "1", "metadata": {"window": "First of all, we have a scaled and \nefficient sourcing operation.  We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "original_text": "We continue to be disciplined in a stable, yet competitive environment. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "209087e92cc6f85ecdaefd590ccfd95852b4d4b43aaba1129bb050d7b88ea7a0", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "417b0282-e9c1-41d4-8eb8-b59277ada195", "node_type": "1", "metadata": {"window": "And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We are seeing some growth in units. "}, "hash": "734602192888c896ae47a99732b8f49383c19f80254b6d7c872e8c20aa963e9a", "class_name": "RelatedNodeInfo"}}, "text": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "start_char_idx": 3700, "end_char_idx": 3800, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "417b0282-e9c1-41d4-8eb8-b59277ada195": {"__data__": {"id_": "417b0282-e9c1-41d4-8eb8-b59277ada195", "embedding": null, "metadata": {"window": "And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We are seeing some growth in units. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "10acac68-9ebd-4946-8fbb-b239fb017bec", "node_type": "1", "metadata": {"window": "We think we source as well as anybody.  And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "original_text": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "eb600666b02b868c18a1bc60dd6aa5d5fb3e6cfae1c30acafbaab9233d9b7d5d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77cc231b-a838-4c14-972b-13f01b61d215", "node_type": "1", "metadata": {"window": "We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n "}, "hash": "8212460ad77bee915a002bec7808852625cb92f4db93b0f58ccdf2dbcb073e34", "class_name": "RelatedNodeInfo"}}, "text": "We are seeing some growth in units. ", "start_char_idx": 3800, "end_char_idx": 3836, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77cc231b-a838-4c14-972b-13f01b61d215": {"__data__": {"id_": "77cc231b-a838-4c14-972b-13f01b61d215", "embedding": null, "metadata": {"window": "We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "417b0282-e9c1-41d4-8eb8-b59277ada195", "node_type": "1", "metadata": {"window": "And we continue to find opportunities from a \nsourcing perspective.  \n \n We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n ", "original_text": "We are seeing some growth in units. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "01dde3fefcd4c40758faf045c55ba6c27a57623bd90a94b8e682d4984587dc9f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3e605679-50bb-49cd-b515-5e846d9daf9f", "node_type": "1", "metadata": {"window": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  "}, "hash": "343b75dddd752ead4da52dd174a95db97cde64865f8d6bc2d6188fa5edf652d5", "class_name": "RelatedNodeInfo"}}, "text": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "start_char_idx": 3836, "end_char_idx": 4075, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3e605679-50bb-49cd-b515-5e846d9daf9f": {"__data__": {"id_": "3e605679-50bb-49cd-b515-5e846d9daf9f", "embedding": null, "metadata": {"window": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77cc231b-a838-4c14-972b-13f01b61d215", "node_type": "1", "metadata": {"window": "We continue to be disciplined in a stable, yet competitive environment.  We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "original_text": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ceb8c2ba57052c9b6a06ac378e0213e495ea6d9a0dd16ea189f5b47c21780924", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c693b4b5-65b0-4155-b989-b9ffbd08ca62", "node_type": "1", "metadata": {"window": "We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n "}, "hash": "0fede4afbd2dfa1f830baa68f9cee91967eddf9db1d61f2943f7adc14d2ebe77", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "start_char_idx": 4075, "end_char_idx": 4420, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c693b4b5-65b0-4155-b989-b9ffbd08ca62": {"__data__": {"id_": "c693b4b5-65b0-4155-b989-b9ffbd08ca62", "embedding": null, "metadata": {"window": "We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3e605679-50bb-49cd-b515-5e846d9daf9f", "node_type": "1", "metadata": {"window": "We think that that is \u2013 those dynamics are \nleading to our ability to generate gross profit growth.  We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "9eb19cff1bea17db35ee9f80effb230b1e35d809430ed2981817f7b2a6055b6d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7eecd516-4bf7-40f5-b086-290251ee5fbb", "node_type": "1", "metadata": {"window": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. "}, "hash": "28c475e83b6f127e7f1c50ac6dd0f52ff511ca376f77ff6512fdc6a6fdebc975", "class_name": "RelatedNodeInfo"}}, "text": "A \nOperator, we have time for one more question.  \n ", "start_char_idx": 4420, "end_char_idx": 4472, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7eecd516-4bf7-40f5-b086-290251ee5fbb": {"__data__": {"id_": "7eecd516-4bf7-40f5-b086-290251ee5fbb", "embedding": null, "metadata": {"window": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c693b4b5-65b0-4155-b989-b9ffbd08ca62", "node_type": "1", "metadata": {"window": "We are seeing some growth in units.  And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n ", "original_text": "A \nOperator, we have time for one more question.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6dcadcf1283adc8e14cb26a70c91e70c2adc8c508ecb74e20f7e7e8d9d9895c1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ceddf902-b0c6-465e-864a-68e5ae8899c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "That question will come from Eric Percher with Nephron Research. "}, "hash": "f80d591cdbec084251a7ca8cca2e3b7ec2fb71dc7e39560a707b54a85090986a", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "start_char_idx": 4472, "end_char_idx": 4768, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ceddf902-b0c6-465e-864a-68e5ae8899c7": {"__data__": {"id_": "ceddf902-b0c6-465e-864a-68e5ae8899c7", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "That question will come from Eric Percher with Nephron Research. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7eecd516-4bf7-40f5-b086-290251ee5fbb", "node_type": "1", "metadata": {"window": "And when you combine \nthat with a scaled and stable sourcing operation and disciplined approach in a competitive, but stable market, we \nthink that those are dynamics that ar e really helping us be very successful in the generics area.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7da1032498890fa5d2303ade25601dd8b5d901d863e9d475b05d3c92adc183e2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "796af208-a541-400c-8dc1-5f7a8882a58c", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Your line is open.  \n "}, "hash": "b1b2b44510116964ed8d756eedb35cd218f430817190931b0a916ce10c012ea1", "class_name": "RelatedNodeInfo"}}, "text": "That question will come from Eric Percher with Nephron Research. ", "start_char_idx": 4768, "end_char_idx": 4833, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "796af208-a541-400c-8dc1-5f7a8882a58c": {"__data__": {"id_": "796af208-a541-400c-8dc1-5f7a8882a58c", "embedding": null, "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Your line is open.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ceddf902-b0c6-465e-864a-68e5ae8899c7", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.   A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "That question will come from Eric Percher with Nephron Research. ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2f6c2f31687d27525524d3b5b936237a951d2ad26db4d4dda9290f71bb27f258", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "302bb800-967d-4f6e-84c6-1523e3c322ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  "}, "hash": "bb12d33280f124fee0a1676810cd6aa5c4cf192b5dded857e4eede14c7545af3", "class_name": "RelatedNodeInfo"}}, "text": "Your line is open.  \n ", "start_char_idx": 4833, "end_char_idx": 4855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "302bb800-967d-4f6e-84c6-1523e3c322ca": {"__data__": {"id_": "302bb800-967d-4f6e-84c6-1523e3c322ca", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "2b148336-aa3d-4525-b1a5-559d8290011d", "node_type": "4", "metadata": {"page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b012e97e57b5e8f37851e3c09f80decf15be9e36c47088b2421ca23657f982d8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "796af208-a541-400c-8dc1-5f7a8882a58c", "node_type": "1", "metadata": {"window": "A \nOperator, we have time for one more question.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "Your line is open.  \n ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "d8c75b00fab5c9824b40c4692080e9f6161eaccc1b1fd0afa7c28abae266fb59", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a335f30a-dcd9-4553-be79-7d27dd921369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "original_text": "McKesson Corp.  "}, "hash": "8dfd81b13b08cb1d3480fd8a414d1e562faddfa8e1a71334d9c445fc974c0d7b", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "start_char_idx": 1540, "end_char_idx": 1811, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a335f30a-dcd9-4553-be79-7d27dd921369": {"__data__": {"id_": "a335f30a-dcd9-4553-be79-7d27dd921369", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "302bb800-967d-4f6e-84c6-1523e3c322ca", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Certainly.  That question will come from Eric Percher with Nephron Research.  Your line is open.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e946034130dab43a3c28dc0da8aa65e779943a333a8cf4cd2d2ba6e04d7bd8f3", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "56aa17c8-ad91-4064-b2fa-0869852c2de2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops? ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. "}, "hash": "bc4cade3df9811a57db427193b487348bab07c5fb75f87bd1d990181d0580aaa", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "56aa17c8-ad91-4064-b2fa-0869852c2de2": {"__data__": {"id_": "56aa17c8-ad91-4064-b2fa-0869852c2de2", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops? ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a335f30a-dcd9-4553-be79-7d27dd921369", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "527da3829ee4a6b5cf26b07d1fcbf9d3b0fff9d1217910abea80610780ef43bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dabc8772-fe01-458e-853f-1a0944e11d42", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through? ", "original_text": "A quick one on Europe. "}, "hash": "f8ac9ab5ba4a6857bc7e2c3a58e95552d984678e92cf5fac8852e540febfe2e9", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "start_char_idx": 16, "end_char_idx": 241, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dabc8772-fe01-458e-853f-1a0944e11d42": {"__data__": {"id_": "dabc8772-fe01-458e-853f-1a0944e11d42", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through? ", "original_text": "A quick one on Europe. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "56aa17c8-ad91-4064-b2fa-0869852c2de2", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops? ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4c6a837f894046f250d3e9d8030cb12d378819a997b508467afe62aecee5aec9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1dfac7d1-db90-498e-ab09-55077cb5c996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "original_text": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. "}, "hash": "44137c4d93b13038811487b08899e08936ba8b3052e09407fbdadd1da21365b7", "class_name": "RelatedNodeInfo"}}, "text": "A quick one on Europe. ", "start_char_idx": 241, "end_char_idx": 264, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1dfac7d1-db90-498e-ab09-55077cb5c996": {"__data__": {"id_": "1dfac7d1-db90-498e-ab09-55077cb5c996", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "original_text": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dabc8772-fe01-458e-853f-1a0944e11d42", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through? ", "original_text": "A quick one on Europe. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b7b783a99ec739080ca473a924a316abc51e53449a9120511270d9b7030fd7d2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6e0e2503-49e2-490b-ba22-554cf445af37", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is it correct that the  German business has not been moved to discontinued \nops? "}, "hash": "4ad3cd52e590a2d3bac00abbee093be6ca28c65a5fae4570fabb8e3e984f2468", "class_name": "RelatedNodeInfo"}}, "text": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "start_char_idx": 264, "end_char_idx": 380, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6e0e2503-49e2-490b-ba22-554cf445af37": {"__data__": {"id_": "6e0e2503-49e2-490b-ba22-554cf445af37", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is it correct that the  German business has not been moved to discontinued \nops? ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1dfac7d1-db90-498e-ab09-55077cb5c996", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "original_text": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5546b8b2f8ab16cf5cfe721a82e2b41f141a2090ca7b506c1ed38f506d056de", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "dfd2e8dd-4da4-4df2-8d60-8237537af393", "node_type": "1", "metadata": {"window": "A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric. ", "original_text": "So, is that still flowing through? "}, "hash": "f3b4407a627d9d181f84e0ef76588ad7edc264f70e3a2717528684496dd77401", "class_name": "RelatedNodeInfo"}}, "text": "Is it correct that the  German business has not been moved to discontinued \nops? ", "start_char_idx": 380, "end_char_idx": 461, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "dfd2e8dd-4da4-4df2-8d60-8237537af393": {"__data__": {"id_": "dfd2e8dd-4da4-4df2-8d60-8237537af393", "embedding": null, "metadata": {"window": "A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric. ", "original_text": "So, is that still flowing through? ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6e0e2503-49e2-490b-ba22-554cf445af37", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "original_text": "Is it correct that the  German business has not been moved to discontinued \nops? ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "16ca2bd674eba6fec3a936349b5b4efe1a7c5636e28d76c97f1702dfd576fe5c", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "17825567-d484-4674-ae0b-eaae72281ee6", "node_type": "1", "metadata": {"window": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "original_text": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n "}, "hash": "f0a4acbff755ff6e18530a883093dc3e7c1337ef767a79c36fd0df18258f2381", "class_name": "RelatedNodeInfo"}}, "text": "So, is that still flowing through? ", "start_char_idx": 461, "end_char_idx": 496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "17825567-d484-4674-ae0b-eaae72281ee6": {"__data__": {"id_": "17825567-d484-4674-ae0b-eaae72281ee6", "embedding": null, "metadata": {"window": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "original_text": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "dfd2e8dd-4da4-4df2-8d60-8237537af393", "node_type": "1", "metadata": {"window": "A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric. ", "original_text": "So, is that still flowing through? ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "96913d210b5052bba015c27370cffca5cf7ad97b0e4a53bf3f0b73084585a4da", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ccd30380-e208-4b2d-ab53-03cdbf99b801", "node_type": "1", "metadata": {"window": "Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  "}, "hash": "f290a62401eb8fbb21ea15a7e6fbd6ba912627a70b578dc2c79cd917134b10bc", "class_name": "RelatedNodeInfo"}}, "text": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "start_char_idx": 496, "end_char_idx": 633, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ccd30380-e208-4b2d-ab53-03cdbf99b801": {"__data__": {"id_": "ccd30380-e208-4b2d-ab53-03cdbf99b801", "embedding": null, "metadata": {"window": "Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "17825567-d484-4674-ae0b-eaae72281ee6", "node_type": "1", "metadata": {"window": "Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit.  Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "original_text": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0d665b22aa8ec39401b4850b604b86188db8df7199efa917d20841cb80b3f638", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "7d212ff4-1fed-40f8-973c-23b9786acee3", "node_type": "1", "metadata": {"window": "So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n ", "original_text": "A \nMorning, Eric. "}, "hash": "061fa2f01251640dfa2481abfa76cffca088547bd88c9ca07224c803968f9e45", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "start_char_idx": 633, "end_char_idx": 994, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "7d212ff4-1fed-40f8-973c-23b9786acee3": {"__data__": {"id_": "7d212ff4-1fed-40f8-973c-23b9786acee3", "embedding": null, "metadata": {"window": "So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n ", "original_text": "A \nMorning, Eric. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ccd30380-e208-4b2d-ab53-03cdbf99b801", "node_type": "1", "metadata": {"window": "Is it correct that the  German business has not been moved to discontinued \nops?  So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "0065355c8885f7c1e3aa41423b84ed0ef3262d7a0ac5066d28ca7d70868e12bf", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a0df0668-052e-4d40-8493-a875657f06ba", "node_type": "1", "metadata": {"window": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "original_text": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. "}, "hash": "fff09aae0038cbd9949e59822c561d7fc44e235f957367542b253e79ddaa3078", "class_name": "RelatedNodeInfo"}}, "text": "A \nMorning, Eric. ", "start_char_idx": 994, "end_char_idx": 1012, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a0df0668-052e-4d40-8493-a875657f06ba": {"__data__": {"id_": "a0df0668-052e-4d40-8493-a875657f06ba", "embedding": null, "metadata": {"window": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "original_text": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "7d212ff4-1fed-40f8-973c-23b9786acee3", "node_type": "1", "metadata": {"window": "So, is that still flowing through?  And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n ", "original_text": "A \nMorning, Eric. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7054d7f4e4c2ddb46420a6b7c5d0edb5c016cc765777b260031e4f37191ffc54", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6542ffcc-632e-4de6-b49a-f84d92b9246b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n ", "original_text": "I did talk about a GAAP -only charge that we took in the quarter. "}, "hash": "675197d8b873a522d8108baf5949b94f1c9b80505832299d4963cbfbd73e1d41", "class_name": "RelatedNodeInfo"}}, "text": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "start_char_idx": 1012, "end_char_idx": 1124, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6542ffcc-632e-4de6-b49a-f84d92b9246b": {"__data__": {"id_": "6542ffcc-632e-4de6-b49a-f84d92b9246b", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n ", "original_text": "I did talk about a GAAP -only charge that we took in the quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a0df0668-052e-4d40-8493-a875657f06ba", "node_type": "1", "metadata": {"window": "And at some point, would we see that a benefit or maybe a loss might be \nremoved from that segment when the JV is struck or approved?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "original_text": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7d6b7f18236f8d95173c287e485295f46513d0f949f5f5926dada9725213b7a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "105aa91d-4bb2-4944-9609-6ef976b4f916", "node_type": "1", "metadata": {"window": "A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "And we  have the assets as held for \nsale on our balance sheet.  \n "}, "hash": "1fdbdcd25c951ddf7a165f98e2b2242833828744fb0bfa5f68000024af0b68da", "class_name": "RelatedNodeInfo"}}, "text": "I did talk about a GAAP -only charge that we took in the quarter. ", "start_char_idx": 1124, "end_char_idx": 1190, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "105aa91d-4bb2-4944-9609-6ef976b4f916": {"__data__": {"id_": "105aa91d-4bb2-4944-9609-6ef976b4f916", "embedding": null, "metadata": {"window": "A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "And we  have the assets as held for \nsale on our balance sheet.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6542ffcc-632e-4de6-b49a-f84d92b9246b", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive V ice President & Chief Financial Officer, McKesson Corp.   A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n ", "original_text": "I did talk about a GAAP -only charge that we took in the quarter. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "83408b0965190fcfd06a8dd8f7d6d754913fb94f09c3a3df19a8671b395ce400", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "81d7b4e2-97d8-4e42-9985-241b522fdf55", "node_type": "1", "metadata": {"window": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. "}, "hash": "652eedb0f57a3cf13b0e520f8a30260b15d393c52c6fb2017aacfc5720e8afac", "class_name": "RelatedNodeInfo"}}, "text": "And we  have the assets as held for \nsale on our balance sheet.  \n ", "start_char_idx": 1190, "end_char_idx": 1257, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "81d7b4e2-97d8-4e42-9985-241b522fdf55": {"__data__": {"id_": "81d7b4e2-97d8-4e42-9985-241b522fdf55", "embedding": null, "metadata": {"window": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "105aa91d-4bb2-4944-9609-6ef976b4f916", "node_type": "1", "metadata": {"window": "A \nMorning, Eric.  It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "original_text": "And we  have the assets as held for \nsale on our balance sheet.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "c4f7eb838e196941e5aa6d871e9f7c75549796fe6cc2c43d88a2fb7f593ca149", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "1a934b7f-ef33-41ea-86fa-cff72b2660eb", "node_type": "1", "metadata": {"window": "I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And can you state anything on whether that is in a loss position?  \n "}, "hash": "2e5bd19978b2490cbb614baa21a1bc7e4d1311a49618d346bb1a4fc6168dc4b9", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "start_char_idx": 1257, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "1a934b7f-ef33-41ea-86fa-cff72b2660eb": {"__data__": {"id_": "1a934b7f-ef33-41ea-86fa-cff72b2660eb", "embedding": null, "metadata": {"window": "I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And can you state anything on whether that is in a loss position?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "81d7b4e2-97d8-4e42-9985-241b522fdf55", "node_type": "1", "metadata": {"window": "It is true we have not moved it to discontinued operations and it doesn't qualify for discontinued \noperations.  I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "695b6fc5609f484ee7523d750ff62ffe8d2b0d65ad824ce41727405fe9359a83", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce", "node_type": "1", "metadata": {"window": "And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  "}, "hash": "dc539e6767aebca8bd523b0d3284c639d4f99e5f3bca8ca79ab8a2efc8254b00", "class_name": "RelatedNodeInfo"}}, "text": "And can you state anything on whether that is in a loss position?  \n ", "start_char_idx": 1584, "end_char_idx": 1653, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce": {"__data__": {"id_": "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce", "embedding": null, "metadata": {"window": "And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "1a934b7f-ef33-41ea-86fa-cff72b2660eb", "node_type": "1", "metadata": {"window": "I did talk about a GAAP -only charge that we took in the quarter.  And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "original_text": "And can you state anything on whether that is in a loss position?  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "378b7ae12d62c0164113d44541310c1e912e08c6b81a37b1f49e4f640e7eb065", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "6c21301c-3bec-439c-b8bd-35dac86b02b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.  ", "original_text": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n "}, "hash": "4c0b475a08e19676080ed69dd654da14cc321de60a2b3f27bfec731f24e48080", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "start_char_idx": 1653, "end_char_idx": 2014, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "6c21301c-3bec-439c-b8bd-35dac86b02b5": {"__data__": {"id_": "6c21301c-3bec-439c-b8bd-35dac86b02b5", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.  ", "original_text": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce", "node_type": "1", "metadata": {"window": "And we  have the assets as held for \nsale on our balance sheet.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "525211d85c7c0ea1d63d7df9eeca5259fbcc9215e56ca42b9f79260a7f074b18", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "4a711d48-00d8-4501-93cc-30cc63f4b10d", "node_type": "1", "metadata": {"window": "And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n"}, "hash": "aec395e4ae6b1f02214b6b6a6e7e3fdcca7d58fbb839f164f8d4e05415e5852f", "class_name": "RelatedNodeInfo"}}, "text": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "start_char_idx": 2014, "end_char_idx": 2154, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "4a711d48-00d8-4501-93cc-30cc63f4b10d": {"__data__": {"id_": "4a711d48-00d8-4501-93cc-30cc63f4b10d", "embedding": null, "metadata": {"window": "And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "6c21301c-3bec-439c-b8bd-35dac86b02b5", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nOkay.  And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.  ", "original_text": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "94dd2fba92650fc05d2cfebdf5e55d0498073e2d67205e3bd11bbd2ec8c32072", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "953000e0-7be3-4cdb-b328-f8686606e0e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call. ", "original_text": "Okay. "}, "hash": "6451b93c82f79b12ee7637de583f13174ac9e3725c2a7c03b0baf3643abb2bae", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "start_char_idx": 2154, "end_char_idx": 2496, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "953000e0-7be3-4cdb-b328-f8686606e0e9": {"__data__": {"id_": "953000e0-7be3-4cdb-b328-f8686606e0e9", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call. ", "original_text": "Okay. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "4a711d48-00d8-4501-93cc-30cc63f4b10d", "node_type": "1", "metadata": {"window": "And can you state anything on whether that is in a loss position?  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "592bda30f38a9c81e43eb984fd24084179aafc82a95d1cb74ce4e3abdd8ee3b2", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "f7d59b91-8fae-4522-af04-ed1e35d7a8a7", "node_type": "1", "metadata": {"window": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "original_text": "Well, I think that runs us out of time.  "}, "hash": "ec75f912b5190693242fa34036d7f37b67202cb72a98505704ddd49ea73bb7b2", "class_name": "RelatedNodeInfo"}}, "text": "Okay. ", "start_char_idx": 1578, "end_char_idx": 1584, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "f7d59b91-8fae-4522-af04-ed1e35d7a8a7": {"__data__": {"id_": "f7d59b91-8fae-4522-af04-ed1e35d7a8a7", "embedding": null, "metadata": {"window": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "original_text": "Well, I think that runs us out of time.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "953000e0-7be3-4cdb-b328-f8686606e0e9", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBritt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson  Corp.   A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call. ", "original_text": "Okay. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2857696d437412341a229a91febe4131a20abfc155c10efadc520d785dec849f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "8ed718e5-fc7a-4c03-884d-98194b2d37c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "original_text": "I want to thank everyone for your great questions and your continued \ninterest in McKesson. "}, "hash": "bb1b5cf1badc3dd87eefbc97105395b21ee39c953528b753d86daef3585e38f8", "class_name": "RelatedNodeInfo"}}, "text": "Well, I think that runs us out of time.  ", "start_char_idx": 2502, "end_char_idx": 2543, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "8ed718e5-fc7a-4c03-884d-98194b2d37c4": {"__data__": {"id_": "8ed718e5-fc7a-4c03-884d-98194b2d37c4", "embedding": null, "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "original_text": "I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "f7d59b91-8fae-4522-af04-ed1e35d7a8a7", "node_type": "1", "metadata": {"window": "A \nI'll just go back to my comments in terms of the loss that we recorded from a GAAP -only perspective in the \nquarter of $282 million.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "original_text": "Well, I think that runs us out of time.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "2dbcb5b87cb3edb9dc00104569dc75f4b3dc564817c3e379b031b378fdce8dc1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "d4022c3e-4508-4e9e-9750-02694a816287", "node_type": "1", "metadata": {"window": "Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson. ", "original_text": "I want to thank Jack for facilitating this call. "}, "hash": "6aa4a6dc2f9742ea916de372c6595ef50b15548c7d4d7a51f7d19efdc7274ab1", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "start_char_idx": 2543, "end_char_idx": 2635, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "d4022c3e-4508-4e9e-9750-02694a816287": {"__data__": {"id_": "d4022c3e-4508-4e9e-9750-02694a816287", "embedding": null, "metadata": {"window": "Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson. ", "original_text": "I want to thank Jack for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "8ed718e5-fc7a-4c03-884d-98194b2d37c4", "node_type": "1", "metadata": {"window": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "original_text": "I want to thank everyone for your great questions and your continued \ninterest in McKesson. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6f30d00b404c581367d11a1f16b55f87892f299d20ffdd451c52169964fcb16d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "24fffe79-4d26-48c5-bb83-217466b23488", "node_type": "1", "metadata": {"window": "Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May. ", "original_text": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. "}, "hash": "94380fd42630683d2216d569a85a504a84f48bb1301e04ea5aa55cd203a88c32", "class_name": "RelatedNodeInfo"}}, "text": "I want to thank Jack for facilitating this call. ", "start_char_idx": 2635, "end_char_idx": 2684, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "24fffe79-4d26-48c5-bb83-217466b23488": {"__data__": {"id_": "24fffe79-4d26-48c5-bb83-217466b23488", "embedding": null, "metadata": {"window": "Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May. ", "original_text": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "d4022c3e-4508-4e9e-9750-02694a816287", "node_type": "1", "metadata": {"window": "Okay.  Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson. ", "original_text": "I want to thank Jack for facilitating this call. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "5dcdb471f35727091ef0841d5dd342b502f7c257388e380a0195aee15b953327", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a2290f6d-9c49-4d56-94ce-a468f6f5500c", "node_type": "1", "metadata": {"window": "I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then. ", "original_text": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. "}, "hash": "a8e504028434f50cc8339cfd0a1fb04b0233054a60fd47970155b5d45b4f8aeb", "class_name": "RelatedNodeInfo"}}, "text": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "start_char_idx": 2684, "end_char_idx": 2807, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a2290f6d-9c49-4d56-94ce-a468f6f5500c": {"__data__": {"id_": "a2290f6d-9c49-4d56-94ce-a468f6f5500c", "embedding": null, "metadata": {"window": "I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then. ", "original_text": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "24fffe79-4d26-48c5-bb83-217466b23488", "node_type": "1", "metadata": {"window": "Well, I think that runs us out of time.   I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May. ", "original_text": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "ad5b8a9ba79503e5c9597d7b7043dac8808e57c619a62a6bc432f7a7c41c97fb", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d", "node_type": "1", "metadata": {"window": "I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n ", "original_text": "Th anks \nagain for your interest in McKesson. "}, "hash": "b4d21069e06d24630ce71d643ac6ab3fb204dc319d749256b69429c084208d0c", "class_name": "RelatedNodeInfo"}}, "text": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "start_char_idx": 2807, "end_char_idx": 3057, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d": {"__data__": {"id_": "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d", "embedding": null, "metadata": {"window": "I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n ", "original_text": "Th anks \nagain for your interest in McKesson. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a2290f6d-9c49-4d56-94ce-a468f6f5500c", "node_type": "1", "metadata": {"window": "I want to thank everyone for your great questions and your continued \ninterest in McKesson.  I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then. ", "original_text": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1465cc737bc3db158aade95bafaf86e2f2dc5d40e47af19e1ce5a1756cb58909", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "02089440-384b-4cc4-bd7a-041489614548", "node_type": "1", "metadata": {"window": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We will release fourth quarter earnings results in early May. "}, "hash": "5d2eda492309446152ef9107f750961c7f4166360695341dffbc948bca16dbfe", "class_name": "RelatedNodeInfo"}}, "text": "Th anks \nagain for your interest in McKesson. ", "start_char_idx": 3057, "end_char_idx": 3103, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "02089440-384b-4cc4-bd7a-041489614548": {"__data__": {"id_": "02089440-384b-4cc4-bd7a-041489614548", "embedding": null, "metadata": {"window": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We will release fourth quarter earnings results in early May. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d", "node_type": "1", "metadata": {"window": "I want to thank Jack for facilitating this call.  To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n ", "original_text": "Th anks \nagain for your interest in McKesson. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "bc4fd5993a395ac2f60906533e9cb2d448e5f79d63e1c8fbb7b11379f88d7481", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c4a8b08e-55bf-40a1-bd32-da5ef91f7749", "node_type": "1", "metadata": {"window": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Look forward to \ntalking to you then. "}, "hash": "29f17e864c558dd75de200ffb8c9236d7679c3a7ac9a422f54ea456afd1a6aa9", "class_name": "RelatedNodeInfo"}}, "text": "We will release fourth quarter earnings results in early May. ", "start_char_idx": 3103, "end_char_idx": 3165, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c4a8b08e-55bf-40a1-bd32-da5ef91f7749": {"__data__": {"id_": "c4a8b08e-55bf-40a1-bd32-da5ef91f7749", "embedding": null, "metadata": {"window": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Look forward to \ntalking to you then. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "02089440-384b-4cc4-bd7a-041489614548", "node_type": "1", "metadata": {"window": "To conclude, McKesson continued to execute \nwell in the third quarter and we remain confident in our fiscal 2020 out look.  I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "original_text": "We will release fourth quarter earnings results in early May. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "117730365b6ad956067e16abb4afd82c3c424ca312068f20bfe5023181df012b", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ab33eec0-2e1b-4f01-91e1-d7210fbe699e", "node_type": "1", "metadata": {"window": "Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Goodbye.  \n "}, "hash": "0cff03f3416f4b3035442dcebbe7b43664a14cdcc929fb3c9e783814d57cb648", "class_name": "RelatedNodeInfo"}}, "text": "Look forward to \ntalking to you then. ", "start_char_idx": 3165, "end_char_idx": 3203, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ab33eec0-2e1b-4f01-91e1-d7210fbe699e": {"__data__": {"id_": "ab33eec0-2e1b-4f01-91e1-d7210fbe699e", "embedding": null, "metadata": {"window": "Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Goodbye.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c4a8b08e-55bf-40a1-bd32-da5ef91f7749", "node_type": "1", "metadata": {"window": "I am extremely proud of how our \nemployees are embracing the Team McKesson culture and I want to thank them for everything they do day in and \nday out not only to deliver these results, but most importantly to improve care in every setting we serve.  Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Look forward to \ntalking to you then. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "407695dc37fab70f55cf9a55bc96395dbb11c005134c68ae5f01ef3c2ecf39a6", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "575ba165-6267-4738-8ecd-daaa28861121", "node_type": "1", "metadata": {"window": "We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. "}, "hash": "41f21e6721687f765f25d1d21ae0a5d683623118634a9a144a928fde2e11d96b", "class_name": "RelatedNodeInfo"}}, "text": "Goodbye.  \n ", "start_char_idx": 3203, "end_char_idx": 3215, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "575ba165-6267-4738-8ecd-daaa28861121": {"__data__": {"id_": "575ba165-6267-4738-8ecd-daaa28861121", "embedding": null, "metadata": {"window": "We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ab33eec0-2e1b-4f01-91e1-d7210fbe699e", "node_type": "1", "metadata": {"window": "Th anks \nagain for your interest in McKesson.  We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "Goodbye.  \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "a5320d07288fa00ba6cb1f5e6af1c8c8162185d93c84f29a35c8f35a0c7a0777", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fa65bfc0-afea-4251-8f1d-692ee15954b9", "node_type": "1", "metadata": {"window": "Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n "}, "hash": "ef4410f7fff31c77ab456d6ae332ab10550d040e0c58c2d37f6e62be0c225b71", "class_name": "RelatedNodeInfo"}}, "text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "start_char_idx": 3215, "end_char_idx": 3547, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fa65bfc0-afea-4251-8f1d-692ee15954b9": {"__data__": {"id_": "fa65bfc0-afea-4251-8f1d-692ee15954b9", "embedding": null, "metadata": {"window": "Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "d5f55c8e-9070-4f52-8251-055d730c7a98", "node_type": "4", "metadata": {"page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "902c03f88a2e6f901a53b464e0bffdc1b556a562e362de65b045384b5716c4cd", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "575ba165-6267-4738-8ecd-daaa28861121", "node_type": "1", "metadata": {"window": "We will release fourth quarter earnings results in early May.  Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call. ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "1c10bacc34bfd5d48f28d56602cca808cce548b362d26a3978a46e962e8e9444", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "15ec13b7-58eb-48d1-b5e7-31c3f8fe315e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "original_text": "McKesson Corp.  "}, "hash": "1d51b59fa63bda93a413d5c297e20974ae6dfcf3d5f18d1e8a56492c888c9302", "class_name": "RelatedNodeInfo"}}, "text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "start_char_idx": 3547, "end_char_idx": 3609, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "15ec13b7-58eb-48d1-b5e7-31c3f8fe315e": {"__data__": {"id_": "15ec13b7-58eb-48d1-b5e7-31c3f8fe315e", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fa65bfc0-afea-4251-8f1d-692ee15954b9", "node_type": "1", "metadata": {"window": "Look forward to \ntalking to you then.  Goodbye.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : Thank you for joining today's conference call.  You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "original_text": "You may now disconnect and have a great day.  \n \n \n \n \n \n \n \n ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3738e5fbf518dfd9e9349f434e8930a7c87309c5b3f7fd97d15a6407a31e8ab1", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "c1a5b2be-102d-4f04-82d1-be16f90ebfe1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n"}, "hash": "802622430b132b7664473c02f4b0d5141056b19a7c537804431578fc6d22790a", "class_name": "RelatedNodeInfo"}}, "text": "McKesson Corp.  ", "start_char_idx": 0, "end_char_idx": 16, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "c1a5b2be-102d-4f04-82d1-be16f90ebfe1": {"__data__": {"id_": "c1a5b2be-102d-4f04-82d1-be16f90ebfe1", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "15ec13b7-58eb-48d1-b5e7-31c3f8fe315e", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "cb7c30085d16ed42bae30d49d5b8cf5fda6c578088c79c80f764821a5ef3be2d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "39915d77-5c5d-4673-946f-41759e83a2e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. "}, "hash": "42dfb69cfb11a6cc07d6a91e07c21164bf39f5cd2ea42feac4c926d567ee2661", "class_name": "RelatedNodeInfo"}}, "text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "start_char_idx": 16, "end_char_idx": 396, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "39915d77-5c5d-4673-946f-41759e83a2e5": {"__data__": {"id_": "39915d77-5c5d-4673-946f-41759e83a2e5", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "c1a5b2be-102d-4f04-82d1-be16f90ebfe1", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions. ", "original_text": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "35c0efac0231b74a8bc33b5dca8fea3cdd4b798aeda7ca6c0b5c575ace99bd5a", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "a5825f85-8721-4dff-931e-18c7f4b88f38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. "}, "hash": "08046d2806ad2b5ace0c9c14fda7cebd61152bd71996c45f8dd1e69833a913a7", "class_name": "RelatedNodeInfo"}}, "text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "start_char_idx": 396, "end_char_idx": 518, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "a5825f85-8721-4dff-931e-18c7f4b88f38": {"__data__": {"id_": "a5825f85-8721-4dff-931e-18c7f4b88f38", "embedding": null, "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "39915d77-5c5d-4673-946f-41759e83a2e5", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "original_text": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3c8027db17b4ef30151198ed694a859bbe4769f47f94a1a946ab922a7ac2c14f", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "018c8b9d-901f-4a17-b7bc-cd233c697e39", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. "}, "hash": "4046a43b76dc9468e7f872bd2a9dbd03cf663aa59ed4daa4c5fce25c7596cf51", "class_name": "RelatedNodeInfo"}}, "text": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "start_char_idx": 518, "end_char_idx": 719, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "018c8b9d-901f-4a17-b7bc-cd233c697e39": {"__data__": {"id_": "018c8b9d-901f-4a17-b7bc-cd233c697e39", "embedding": null, "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "a5825f85-8721-4dff-931e-18c7f4b88f38", "node_type": "1", "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice. ", "original_text": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e49b4a0f9828c3ebe362125b0a4bc277c526a509c5823de81fdf447dbf128c80", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "2e13711f-e93a-486f-98f6-36d25132824d", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. "}, "hash": "6c85982de2d7157f7d9f9e4726db1efaca43fe9588f052f114ec0e54b8bd1e76", "class_name": "RelatedNodeInfo"}}, "text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "start_char_idx": 719, "end_char_idx": 810, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "2e13711f-e93a-486f-98f6-36d25132824d": {"__data__": {"id_": "2e13711f-e93a-486f-98f6-36d25132824d", "embedding": null, "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "018c8b9d-901f-4a17-b7bc-cd233c697e39", "node_type": "1", "metadata": {"window": "(MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "original_text": "This information is not intended to be used as the primary basis \nof investment decisions. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "3eee064290a39a8860902ee3d54ce2aca54ab05913c1be30d95cd5d173991eb9", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "fd86c9b8-96a8-43d4-89b7-1fba9409aac0", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on th is date is subject to change without notice. "}, "hash": "8291f16c720846e6a6edd9ba9af434b95fd224cc2734cdea17e7bd86ad042a1a", "class_name": "RelatedNodeInfo"}}, "text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "start_char_idx": 810, "end_char_idx": 1173, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "fd86c9b8-96a8-43d4-89b7-1fba9409aac0": {"__data__": {"id_": "fd86c9b8-96a8-43d4-89b7-1fba9409aac0", "embedding": null, "metadata": {"window": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on th is date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "2e13711f-e93a-486f-98f6-36d25132824d", "node_type": "1", "metadata": {"window": "As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "original_text": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "61211613195ebeb0a13fcc1373be70d4f6a600960c75e40712dd91a93b72c60d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "af9fcaab-0557-403e-b1f9-11a70cb51cc6", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. "}, "hash": "0ce994c5a67f85120dc9a052e24f752457a167ef875edead50c93723277fe478", "class_name": "RelatedNodeInfo"}}, "text": "Any \ninformation expressed herein on th is date is subject to change without notice. ", "start_char_idx": 1173, "end_char_idx": 1258, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "af9fcaab-0557-403e-b1f9-11a70cb51cc6": {"__data__": {"id_": "af9fcaab-0557-403e-b1f9-11a70cb51cc6", "embedding": null, "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "fd86c9b8-96a8-43d4-89b7-1fba9409aac0", "node_type": "1", "metadata": {"window": "You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information.  This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "original_text": "Any \ninformation expressed herein on th is date is subject to change without notice. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "7abe75e1302942185fe480e9e63c71210764d82a47fbdae8481e4ba4bdef7732", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "9b9a953b-c94f-4747-8882-6c0ebde6189f", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n"}, "hash": "f124c3d906d6cc9ef83ed72d0efe3c1c80010a81bbb0b09f8694f12a49391b90", "class_name": "RelatedNodeInfo"}}, "text": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "start_char_idx": 1258, "end_char_idx": 1386, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "9b9a953b-c94f-4747-8882-6c0ebde6189f": {"__data__": {"id_": "9b9a953b-c94f-4747-8882-6c0ebde6189f", "embedding": null, "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "af9fcaab-0557-403e-b1f9-11a70cb51cc6", "node_type": "1", "metadata": {"window": "This information is not intended to be used as the primary basis \nof investment decisions.  It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "original_text": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "aa82b6713fff05845401094b0ec172f6e1e03e37956ffa47358954398b251792", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. "}, "hash": "fa7fb92fd76f608b34be66087e27c60f2c20dd520fb153378b9866cb8c81e300", "class_name": "RelatedNodeInfo"}}, "text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "start_char_idx": 1386, "end_char_idx": 1549, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b": {"__data__": {"id_": "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b", "embedding": null, "metadata": {"window": "Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "9b9a953b-c94f-4747-8882-6c0ebde6189f", "node_type": "1", "metadata": {"window": "It should not be construed as advice designed to meet the particular investment needs of any investo r. This report is published solely for in formation purposes, and is \nnot to be construed as financial or other advice or as an offer to sell or the solicitation of an offer to buy any security i n any state where such an offer or solicitation would be illegal.  Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "original_text": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4d05d436eabdc243ac95e681beae885c1672a9df6011743edbc54e9e57821758", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "365aa5ef-007f-4204-92ab-1fbad94c9fc9", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n"}, "hash": "3ed2f8facb5e20288a069fd72c109f950b32cd757d8375171b65aa472ddaf50d", "class_name": "RelatedNodeInfo"}}, "text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "start_char_idx": 1549, "end_char_idx": 1984, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "365aa5ef-007f-4204-92ab-1fbad94c9fc9": {"__data__": {"id_": "365aa5ef-007f-4204-92ab-1fbad94c9fc9", "embedding": null, "metadata": {"window": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b", "node_type": "1", "metadata": {"window": "Any \ninformation expressed herein on th is date is subject to change without notice.  Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies. ", "original_text": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "6de79a416a846768b2445916c695dbfdedfe15da2e2bc53fd5e70d08bb5d8a13", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "bf01832a-5c6e-4ed0-825c-1bfa80e70ded", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. "}, "hash": "de9c42849807f4a0d7c49d76decf89ba7c5ceec70df45a9b85ffb4aeb0393e41", "class_name": "RelatedNodeInfo"}}, "text": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "start_char_idx": 1984, "end_char_idx": 2665, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "bf01832a-5c6e-4ed0-825c-1bfa80e70ded": {"__data__": {"id_": "bf01832a-5c6e-4ed0-825c-1bfa80e70ded", "embedding": null, "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "365aa5ef-007f-4204-92ab-1fbad94c9fc9", "node_type": "1", "metadata": {"window": "Any opinions or assertions contained in this information do not represent the op inions or beliefs of FactSet \nCallStreet, LLC.  FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "b3caedb587125cca129438e604cd18c9fe639e0d86f5b7f847cb8d0212b35c8d", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "ff832a80-b6a2-4941-83ed-dbdd5f0c226e", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. "}, "hash": "62b3baf6ba1c4c90536f30fda0b4a1d9c305a3c858843cfc5862ca2723b64fd6", "class_name": "RelatedNodeInfo"}}, "text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "start_char_idx": 2665, "end_char_idx": 2855, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "ff832a80-b6a2-4941-83ed-dbdd5f0c226e": {"__data__": {"id_": "ff832a80-b6a2-4941-83ed-dbdd5f0c226e", "embedding": null, "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "bf01832a-5c6e-4ed0-825c-1bfa80e70ded", "node_type": "1", "metadata": {"window": "FactSet CallStreet, LLC, or one or more of its employees, including the writer of thi s report, may have a position in any of the securities discussed herein.  \n \n THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "20ab869ddcdf2e6433c2a961c9907de675f65d4e3603884f158953a51072a476", "class_name": "RelatedNodeInfo"}, "3": {"node_id": "e2d9ba06-4e43-4c09-a63b-8c40726242b0", "node_type": "1", "metadata": {"window": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  "}, "hash": "67f20099d4166f22d5c8025393b1d00bdf80fb7a1bba4e9530574766da30935f", "class_name": "RelatedNodeInfo"}}, "text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "start_char_idx": 2855, "end_char_idx": 2933, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}, "e2d9ba06-4e43-4c09-a63b-8c40726242b0": {"__data__": {"id_": "e2d9ba06-4e43-4c09-a63b-8c40726242b0", "embedding": null, "metadata": {"window": "TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All rights reserved.  ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "excluded_embed_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "excluded_llm_metadata_keys": ["file_name", "file_type", "file_size", "creation_date", "last_modified_date", "last_accessed_date", "window", "original_text"], "relationships": {"1": {"node_id": "01d9de39-90cd-4a6c-be0b-62af53fead90", "node_type": "4", "metadata": {"page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "e4a666ed822d285beae28d960d4de031fc1510630d192010607af6ee3218b0a8", "class_name": "RelatedNodeInfo"}, "2": {"node_id": "ff832a80-b6a2-4941-83ed-dbdd5f0c226e", "node_type": "1", "metadata": {"window": "THE INFORMATION PROVIDED TO YOU HEREUNDER IS PROVIDED \"AS IS,\" AND TO THE MAXIMUM EXTENT PERMITTED BY APPLICABLE LAW, FactSet  CallStreet, LLC AND ITS LICENSORS, \nBUSINESS ASSOCIATES A ND SUPPLIERS DISCLAIM ALL WARRANTIES WITH RESPECT TO THE SAME, EXPRESS, IMPLIED AND STATUTORY, INCLUDING WITHOUT LIMITATION A NY IMPLIED \nWARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, ACCURACY, COMPLETENESS, AND NON -INFRINGEMENT.  TO THE MA XIMUM EXTENT PERMITTED BY APPLICABLE \nLAW, NEITHER FACTSET CALLSTREET, LLC NOR ITS OFFICERS, MEMBERS, DIRECTORS, PARTNERS, AFFILIATES, BUSINESS ASSOCIATES, LICENSO RS OR SUPPLIERS WILL BE LIABLE FOR ANY \nINDIRECT, INCIDENTAL, SPECIAL, CONSEQUENTIAL OR PUNITIV E DAMAGES, INCLUDING WITHOUT LIMITATION DAMAGES FOR LOST PROFITS OR REVENUES, GOODWILL, WORK STOPPAGE, \nSECURITY BREACHES, VIRUSES, COMPUTER FAILURE OR MALFUNCTION, USE, DATA OR OTHER INTANGIBLE LOSSES OR COMMERCIAL DAMAGES, EVEN  IF ANY OF SUCH PARTIES IS A DVISED \nOF THE POSSIBILITY OF SUCH LOSSES, ARISING UNDER OR IN CONNECTION WITH THE INFORMATION PROVIDED HEREIN OR ANY OTHER SUBJECT M ATTER HEREOF.  \n \n The contents and appearance of this report are Copyrighted FactSet CallStreet, LLC 2020  CallStreet and FactSe t CallStreet, LLC are trademarks and service marks of FactSet CallStreet, LLC.  All \nother trademarks mentioned are trademarks of their respective companies.  All rights reserved.  ", "original_text": "All \nother trademarks mentioned are trademarks of their respective companies. ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}, "hash": "4e7fefdcc241fb6371aa1e2eb54f1abb55a978f714c286832ece7107076b03d3", "class_name": "RelatedNodeInfo"}}, "text": "All rights reserved.  ", "start_char_idx": 2933, "end_char_idx": 2955, "text_template": "{metadata_str}\n\n{content}", "metadata_template": "{key}: {value}", "metadata_seperator": "\n", "class_name": "TextNode"}, "__type__": "1"}}, "docstore/metadata": {"ced60568-d2a5-47ca-be3f-4b1221fadfd8": {"doc_hash": "987c7e288c0b65e4c3821bf9fedc10e428f8fbc23faa89363f6f62614c6141f0", "ref_doc_id": "dc7d7933-c282-4a34-8135-fd2e56d54c53"}, "f93757a5-cf45-4801-a31c-6c6a9603263e": {"doc_hash": "1a9156ff0853df186f2ee9e42ee650a53712d44d56a0c21a2e38e7833193f7f9", "ref_doc_id": "dc7d7933-c282-4a34-8135-fd2e56d54c53"}, "6d32b0cd-7263-4886-815b-9fecfeda0165": {"doc_hash": "cc2f24b77ee1671a72fec1179f4821eb10b5f3e52a89d5ed4772d831128eb55f", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "923e453d-a810-4637-b4b0-5fce72db64be": {"doc_hash": "a188e2719ebb327f60d52ea570c33b02df9e7bc216baff96123c9b5c406604f3", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "f9120cb7-3882-4ab7-8fc5-54aedddaa045": {"doc_hash": "7a9ac6e8af7cad895081d4dea0733e34fd0153a5ebdb5880a5910cce1859b263", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "fb197f69-95e0-42ef-a5bb-06add7183c67": {"doc_hash": "1cbfba8727526b6039f278f30c8003833788abfbb3e0a77505bdeb1afb683fbb", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "51d8c595-1c3a-45b7-9a74-50807989b1e4": {"doc_hash": "ff457d5100564757527a13edb301dbbf07927e4a42f309bebecd14f9ef0172c3", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "262e0884-7237-4ab6-ab3e-8bd8f06bafb4": {"doc_hash": "df7d6a8e18f78f6cdec39356325f12760b8fadba8c5f29d2bc8e8773115cd44b", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "b5a85869-f8a4-41dc-ae80-7f2bde26822b": {"doc_hash": "32d60ab913025df85ba280ef22fd944eb448b0a437ec7e2dfb924db19c132799", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a": {"doc_hash": "e3cdf5a6e7d3c09ea4e39882c465739a7f8fefc7a7bdbc41a1d35cb649553e66", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "36689c9b-7624-43fe-9171-e5144f273d62": {"doc_hash": "796ad71e1b425241d500ebc3c6b7f7d37dbda7b0a72f35c0cf0b8ec646780b2a", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "27d2efbe-ba82-41e2-8467-daccdeb2d41a": {"doc_hash": "4d6334f8b7f78041b3e09ee1bc62f362db5245256b44e3f49adbef24964a4342", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "2b29be67-ab79-4289-8b64-b7f6e000750c": {"doc_hash": "911f1fb07ce611e6176badcd4620b928089c2fc5ad414a99d51a72950467a321", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "62ef3b72-cb05-40af-bd47-c95689bdc8cd": {"doc_hash": "d8589c028b642c8fdacb34d8ec08c4de8a445c906d73cc185f95da41ec2e678d", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb": {"doc_hash": "69ef59c85c21b23f098fb7f664c070135f83ea171b17b10be0181392bb9a5fa1", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "706f697d-3016-4076-abac-e26a188a943d": {"doc_hash": "4f8b983bf0a42fd87efaf85499f59e503aa1f65a0f8d75e461505cdbfcb40a15", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "6c4822d5-9562-40e8-9bc9-762928d2afc4": {"doc_hash": "6e02b6f1205f35e2cb191e006c09028f4320eff7e1ab4f2c19eb4683eb124f91", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "cb9915d5-3b0a-44db-a83c-a64dcaf6b259": {"doc_hash": "b1cab8fe7448295bce94297fe0a6a833cef8e30846424ea87f40ca2bfec20ded", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "e002c511-4c8f-43e9-bf9c-118b53b87606": {"doc_hash": "0f9c4931ce5f88f45fc861faea3272b2ddf6b7aec5d7d1c1ba820b4c6dc48526", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "f854ef70-9f71-4308-a71e-77e18f4bd6a8": {"doc_hash": "9d1b72cc0c6821be478fdcd27014ad63f036650b9ed5e03e3f4e72f6dea8b630", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "035781c3-efd8-4b95-a686-b6d979acab16": {"doc_hash": "7ba69d9dfae3f628ed3d49551c12c94f0226527f5789f1672e29c2118ce0e3d1", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "798a678e-58bf-4d8a-b752-3014afada9fc": {"doc_hash": "42516fca600e571a8b446d8a605adb60567596a24cc8f56e4b73af85f1250a69", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "3a2ba373-1221-4a97-979e-477dbbaebb14": {"doc_hash": "db42c09a9b50df0b86c36c3d79fcf9e581d9eeb02a50a5e52e6daf12c8b3254d", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73": {"doc_hash": "c06981ed47a46ac669586f60312a754f3306b32f053888b7da7fee33107397e0", "ref_doc_id": "bc62fdef-a641-4781-a6ff-25b209fd307c"}, "f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03": {"doc_hash": "4934e967a53a78d03eb0781a4e9d031916b8302dd1b4d5564e5a28bf9a8acfd7", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "02407821-4d90-4305-a7b5-90cfa1748685": {"doc_hash": "cb5bcef976d9587e5009dee53f992ae4c9ab50ddf5edca41f76cff43d330240e", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "228b8f36-c823-4e7e-bb7f-2ba39e83eb25": {"doc_hash": "dfd3158281cc92dd9b29631a4847146a2a4da8591326207160d6837a6b43f339", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1": {"doc_hash": "aee2ab3fe7b59c6437392580927815b5a6579cbb3f213357709fb8d5ee5c2ef5", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "2c4389c4-7289-42db-9c6d-e685de368647": {"doc_hash": "14835956af05f23849010637c4efeda56cb833a74d3a1670a6602b073ff7d2d7", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "748e5c38-70f5-45e6-abf5-3263fbf692ff": {"doc_hash": "b517faa850f26cdb7f162de0be2ee1ea29e6d78c877089781bfbf1ae0a4f5d8b", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "2c60a684-2d8b-4608-9d82-85876988f958": {"doc_hash": "2b75062bbd7340d422ca2c24808eed30347ddea25a57dca03bf0c0a4a1abee25", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "83f9e613-59fb-4149-9abb-ee3a32216087": {"doc_hash": "c34a352adbc2a3e81ca9b64292b3134c901e444a444ff7f55f5e80342b598c8a", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "243247a7-e2f7-47d1-8fdf-f2115acfa41b": {"doc_hash": "4b6af468bea4f62f8d311f968573c0a065690ea6467bee0b383d454e0214eadd", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "dc10af32-8265-4675-a8e2-e41dda73bb0b": {"doc_hash": "7a81e146e6c3cd0b1a83910ccbf3b422e8602cde423dca2220c028ef017b98b2", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "cdecaa3a-46d1-4013-9c74-e2845a9fbe31": {"doc_hash": "b5e956f3174b2b041e490e24e9fa68e0b14fcf29f5353fe78eb834f25e2dbf56", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc": {"doc_hash": "169c8242876237a4cb9b45bfedb9495a3cf34c50bf9b6fc6503da0fe9e3bfa73", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "0a794559-ba39-44c5-88ad-a4457c07e397": {"doc_hash": "935452d948c78dd422216f804558150752ddcc8223e85a8612bad9306262874f", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "696be706-3282-4950-b48f-f6368125c874": {"doc_hash": "1d7612fd4c84d4602d6d3c0f4dc8e22f5d051ecac31ab6b29880432a72b2b4c8", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8": {"doc_hash": "7c1252a0f02c98584296ca12779e502364c51967db9b9ca937057993b11b03b8", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "4b6db494-c3dd-4aa3-9a94-4b34518c8488": {"doc_hash": "043c9b4c5c1ffaed06fcf0768739aa5428138fd3724aa263492268adc99bece9", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "70b3ef6c-15a7-4405-8808-9fad2534990c": {"doc_hash": "28187e0ba07defe5085c240f5ac502d20b32cb94db2f572a10bccf9d1e502e0a", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "29b25ca0-82dc-4b88-9f0d-8111883f6457": {"doc_hash": "6ef9bf6cc6f32c9cbbcc119bbf6f7ee8df0f1b8ee8ca9a2391828df7ae7bcb5d", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "331eab10-1ea9-4dc8-9d58-0061c6d25d73": {"doc_hash": "0da3f7abb9dd1f4dfd8ed08ad96740a22edf44a4e4a6f802338bb6dff3ce81d4", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "60a24f84-17ea-4dc2-a16d-3be05e13eb1e": {"doc_hash": "689b8fa326fd6f4e70c1e535c08a3532f9945d17f41d9b182735584db6e08dce", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "f1c2916d-507e-4554-ba98-dc7dcb016a57": {"doc_hash": "008aa0ab83a1393542b9694df70207dad7ac265e112f4f8b6908594e37c2fc17", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "e719689e-396d-415d-9be1-fce19a97e9df": {"doc_hash": "4e0c2a9206d0f5b5af8e9f2a107ed568e5d2bb616281ed193781fc1c11bc8b51", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "02e199f1-36ad-4514-bb1d-ff520df80464": {"doc_hash": "3e874bd5b352ae02b925ef78f13f85386e31a27ce3cf5b584be709c8386ac477", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "e6c50d46-a50b-4d90-a8f9-99617a1e18ce": {"doc_hash": "d64a8eb4b8cecb0939f496babe73519ccebd1dfc93a736220e96aeff534254c8", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "008275fb-510a-4b44-b171-84e5743a61b7": {"doc_hash": "9589815122dedaad819e710bebabb424f5516215515fab9dfe95640daa8e36ee", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "ad9802a6-3ab2-46f6-9006-7c93859bf5db": {"doc_hash": "ea3ebcc408282abaefe7044d7087313ae52af2994d16d9053be8ef080d7d546b", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "3f23f74c-6530-41af-a529-d0597cd58617": {"doc_hash": "e0076d0ab527406e453b4989bb92207b2974158140e507994119ecbef5cae126", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "7e684b7f-25ac-4b45-a3ef-056c631acff2": {"doc_hash": "3e2bf6479f2bf6bc913fc418147d89cfec9edf6ae311a93bb086080f0a674d20", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "542f369e-e3fd-46d3-80eb-a2abf9b51161": {"doc_hash": "7523a4435ded7fadfc20b4e74d4aaa0af91f9b874a7fe3df314e6ef33e113d6a", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "23652aee-ac78-4dec-ba80-ab762845eba1": {"doc_hash": "e23d5383a3cf1327996858ccc389ec7eecf8bc6bdbe8d800d33d3805132cdf70", "ref_doc_id": "7cfeef9a-733f-457b-bb40-0cd5749a74fd"}, "6bd57c28-8f4d-47cf-bfac-d5048adba4c7": {"doc_hash": "f3152d89eefcac906594ee481e7c09c3db7779b3301322987952fb5b116834e4", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "77efcc44-c8ca-42f8-9ad1-7090756c6ef6": {"doc_hash": "0d46bbeb00814e1f841a4bee43d798889da2cf7bf70373d49f6c25b46ab82b7e", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "b66986ce-51b3-4775-90f5-1a95ed787e93": {"doc_hash": "6c025d02ab36ff0fff68e0a25fb69523fa9440c35bb7ccb41d868499dce21c26", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "3ae8de4a-1e05-483f-95bb-6c29593911b6": {"doc_hash": "c59250b8cc58ac4c3affe7b4f8f92f9ca80a33fcbea18aa3f6fc776919c80874", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "d1a6fb5f-1ce3-4848-968e-22e99bd657f4": {"doc_hash": "5121ea76dc42eec6121acc94b2cd8369955cab9f04b769cdfcc67c15209adec1", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "ad6187d8-da53-47fd-9fe4-8463549d97be": {"doc_hash": "5ba68f65835e03640b6544546e3bbdd485f058b1332673ded18bb30bb455f33c", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "7054372a-94a3-40e5-82e8-251c2412890e": {"doc_hash": "fe0b6c7f720ed5d04886d26d9fedc879a01aa7f53d3805d3e313ea509c380e0e", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "49d80812-3669-4ad0-b1d8-4fe739f4ec4c": {"doc_hash": "4181eb218a6d07b8dcd75244630af0187514a52f6987624fe520843b27925e32", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "f542059b-79ff-41e3-b535-d4d7f791c092": {"doc_hash": "89ebfec32cdb17d19686c5a9dbd7ed4cf1112942a89dacf903504cbfeb013936", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "ba6f7c46-3502-4d82-abda-63e8c14237ac": {"doc_hash": "c59564854c1be9225fb98ddb4c8ae6b6f9395e7413eeb557583ebcda92f22355", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "31e7144f-1e0e-4675-ba02-c120c3408fa3": {"doc_hash": "434924a57f52ac5ea36921a8fe75a13a2c784b400ee4fe8a20448c5cda7ad3c9", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "7f2187bc-6339-45e0-94a2-b57726c6f299": {"doc_hash": "26cd3c9d76d5e9bf5040873a2863de4a52bffb318302377edbd987859969ef10", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "2bb5d328-7485-4e1c-b2fd-a326b63a20d8": {"doc_hash": "b592e5d56059346586b467680983d3ff1029d2d7215247b7cdfc76f82afb2463", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "1140797a-c9e4-42fc-a735-4e0498464078": {"doc_hash": "eae60b3e5287842f657f161a7ab3225e2ef9a721edc215921d691bdc2506f8d6", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "4e218340-1e20-4721-b0c0-bce878e0f156": {"doc_hash": "42f8e41375105bf02b04ba572590373b68285a90f2c4218ca72b160acfe87178", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "ffb07214-cd0f-4606-87fd-e69805e35360": {"doc_hash": "b29d7a75966d4aaeb1b5e9d54a97637ff5b5a7cecaf3e7e47718c917719cd563", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "763edc00-db98-49eb-bbfb-4999a266ee1b": {"doc_hash": "a55e589b61cf0efee305ab8ea711feba2431842a3e33da5c3378911093ec19eb", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678": {"doc_hash": "dcd2eae8a25f0abd755aa788ce6f7beeb515938778b6eaad19263eaa6d9849b0", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "4f9b8020-9bf1-45c9-a6a9-dd476a19314d": {"doc_hash": "11e32330d7b72a22d7c5929529a595fa48b0492bbc3d3fe54a9cd4dee3a62cd3", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c": {"doc_hash": "8a9f4162a1eb6613938ac97e7a620e4d809ad3f4bd1c2d37ced66eb9337d2300", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "3b963208-fcc3-49a9-8be8-63c04eecef1a": {"doc_hash": "bd443ef2f385b42348e7088e7ca5000d754fb0c19c250513b2a521ca7aacc446", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "584ffdc4-f3d6-471c-91bf-89610d0c9b48": {"doc_hash": "fe7e8a240c2aa045cdfbb06f96fee7d805d0ad6553e72fb58934840af9736a42", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "742e36d7-c88b-45e8-a5af-a7fb097aa325": {"doc_hash": "00c6dd12be70e7bb293da4870809d1a89471037cc25f3c93ab10a4f1071bc1e4", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e": {"doc_hash": "e8ae886b7a5c7f30110027912054172d1bf4c35de5da3d3aed335c85ee94c65b", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "2129200a-dd3c-4518-9cf7-43cd34153a0e": {"doc_hash": "39f2855fe6917180e0f7c29c8ce0ca15019a6aa2609a89d164f762def2cbaf6c", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "70048add-722e-4e15-91af-02a11d9ecc5b": {"doc_hash": "c3eada8569166107b5f6934455c7ae5741f86adc55dd8a9094b6aec2512cb77b", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "53cf669f-ea88-4cbd-9282-a147573eb31a": {"doc_hash": "d1ef132f65a2a3694cf645820bcd5f8dea58df7ac53fd78d0596932ec070a2b7", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8": {"doc_hash": "72aadfe2162d5c6be1497f0a55890fc900d3ed47a2b236da4f499c167c5c0eb9", "ref_doc_id": "eecae3a1-1d59-46b7-9d6b-99ce0108278f"}, "c5bacfb9-bac0-4f46-a923-aa1e2c545285": {"doc_hash": "f614a2aaac87c180b216ed4ff6b03bd9116b13c66809bf3000f12e33c54f915a", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d": {"doc_hash": "17133b05e6ad82cab3e7f94cf1d611c8d335a0ef17a554c7d7d56632489efc93", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "deec39da-6b9d-4338-8ebb-08c53cce1d18": {"doc_hash": "29bcc3fdbd5625b033109010f33f97aeb86825f52607ccf5f9e582bc29dd657b", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "81350765-839b-46f5-accb-09041989406d": {"doc_hash": "3d1f50a13e5af6a25f30b066760c499cc3bfadbb16538cff956da606601cdcfe", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "65f90d57-842d-4905-b505-5b42c157c1a4": {"doc_hash": "ed78ba35010bbddd9d6011dcfc8e00753b6393200b53ae0a8d2a8e1b4b27940d", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2": {"doc_hash": "c7ad8dc892e4e013a61fdd9ecd42262ed85f62ea8a8c2a6c85db2c805c04ccac", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "68071114-212c-496d-9e3c-75b6dd60415c": {"doc_hash": "18095414eaa7d69c9f1e16846cd50c1b3f8616526b49b5fbb71509d08c316652", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "a2202fa4-6b31-4620-b8b2-c652416d649b": {"doc_hash": "dc53c75219340d4a56ede1680a6e1c9899e7b67a8b9d7c367921927d2a02fcaf", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "234487e3-a96b-459e-b2a7-fd9dfb6777a2": {"doc_hash": "a5ac904988109073022ed3bdea8d9b81057c848cb22a3adc2c6ad0bce75bca90", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "98c65698-b495-4bdb-918e-3501f0f578a2": {"doc_hash": "67ea3cdc70ce51179a46fb6ab48d562d6bbb773326fb1288e63e926a1c407a0f", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "dbaefb05-0d4e-48a5-ad94-040d32fe6deb": {"doc_hash": "ef6aa8a13935abfd323be3aa07b3477b4ffccf1d04f0ebf6b9ea0c82b644ecec", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "0cfa0fdb-815f-467f-ba36-985ab967adff": {"doc_hash": "ae1371a673cbde557fb926f0bde504d48f3817320998bc3da7500d346baf236d", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc": {"doc_hash": "29e2e35dd558264e7072758bca88e57ea007188ceec666a6277fdf82bfb57e36", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "cb392381-f1b0-460e-9b77-13a2531b340c": {"doc_hash": "36597c34baba248bcc3c1a6892df724ee8cfc16d9c1fa01b068d675db7ce4889", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e": {"doc_hash": "134da4730013139ce0635e205a800147e3f035c498d44bb08e4ced845fe33cf3", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "305f67c4-1b99-49ee-ad08-2b9662b84708": {"doc_hash": "6497b8deefeb089ac9068ac15ea0c672c73007bbd4808f76f46446b66ee9ee03", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "0e704bf9-a3c8-4bed-8596-147902a3a3da": {"doc_hash": "13dc7138160d0abaeb80c57f9fdad4f33c6ee2fd64808482129c9cf1e95a90a8", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "a9d5ef85-b95c-4972-8eff-95abcead9391": {"doc_hash": "5fd8f4112950fa45d02a6d74651ea19e5c577c375608a4c83a133738414c5c69", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "2e40d0dc-95b0-46af-9ece-f077e336ea9c": {"doc_hash": "64a751fc846e3704469d3c505fd15b44a8bb8ae56f1399222818de0f2904ff20", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "81b3e48c-3874-4c42-9190-364f41de138a": {"doc_hash": "d174883b847d3606e3eb4beb1eebc10609a80c615a878bd3ced575d18c626a48", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "71f3a476-c1e2-4ebd-9b7c-8717617ce58a": {"doc_hash": "c8da1892ad9a5e4dfe9c27ae8cf86fe3eb1a7b318182e555ea38f3e7926f0457", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "8169dcbe-8654-455e-8104-f264f556246c": {"doc_hash": "3602b9116e628181958a1af06603bcfbe413f627c89c658458f2790c377b155b", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "d4ee66e3-878b-4463-9e1a-4d1b264efa10": {"doc_hash": "fe19332a3fa4e1e34b25eabe7656e6105337de8221482bbce205468cea46ff93", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "82a98709-ca1b-4549-987d-034bb2aa9612": {"doc_hash": "dac30a818d36c304b7df544171f860bed7ff5ed2e3df928975eaccb4b1f9efe2", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "71639d0d-cf0c-4866-8706-e8cf235c5088": {"doc_hash": "07db1da3b5a52b5c5838fa520ae4f7a21a45bd2dd4c289ec487d72a7cacc96f9", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1": {"doc_hash": "a3d450f2ea935ae1bd16a7ed0dc24552b9e6bbea960d852deed8b40c05457622", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a": {"doc_hash": "f75d7e0a165782cda5ee72bcd60e99b2e3580ba758e7f8ca81850551b2a1132b", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "9b4d9d93-003c-478d-b8b6-5699701eb202": {"doc_hash": "cb7138147055848b1c950bf76091af065bbfdb6bc9a67333bc56e44a97a949fc", "ref_doc_id": "7d45e6fa-623a-43b4-b301-8638ca68be6f"}, "31827d05-8548-47d2-9c4d-411d21bc7437": {"doc_hash": "580059057f748e79e4fa20484e249339530225ced398fb0242f4f48d5fbd9780", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "7d8ce46b-4137-46a3-9f18-78062de9f2f7": {"doc_hash": "350a03b9f297a74910442cde2a9f3a410e5b88c8512b8f0d8d3d1174f1282999", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "ef5864e4-acf9-4b69-adbe-5a81e0074089": {"doc_hash": "32794af3894f97cc23e3163648cc7e469e054968491aa8613bade1d2dda94a77", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27": {"doc_hash": "338c213592e11c8d1a06efb973c9e25d9a0ea97d5fa618a55e0e73ce4bb757a2", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "0a8fff23-b45d-4479-ba01-634e3dcc48ba": {"doc_hash": "73421871c9d027cc80a2c3aa0e8603961b7cd40bf2d0723c053106ecfee4646c", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "0722793a-e822-4153-a05d-eccd1bf3aacb": {"doc_hash": "3f88c45ec11c1507ab72e5f1f12e55d24827d33469abc9b969bc05cb6689960c", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "88decd3d-1571-49be-8955-775df235c366": {"doc_hash": "e8e163b74d3b5b4f3a1713f9cc1ae43820fb61e9c411a9cb3d62b9bfba492b7b", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "27ad5bcd-7e15-4e0b-94b7-2b460620c925": {"doc_hash": "465e56fa880f94581c4874ff8345e888bc7b845a5a5192804f81a9e0e3ade3ed", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "a4e63d6d-5d38-4727-868b-7d54ac2451ed": {"doc_hash": "9cafc4f457d3bfdd17ace3c488d2745b43cf1e5568933adc95ca7a0cf9f02f1c", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "cc917a1d-06f4-4ce8-9729-0ddcd732cc67": {"doc_hash": "91eaac36929e899ced1cf7cdbe0f8066cc3655079817ac328727c79213aa2d6b", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "7b2c7871-23b9-49d6-b007-6b2cbffebf28": {"doc_hash": "26ac226fdfe650664a19a7ffb29d9026699b2b4b1a2b40b40f1eda701147923a", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "e645370d-57c0-4b17-92f1-c97c670702ac": {"doc_hash": "df5c5e2b52c311bc6e2df45c6783d7205dd63fab3fa9a64d0e96e1139c5babe5", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795": {"doc_hash": "3be6a6cec7860b8182e2e913a2b085386ef29eb5386997037384abf4054944bd", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "9c237bac-9d57-447c-95a4-b924cb38a7a2": {"doc_hash": "e0596605afbb244246949c57c1981b3b28b4e627cb825a0efec13fd51a2e501d", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "803e407c-a537-4a02-8984-818582401345": {"doc_hash": "9b298097516ffed0f1c660e328b3278e7450f2c3b13a00f7981745a0612e4b1f", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "d90783a4-2239-4204-bbb1-97b40ea127fe": {"doc_hash": "64f70a2c609579de6b809ee8c84b40983261035dc250c352eb5752b16b8ef505", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "51a99653-5987-4818-9013-0bf2c25b2bb1": {"doc_hash": "2c7489da88b14bae660d70fb77d0bd7930560539e2c80987d26cae0d2afe6a52", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "25703993-bd47-494d-82d4-f47449d7793a": {"doc_hash": "b8257502b4ea36c331d6f080806276c5770caa9260f11dae326080417aa65b9f", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "eeebc3c9-dba1-4183-9ef3-794674d6a634": {"doc_hash": "793b58b52e9ae8e74b819fe13128dbca1fbdb84b34a2c22bd753c68c16f8db73", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "0169da04-2a54-47ea-b21b-7acd8d043e45": {"doc_hash": "9dea69b0c6355b7cd885f6896344f67bf21eb966205bff383cd158e61ede57a9", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "b2c9ce5e-04c7-4631-83cd-41db2588a702": {"doc_hash": "9dfd35875107ef1c2af7d2b418a45ad50d833b3cfdd5e2a7e85143682e856771", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "26e70c60-1324-4469-ac59-aad6c272e2a6": {"doc_hash": "e6171dcbf434cb86355890d59448a0b0b5a5b6c848fa2773b9da549d479ea835", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "a7adf702-eb63-4162-ab44-2dc75a9a712b": {"doc_hash": "b11441f78c9fff02213a501db9a06ad8b9c302a5fe5308a02c626a3e07972f5a", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "d02741a3-f166-4baa-88ad-9c8e26d08a39": {"doc_hash": "d1478c4bd59c108be65b04aef85abbf3a53804c5bc8990eec4a624e1ac9c4424", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "f7558abc-1155-4cfe-8a4c-d9462e662890": {"doc_hash": "c6fdf39d6116031f2f032a20cc05b5e598cdcbba62188e3f29bb5291f6ca689b", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "261849e4-9834-41fa-aedc-9ef218aec488": {"doc_hash": "b71d04f424acd5e8d2f72a14ca66f9df196d907b14a94f6ba5d3cdf6a61fa6e4", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "d21c5de9-e4f5-423d-a036-a6215ded0f93": {"doc_hash": "07e7efaa6760bbf692d856eea29def76cfb83dffd00ad887f69263c8fb16d3c0", "ref_doc_id": "c80a7a4c-439a-406d-9f68-1a3320ac7571"}, "fed49091-f9c9-4402-a6a0-1aa3c77ea148": {"doc_hash": "0c2cf086e50108d37c9c7fbcde74ce61c38de32723a58d4aa31493ab6b742015", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "9e7e2961-35f0-4112-9907-24d2868e0b67": {"doc_hash": "b6fa5770cae91265b46c2af64c479d3703edf8f2b2f7d3e3346fa91b7c907c36", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "146a4d98-1b29-490e-86e1-6b54daf7d794": {"doc_hash": "939476c6e627155e6219b96a8a5e724d164c61b7142813378b6a81b7f108dab7", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "15da271b-f3f8-4977-a6f7-63c2dbbf39e8": {"doc_hash": "5011bb1e818f1799fb030c6471476af23871289e42ceae97ad5e4747f04139ae", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "ebc35d8a-ad7a-4935-a759-e935fe5f77d5": {"doc_hash": "68b4f74f378bbe33ba9980e2d3ac95d33a851fa85e240bdb2999e6ecc8b4ad08", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "d13db75a-1b90-4e25-aed0-98b5b2b7edb2": {"doc_hash": "eef395c11eaad561e30048bb72cd54e90aa1958ae8dfca7d3a6b6cbe363a1046", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "2ce29e6c-b1ff-4048-b542-d066e38c7e46": {"doc_hash": "4ab090244e323e555f2806862884df54245a4b580e6a6e3eafff154cd1d210e8", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "262db2b9-669e-41a4-bd73-14b20acf6ace": {"doc_hash": "dba20388c85a22c35e8bf6ff96bc34710b0f863626f3dc55d132f1e582051890", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "88219d88-297d-4e7d-b83e-9bb58de6a840": {"doc_hash": "e6a5e0c854a89b2416cdda850ddcc207fe71d06aeac91089303911843e6b7bac", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4": {"doc_hash": "118249dcdb0f9d947fc7859298c2bdcd88307a3f606864e2cdbea8c8491470d8", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "285fe989-ff80-4c02-be38-8d52aedcdfd3": {"doc_hash": "836e3415acdb5a69c62023f2215897e955b9223c6d940981802ddac16b710572", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7": {"doc_hash": "4f4cefe994ba2103d58ba87c3cb6b7e41b51718b93d35f29fa9be3cf50defc43", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73": {"doc_hash": "09ec9f1a5aafa4202f20300ca07e0b5a63febb31f246cbf057c5ef7108574513", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab": {"doc_hash": "3486542acbff65f298e70f86c727c7c08d0d32fabcbf8bfe10895d03fd9b0bed", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "f26ada04-55ae-4cf2-a974-a768f2571fc2": {"doc_hash": "e29a0bf87abe940a409160f7e902d36da983c20cdb95f4629d0c36158b3a8380", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "8d9adfe9-0f15-46dc-a218-c2bad5c75c56": {"doc_hash": "13d9c7597263a0268339ecae1ab7def80a9e50c0b1c1264d525272004d002118", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "6a5f543e-c180-47ce-a1f0-554f4a3b0efe": {"doc_hash": "9c5c745540b74edb7ffcfc6d255512557edc5079b6dfc5f9a898c8583b088079", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "4784347e-3fc7-4f56-9af7-3fab3b0e89d8": {"doc_hash": "77d7d20f4ad4a68b7be69136df5a843ba711adee2eb5476d4625b6c78fec626e", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "74c9eaa1-92ad-4206-80cf-14d3feecc874": {"doc_hash": "99e2ba4044cde4edd91f441dc580ceab44786b18a8270e545c410188d8eda9d3", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "cd7000f0-45b1-4a79-808e-5760f3ba9215": {"doc_hash": "48d0860aa92eb0e1bc451e1cc0a97bfa45dd8978adc97b7ccf14063484e5e0c0", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "9f74eac9-b3ba-4681-822f-0b9b05bd97c4": {"doc_hash": "98f686aa127dfe515ed660ba66ef7c59965f8d925658d3111329cf5e9234c86c", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "b7fa1d4d-8386-44b4-ac62-fb46d28535c0": {"doc_hash": "74bfe3143ce9136aa0390339c1afee726b8056a555a29324ba041eab3e5cc17f", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "8841a76e-f12e-4148-b683-d4b7c71fb55b": {"doc_hash": "f0cdd8b498fa3f8f41b77148eed8cec9cbbcd59a21e10c0fc40982ecf27492ed", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c": {"doc_hash": "2a2b0f1de6b2f4e9f0a5aacfc87d29befda8ea7ee0f3d2e15f3874d9c6f6250b", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "bbd23663-091e-427d-b616-55b6c3954660": {"doc_hash": "a57f05f441a81197de83741da55dedf3c0061d1c0963bafc71526b715f61dbc5", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "b054ac7e-38a7-472b-906d-942fbea0a541": {"doc_hash": "9e40dd17d463f7b08d13f3344596de23bcfb42f3fa268727828b3524e7f14afa", "ref_doc_id": "652ed7e9-96f4-4fc4-ad75-f781e9f788a5"}, "abe55df2-31dd-474a-871b-014bd3b446c5": {"doc_hash": "0b5cea250bece3ae8cb973cddcc998a1d1b4707c3e2b830d0818982bd14d5399", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "2d17a13d-06af-428c-917d-542df32a09f3": {"doc_hash": "26800beb0a1e6f73be35fb3f7fcd7ce35357b306e9fe179a5068b01e0229e04a", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "abd3c817-cd11-4154-9dea-bc56a443a7cf": {"doc_hash": "b32f51046903e9dc788d5566867311d3122cc511d0c88ba5b2bffd5d0bcb7b63", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d": {"doc_hash": "5c2f7df6893c25446c332c6b9ba2d27d8d9bbc4ec511c366eb0427a3aa259034", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "d206c2fd-23b1-42d9-80bc-53497d0abb16": {"doc_hash": "43d92ce00cef5acced6332dd023513777b835d48d92389a47e30204061b6697c", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b": {"doc_hash": "eae6ef14e75784e65cde78c5d3124017d53aaaf26f9c03814fcc66fa437c6bb6", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "c203dd97-1246-4dce-91ed-59bd95ee1019": {"doc_hash": "d23295108699f3580e0a9612381bb2affad5ef7857af19c438f868e1ed067347", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "24b85c5c-3c6c-4ccf-a403-44de862098b8": {"doc_hash": "9ff57cab9b2abdf592f6bc4fef48b59954c717435ebbd4f05e672e16bf2a5ce1", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "8a490ddf-a10b-4641-8938-cb01dd03f681": {"doc_hash": "d612d96aa3f19f1a7e192e05fcd1b69b6ff41f7d3727e9c14d26236b57886fa6", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "9ffa0adb-082b-4f7f-a303-f26093681c93": {"doc_hash": "32c5ea1ae6f5bfb7c114ae03f4177d19442e8938a23a49397bd9a3edcbba6a0d", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "8a3001e4-b94d-4ad1-bbdd-16b73d496938": {"doc_hash": "8e3427979dbd3469d76d9730c854bb00ce382f974c6f7609017b8663cb4415a2", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "59c62317-c987-4bc9-9ae3-6b9ba97e3c32": {"doc_hash": "41d8e70f7a88b694c67f056710238970eb4db45fe3d6807fa8e3ad8c80ad54a9", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "ae130a12-56f9-47da-8843-69fc5dbd0806": {"doc_hash": "6e95ee009fb3a018e5a70d8a588408a085678247000bba297eef9bb591ba45f3", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "23441e52-44e0-4aca-99b6-87554cff3158": {"doc_hash": "7b6c81d4918a8590d979883099a62359cb71935912566a2c61df24cf724d45ea", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "ba450eef-f988-4aa4-8d90-b9506732f14e": {"doc_hash": "ef5aee7727ec9609ad3753e9541567875e44abbb6ee140d867d0afa3ad06b426", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "b5befd3e-7a70-43a8-8128-49fcaa30ce8f": {"doc_hash": "87c07824a83da9ce79224b61675a4121d62635b0864e0a654c9bfc29bb266ae7", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "79e5a024-aed3-46c9-880b-3d8ba57e8899": {"doc_hash": "349a87e95ec447dee2b5cf0ee3e600c4ea88801288caef8dcadb358ff7b610de", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "07861af3-e06f-499b-ad23-90c6ebf76ccf": {"doc_hash": "f7325d8505de4cca7147b41ecaab2cc49e099737bd223da665174baac0af1110", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "fed4b902-dad5-4b46-b4b6-0be887d6cfb6": {"doc_hash": "fb20b006f427dd5107c2cbc8a413f45dbe430f05180ea692113aac8f9cd2d216", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "22c18147-d05e-4f80-9bd2-ce8db5f5232a": {"doc_hash": "07eab8162555f8afb64baabb7dec9f5ff36dc4c77fa25050a252cdfbefac2c21", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "f077a5c1-6597-4231-9a83-69e4c536d82f": {"doc_hash": "51140d13f95080b616c06b4fb800b0bda9418b27db8ab20b8e6b1d77dd7401ae", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "734f93e5-2f04-4f4a-8ff0-187c3e81cb49": {"doc_hash": "3db72334ce84f0267a7262c6af178613fcfee3b9d2daf41af950778c574aa47f", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "30aaeac0-3197-4a4c-8989-bf472c5572a1": {"doc_hash": "dced41f23eb368fa1a1ba339853983fe0bb0d7581ae91db17fcb69a2bc29c6d1", "ref_doc_id": "f643f16a-f46d-4fa4-b28f-9208162c8a0d"}, "d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4": {"doc_hash": "4de018761353ffdb2a6223cdab44dfed5b9cc75ddf8ac11a0082bd20d0058b79", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "8940e8fc-f6a4-436b-a1a6-344cbc4ece08": {"doc_hash": "33eed1a5bcc8a0387831799d361443ec248f4e7c9e18c1c7f1a2d0251d6132bd", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5": {"doc_hash": "54affca04a6f841fcc1a4d232b8f8efcff60b0685dc9b8c6badc981fd23db8da", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9": {"doc_hash": "b2ae22cff0d1bb8570e77b10a6d67e1495b7ebca8faab71a619939b18b778d78", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf": {"doc_hash": "46627c2419ee0a6c351b0637cafb0377f70a5cdc66dc0d2ce627fefa0789d31e", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "4923a773-07b5-44fc-96f6-6d5861b4d140": {"doc_hash": "c7f78075147b730e4f90f253455db3d351f9caadfcb49c651342cf561b89a981", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "a88e6803-8cae-4f38-8e4e-9b962c2795bc": {"doc_hash": "ba12c047831dd5575534e8f139b550f2a91112a1755ded8f35c176682dcbe439", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "a6ef4340-2a0d-411f-a2a9-7017b879bd8d": {"doc_hash": "492a71b6d12af4851e0f78ee4f10ef1492c9cc25507a4a0d640ed684799918a4", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "39636ac3-7925-44f8-807e-7f2de9afd743": {"doc_hash": "72bff029bc0d7addd9437009252ceaf3927f4f8dbfb71a25850e211d73ded169", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "764eaee9-cfce-4812-a32a-b6047b1d44b5": {"doc_hash": "af716226d8635222f21aa8177810b95f02d188e58b7cd744676a6a43889c77a6", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "76d53e28-9073-467c-a16e-0eb65ab094c6": {"doc_hash": "503fef643b8853cc42347994b2e22be3667f63ca00c4d635d7c86f3453b43fc1", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "7a76f092-c9f2-41ee-a4b1-565e80fba1c3": {"doc_hash": "360491f4840fc2e731bada16d7b2b19262946ddb41a3577acbb28a7aef91cb0b", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "828c5cf3-e433-4bd5-ada4-b10f4ae36638": {"doc_hash": "aacf61775edb0591eddaad3fcdaa27acd77157096b2e613981c23ac5fcfc31da", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc": {"doc_hash": "bedeab16becd29c22f6f4f7b1cfc6ef23a15469814425cecf64618fedb178bd7", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "e814365a-cf87-4e62-bdf2-27a6b001000e": {"doc_hash": "5ea186321346c45e9f5a074aac9ce1078141a9c7dd159e2971d2c2e3f34e7507", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "1d21b476-e84d-40c7-8e07-bc1df6b4db26": {"doc_hash": "c41c06ca97e386ca20c1b21d8826084e51b3e3f681c13f3389f5d02aadf80ae2", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "5015f498-7bdb-4b2f-895b-1eb560254d89": {"doc_hash": "497274e26b80fd4b0caaa585a704b03fd6d628bcac8c953b757c75a79f6b43b6", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "3670b3b9-5590-4458-8a60-5c4279bbcedd": {"doc_hash": "b8d81449997b195207384fcfd845c30a4549f45d48bebe2c611a76c2c4ef94b0", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "0c87db11-0056-4b82-804b-16f244e990f2": {"doc_hash": "241160631fcfe7abc90ed6578c3a1a72105db98ef130e10ad388696c261478bd", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "5ac47a27-70e3-420f-a760-184773eb0d82": {"doc_hash": "fbff84cd1ae9db82378a6c3b5b4ad88184bc861d9fb7aea5ae5ff97b5093eb25", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "3a1e6b18-9cb3-400c-8130-0237b470afd6": {"doc_hash": "f6e42db7c84b9f80f4408d31a4359fb7e6ba1dc75fdf6bfa48506dffc74fdff9", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d": {"doc_hash": "ec4d321ffcf5d3ed6d63fb15b9d66e57ccf49602e3f038e5ef8574450217ae21", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "71195d66-4360-4c68-aa2f-9d248705a566": {"doc_hash": "5eb15d29790f1f1bab1e2d90513fce613cdf4b3886e54e47dae06a53ae742e70", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "d0e396e3-e950-4a93-b5a2-ca91df50c827": {"doc_hash": "a74806af4099dcbf1abaceda17f095a9ada0fa19a0c982f3e82f38356a2646a2", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "045ece9a-a56f-42ac-a275-9fbb02aa6a32": {"doc_hash": "c65a92d6f0fdb1435d8ff3d31e8de52dc164c6a8aaa5a1b1b532e115da75de89", "ref_doc_id": "ede72898-bed3-47bf-9e1d-565fb8f929bd"}, "f6220d97-f3e3-4476-a7b8-4168008e3bcd": {"doc_hash": "996529d4632342a799040607f07e2c0af0482ea42f342e2d565a37c7fd0c72a1", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "f759ef81-8c94-4bb9-bae6-50dd8480a3de": {"doc_hash": "cef5546e015dc567c420ed3b418d39bb8e0c2eafe8f0ad618400f87afbe8e4f5", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "cea36626-5b03-4fc4-92f4-8e10213d70f4": {"doc_hash": "d1935626361d9aa86582ecb177bddc2def5f9c866faddab09993c2cfd2f6af6a", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "ed9e29ee-e3f2-494e-9119-1b524a033d72": {"doc_hash": "ecdd43388dd5c019dd3bd0d153cf52b6f3679d3c8103188d943dc01fdc1c6204", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "f7db2c06-bbd8-43da-8338-c58a96b2f424": {"doc_hash": "d0e9dd7f46dea4ba0b2aa1426ffa99d3bf35ba0c860974de6db697b1e6cbc784", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "eb13e694-e17c-417a-b15e-2872476b874b": {"doc_hash": "c042f2c6666112d1c898cf1cd0517bd2b3bd92a1feef95094190db56c3a3e056", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "4b382532-e5b4-4adf-8597-1492976992ff": {"doc_hash": "310ebe90f9bda4fced9497a1720abcfe93ed0c986d641735a1f5828c1c50b2b9", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "dd8fe1f0-c710-49c7-9c95-23e51415f0e9": {"doc_hash": "eee6ff967cd3f5d4552729a2194c4abc37fee4b3b3f946ad800d598c24909f43", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5": {"doc_hash": "197cb4d564fab4c85d98b36ab8e05195ab4bacd89528902d20216e0be133c254", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8": {"doc_hash": "0f07ce5cff1969ddc7aec7f7117263499b0f8df08a649bca20b1cd821cc98c77", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "71b4b3f9-74fe-4873-ad8a-fa426117bc13": {"doc_hash": "ab9637caa4607c30a7860005dc8fb9df377078b774a869ab206c401a012446e6", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "e800dc3c-88b9-4eeb-813d-387467f9c46d": {"doc_hash": "9bf9930097049cafb63e8768bba4eca4d824a61f82901df48aaa980e71155ee1", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "e50ab97e-e560-4f56-abfb-30b67e8327db": {"doc_hash": "a43034a0e59a8094275b551412b6defb26e1afc9325b8185bb025d60d5f1010e", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "b0878bc9-cd3b-48db-b3e8-0939bacccb8e": {"doc_hash": "f4d8917070f2a179ff732c370b7fce94af0246ce440b622bd56fce4c72445341", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "7c72e871-2ca3-4588-a274-4678ef501f58": {"doc_hash": "925cbcbb41f7ce17b9f743fb8dd40c8ae2d20d76a541aee2502ed77dc3524442", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "d354dd42-7bea-4cf7-8a21-f9e80013c92e": {"doc_hash": "4d62c6e2e6191c057acf2bd14da02626166a22224747da4603d6c0766daf6129", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "7e44c3f3-b322-4f4b-888f-808343121ff6": {"doc_hash": "b8eb5b1467048a3d1b93cbd784a5b08f7d1c28f4dc95abf91e6cec9d4108f34e", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "c20565ee-21f9-45a1-9b2d-297fbd4bad17": {"doc_hash": "2169249927767eb7a0068329b04d95c124fa65afac0f4743be7813fb16cf08ec", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc": {"doc_hash": "6f9bec8dbed3abd76b792f54d12c1ff40d562d60c4d74382c43ce576160df18b", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "eff013ec-06b2-4fca-a201-14f02990da77": {"doc_hash": "da8a9d84e131111b1eeb05e4d56a64c74c48b939d6e17a076ccfa537ad6a1ef1", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "b5c7e6c3-1f77-4346-a3fb-b983e5073497": {"doc_hash": "a24bf52dd46563887d5134eeac2be7749e26ebeccfea4cd550b8d402e7851582", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "11c9deb7-f056-4afe-8b89-35e5b4862260": {"doc_hash": "b57838969a09d71735cb363c2885e73c689c73d07b8fd5ccf547e4098d7a4354", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "f6615aaf-dd52-4efa-b8c3-784181d6ccd7": {"doc_hash": "94e64a1e15856df825990bc1522abae1ed24a458da6b7dc86bc75f1c25b2dee6", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "c4623f08-6ccc-490d-9b2d-cb49a01d139f": {"doc_hash": "f9823dd9a62146de6cec841572cbb75218b67b99052942526f757e64be01f6bd", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab": {"doc_hash": "fa03527990194b7dca01c5e46c52ac7247f9bdb744e083231c221d030feb8622", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "3ce55e8e-199e-47b3-a008-4610ffa6ab86": {"doc_hash": "2df716cbfb1218f5e22248edbdead57ade29d0b01f60b095db57f390b8356ae8", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "28334526-9b98-4d91-a66b-80c6e07359e2": {"doc_hash": "ecc503d7a878aa2248e9d8a426ffb7fab5376f7748b04764d6b5ce48a9f5fc3a", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "7c880145-9e52-419a-9139-66fefcc0d15c": {"doc_hash": "4997022521a15ab1e034be3feec02e1a11abacc0e7edf28bee2629f64dfd0dbe", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "1858fe23-6034-4043-ab60-068fd05d6c88": {"doc_hash": "3befd6336bcef87013b3ca2296affc63714eaa8c76e12e3bb3a88ad6c6fea034", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "27be2fe9-5ada-405d-b99c-4ae10007b93a": {"doc_hash": "4c7b268f467625f12912e0d5627611f3fce41f6010f328069a0f9505aa82968a", "ref_doc_id": "188b07de-641e-48cd-89a4-dbbcdd0961e9"}, "18b4c702-a1e2-45a3-8047-8c242fc171d1": {"doc_hash": "071f7289042f7df4c4802fe802be430f8442d51b4387505dc8a74cc12d63fdcf", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "537bdb29-b92b-4d05-914a-8b9ef412f126": {"doc_hash": "0a760b42d270b83de7a5b1a4cdf7b43cfc00cb0735b79ef0e5df15807f0f2345", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686": {"doc_hash": "a005a527d0334cebd6271628cb9fb26beaab402d6bf277add0b576b66183cf85", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "af21af63-0494-4425-be67-03432ec7c351": {"doc_hash": "bdc521ddba3fe17bfadc80f3b3d7595d1ac6107209eabda32dc533fdd297cb1c", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "f8f39e64-a79d-4986-8119-54e1156a76a6": {"doc_hash": "4ec7a545463d819cbe1a25734acc37bcaf9d4e797b5c09a58de829b141310a14", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "03c3c982-71cb-420d-a14e-d1f4b723043e": {"doc_hash": "adc741a424b2afdc559bc64c2c0676954788302131511e91b59695093af62168", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "1f117cd3-3831-445d-aa35-d4b0edfcdef0": {"doc_hash": "e4dd29bcbbd5685bfb1f9b9e84fdbf01deb01f33aae98e5bf27e444d1add08c0", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2": {"doc_hash": "45eefe53b171194e77af011220138428bfcc6b6a316fe5577947ea3106090805", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "cce68de8-ac56-4c1f-af77-18b299828f30": {"doc_hash": "d30ec89aa24f146b728ac74bfcb81f9c5d64024571ebb00ba81d9c2973e24f16", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "77b8acc7-283c-440c-8ab9-39d19d5967f4": {"doc_hash": "efe25920f8780cb51c82532bfba97ecbdfcfc8b4647db3309fcf10426699011a", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e": {"doc_hash": "4282d6fff8ee7083ab7acd2acc1868d8615ad7326b31d7d6f9daa5b3521192b6", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "fed0063b-ae8f-465a-86ef-545deb87d65c": {"doc_hash": "7982f794c1d2a8c12c174d96001353401cce1f69aac11f37596f4e2f933fc6f9", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "163236cb-8b96-4d61-bd98-c364657b9a7b": {"doc_hash": "00619367dff1569327519b576cb8b5ca6426a16a0619dbd2effdcdb240dc803b", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "2446827d-558e-4a39-b145-6a7bd19c14a9": {"doc_hash": "6006c94a91928394514c1c500d2bd6b5afe61d36545d15e178c4adc9109cb479", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "c078654e-2641-40b1-8adb-fa65feee04d5": {"doc_hash": "6c4b89055df358096aee9983a84542205b935ff85aecbec15c84f7eb01054a31", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "f5078eb6-d92e-435f-a75e-70a46b603376": {"doc_hash": "cd38b209252de0e1844ceab644bd98abcd620afcedb7b7ab82db71cd6afed5f2", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "8ca75a93-d5d2-4b5d-802e-eb80a99969b0": {"doc_hash": "696e9eaed0f2474fb0bdcd57494574a09a75ac2faaf4a5dfbae117afd467451a", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "02f7c31a-3509-41fb-a373-fda5b877168a": {"doc_hash": "b93e757d506d65bd32a3bc003525873315385fbdcd18376d5bd706c9632a88cd", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "7efa958a-edbd-44fa-99bf-0b42967e63b3": {"doc_hash": "80059d19b3f9fb00d26110a40e17757a61e6ab633262a824facf79cdf8b1a03c", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "1f415be2-3d32-4ea1-b7c4-e29ec731165e": {"doc_hash": "944785c10a7dde6c9c0681c417be006647783c82479a7858add672e733bd6007", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "99d2a2f0-4d67-4587-b613-5aa51618f675": {"doc_hash": "57aff886f2fc66a8f451278dbf0541db4da57db165fa4e8dce5b3910df9b1fba", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "83a961b4-3435-4ab0-ac95-ce45659d8caf": {"doc_hash": "8a7134a8021e3ed0320cd72bfb202fb3419f833354c282a96b340fe88b1e878e", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "a8729388-e619-4179-9330-da803fbb1d99": {"doc_hash": "885733a0d76499ce010499d785e920ef89bdb630425e9e291d69024cd8dfc426", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "39078449-47ba-4c56-a200-5ff5e4d32a8a": {"doc_hash": "137a4591400e436785d9026a80a38286e7a95b953c3f7729bf3c0a5ee5195689", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185": {"doc_hash": "00b1c10289c3c384d7187c49e8a1b02416eac6909c07b90527bad834fbb7462b", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "9923d52f-db5c-475f-ae09-963bfd2a19fd": {"doc_hash": "524290be1b6a5a4eaf222906fcc22df5ece8d62284f67736e43190bd8f0acd63", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "d9209479-341c-4ff1-b4c0-bfdc1ea4535f": {"doc_hash": "f8958130fe67ff2e1b97e9af0a86b34b9353439ee00d3e096f0566b4c2ab49af", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "f2950c40-7674-4dac-a891-b818b6478063": {"doc_hash": "51a71eb3fda6a1146772aa624c3bdbc97addbfed422876a57094ff6cb0b36d3c", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "97925442-ced9-486b-9c80-57513b05a298": {"doc_hash": "03e75aeb3906275d60a921da969aae7d264c0acf30ba19aedd6ef482756fdf6c", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "2d400cda-3f48-4a68-b4fd-1e275f0458aa": {"doc_hash": "80035a4a29b456fdf5f2f2e380553b3a997d8503362875f7a5b5c8f0a392a0b5", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "7f35fecc-6026-4e14-927e-552f63cc571c": {"doc_hash": "852332df6e221dff4ce2cc7068bb1d38df5d22033ed7fd0d745c5d5add77ce05", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "289032ac-87d0-45cd-9c2e-eaf501e9ddc7": {"doc_hash": "f3f6a0f51caf66b4408912f9524058638b4ba5788e4f4611767cb769e352c5fb", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "f494131a-7a83-40d5-8bef-abe375896952": {"doc_hash": "f8e96125528af1aad0bebfb18202fdf13f05fde32ccea0a5a8e885cde65fff30", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "74e85b4a-33a9-4af6-b5bf-b86a48de7317": {"doc_hash": "f571d6f9388299d8007340d095a43d3725c0cc8d2f82c123d7384c5fee8ce305", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "06f36781-0bdc-4cbe-8017-a8cb2029b4c2": {"doc_hash": "9c0486166781634dd4a707d7b57a5b2665360885b80130fbc4440ef6b3202452", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "32eb1574-1dff-414c-86b1-fb61ed653fb9": {"doc_hash": "2d92c97c1088f94504b61b77e7c41445c09dba11be721ff0f97a540d529b3084", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "0ba4dd2d-df84-4629-add6-e95b616d9f59": {"doc_hash": "873395f8e9d4125b7496d98a5415cfec8d74bbfc514b90627e477257ac90f0ca", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "78c9c329-453a-42e3-b8c0-cd69f6d62904": {"doc_hash": "b09786bc75b79654699be0d39a141e39079bf7b298a686cec8e1d67623058680", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "b671f24d-7b15-4e16-b183-927693eeaeac": {"doc_hash": "7dda32eec37520c73522aeb33ace73abf2fbc45137d338849c093c1becea647a", "ref_doc_id": "862e1938-6d97-499c-a474-4304eea1cef2"}, "aa171cf7-4e46-42e4-9107-b8063abf23ab": {"doc_hash": "656fcd7da56a5125777901b8563e4884821d6e5d8012667cb7817b70c277a1c9", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "85ef0847-1a5b-4831-80f7-c2015b67981d": {"doc_hash": "7b96a358dce7db1d669bc23ced703b802ecd1d17d78313b664cd7dc60c543ad2", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "d3c2969c-d078-441f-9c55-e7d3286e6d36": {"doc_hash": "0403acf54c03914b12c4b80386ecf88658cf974fcb00cf0a2cc1b768504ada47", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "922d802d-8aa3-48bb-a5d6-16ff463a85c3": {"doc_hash": "bdcba1dab25732cac259c9cc681bd7b5f46678a0c71ee92f2524aa586869ba7c", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "1373e821-346f-4a68-bfa4-41de03aa617e": {"doc_hash": "bf6b59ae6a63e1f7c31c612e01185ce2058966a0fe3241cfeabf20b303c47f5c", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "499232bb-750f-4665-ae12-288b1d7e460a": {"doc_hash": "2db2da7b69a6a3a51416c6de8fa02504ad55bbb51b4a96abf74d3a0a36140f57", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "27bf8026-d1a0-4afc-9a31-df8fdef6c0da": {"doc_hash": "1e2d1ccc2418db400a0b61fc5780826cefabfa79c86619f5daa8ff70d58bab0a", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "9cd7ac18-fcee-4c12-a54a-8ce656dd862f": {"doc_hash": "9509f7e73578dc2d25e02db1f6c2fe21e0706edf7e54350292231040fe761220", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "e86e9163-3963-4433-8b75-6f7bd51baaee": {"doc_hash": "4b341ece04e4575bcae6fa2721b86c5d8377ac01bebdfb0114f049be5e432f5b", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "3fccc0f2-aa0a-486d-9a65-69717afbb848": {"doc_hash": "f628ce0a1db65896a4e9cb4372e776335e457730c11bf1265f37fc98eda13543", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a": {"doc_hash": "f66eaa4137a25c2ec97496533113d016b3e2128346e933c9145a16584a3f5b30", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "94912769-d28e-441e-b7d7-6e5a3a8394b0": {"doc_hash": "bb0fa6484b5908ba7ca68722d095e7b46906e1b14542d9c1d9d13c6131e343a0", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c": {"doc_hash": "ae25ccbc7d3a51d6d3cbfef50d8edf2f7e736cceaef8fe60c2e17a62c2ec8bdf", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "f82211b0-2418-4ac1-b01a-3ed1a461f53f": {"doc_hash": "7e1619bb5389a4b5ee82918f680bb58c5781b00afa426f32df492ec3b8888f74", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "4f497cb3-0e38-4927-91fd-cbf12895fc6b": {"doc_hash": "e2c2647c6a33f632483be03d882cbf3cf903a06e61f311eb38988038ed9f32fb", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "d1e9a38f-eea1-4249-9bcf-6981c4626c8a": {"doc_hash": "ac751fd5114ce56c1d498050064056fef04e1ca8f7c57d3f71dfb9a5a6e08f41", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "107909fc-5832-44f2-b39f-7728d5a68e1a": {"doc_hash": "c984e4db3501a2e55a5431d0bb0ce893049d65881d5add96c76920952cfab4c8", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "a7fecc35-5d82-4c4e-b837-984620879911": {"doc_hash": "7875cefb69f02f800f623868b2bc9a3a3fb5ccbe51fecfdb9d00c7fe4d833afc", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "5010fac3-d5f2-4013-bde0-74fe0920d4ed": {"doc_hash": "ed8327909f08f37c5033d0cf8fb14cfde0e6d6432de5c4aa87124806619b8dac", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "05aa294a-8a18-4dc1-9a66-8d5987a77a0d": {"doc_hash": "cb48adc5fc797e871ce27873e7f2e0597eb4eb7038db9c74fd3474ebbb223d5c", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "4f40c597-ddcb-44b1-81cd-acda1f2d0f94": {"doc_hash": "c3f17fefaff305521aa4d64bfef401e4511ef7f947a64b51d7d06f75303ebedd", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "68f7f8e2-d8fc-4c8d-923d-2de016a587da": {"doc_hash": "12c6704fca246f1207ea16409279f83bd6b133d6f68b566196b9668075a67c72", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "d464d2b3-948d-4970-a50d-724ee1a3ed6e": {"doc_hash": "465bf50bf516008456a211b8970fa19a139150032b41a3af89e2054f7fd698e9", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "44913343-8779-4965-88a8-71f2e1707003": {"doc_hash": "f6ca06777cf4640e1eb47441ae5d67f42479735e4d282c39d55c67a429d70abb", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "b8f8a27d-6745-4851-8fac-3ddbebdffee1": {"doc_hash": "81884395cd725f624db4abb442f333e0bfa1b1e894e7dbfb0526e8d72efc9f09", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "b0add6ae-83e7-449e-ba71-e654147038a9": {"doc_hash": "42f96aa3d75f766341c47d699c31b83d9e78864242e4c857e187f0ecb2f7e909", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "4bcef189-1bb0-4506-bdd0-8432d9f1a482": {"doc_hash": "52066ecd7cbee29f3372d93c190bbb6c7c60b75fefd30b50da56614b1949778a", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "8ac9e391-2315-49e5-9592-584dd2c5fb4b": {"doc_hash": "6811ca652a8d178f93de06ecb6f52597c2d438b4a4ae878b9e0f28e685713a4d", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "eb1d164c-db36-4cc0-816e-b07427fd084b": {"doc_hash": "8ce29f244546f7b4b633d61a443b81d6e1cf8b0fa6c654b13c7f4bbefabcdc01", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "874c26e4-625d-4d8d-a216-09df3a2216e9": {"doc_hash": "69989db3d76df16f59752ef5c2ebc1697fcf39c6a0c766488d3f05382d8838a0", "ref_doc_id": "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5"}, "792ca380-fac8-4716-8adb-07aeed6db45b": {"doc_hash": "afe9b5a4c48ef5b9343d9ac1fc063a8ba54fa5328793c601193434250491d40c", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "e879e79a-a400-40a2-8aac-ac8e73bc997b": {"doc_hash": "2c84ec50a35593e7dca5f070d72221984acff3ff68c6bea6529c3fae852a227f", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "49922953-162a-4795-a15d-865f00f77376": {"doc_hash": "f78b36b30249135b4c9070b0a1f2d9b1f07eb6fd035d45863d1115f392bc5b8e", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "45278803-e4cd-491e-ab46-959f51f61b28": {"doc_hash": "82555e1d95d10c0655dd34f5d64f6dcf2b6ea87ce4756aff38a521460b837e45", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "58516f36-faa6-4750-81c2-f57c31d94fff": {"doc_hash": "f4bce4dec28c4dec8df0dffa300d8a35830becf62c1d1c9e5749c6c9f75894ed", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "a3ab2d56-4035-4651-9165-974b3f814100": {"doc_hash": "0cca3514adc061be05d91360ce93a23eec558e236010f5ca437aebb8b866e9a5", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "0e98a3db-95fb-4953-9199-cef8992d8752": {"doc_hash": "0c02d0b944c65fffab9a08f9c60a0ae4cb7452a82daf335653c3f9e5d8fc1a59", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "0a6f4187-74eb-4afc-81cf-76df14289826": {"doc_hash": "f305db01686c64df47491f693f7c0e80f5748a8f4e6a9af4576f7ec96a0356b3", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "26024142-e50f-4c63-b6bd-995b1ea6331f": {"doc_hash": "8da4a76c9aaef4001aff635fea62ffb8353d349f9de3ccfafb431109a5108ebb", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "6ac0a699-efa8-4b1f-820a-806b4782f617": {"doc_hash": "2fb8a7b301d0d01f5b6d20d186417d9c7c4cbaee621d49748f66c3332ca4bff2", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "34ed8821-0310-45d0-bbc6-06c10c5e66a5": {"doc_hash": "0b85bc2a1e1c54a83dd4e15ffe6f852534df16296af5d5e45bc1aeb322e8d1b1", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "2bac0d47-5370-4620-83f1-6eae30386112": {"doc_hash": "8d1e2829d9c0807ff2f8e068366da97b8ff87be62fd948c776538a10a96aaa80", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "b2254ffd-77bf-4e43-88c2-852851710bae": {"doc_hash": "0e6534edc4dc31b9f806d5309df5fadf9632aa0663e056d14ad8672a58fbb9b6", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "13347dab-1b85-4a19-9e05-3240219d7d93": {"doc_hash": "06a8b2b893cae4d89cbaff5adbc3261964f959e1e047e99a7688a1012d1fb9d6", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "79e9fea0-d404-41d3-be82-d75f90dc827e": {"doc_hash": "0544b0e48a1466eac95c6c13133dbc2aa7cf21fce4a435dec0fc7c683a630d4c", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "b9ada613-ec47-40d3-bd47-cbab7de5e9b8": {"doc_hash": "05a425a397f29c577c2319971eeefd5e99f2a275668689b2a06366fb0c16c72d", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "db297077-ff8c-4e6c-aad4-a251a24eb7e1": {"doc_hash": "cf42f474f3d15c5c462a66ae61b08414390d9f1230f8bcd5476cf47d5a803c6d", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "b6314490-afce-4db1-b48c-04dd9e0cbc73": {"doc_hash": "210e3905243d1874bc5a4c83402f299f7dc40c54cff74ce029162eeb10dff4b0", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "6c6c6d19-b984-449b-97ca-708c0b314d16": {"doc_hash": "805019c6ad239982f2778cbde29ab158269d3588308468af255a8c239fb99a4f", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "5b2c883a-d71c-46b3-b559-5d1685555bc8": {"doc_hash": "4e1044f4d306c5ce80f56f6d05dacac3cd28c4441dbee34a605c5dfa2bd07a56", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7": {"doc_hash": "328b69e274700b6234fcc9b1c2ca43460b9b824a6eeb5b4eb37aad0224cb4c2d", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "efd44c8b-c9fe-452b-9956-97010041a70f": {"doc_hash": "1913515cd1e6967e83fb9321a3b8595edbda6c6c46cc12fa6b9b28be3a9021b6", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "5459581d-a3fd-43db-86af-41647cdbc619": {"doc_hash": "0a23fef4dc7e0cfe2fd526b7e232642af5c7acb90cc345cd950349d938357c61", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "20487140-c2cb-4059-951f-913739aa3b29": {"doc_hash": "c101a12a5b247a00f9b1c42eda5caa5d028937c3b4da8f88d752638e3ffc1466", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "a9cb4ac4-e79c-461b-bdba-94605ed127ae": {"doc_hash": "a9cfcab5204d26260facfad8d403eee34e758821bd29236f5307646daf02669f", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "9ae85804-eee6-40e1-a6b7-1b2799663b2a": {"doc_hash": "fb57b3df80d058e973f2ab3ee8009f01e79905b7fd1b822e98e350e1ebb9e67c", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370": {"doc_hash": "93f935462a9141560adf950eee2213ae2d4228a185fc6df3213e892d77d906cb", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b": {"doc_hash": "a09ad387436ad7bde4a218687bdd3194a5abc7b43646826f6e24b06afa31a00c", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "b094c53a-4119-4ab1-9ba1-2a387ee5ab34": {"doc_hash": "35ec2b5bb214603a5c711ddebb069749fdd07110ed6871652ff7a73e257013f2", "ref_doc_id": "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081"}, "5cc71b01-8152-46c1-8059-6c7286116457": {"doc_hash": "0af4c6c87114a14c1103420268522d8af0a300f729317a4d20211589bb53011b", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "a6252d7e-8400-4ad8-a2f9-434d874a3690": {"doc_hash": "4d439ce5ae3e8018ee55f6de64747d6a96d35a6791099c4fe100492e32418c8f", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "b70896e7-41a7-430d-8080-656fba9fe054": {"doc_hash": "401211bb1d3707acf451f9e83819baf486f6c59a954b4f26a652e27ca0ae743e", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3": {"doc_hash": "23badf618414a949d08190321188bfef7bad3d3976361e377735abe80d4ae3bc", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "f4f46f62-e0b3-45c5-a935-c0f9b9215425": {"doc_hash": "53b49cb80ca5cd7c3624f6b4549a6bc3b98d72bdb4f85728ff5370b834ab231c", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82": {"doc_hash": "91b48f95134307de05deb391335395b686e3d68809786dca3add4d1eb1e22b77", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "5fc36a86-b882-4631-862d-dfa8902ed3c9": {"doc_hash": "bd05238d5438ffbd1d5747833969a3de62cea82365e49b53c999857286d8dd54", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "34f97fbf-f68a-408c-98ba-b74777ac6ff0": {"doc_hash": "c19d7273cf5f2a0587978f0165477e0a9929a4ed6e82f9639b7a1851d4ea23f9", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "ebb56970-5e9d-4909-853c-ee869950ddc7": {"doc_hash": "c6e85994295366983b7b843e45e4aafc79267e2982fa19fc5138bfac80514f30", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "f77af948-1c36-4058-9e44-4ab030be7c85": {"doc_hash": "a30a4b74d133fc609a82176c74027fa6d946bde58b9f611acc432caee755c55d", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "61856695-56ae-4a29-95a6-c24d78c4bc5d": {"doc_hash": "3a71f5e329fed6333bf9f42170738e8d020f4c6f636a7bbb5dccd6946747c2b5", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "1665c421-687e-4e9f-ae44-bdacf3a97309": {"doc_hash": "496f25c27badef07e9405c3cd2e92c23c2d7447d8477a7f8e4ee0ce2452ad672", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "771d07bc-d309-429c-8593-c19b8fb9b6d9": {"doc_hash": "d5e20c7e92f7b8444cb5a3b5e7be824487f83184a2f69f6e90180b0f56d9ced6", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "0dab892d-7109-4230-9c17-0c10c9741a63": {"doc_hash": "9150e5b369043f26e929517c1ef2b909b56b2a358c78e5d6dc4a531a168bd9a9", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "408c5946-b07f-4dc1-ab1d-091b980ccae3": {"doc_hash": "946c7c42952fdaaa168be68c2f6ecbe7ba870cad67c74ec6105b27600972aa7a", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "f2b12a39-2531-4280-a052-ef2cbf03f5cd": {"doc_hash": "71231983e915e927077269cf21a07a14f68adf373747aab462a5b42eea100a52", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28": {"doc_hash": "7bd8fdb630177b904cef0d5a53119124ad3fae7392011b78bdf61e6c2e1e3e58", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "76390cb2-dff3-4644-844a-d66ae0f0af25": {"doc_hash": "4978b96426d116738f06a299f03f6ded7248c7bd8af93a6a22dadb85b799ad48", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b": {"doc_hash": "49221c827f0f89d1a3b5d09a91b094e9d6b90d9c4e1ea2f989883f78e9d6df0d", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb": {"doc_hash": "f3553b4557051bfc134db9f5ae280ff6268f406d7abafdc015039a546212da81", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4": {"doc_hash": "330b2bf8e9174c51a6df4e03e52353ed57cf884728ed8217efeccdcbf34d207b", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "b15f0657-6496-4da3-bb26-c40112607f4e": {"doc_hash": "93aa970f09694baa669a217e2cbb3c3a2aca63e252abb9028c2a56115a1f5f64", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "6e7d4e2c-ae28-4ede-9196-bad98da61ea1": {"doc_hash": "1a799d4f7fd0dc995ca782c875e39fdb71c56061dc420ea57a12b91db36e52bf", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "3b22e94d-282e-49d3-8fd8-104eef50c869": {"doc_hash": "4434f0ee0bd55be20729745eab2bff415cde212fdfd26511436c1a899443913b", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "0854f6a0-7380-466c-b21b-2d0af6a98d02": {"doc_hash": "6e9896efe5447fc23165ef3f21a5543e2a6c2ac9e91e26954d74f6a45780e998", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "969a6c96-3f6e-4c93-902a-e1dcb3280f8c": {"doc_hash": "40994bb8cef345ef5e6fbecebc169d2286d597bc8ee64cdcac9f773840fd4783", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "be36b1fc-d932-4d9b-94df-17d1c03c8ce2": {"doc_hash": "36d88bc887961f1d3f6252f4bfb187fa7211f0487b4e58440543fcd5955b4fdc", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "408f8421-d2a8-4c92-8fc6-7b0d58426bce": {"doc_hash": "6f4703e3a3c7d00f276d4e23941e35d8e8d15808a42abc96b5ebeb26a13aecc3", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072": {"doc_hash": "1e40fa8442039fbc2bdf245ba7d5af25595dcaf1d8aa0a234e4a9b6d2f38f60e", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "1d3ccebc-799b-4161-babb-5cc5ae1495ea": {"doc_hash": "ae153ca5b574ac36e107804aeda8803dba3031d5783373aabe5039155c54b754", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "f5a23d90-54c2-42e3-9426-fc925b55f5c4": {"doc_hash": "4d24712e311410908add4b2e954ba86acc99958c7b3612b56bfeb57f7851a2a1", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "16713678-05f7-423a-8ad6-41f6f6eef755": {"doc_hash": "30c93b5e59b63c955a7b963b122aaac461c27233d07b3616d47deb754c6fb110", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "e2db397e-89e1-47b0-bc8f-367a234ac7d3": {"doc_hash": "5ad979b4a79b023bfb32dc0910b67d911fea821eb5029561af686af6995aeb66", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "c98f13a0-cc75-442e-aae2-4796c737f963": {"doc_hash": "e0fe23fdb9c49614251a08038b54c3fef1f5c6fa25cca7a341f5a60196461416", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "b2b16850-e11a-483e-982d-d0978fda0d16": {"doc_hash": "56db19664a74d40d6945e4a32ace7b349d257fd0d6444f25620acd95f13cadba", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "247277fe-b7a1-46a5-a492-10019692e4e7": {"doc_hash": "d5841147a85b88d6b19259d0377f204bab2a317a4e2f57c48d9caef925efeb8e", "ref_doc_id": "1510173a-ecd3-4f24-a812-98c86bfd459d"}, "907e31c8-16e1-40c8-8d43-44b78d08cc6e": {"doc_hash": "9b10ff417b4f89261198226b34b908d761b9942a4df4660b595c99fe953e1b0e", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "952a12b9-d6a3-459f-a711-fff5da9100fb": {"doc_hash": "2e39dc0a93e00972242f63e3618234ff6e3b3e26b13477fed56c021c579ac59f", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "c6a321ed-635f-4133-a19c-ddae2dfb619a": {"doc_hash": "c6358f90c2f0e668dd77a51b5f97e8cf421fcc2466fc80f6ba8d1c063927829d", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "939dac22-ec6d-4927-907d-79b03d4417a5": {"doc_hash": "53009d5184e59279b0a72b2a968cbf230a76c1a3ba24d4b064fe084861dbe0ea", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "54b748c3-9afe-44c4-b36a-895d4706cd48": {"doc_hash": "b398d4799b14454e66fdb2388d6546b2a8059916c1c26a63d6aed208b12e3182", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "80e05c75-a236-497e-aba1-40e5a2fcfe18": {"doc_hash": "c90c5e9574ea8c7e5ff1720297b9926f119f29fd89bb6bf4590aa8270bad6d17", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "4360a740-2efe-41b7-9ec4-c161b1679329": {"doc_hash": "4a2190f9d7397738e558e325d47197e5d8b8b3ff919fdb3c4d74af801bd50061", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "dc9b3723-83af-49be-a3b2-f35dd84c6e99": {"doc_hash": "846f5a68302e69fe4833ffdd686440a295be34d61bd658ebcd1d76c9d1108d8c", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "8e5d658b-613b-4c87-9d08-57014b8fed89": {"doc_hash": "8705a92c319953635a1d056463f3812ea0779855fba837bc8202b4f6a5003651", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "f4ce8af9-7674-4627-bda8-41476dfbccda": {"doc_hash": "588df152300d28cd4bbeaa9ccd19678bf65751552c3ec5327bfd2727786c813c", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "272f8d13-d546-47ff-91ae-f8e32bd30c21": {"doc_hash": "97e66256a1cc8a0507259326fbd336dbb7bdcc35411ed4cd6be19b9198aac57c", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "9a51d6c7-5b32-4525-a603-717d087ef74f": {"doc_hash": "65e3d87fcaee96b83bde266ae2cc8e1762d4f45fc772cbed8d036189ed4e7d20", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "095f701d-43b5-41a0-a7cf-0b3820847784": {"doc_hash": "a40f06625e27ebf4db572133441a0ab9fb668ba6c914a0f6ed88aa04a71498a9", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "de8cb963-2d9f-41e4-b107-efb4eba786fc": {"doc_hash": "a44d8491daee59a57afc51c69f38ee0374870e4c79b5c366508252d70cac4c94", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "49ca42ad-a794-4dd3-97dc-121a9b5f7759": {"doc_hash": "685320a42105fa8b575e68a5df46aa33a932ed86206d94ed3af96934e8524661", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "20aedfba-e4f3-461e-8c2d-01f29c937f20": {"doc_hash": "9486a396127b59eb85f948c15755abf76986a3df0e3d94e8b5ff6796cc6e07f5", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "8d5fa321-8486-4ee5-ae15-27c389cd3f2c": {"doc_hash": "5b75380b9ccb5e11461b9f49979f369485b0b688a265951b70674d5254f6dc64", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "e2750933-3b35-4ddd-b2bb-78ef873bc3d6": {"doc_hash": "52fd1305c8111f61ad5588c1eb3396940663e1b57ae6133d81696a0ba003bee6", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "9cdf51d2-52da-41ad-9b01-c50517ab756a": {"doc_hash": "7c89ee2cb348b9a376b613f3954ba39d7a860507a749eeb2ea66ef520099fdca", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "734f614f-8a29-444d-a1e7-db6685942582": {"doc_hash": "dab42ef6bb78f1fc7d3bc1d74f1183a7220eb02f0d2a1b40ef5358e13cc9f4ac", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "54a00d97-5371-45da-9a93-8d4672989ff2": {"doc_hash": "140e68a32b8cb9261bf766cb290caadd236d811df5af3632e6a05545007337fd", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "83616195-07fa-4d80-a055-b3630e254146": {"doc_hash": "f389ae9a9a2a82c08936ec47aaf74b3200e00edd4e7fede5b092815c24f3b9fe", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "a5c9defa-9c96-40ea-93b0-873b7110161c": {"doc_hash": "c57aeb0957031674b75eb687fdba3eb8241200b384a7586c3aaa5764b7b2c912", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "a49bb762-dea7-4c5a-9786-f64a4e78b160": {"doc_hash": "9b826ac73b7c12b619b92fe969ce262eafb9653d8cc7d84c1fa29a7012122e44", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "f9c6bdb0-4564-4d67-afb8-92eada705ef6": {"doc_hash": "bae7a1fdfcd6cfd4e85ed32bee473f42b8398798f8565609fdc44adedec87d45", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "182a9263-3bfb-49b3-8663-90101c1ab82a": {"doc_hash": "8f3ec4f220ad084b01a3a69407189213c7fa36caee8426348c60236c7537001f", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e": {"doc_hash": "34262a5f7a195448d2d1f1a3fc083bebe580df6c222f592b0b9d8158fa3834af", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043": {"doc_hash": "3c523b364d26e2748a224a6b7b2a3ffc3e8b199337f64d04384fe2f2aed1cd3a", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7": {"doc_hash": "0b4cda9f02caa5dbd1ce6564a6ab84fe20ae77cecd73a5f5bea69cac98db07d2", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "2951060d-c620-49d7-b071-8b8476c321db": {"doc_hash": "611d55e81d787cfe262885e525075afbc3041db6bc0b7889dbfc679acad14c25", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "cbfa4b3e-8403-415a-b330-4b06cdb94ce0": {"doc_hash": "be731283ae93935489ac48d6fd594e856b0bbb7da56da3b34a045164cef26b7c", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "92f79018-f9f5-454c-91a1-416ee0bd0b1d": {"doc_hash": "b1cba8782a9de781867301f70bf57483ed5c33e3c4f538ccd6450a178e3d403a", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "f73af628-dae8-4670-9c7e-49cd41e3bf6f": {"doc_hash": "88cbf98c8271d2604dd2d779e3b36d0865be45af0ea0c8c2dcfd95a45f3e2ac3", "ref_doc_id": "54883497-6044-4c3b-acfe-65b40ed873b0"}, "8c108cd7-5abe-417a-b5eb-016b7d970dee": {"doc_hash": "0576665486c3ba46bb24985614a7801dcb74f51b40a85307e59a09693259dcfb", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "a485c554-5068-4b1c-84ad-817b4bed427a": {"doc_hash": "c831a4d90acecdf70639f9ca7b8cac53c4be5bdd12fea318968fbe5ffabf2a09", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "7a311813-98ab-4f0c-9b35-2c1c688c27f1": {"doc_hash": "0d175b6ed99546a5ae4fa6fd88bfc62c7ab691c23122c912bc8e56a7e79be6dc", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "efeaf1f5-74de-4520-8234-28f9d7cd49e4": {"doc_hash": "aef8e2addf7d91329d3a7d1b626532bfa9141f0a1377f9c9507a4353869f16af", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "23dbebbc-4660-4a2f-a1d7-c10bd9655886": {"doc_hash": "0dee7166e9710e8b5f7a9bb66f811e04d4dd690a25ccbfbebc5f0260c9c35f71", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "786a24d8-c50e-46d6-a170-b66c35d140d4": {"doc_hash": "bbc601d303cade2b659c6b5d69eae250a6b09e73ce565735845a7c579cd335f6", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7": {"doc_hash": "2ce1ffca4c5ab6e5bd1b6110fe1b35440db2adfb54ad7121fd9557091d2374a0", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "351ee781-ca26-4489-bfde-20b17498e0a0": {"doc_hash": "c2e666db636fbd8b2b2d6e3708b8e72636a45a3dc8a5df2cd2b116902270d05e", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "422df89b-387f-4762-a910-57742912377a": {"doc_hash": "c48ef51b854fbe9284311ed0d0922c324d04a0cf6cfc5f6750c8d1e2d57d9693", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "f55171c1-f3b0-4fed-ba42-89abf5fb1894": {"doc_hash": "0cd8532515f6547c69ce4eaaa0b1f59f4e6776eba91da74eaa5e32d0bb08dc70", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "baae808c-8101-4048-a1e8-5d31a7ef81c6": {"doc_hash": "3cc29e7678ca30e0ab8583f562ee0ff092e38ef518f78b4921d37cc5c4f0b351", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e": {"doc_hash": "c791ac5d950c89b34ef12358662e0bb7ff62914d561a369e401b92290baa0c35", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "65649958-a5f5-421b-aecb-3718a7449643": {"doc_hash": "2e9f22f5b8737a542439c1b1e84fbee2da45917631e7ef3e69979e40754d83ae", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "0f13e637-ba92-4137-91e4-bf15d767c1a2": {"doc_hash": "b9f726457aa4769609f92215e1b9d65540c1c7b33b019a2b06e00bd3b3a6cf09", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "740a091f-0af6-44d8-89f3-3cc0218a23eb": {"doc_hash": "dfcb696b7368ee1078134cb0ffff7b2d32b880e1b097203b62e26ca1bf725b71", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "0a5f2b96-8e81-4dd9-b042-72693d92cb33": {"doc_hash": "669c3d4da0696fd1578803864637f03c8d394f4f79e19263e1262f676c38975c", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2": {"doc_hash": "22ab8e81b0b7d24bcb547a6c686fc3ace1008f03d786cceaad4a1f7dc02d1f4d", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "820f29c9-3a64-41ce-8167-f432cf1c1b14": {"doc_hash": "549e1c45bb65c3abbb06d40f5cec7b2d89aa09f226ef49137a263605252b713f", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7": {"doc_hash": "920cfc3f31cc7c998c2519aca3601235dfdb7eebba6987ac07e08e45d57a64ba", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "44dd30c8-01e7-4e51-ab37-755406c559f9": {"doc_hash": "de5c2bbdd68f83944edb411d193694d819495c5e96e71b2561cef4584eded869", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "2683f5a8-45d5-42b3-8935-dba1703e09d2": {"doc_hash": "0a767be5cd3a9dd71b9a9e28f447969e7120440980487ae412949a3b410142d5", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "8399d6e8-70ec-447e-a913-d4e6471cf0b4": {"doc_hash": "0c7366de232ae2efbad428c933aceae1c7774f3f24c7e7ebe553358787b22e43", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32": {"doc_hash": "1ec4fbc4ec00c7d789929b7e58e5341d66338b39e277c188b2bde87f141ce1e5", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "9674d575-81ec-4c10-91ca-ac6c22dc28fd": {"doc_hash": "309917a40e88afc231fe79a25076ec727a67c53b53a583e6bad30a4efcb9bc28", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "a2c7c26d-dc90-4889-b798-d43c91625aec": {"doc_hash": "2313ac051eee2473c504f939d317e904a6a1829b1b6e702d1c5bdc15dc938ccd", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "f0b05edd-597e-4c29-aa5b-c6a65bdb998d": {"doc_hash": "e3abe711968dc481bf6c5d602d92e20cab54024e36367229e64f0ebc9bee8c10", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "76fe6634-dc0a-460c-9b1f-608708e03334": {"doc_hash": "6a7ed5864852429cb7d3752ae1e3f2fb4d68444aac4dd8ac484ed10a81b21939", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d": {"doc_hash": "43623d07aafc5a9930f559f6e1046096decb9d703365c86deda8b007ebbebbb6", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "2a22c804-5ca6-4257-b516-32f7fbc1ee47": {"doc_hash": "4f7b345ac0823bf2be9cb379d075b78f66ad809358d67c708aa60f9034122a4c", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "e18924fb-964f-4f23-9182-0a65f26fda23": {"doc_hash": "a20e41920fb81501428122b90ea071e933dada7d9d468c4a2f0adb9a74f3be06", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "b928815e-38c2-40d4-b637-d35d45b8dd96": {"doc_hash": "b594ed9c4d5d311372f60759bc9b1479a728c7032a7dc09ce3b1064b1096c908", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539": {"doc_hash": "674e5c206b3498134fc651caf3047bb4aac1b86bb63de2066d9a5fccd073cc0b", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "9b904e35-7106-41ed-b0b7-53596872ea2a": {"doc_hash": "0afbeb96624f2a66e6ad666c6036a8aa4842f0d9c543d77e92e3d53cc42fad3d", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "f268ceb1-f566-4a1c-ac0f-8955cded8732": {"doc_hash": "6d29ebbe18c3df97512ac58eac95f4e5d63d4a849fdfc8ceacc079862fac2a72", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "a4e9e66a-6c71-48ed-9788-0129f1c4971d": {"doc_hash": "e5dc28084bb4621af1cd660251ca7cf4eb7c49d8c117f9c9b1ddf6d0e23deb4d", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "c6d3ef4e-7745-421f-ab09-a30e19763ff9": {"doc_hash": "edeaccdf841e7bf53fcd1d022c6c0b689ce63924408c64b41692c7a445b25bcf", "ref_doc_id": "9499270a-7af5-4ef0-8315-eb13e53c8613"}, "2bccc890-e091-4c5c-85ba-cc6aa9e42c46": {"doc_hash": "f8c1fc54c81af54759186f091300a71854b6e7e851aa435620205297cb69ffcf", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "ae91e9a6-edd5-4026-9c46-e87d9f9ce009": {"doc_hash": "3543f1bb4240ee6b9441ead8aae30e36e514a828cec5b0b448ee3c2c48684663", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "e423da95-2d38-4c85-9d9a-57d83eb9da49": {"doc_hash": "73cddbd8b50cdbcebe66235a539363fffaa41a429f803f78bcc3cbb3ba739f2a", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "300084a9-a3a3-49be-a286-f6f217452209": {"doc_hash": "f7341898a6f2d65f94963ac974977b9a0764d0b8e1519fe69f00deacceadd5f8", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27": {"doc_hash": "67840d19aaa50c330542c95cebc79fc219301eb13c321988b40ccc751d2f0ad9", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "ee24867b-d2fe-4b67-9910-de21e313856e": {"doc_hash": "ca4eacd1e86efedd22b46283bf2d462ca08cf907bbdbfcec57786029f833ef00", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "827243a2-24a1-456c-844d-5d77a9c6fc57": {"doc_hash": "9ac4e3cb2d6a9cf1cf13bd6e81a40ab544e12282bfe025c274c758de7c19a5dc", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "2c907959-a6f8-41fd-908f-dd317b67cee1": {"doc_hash": "52512c9c87051a45b62f079cd4b4bf43d1f49ec88e93e1ba5371bbaac725733a", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "28031336-03e8-4383-b7f9-d57dea2dca1a": {"doc_hash": "5416c6a639d90dc0fef7b358f8f4ebce17886abddc9ca3647f7fdd6e58396dcc", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "483ebc3f-2308-49f4-ae35-4d2d920046f0": {"doc_hash": "a5f4557ded4b4baec5fa64fbeb3809d951c3e34e76b8c9e5e6b4d6c3202841be", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "205bd97f-70d9-4232-8045-c5a76c9567e1": {"doc_hash": "8bea01df2242378b6b01d9fd3358aa3c191695eaa5e52801468112b8d50fdce6", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "4faa18bd-3f04-44a4-8098-07ddb6027989": {"doc_hash": "5abb3627fd203bba795d75b3c84e6b3b4ef71119d2a5d3f47bc624772a0b0011", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b": {"doc_hash": "203edd5cec645dff0df6b45a57df491ce1c772b4974a426f2d7fac0f7e31012a", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "ce8e4918-6270-407c-adbc-64eeb85cbf09": {"doc_hash": "974a13638081be13b6310dff0f32f07332d701f69317672dcf51d927269c2271", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "91aa5270-01b7-47e7-abb5-236784f64b14": {"doc_hash": "b75878168950b013b3d56c580a1dde1eae7d7c453bab6254de2a87af2a832090", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "47ed7284-e789-4604-86da-8d451f156ba0": {"doc_hash": "8076ef5bd6ab31cc1c6750a51f29107ee8cce5c3f086dede629fa77f3c8ad084", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "7414504b-5b5b-4c96-9e79-b4699a329725": {"doc_hash": "e66fd822bc0c6df1afb8cb12c272ea1790cd47f0f69d238bbc99ea53606d29e7", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "b61262ce-0946-454d-ba59-4f10361658ce": {"doc_hash": "aa9faba766d41b1f633e3cf9dbd720ec3df3ff9642b04c8e1d52b156991b7f38", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "c090daf5-9e66-4135-8049-289a618afcaa": {"doc_hash": "50ff03d7c8bfe2c257f234353655f8c64ba3f2dc5afeb9a95cffa5348956974f", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "7f2084a2-ca63-4ad2-9562-40beb9a066ab": {"doc_hash": "135e4110242cf9e8fff262bcce86447bc295955a1ca7a6c2187b81e39f4081a2", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "75ade40f-fa78-4f99-8481-b05fbe3e5e53": {"doc_hash": "6cd1506c804a4aeddfa8c585a56c88b64a6d5728d1326dabd0eaf63ff07c5b23", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "ade6fe83-d661-407b-9ace-f453f2446e4d": {"doc_hash": "26f0f1c7c1cb285cfbb158527386dd0bb5434f33997954b924ba9d1491bf365a", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "8ac38b28-df2c-4578-8a83-d29a7a78dfa2": {"doc_hash": "72a89c0ffbc880eea842d546ff70a073762043fb585c58862344dd0673517fd7", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "b9085612-c533-4769-8e79-47f2b61ab6ac": {"doc_hash": "c5a1fb77dbbd4369aa8feb8b08a5074c756105b89ff95c184b92292a020e85e5", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "449be7d3-d35b-4a8c-81fa-378c63ba4bbf": {"doc_hash": "db2ec9f1ceba2343e80ed2995e44481ca24286e823939d49e657be8b98871d6e", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "68910868-73d1-40cf-93f4-424a9728366c": {"doc_hash": "84eb43ba77281fa0d43a100f4d48990d7cbe2f8670c218e53dbf8bb28733024c", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "5d4997ed-9cfa-4c80-a34f-089b163d2be1": {"doc_hash": "d6c1dc887a987dfc4415a18bd2e71dbec6cd3bea3cfc2165b4f7ae6bb24397a2", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9": {"doc_hash": "effa1ebbf9e8a57c517a72fc8c1a33875c84372e237b8640fc1ddc981fc23e13", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "fd50eb44-4c33-42fc-9b59-0cc0a4155396": {"doc_hash": "4e9b3733485319a611400cd737e3898e546e6d043d0198ed9ca0aaa75a083c47", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "bc3e2cda-5265-40fb-b865-0aad14f9b2a5": {"doc_hash": "1b482a9062cca060af7f123355be4792c835a0b41d859cff953000cc32ecb5b0", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "4ea59e98-cdbe-4689-b35d-d7ef2ad25543": {"doc_hash": "2365ea8512cc91fb85f024aeef8071c2e08c02471cb20735ad8146f044a04610", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "bef86e86-f9f1-44c0-ab70-81d4dc2918b6": {"doc_hash": "30c761405327b87a00aa4b9970ed32f58d979051020ee103ccde61ca2c76fa1e", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "99be23b1-4127-4716-a184-c7fbe88e5451": {"doc_hash": "92f9170116c52dcbb84169bb75abf9545c7f9f2e86e9ff3d12d0902972b233a2", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d": {"doc_hash": "990b10cf736acc3e520976b60f606bfff9e536916ae8ff79760f23d764c2b159", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "8bf1f6e3-ca93-47b6-b262-82964cff6117": {"doc_hash": "fddb93496f651ad2273ff80b606e9f8294cc12565c39caafb5b456f6b8e9e5b1", "ref_doc_id": "fcf436d0-8977-4423-ae40-830e59ee55f9"}, "0adf2d6a-1ae7-4f61-9afb-0561964d0904": {"doc_hash": "5891a9c514d6ff9437363fc4ddb83ce175d282c4850f21ab38327621e103cda5", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "ef46d05a-b76d-406d-8d4e-13132fcf369f": {"doc_hash": "92b621fc23981f29639101f9e869f473dd727cfb0fccecd7a745bd89b18885f9", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "829cbd28-7cd6-434b-80a5-f2cd7e4d7081": {"doc_hash": "f363b8be592d62e86ec667799ed4385b519566c71ae19f9b5ba5082b99efd31f", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "a50a9f7c-a97b-4813-8ee2-25be289b79b5": {"doc_hash": "5f6f197c0987663285a20ff4e30ed219ee31eb8a148e607acc20614b8e497a94", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "808608fc-c58a-4a5a-b4e8-5df612cabce9": {"doc_hash": "e914edd338727d6363335efad35975c313a3aeedf6f30380b48057ed0c1f43ad", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "9ca020e3-3e05-4ad3-995c-b9005596c153": {"doc_hash": "da8cf5c138bb7be1227fa552664981b04addefbf4c07ebe5ff5dc734cf1b1e0d", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "33e25f73-7b51-4f7b-ac43-caca18302646": {"doc_hash": "dfef616c8f880e793153dad95b14d68c147fe520a928fcb830334cfc1ebbc203", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "e421efaa-a891-404c-93d2-b6c021e4add9": {"doc_hash": "5b336859da04abb147ef71976b9a18e20cc6c46d8a39098c0ac723eca9d58daa", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "16827b63-223d-44de-97cd-99a85916ba23": {"doc_hash": "ebd8ab7736d480e3f2ca3e0441b569d995e066b714ebcf8d80664c515611d0b9", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "fd6413ce-d32c-4bfc-8116-0578fe028981": {"doc_hash": "57d0d16c7f5c47800f1f992fa4455a317b8e87276cdbc310d4ca5b907ef9ac9f", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "c49858b4-3039-4e31-a22e-0083516ba4f9": {"doc_hash": "8f62257824490654ca0d0f4e4f897f252815566ab5a242136790aa7556592de9", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "da691378-ef70-46ed-b9e0-b7714b794b02": {"doc_hash": "9907568ba76ed9dcd101c5ac8c127394d5e736f9265c574ec7f6368b47778016", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "4765a2da-85ba-44a3-a094-8801b508c5a1": {"doc_hash": "2e931f66b05fc34f2c17eb0e5c53d65066bc33c1537877a01057276a3de77779", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "866df582-8f2e-4957-a34b-0acdc58575b2": {"doc_hash": "9e8a16e35f8f5bef19130078f2579fb7e2bd2a70e18e2b500ecaed52412f1274", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "efe4629d-cec0-49c3-a656-0558a821e06f": {"doc_hash": "0c16e4799f26d25582d82b77d01530a88dc11381dca9176afc705a685394dc7b", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5": {"doc_hash": "91e260f7447475d346004fd64ee2e8cf1e059ac6b401b5eb86e1ee8fa3a76447", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "525e5693-90ba-4c9f-bbb2-415fdc390271": {"doc_hash": "b60acf315f23105e37edce99dba9e8f91b8807ebcc59917f1df9eaed5f8b3ed8", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "0824275f-4d1b-48d3-a319-85ca3db84021": {"doc_hash": "bac531393c18261a8a5827b373a4d539eeea0d9d1ab6076926bc08b023370a74", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "e81d6b20-f384-40ce-99c8-7b74bda282ad": {"doc_hash": "5e96e833afe4b0ec4fb027cda689d987146ddc50754fa127b3a6e5156bd7dcbb", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "287b0305-e7d0-44c0-8e18-93f9ad06a55a": {"doc_hash": "be0264b7c3b2ed2365f52cb808728d8feae574df36c1bff07bd002a8476c2cdd", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "d0198e2e-49a6-4f16-8576-b8c3ee36d799": {"doc_hash": "28bd9d104fb3b789a9f67935fcab96c2fe2457ff663752569c3e077170599930", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "e2536282-da0e-4217-996e-acdd53f797e9": {"doc_hash": "8de12b49f32120470f84035b4e18e81826a66d80f0da25b5877b5bc180d851bd", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "a6979613-7cdc-4f18-b8aa-de405f56620f": {"doc_hash": "9b6e3242f875c3460295affd65754296e2336f1bc7e315c7e67e4e6b3db66d62", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "2dd1f7cc-a76f-446f-904a-d090bc223e0f": {"doc_hash": "6ddced4341bfbd833edad0bdf1bad8cb28433e9aba629e2b14c7531369c3cc09", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "563f1b73-bd64-4d5f-80a0-40eb07415831": {"doc_hash": "a6f54b705f8000062f793f272f3ea51139907315b8a4fa15533f1187698da737", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "ebe1dafb-0a7c-4146-a32a-d99738947bf0": {"doc_hash": "55089905a7bf6149cadb82a962d33fc1f45f87a9dac0c67df9cb62f53a0bb82d", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1": {"doc_hash": "86acbbaebff330b06228673b83bc20dd3f1db2dc0205f73efc1296ab5eed47c4", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "9c121c78-3197-4259-8bd6-6e894b54fbba": {"doc_hash": "c69a4eca4c9582d905927c1aab56cd599de6a7e56da9a208f362194053bc0ce9", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "a21d7908-3b86-4d66-9381-08342178ccf3": {"doc_hash": "7eaed1ab09e3e34921b2737a8e42939095edda9087f1547afd6593698d9b6a1e", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "5b7420e2-0a73-4aba-b234-9d41614fe889": {"doc_hash": "ad498a0c1f2bc0deb1e59d8903233f41a07149ba9aea386ac4434c74d7cd7449", "ref_doc_id": "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3"}, "ecaf43c6-2498-45b8-800b-4297f15de201": {"doc_hash": "2e4b026eff3ce8b1cb50eabe3fec72c4204762fb958d8156cf0308ec01497714", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "defa66c3-f5d3-4c67-93af-2745f4ba7e1a": {"doc_hash": "2f85e0d3b640141fba1d348c278df40af941d4ff8a35f023dbcdbefc0bc3585a", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25": {"doc_hash": "209fa18081355d498dfcd601948d9bda6e844a3466ecf1e0f8f0c73fb7e321ea", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "b2042e6f-9da3-4a88-9ada-78f55962c06f": {"doc_hash": "1f7dd4ed09308e01654e6ce7f02e8e2554405ae2f39a91afe4e55b9ce2f2d387", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "2612b332-abd1-4f03-ade5-c958e4a64e8e": {"doc_hash": "ec945c7985e154e6021cd371641eee4b37a9996a3f71bb9cb5037f9f80f107e6", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "50841597-9b34-4fa8-89f1-e6367f260fd5": {"doc_hash": "18e8c63491bb67f66322ae8f25b864e813b0fde40276d1111a1f76ddea001cdc", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "f8735ca3-bf26-4689-8ba0-da071dd45d3d": {"doc_hash": "2ba8cbad9798f53c0d668890915f08f1a43ada32cf1c4e6dbf2362d5b289eef0", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "f2d12c19-1282-42e1-aca0-9138a2d54c8a": {"doc_hash": "8ab6c4dad5f6efa5403d8c94a7147cc6e04190ec96802a4fc6d3e993a33bf5a9", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "eac03119-1d2d-44ec-a23a-5ce58e06b9f3": {"doc_hash": "882f55e15a562bbbe01f6a95974a5bd73a9ad9e8445684cd9d4e4de7fe292ecb", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "963e761f-2f04-486d-acf0-713e8cd142ec": {"doc_hash": "f9389fc0405ca84dac23f220efeb247153b3020650ecc9cdca1e7f2dd92895eb", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "c20c6b96-7fc7-4382-9f82-a70584f16443": {"doc_hash": "5107acac668859c65b4ae5685a7e66c05781f08f6de7e262a7b03f885ae359ec", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836": {"doc_hash": "1ffd6a6583f7b093b6eae63ffbdd00712901fead08e3590dda7d6e40c2bb86c1", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "b470c5d3-1f72-4baf-8c93-497c46a0ceb7": {"doc_hash": "574c5432bb5e966b201ab3e1e5cd1d6570a054414e29df1577cdc909fe121f98", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "4a1c08e5-cdbf-4731-936a-d977ed333d37": {"doc_hash": "98b7f2529eedd9122abb19566c867feb340ca8dcdcdb3d494252706dc62c48b9", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "ec004370-b16d-46f0-9fec-f30cca13ee85": {"doc_hash": "2bc5f912a9f852bb0baa36cde07b4ca6e2ef3a100b22c41c1b4493caa262cc6e", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "bd68a4cb-32fa-44b0-9853-cb01858d80e1": {"doc_hash": "4aa0fd062bae0e288b9c364d74306102d058ef4ef641e239aeb9411ca09088df", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "c5c8ac45-6747-4155-8df1-b55f7c1917aa": {"doc_hash": "9375c1b7680cb15c1cd72342e8abc2c1a9381b8f3dcc3f11deb05a5943e91cc5", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "b1ea3200-8e0a-440d-a1dd-f35de316e542": {"doc_hash": "995c73791a73b8a76d5de76d4ba787ca903e97f3bac62680f68242035ddad62f", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "64726c32-5fa6-4dff-90b0-4d6a5d10b022": {"doc_hash": "25c2ae0c1671ea23b71526269b42e0258c34cc787c08690669652098a33f086d", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "c17b148e-9795-43ac-8f9d-891064202b09": {"doc_hash": "4526c89218540fdd0bcc09ef8b0655c70179566eed277ddd76ab26a6fc061004", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c": {"doc_hash": "4e181188ae946592567fd9809092fac8146d387cd6941564e834119e73dd886a", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "17b2c6cb-5630-4f7a-8c07-94db71d1a60b": {"doc_hash": "676cbd43339377e59f87fa2fe3d9dcf973bb1d1c9672b23e7f41dc82afe8a7ea", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "3710b61d-d460-41c2-9feb-5f3250578315": {"doc_hash": "2f43154ac0665a58bdd33e789865de3c2e4ae961c3ea6df91aff0d5d9d4b4fc5", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "d4a8a010-db67-4ab4-a22f-2659d90f6709": {"doc_hash": "19b05e8c36b142d0804e03bcbdc3ac5508c0f3fa03ef73efa6c0435aa64e8474", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461": {"doc_hash": "096c1e22d910aed3f7cfb0f6c7361b01eb1979d94a5c412cd9ff028c411b0dab", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "89fd4b1b-37ee-4a01-8e4b-7078b259bac2": {"doc_hash": "b805e233bbf2859af96551ba690441806efdfbf969431cf801e26fdce460452f", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "17b8ff01-4f25-4c1e-ac70-4a8347c94808": {"doc_hash": "8eeaa5e6fc651ca811695fce36520706b1bfd428a368085a7804f865252d0f50", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "463e723d-979f-4492-a653-30862917733d": {"doc_hash": "80fe1c9f4162408ab1cc427c1b351acc3b93729fa38de5d3ea1c0b8f4591e909", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "2bbb2678-bcbd-4986-888b-4b63facc5a38": {"doc_hash": "68cc9f48058b00cee63d39cb8e16b8a6f37b4788990e197ef4a995448f9dbd3c", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "d02987d7-6595-424a-8b0c-af089b299a72": {"doc_hash": "209087e92cc6f85ecdaefd590ccfd95852b4d4b43aaba1129bb050d7b88ea7a0", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "10acac68-9ebd-4946-8fbb-b239fb017bec": {"doc_hash": "eb600666b02b868c18a1bc60dd6aa5d5fb3e6cfae1c30acafbaab9233d9b7d5d", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "417b0282-e9c1-41d4-8eb8-b59277ada195": {"doc_hash": "01dde3fefcd4c40758faf045c55ba6c27a57623bd90a94b8e682d4984587dc9f", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "77cc231b-a838-4c14-972b-13f01b61d215": {"doc_hash": "ceb8c2ba57052c9b6a06ac378e0213e495ea6d9a0dd16ea189f5b47c21780924", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "3e605679-50bb-49cd-b515-5e846d9daf9f": {"doc_hash": "9eb19cff1bea17db35ee9f80effb230b1e35d809430ed2981817f7b2a6055b6d", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "c693b4b5-65b0-4155-b989-b9ffbd08ca62": {"doc_hash": "6dcadcf1283adc8e14cb26a70c91e70c2adc8c508ecb74e20f7e7e8d9d9895c1", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "7eecd516-4bf7-40f5-b086-290251ee5fbb": {"doc_hash": "7da1032498890fa5d2303ade25601dd8b5d901d863e9d475b05d3c92adc183e2", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "ceddf902-b0c6-465e-864a-68e5ae8899c7": {"doc_hash": "2f6c2f31687d27525524d3b5b936237a951d2ad26db4d4dda9290f71bb27f258", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "796af208-a541-400c-8dc1-5f7a8882a58c": {"doc_hash": "d8c75b00fab5c9824b40c4692080e9f6161eaccc1b1fd0afa7c28abae266fb59", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "302bb800-967d-4f6e-84c6-1523e3c322ca": {"doc_hash": "e946034130dab43a3c28dc0da8aa65e779943a333a8cf4cd2d2ba6e04d7bd8f3", "ref_doc_id": "2b148336-aa3d-4525-b1a5-559d8290011d"}, "a335f30a-dcd9-4553-be79-7d27dd921369": {"doc_hash": "527da3829ee4a6b5cf26b07d1fcbf9d3b0fff9d1217910abea80610780ef43bf", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "56aa17c8-ad91-4064-b2fa-0869852c2de2": {"doc_hash": "4c6a837f894046f250d3e9d8030cb12d378819a997b508467afe62aecee5aec9", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "dabc8772-fe01-458e-853f-1a0944e11d42": {"doc_hash": "b7b783a99ec739080ca473a924a316abc51e53449a9120511270d9b7030fd7d2", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "1dfac7d1-db90-498e-ab09-55077cb5c996": {"doc_hash": "a5546b8b2f8ab16cf5cfe721a82e2b41f141a2090ca7b506c1ed38f506d056de", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "6e0e2503-49e2-490b-ba22-554cf445af37": {"doc_hash": "16ca2bd674eba6fec3a936349b5b4efe1a7c5636e28d76c97f1702dfd576fe5c", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "dfd2e8dd-4da4-4df2-8d60-8237537af393": {"doc_hash": "96913d210b5052bba015c27370cffca5cf7ad97b0e4a53bf3f0b73084585a4da", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "17825567-d484-4674-ae0b-eaae72281ee6": {"doc_hash": "0d665b22aa8ec39401b4850b604b86188db8df7199efa917d20841cb80b3f638", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "ccd30380-e208-4b2d-ab53-03cdbf99b801": {"doc_hash": "0065355c8885f7c1e3aa41423b84ed0ef3262d7a0ac5066d28ca7d70868e12bf", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "7d212ff4-1fed-40f8-973c-23b9786acee3": {"doc_hash": "7054d7f4e4c2ddb46420a6b7c5d0edb5c016cc765777b260031e4f37191ffc54", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "a0df0668-052e-4d40-8493-a875657f06ba": {"doc_hash": "7d6b7f18236f8d95173c287e485295f46513d0f949f5f5926dada9725213b7a6", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "6542ffcc-632e-4de6-b49a-f84d92b9246b": {"doc_hash": "83408b0965190fcfd06a8dd8f7d6d754913fb94f09c3a3df19a8671b395ce400", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "105aa91d-4bb2-4944-9609-6ef976b4f916": {"doc_hash": "c4f7eb838e196941e5aa6d871e9f7c75549796fe6cc2c43d88a2fb7f593ca149", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "81d7b4e2-97d8-4e42-9985-241b522fdf55": {"doc_hash": "695b6fc5609f484ee7523d750ff62ffe8d2b0d65ad824ce41727405fe9359a83", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "1a934b7f-ef33-41ea-86fa-cff72b2660eb": {"doc_hash": "378b7ae12d62c0164113d44541310c1e912e08c6b81a37b1f49e4f640e7eb065", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce": {"doc_hash": "525211d85c7c0ea1d63d7df9eeca5259fbcc9215e56ca42b9f79260a7f074b18", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "6c21301c-3bec-439c-b8bd-35dac86b02b5": {"doc_hash": "94dd2fba92650fc05d2cfebdf5e55d0498073e2d67205e3bd11bbd2ec8c32072", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "4a711d48-00d8-4501-93cc-30cc63f4b10d": {"doc_hash": "592bda30f38a9c81e43eb984fd24084179aafc82a95d1cb74ce4e3abdd8ee3b2", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "953000e0-7be3-4cdb-b328-f8686606e0e9": {"doc_hash": "2857696d437412341a229a91febe4131a20abfc155c10efadc520d785dec849f", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "f7d59b91-8fae-4522-af04-ed1e35d7a8a7": {"doc_hash": "2dbcb5b87cb3edb9dc00104569dc75f4b3dc564817c3e379b031b378fdce8dc1", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "8ed718e5-fc7a-4c03-884d-98194b2d37c4": {"doc_hash": "6f30d00b404c581367d11a1f16b55f87892f299d20ffdd451c52169964fcb16d", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "d4022c3e-4508-4e9e-9750-02694a816287": {"doc_hash": "5dcdb471f35727091ef0841d5dd342b502f7c257388e380a0195aee15b953327", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "24fffe79-4d26-48c5-bb83-217466b23488": {"doc_hash": "ad5b8a9ba79503e5c9597d7b7043dac8808e57c619a62a6bc432f7a7c41c97fb", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "a2290f6d-9c49-4d56-94ce-a468f6f5500c": {"doc_hash": "1465cc737bc3db158aade95bafaf86e2f2dc5d40e47af19e1ce5a1756cb58909", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d": {"doc_hash": "bc4fd5993a395ac2f60906533e9cb2d448e5f79d63e1c8fbb7b11379f88d7481", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "02089440-384b-4cc4-bd7a-041489614548": {"doc_hash": "117730365b6ad956067e16abb4afd82c3c424ca312068f20bfe5023181df012b", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "c4a8b08e-55bf-40a1-bd32-da5ef91f7749": {"doc_hash": "407695dc37fab70f55cf9a55bc96395dbb11c005134c68ae5f01ef3c2ecf39a6", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "ab33eec0-2e1b-4f01-91e1-d7210fbe699e": {"doc_hash": "a5320d07288fa00ba6cb1f5e6af1c8c8162185d93c84f29a35c8f35a0c7a0777", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "575ba165-6267-4738-8ecd-daaa28861121": {"doc_hash": "1c10bacc34bfd5d48f28d56602cca808cce548b362d26a3978a46e962e8e9444", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "fa65bfc0-afea-4251-8f1d-692ee15954b9": {"doc_hash": "3738e5fbf518dfd9e9349f434e8930a7c87309c5b3f7fd97d15a6407a31e8ab1", "ref_doc_id": "d5f55c8e-9070-4f52-8251-055d730c7a98"}, "15ec13b7-58eb-48d1-b5e7-31c3f8fe315e": {"doc_hash": "cb7c30085d16ed42bae30d49d5b8cf5fda6c578088c79c80f764821a5ef3be2d", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "c1a5b2be-102d-4f04-82d1-be16f90ebfe1": {"doc_hash": "35c0efac0231b74a8bc33b5dca8fea3cdd4b798aeda7ca6c0b5c575ace99bd5a", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "39915d77-5c5d-4673-946f-41759e83a2e5": {"doc_hash": "3c8027db17b4ef30151198ed694a859bbe4769f47f94a1a946ab922a7ac2c14f", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "a5825f85-8721-4dff-931e-18c7f4b88f38": {"doc_hash": "e49b4a0f9828c3ebe362125b0a4bc277c526a509c5823de81fdf447dbf128c80", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "018c8b9d-901f-4a17-b7bc-cd233c697e39": {"doc_hash": "3eee064290a39a8860902ee3d54ce2aca54ab05913c1be30d95cd5d173991eb9", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "2e13711f-e93a-486f-98f6-36d25132824d": {"doc_hash": "61211613195ebeb0a13fcc1373be70d4f6a600960c75e40712dd91a93b72c60d", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "fd86c9b8-96a8-43d4-89b7-1fba9409aac0": {"doc_hash": "7abe75e1302942185fe480e9e63c71210764d82a47fbdae8481e4ba4bdef7732", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "af9fcaab-0557-403e-b1f9-11a70cb51cc6": {"doc_hash": "aa82b6713fff05845401094b0ec172f6e1e03e37956ffa47358954398b251792", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "9b9a953b-c94f-4747-8882-6c0ebde6189f": {"doc_hash": "4d05d436eabdc243ac95e681beae885c1672a9df6011743edbc54e9e57821758", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b": {"doc_hash": "6de79a416a846768b2445916c695dbfdedfe15da2e2bc53fd5e70d08bb5d8a13", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "365aa5ef-007f-4204-92ab-1fbad94c9fc9": {"doc_hash": "b3caedb587125cca129438e604cd18c9fe639e0d86f5b7f847cb8d0212b35c8d", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "bf01832a-5c6e-4ed0-825c-1bfa80e70ded": {"doc_hash": "20ab869ddcdf2e6433c2a961c9907de675f65d4e3603884f158953a51072a476", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "ff832a80-b6a2-4941-83ed-dbdd5f0c226e": {"doc_hash": "4e7fefdcc241fb6371aa1e2eb54f1abb55a978f714c286832ece7107076b03d3", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}, "e2d9ba06-4e43-4c09-a63b-8c40726242b0": {"doc_hash": "65c5a3ba2bdf1ce0e993459b041fc0c8f607e33504c52fb30889de26c51f8357", "ref_doc_id": "01d9de39-90cd-4a6c-be0b-62af53fead90"}}, "docstore/ref_doc_info": {"dc7d7933-c282-4a34-8135-fd2e56d54c53": {"node_ids": ["ced60568-d2a5-47ca-be3f-4b1221fadfd8", "f93757a5-cf45-4801-a31c-6c6a9603263e"], "metadata": {"window": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.   (MCK ) \nQ3 2020 Earnings Call    ", "original_text": " Corrected Transcript  \n \n \n1-877-FACTSET   www.callstreet.com  Total Pages : 21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n04-Feb-2020  \nMcKesson Corp.  ", "page_label": "1", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "bc62fdef-a641-4781-a6ff-25b209fd307c": {"node_ids": ["6d32b0cd-7263-4886-815b-9fecfeda0165", "923e453d-a810-4637-b4b0-5fce72db64be", "f9120cb7-3882-4ab7-8fc5-54aedddaa045", "fb197f69-95e0-42ef-a5bb-06add7183c67", "51d8c595-1c3a-45b7-9a74-50807989b1e4", "262e0884-7237-4ab6-ab3e-8bd8f06bafb4", "b5a85869-f8a4-41dc-ae80-7f2bde26822b", "2fbc3b53-4af3-4936-b3d3-15a0d78ca29a", "36689c9b-7624-43fe-9171-e5144f273d62", "27d2efbe-ba82-41e2-8467-daccdeb2d41a", "2b29be67-ab79-4289-8b64-b7f6e000750c", "62ef3b72-cb05-40af-bd47-c95689bdc8cd", "08d73a73-9865-4386-a4cc-0bbaa3ea4ddb", "706f697d-3016-4076-abac-e26a188a943d", "6c4822d5-9562-40e8-9bc9-762928d2afc4", "cb9915d5-3b0a-44db-a83c-a64dcaf6b259", "e002c511-4c8f-43e9-bf9c-118b53b87606", "f854ef70-9f71-4308-a71e-77e18f4bd6a8", "035781c3-efd8-4b95-a686-b6d979acab16", "798a678e-58bf-4d8a-b752-3014afada9fc", "3a2ba373-1221-4a97-979e-477dbbaebb14", "76b48ce1-1c2e-4ee2-bd11-79ebd5196d73"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   2 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nCORPORATE PARTICIPANTS  \n \nHolly Weiss  \nSenior Vice President -Investor Relations, McKesson Corp.  \n Brian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   Britt J. Vitalone  \nExecutive Vice President & Chief Financial Officer, McKesson Corp.  \n ", "original_text": "McKesson Corp.  ", "page_label": "2", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7cfeef9a-733f-457b-bb40-0cd5749a74fd": {"node_ids": ["f3b99775-2eaf-4e55-a2d0-fd3ec0c43a03", "02407821-4d90-4305-a7b5-90cfa1748685", "228b8f36-c823-4e7e-bb7f-2ba39e83eb25", "8cfd1c52-3294-45ac-80f1-8c4095aaa6b1", "2c4389c4-7289-42db-9c6d-e685de368647", "748e5c38-70f5-45e6-abf5-3263fbf692ff", "2c60a684-2d8b-4608-9d82-85876988f958", "83f9e613-59fb-4149-9abb-ee3a32216087", "243247a7-e2f7-47d1-8fdf-f2115acfa41b", "dc10af32-8265-4675-a8e2-e41dda73bb0b", "cdecaa3a-46d1-4013-9c74-e2845a9fbe31", "41526f0b-7f0e-4b0a-aa0a-195840e8b3dc", "0a794559-ba39-44c5-88ad-a4457c07e397", "696be706-3282-4950-b48f-f6368125c874", "83390cc0-37aa-46dd-b5b3-9e4b40b0cdc8", "4b6db494-c3dd-4aa3-9a94-4b34518c8488", "70b3ef6c-15a7-4405-8808-9fad2534990c", "29b25ca0-82dc-4b88-9f0d-8111883f6457", "331eab10-1ea9-4dc8-9d58-0061c6d25d73", "60a24f84-17ea-4dc2-a16d-3be05e13eb1e", "f1c2916d-507e-4554-ba98-dc7dcb016a57", "e719689e-396d-415d-9be1-fce19a97e9df", "02e199f1-36ad-4514-bb1d-ff520df80464", "e6c50d46-a50b-4d90-a8f9-99617a1e18ce", "008275fb-510a-4b44-b171-84e5743a61b7", "ad9802a6-3ab2-46f6-9006-7c93859bf5db", "3f23f74c-6530-41af-a529-d0597cd58617", "7e684b7f-25ac-4b45-a3ef-056c631acff2", "542f369e-e3fd-46d3-80eb-a2abf9b51161", "23652aee-ac78-4dec-ba80-ab762845eba1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   3 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWith that, let me turn it over Brian.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.  \n Thank you, Holly, and good m orning and thank you everyone for joining us on our call this morning. ", "original_text": "McKesson Corp.  ", "page_label": "3", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "eecae3a1-1d59-46b7-9d6b-99ce0108278f": {"node_ids": ["6bd57c28-8f4d-47cf-bfac-d5048adba4c7", "77efcc44-c8ca-42f8-9ad1-7090756c6ef6", "b66986ce-51b3-4775-90f5-1a95ed787e93", "3ae8de4a-1e05-483f-95bb-6c29593911b6", "d1a6fb5f-1ce3-4848-968e-22e99bd657f4", "ad6187d8-da53-47fd-9fe4-8463549d97be", "7054372a-94a3-40e5-82e8-251c2412890e", "49d80812-3669-4ad0-b1d8-4fe739f4ec4c", "f542059b-79ff-41e3-b535-d4d7f791c092", "ba6f7c46-3502-4d82-abda-63e8c14237ac", "31e7144f-1e0e-4675-ba02-c120c3408fa3", "7f2187bc-6339-45e0-94a2-b57726c6f299", "2bb5d328-7485-4e1c-b2fd-a326b63a20d8", "1140797a-c9e4-42fc-a735-4e0498464078", "4e218340-1e20-4721-b0c0-bce878e0f156", "ffb07214-cd0f-4606-87fd-e69805e35360", "763edc00-db98-49eb-bbfb-4999a266ee1b", "7c31ecfd-5a1d-4ff3-8634-c4b522c6d678", "4f9b8020-9bf1-45c9-a6a9-dd476a19314d", "fe25c16b-d583-4ff0-a4f1-15cad4bfca5c", "3b963208-fcc3-49a9-8be8-63c04eecef1a", "584ffdc4-f3d6-471c-91bf-89610d0c9b48", "742e36d7-c88b-45e8-a5af-a7fb097aa325", "7f50aaf4-99f7-43fd-8ba5-0f02fcd7614e", "2129200a-dd3c-4518-9cf7-43cd34153a0e", "70048add-722e-4e15-91af-02a11d9ecc5b", "53cf669f-ea88-4cbd-9282-a147573eb31a", "c0bf7d42-0ce7-4f2a-9fc8-918dd0483cc8"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   4 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \nMoving to specialty, as you've heard me discuss at several recent events, we have a differentiated portfolio of \nassets and capabilities that we've built over time with targeted internal and external investments.  First, we \ndistribute specialty pha rmaceuticals via the traditional wholesale model to retail and hospital pharmacies.  And \nalthough these products are margin rate -dilutive, we benefit from this growth at the top line and in our gross profit \ndollars. ", "original_text": "McKesson Corp.  ", "page_label": "4", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "7d45e6fa-623a-43b4-b301-8638ca68be6f": {"node_ids": ["c5bacfb9-bac0-4f46-a923-aa1e2c545285", "3f5215c0-e86a-47cc-ab0f-2c8c00dde90d", "deec39da-6b9d-4338-8ebb-08c53cce1d18", "81350765-839b-46f5-accb-09041989406d", "65f90d57-842d-4905-b505-5b42c157c1a4", "da0b5b6b-dce5-4e2a-aa3a-bb2313186ac2", "68071114-212c-496d-9e3c-75b6dd60415c", "a2202fa4-6b31-4620-b8b2-c652416d649b", "234487e3-a96b-459e-b2a7-fd9dfb6777a2", "98c65698-b495-4bdb-918e-3501f0f578a2", "dbaefb05-0d4e-48a5-ad94-040d32fe6deb", "0cfa0fdb-815f-467f-ba36-985ab967adff", "c3e4a3c8-fe77-4ce9-9b8c-05325d96f2fc", "cb392381-f1b0-460e-9b77-13a2531b340c", "0aa7d1e6-49b8-48c4-a691-a1867fe1c93e", "305f67c4-1b99-49ee-ad08-2b9662b84708", "0e704bf9-a3c8-4bed-8596-147902a3a3da", "a9d5ef85-b95c-4972-8eff-95abcead9391", "2e40d0dc-95b0-46af-9ece-f077e336ea9c", "81b3e48c-3874-4c42-9190-364f41de138a", "71f3a476-c1e2-4ebd-9b7c-8717617ce58a", "8169dcbe-8654-455e-8104-f264f556246c", "d4ee66e3-878b-4463-9e1a-4d1b264efa10", "82a98709-ca1b-4549-987d-034bb2aa9612", "71639d0d-cf0c-4866-8706-e8cf235c5088", "06de48ab-2f8c-4aaa-bbda-3a9839fc78e1", "ef18e2c7-5ff6-41ec-b7bf-2153cb54508a", "9b4d9d93-003c-478d-b8b6-5699701eb202"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   5 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \non operational excellence, breadth of product and service offerings, al ong with one of the largest and most \ntenured sales forces in the industry.  \n \n We also saw an early start to the influenza season in the third quarter, which we are continuing to monitor for \nseverity and duration.  In addition, our results continue to reflect the integration of the MSD acquisition, which we \nlapped during our first quarter, and our focus is now on driving synergies. ", "original_text": "McKesson Corp.  ", "page_label": "5", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "c80a7a4c-439a-406d-9f68-1a3320ac7571": {"node_ids": ["31827d05-8548-47d2-9c4d-411d21bc7437", "7d8ce46b-4137-46a3-9f18-78062de9f2f7", "ef5864e4-acf9-4b69-adbe-5a81e0074089", "a184a5e3-bd4c-4a7c-a7a6-fbc2df901b27", "0a8fff23-b45d-4479-ba01-634e3dcc48ba", "0722793a-e822-4153-a05d-eccd1bf3aacb", "88decd3d-1571-49be-8955-775df235c366", "27ad5bcd-7e15-4e0b-94b7-2b460620c925", "a4e63d6d-5d38-4727-868b-7d54ac2451ed", "cc917a1d-06f4-4ce8-9729-0ddcd732cc67", "7b2c7871-23b9-49d6-b007-6b2cbffebf28", "e645370d-57c0-4b17-92f1-c97c670702ac", "ade375ed-dd0a-4c4c-9b2f-4f82ebe40795", "9c237bac-9d57-447c-95a4-b924cb38a7a2", "803e407c-a537-4a02-8984-818582401345", "d90783a4-2239-4204-bbb1-97b40ea127fe", "51a99653-5987-4818-9013-0bf2c25b2bb1", "25703993-bd47-494d-82d4-f47449d7793a", "eeebc3c9-dba1-4183-9ef3-794674d6a634", "0169da04-2a54-47ea-b21b-7acd8d043e45", "b2c9ce5e-04c7-4631-83cd-41db2588a702", "26e70c60-1324-4469-ac59-aad6c272e2a6", "a7adf702-eb63-4162-ab44-2dc75a9a712b", "d02741a3-f166-4baa-88ad-9c8e26d08a39", "f7558abc-1155-4cfe-8a4c-d9462e662890", "261849e4-9834-41fa-aedc-9ef218aec488", "d21c5de9-e4f5-423d-a036-a6215ded0f93"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   6 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nactivities are currently underway.  For customer renewals, the VA contract goes into effect in August 2020.  As a \nreminder, we have stated that this new contract will not be a material headwind to our fiscal 2021 outlook.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "6", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "652ed7e9-96f4-4fc4-ad75-f781e9f788a5": {"node_ids": ["fed49091-f9c9-4402-a6a0-1aa3c77ea148", "9e7e2961-35f0-4112-9907-24d2868e0b67", "146a4d98-1b29-490e-86e1-6b54daf7d794", "15da271b-f3f8-4977-a6f7-63c2dbbf39e8", "ebc35d8a-ad7a-4935-a759-e935fe5f77d5", "d13db75a-1b90-4e25-aed0-98b5b2b7edb2", "2ce29e6c-b1ff-4048-b542-d066e38c7e46", "262db2b9-669e-41a4-bd73-14b20acf6ace", "88219d88-297d-4e7d-b83e-9bb58de6a840", "12e880c1-1a1e-485d-b4a9-fa6f996dcdf4", "285fe989-ff80-4c02-be38-8d52aedcdfd3", "3fe6c840-ca56-4097-8a0f-b7742c5e8fe7", "f6d163ee-f1e9-4d51-b1ad-4c3305c39b73", "7b5d822d-ec2e-4957-a3b0-0cb2a00607ab", "f26ada04-55ae-4cf2-a974-a768f2571fc2", "8d9adfe9-0f15-46dc-a218-c2bad5c75c56", "6a5f543e-c180-47ce-a1f0-554f4a3b0efe", "4784347e-3fc7-4f56-9af7-3fab3b0e89d8", "74c9eaa1-92ad-4206-80cf-14d3feecc874", "cd7000f0-45b1-4a79-808e-5760f3ba9215", "9f74eac9-b3ba-4681-822f-0b9b05bd97c4", "b7fa1d4d-8386-44b4-ac62-fb46d28535c0", "8841a76e-f12e-4148-b683-d4b7c71fb55b", "c19f507b-e1a0-4b94-9a7a-0bec1e015a8c", "bbd23663-091e-427d-b616-55b6c3954660", "b054ac7e-38a7-472b-906d-942fbea0a541"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   7 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nDuring the third quarter, we recorded a pre - and post -tax charge of $282 million for the remeasurement to fair \nvalue of the net assets from th e majority of McKesson's German wholesale business, in relation to the expected \nformation of a new German wholesale joint venture with Walgreens Boots Alliance.  \n \n Moving now to the adjusted earnings results for the quarter.  Our third quarter adjusted EPS wa s $3.81, an \nincrease of 12% compared to the prior year, which was primarily driven by organic growth in the US \nPharmaceutical and Specialty Solutions segment, the Medical -Surgical segment, and the European segment.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "7", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "f643f16a-f46d-4fa4-b28f-9208162c8a0d": {"node_ids": ["abe55df2-31dd-474a-871b-014bd3b446c5", "2d17a13d-06af-428c-917d-542df32a09f3", "abd3c817-cd11-4154-9dea-bc56a443a7cf", "6af6aafe-198d-4f15-99b5-fdbc1c36bd0d", "d206c2fd-23b1-42d9-80bc-53497d0abb16", "13b90f3c-8ba8-4ce5-8ecc-bb9de2ec4b2b", "c203dd97-1246-4dce-91ed-59bd95ee1019", "24b85c5c-3c6c-4ccf-a403-44de862098b8", "8a490ddf-a10b-4641-8938-cb01dd03f681", "9ffa0adb-082b-4f7f-a303-f26093681c93", "8a3001e4-b94d-4ad1-bbdd-16b73d496938", "59c62317-c987-4bc9-9ae3-6b9ba97e3c32", "ae130a12-56f9-47da-8843-69fc5dbd0806", "23441e52-44e0-4aca-99b6-87554cff3158", "ba450eef-f988-4aa4-8d90-b9506732f14e", "b5befd3e-7a70-43a8-8128-49fcaa30ce8f", "79e5a024-aed3-46c9-880b-3d8ba57e8899", "07861af3-e06f-499b-ad23-90c6ebf76ccf", "fed4b902-dad5-4b46-b4b6-0be887d6cfb6", "22c18147-d05e-4f80-9bd2-ce8db5f5232a", "f077a5c1-6597-4231-9a83-69e4c536d82f", "734f93e5-2f04-4f4a-8ff0-187c3e81cb49", "30aaeac0-3197-4a4c-8989-bf472c5572a1"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   8 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nLet me now start with US Pharmaceutical and Specialty Soluti ons.  Revenues were $46.9 billion for the quarter, up \n6%, driven by branded pharmaceutical price increases and continued growth by our largest retail national \ncustomers, partially offset by branded to generic conversions.  Third quarter adjusted operating pr ofit increased \n11% to $658 million, primarily driven by the execution and growth in our differentiated portfolio of specialty \nbusinesses.  \n \n", "original_text": "McKesson Corp.  ", "page_label": "8", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ede72898-bed3-47bf-9e1d-565fb8f929bd": {"node_ids": ["d3e8cb79-2467-4ca6-bb0d-2f4e5ccff8d4", "8940e8fc-f6a4-436b-a1a6-344cbc4ece08", "82e3c79a-0bec-4fe6-860b-0a92ee7db7f5", "cbd27432-9a88-4783-bc73-1d4a6ae9b7b9", "6f9a9f31-2159-43b0-8f1f-8f44a201b1cf", "4923a773-07b5-44fc-96f6-6d5861b4d140", "a88e6803-8cae-4f38-8e4e-9b962c2795bc", "a6ef4340-2a0d-411f-a2a9-7017b879bd8d", "39636ac3-7925-44f8-807e-7f2de9afd743", "764eaee9-cfce-4812-a32a-b6047b1d44b5", "76d53e28-9073-467c-a16e-0eb65ab094c6", "7a76f092-c9f2-41ee-a4b1-565e80fba1c3", "828c5cf3-e433-4bd5-ada4-b10f4ae36638", "cea507c0-1ea3-44bb-bc7a-d262d9bfabdc", "e814365a-cf87-4e62-bdf2-27a6b001000e", "1d21b476-e84d-40c7-8e07-bc1df6b4db26", "5015f498-7bdb-4b2f-895b-1eb560254d89", "3670b3b9-5590-4458-8a60-5c4279bbcedd", "0c87db11-0056-4b82-804b-16f244e990f2", "5ac47a27-70e3-420f-a760-184773eb0d82", "3a1e6b18-9cb3-400c-8130-0237b470afd6", "00b59d9d-f02e-4d40-b6f3-20e7e2d8979d", "71195d66-4360-4c68-aa2f-9d248705a566", "d0e396e3-e950-4a93-b5a2-ca91df50c827", "045ece9a-a56f-42ac-a275-9fbb02aa6a32"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   9 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nI'm finishing our business review with Other, revenues were $3.2 billion for the quarter, which was up 6%, driven \nprimarily by organic growth in the Canadian wholesale business.  Other adjusted operating profit was down 4% to \n$214 million, in part driven by higher strategic product investments i n our Prescription Technology Solutions \nBusiness, or MRxTS, partially offset by growth in our Canadian wholesale business.  \n \n Closing our segment review with Change Healthcare, adjusted equity income from Change Healthcare was $51 \nmillion for the quarter. ", "original_text": "McKesson Corp.  ", "page_label": "9", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "188b07de-641e-48cd-89a4-dbbcdd0961e9": {"node_ids": ["f6220d97-f3e3-4476-a7b8-4168008e3bcd", "f759ef81-8c94-4bb9-bae6-50dd8480a3de", "cea36626-5b03-4fc4-92f4-8e10213d70f4", "ed9e29ee-e3f2-494e-9119-1b524a033d72", "f7db2c06-bbd8-43da-8338-c58a96b2f424", "eb13e694-e17c-417a-b15e-2872476b874b", "4b382532-e5b4-4adf-8597-1492976992ff", "dd8fe1f0-c710-49c7-9c95-23e51415f0e9", "38ed3ea8-fde9-4ce3-bd18-6a83c29e3df5", "cbb765e7-db50-41c2-bf2f-08e43ffa6bc8", "71b4b3f9-74fe-4873-ad8a-fa426117bc13", "e800dc3c-88b9-4eeb-813d-387467f9c46d", "e50ab97e-e560-4f56-abfb-30b67e8327db", "b0878bc9-cd3b-48db-b3e8-0939bacccb8e", "7c72e871-2ca3-4588-a274-4678ef501f58", "d354dd42-7bea-4cf7-8a21-f9e80013c92e", "7e44c3f3-b322-4f4b-888f-808343121ff6", "c20565ee-21f9-45a1-9b2d-297fbd4bad17", "adf04b0b-b217-411c-86b2-a5d8a8d2e9cc", "eff013ec-06b2-4fca-a201-14f02990da77", "b5c7e6c3-1f77-4346-a3fb-b983e5073497", "11c9deb7-f056-4afe-8b89-35e5b4862260", "f6615aaf-dd52-4efa-b8c3-784181d6ccd7", "c4623f08-6ccc-490d-9b2d-cb49a01d139f", "c1d1d4df-101a-4f2a-8b92-fa6dccd496ab", "3ce55e8e-199e-47b3-a008-4610ffa6ab86", "28334526-9b98-4d91-a66b-80c6e07359e2", "7c880145-9e52-419a-9139-66fefcc0d15c", "1858fe23-6034-4043-ab60-068fd05d6c88", "27be2fe9-5ada-405d-b99c-4ae10007b93a"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   10 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nduring our fiscal third quarter, primarily driven by the build in inventory for the holiday season.  In our fiscal fourth \nquarter, we typically generate more than two -thirds of our annual operating cash flow.  \n \n During the quarter, we repurchased approximately $500 million of common stock. ", "original_text": "McKesson Corp.  ", "page_label": "10", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "862e1938-6d97-499c-a474-4304eea1cef2": {"node_ids": ["18b4c702-a1e2-45a3-8047-8c242fc171d1", "537bdb29-b92b-4d05-914a-8b9ef412f126", "7fd79b9a-3f3d-4f67-b5b6-cbbd2fc10686", "af21af63-0494-4425-be67-03432ec7c351", "f8f39e64-a79d-4986-8119-54e1156a76a6", "03c3c982-71cb-420d-a14e-d1f4b723043e", "1f117cd3-3831-445d-aa35-d4b0edfcdef0", "d5ce6c7b-89ce-400f-8870-98e2cf2ba4a2", "cce68de8-ac56-4c1f-af77-18b299828f30", "77b8acc7-283c-440c-8ab9-39d19d5967f4", "8eb593bd-5d0d-4d1f-9ba5-1828ad22c17e", "fed0063b-ae8f-465a-86ef-545deb87d65c", "163236cb-8b96-4d61-bd98-c364657b9a7b", "2446827d-558e-4a39-b145-6a7bd19c14a9", "c078654e-2641-40b1-8adb-fa65feee04d5", "f5078eb6-d92e-435f-a75e-70a46b603376", "8ca75a93-d5d2-4b5d-802e-eb80a99969b0", "02f7c31a-3509-41fb-a373-fda5b877168a", "7efa958a-edbd-44fa-99bf-0b42967e63b3", "1f415be2-3d32-4ea1-b7c4-e29ec731165e", "99d2a2f0-4d67-4587-b613-5aa51618f675", "83a961b4-3435-4ab0-ac95-ce45659d8caf", "a8729388-e619-4179-9330-da803fbb1d99", "39078449-47ba-4c56-a200-5ff5e4d32a8a", "00e86d7c-34b5-4d27-a9e9-70c9e1eaa185", "9923d52f-db5c-475f-ae09-963bfd2a19fd", "d9209479-341c-4ff1-b4c0-bfdc1ea4535f", "f2950c40-7674-4dac-a891-b818b6478063", "97925442-ced9-486b-9c80-57513b05a298", "2d400cda-3f48-4a68-b4fd-1e275f0458aa", "7f35fecc-6026-4e14-927e-552f63cc571c", "289032ac-87d0-45cd-9c2e-eaf501e9ddc7", "f494131a-7a83-40d5-8bef-abe375896952", "74e85b4a-33a9-4af6-b5bf-b86a48de7317", "06f36781-0bdc-4cbe-8017-a8cb2029b4c2", "32eb1574-1dff-414c-86b1-fb61ed653fb9", "0ba4dd2d-df84-4629-add6-e95b616d9f59", "78c9c329-453a-42e3-b8c0-cd69f6d62904", "b671f24d-7b15-4e16-b183-927693eeaeac"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   11 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nThank you for the question, Charles.  And I think the way you framed the question naming the number of parties or \ncounterparties or folks involved in this discussion helps to frame why it's moving at the cadence that it's moving.  \n We do continue to be in constructive dialogue with the AGs. ", "original_text": "McKesson Corp.  ", "page_label": "11", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "292fb6eb-bd09-48a6-b8d6-2dbd0d2b36e5": {"node_ids": ["aa171cf7-4e46-42e4-9107-b8063abf23ab", "85ef0847-1a5b-4831-80f7-c2015b67981d", "d3c2969c-d078-441f-9c55-e7d3286e6d36", "922d802d-8aa3-48bb-a5d6-16ff463a85c3", "1373e821-346f-4a68-bfa4-41de03aa617e", "499232bb-750f-4665-ae12-288b1d7e460a", "27bf8026-d1a0-4afc-9a31-df8fdef6c0da", "9cd7ac18-fcee-4c12-a54a-8ce656dd862f", "e86e9163-3963-4433-8b75-6f7bd51baaee", "3fccc0f2-aa0a-486d-9a65-69717afbb848", "068f0440-4b4d-48d1-9e1a-3bb7e9b1f77a", "94912769-d28e-441e-b7d7-6e5a3a8394b0", "4e8c14d1-26b3-4cd9-8698-5154f9b40f4c", "f82211b0-2418-4ac1-b01a-3ed1a461f53f", "4f497cb3-0e38-4927-91fd-cbf12895fc6b", "d1e9a38f-eea1-4249-9bcf-6981c4626c8a", "107909fc-5832-44f2-b39f-7728d5a68e1a", "a7fecc35-5d82-4c4e-b837-984620879911", "5010fac3-d5f2-4013-bde0-74fe0920d4ed", "05aa294a-8a18-4dc1-9a66-8d5987a77a0d", "4f40c597-ddcb-44b1-81cd-acda1f2d0f94", "68f7f8e2-d8fc-4c8d-923d-2de016a587da", "d464d2b3-948d-4970-a50d-724ee1a3ed6e", "44913343-8779-4965-88a8-71f2e1707003", "b8f8a27d-6745-4851-8fac-3ddbebdffee1", "b0add6ae-83e7-449e-ba71-e654147038a9", "4bcef189-1bb0-4506-bdd0-8432d9f1a482", "8ac9e391-2315-49e5-9592-584dd2c5fb4b", "eb1d164c-db36-4cc0-816e-b07427fd084b", "874c26e4-625d-4d8d-a216-09df3a2216e9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   12 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nThank you, Charles.  \n  ................................ ................................ ................................ ................................ ................................ ................................ ................................ ................................ .....  \n \nOperator : And next will be Brian Tanquilut with Jefferies.  \n ", "original_text": "McKesson Corp.  ", "page_label": "12", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1fc3f368-fd8b-4c5d-b471-1f27e0ffa081": {"node_ids": ["792ca380-fac8-4716-8adb-07aeed6db45b", "e879e79a-a400-40a2-8aac-ac8e73bc997b", "49922953-162a-4795-a15d-865f00f77376", "45278803-e4cd-491e-ab46-959f51f61b28", "58516f36-faa6-4750-81c2-f57c31d94fff", "a3ab2d56-4035-4651-9165-974b3f814100", "0e98a3db-95fb-4953-9199-cef8992d8752", "0a6f4187-74eb-4afc-81cf-76df14289826", "26024142-e50f-4c63-b6bd-995b1ea6331f", "6ac0a699-efa8-4b1f-820a-806b4782f617", "34ed8821-0310-45d0-bbc6-06c10c5e66a5", "2bac0d47-5370-4620-83f1-6eae30386112", "b2254ffd-77bf-4e43-88c2-852851710bae", "13347dab-1b85-4a19-9e05-3240219d7d93", "79e9fea0-d404-41d3-be82-d75f90dc827e", "b9ada613-ec47-40d3-bd47-cbab7de5e9b8", "db297077-ff8c-4e6c-aad4-a251a24eb7e1", "b6314490-afce-4db1-b48c-04dd9e0cbc73", "6c6c6d19-b984-449b-97ca-708c0b314d16", "5b2c883a-d71c-46b3-b559-5d1685555bc8", "5d0aad36-bb68-40da-a6c2-6ad9d7acf3c7", "efd44c8b-c9fe-452b-9956-97010041a70f", "5459581d-a3fd-43db-86af-41647cdbc619", "20487140-c2cb-4059-951f-913739aa3b29", "a9cb4ac4-e79c-461b-bdba-94605ed127ae", "9ae85804-eee6-40e1-a6b7-1b2799663b2a", "8e7e0d48-6f9f-4b37-b1b3-e8a788c3f370", "0f9140c8-a73d-4fd5-aa31-ac465b0a8b4b", "b094c53a-4119-4ab1-9ba1-2a387ee5ab34"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   13 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthere's still opportunities there as the size of our enterprise allows us to continue to work across and collaborate \nand drive additional cost synergies.  \n \n So, I would say that that program as we talked about is \u2013 we expect it to be substantially complete by the end of \nfiscal 2021.  However, as the business grows and our focus and execution in specialty continues, there's still \nopportunities for us to leverage our s cale and transform our back office functions.  \n ", "original_text": "McKesson Corp.  ", "page_label": "13", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "1510173a-ecd3-4f24-a812-98c86bfd459d": {"node_ids": ["5cc71b01-8152-46c1-8059-6c7286116457", "a6252d7e-8400-4ad8-a2f9-434d874a3690", "b70896e7-41a7-430d-8080-656fba9fe054", "09e31f35-9dc2-46d1-94f1-c4ac4bd0cbc3", "f4f46f62-e0b3-45c5-a935-c0f9b9215425", "3f7f3e88-9cdc-468b-b78a-82a1ccfa0e82", "5fc36a86-b882-4631-862d-dfa8902ed3c9", "34f97fbf-f68a-408c-98ba-b74777ac6ff0", "ebb56970-5e9d-4909-853c-ee869950ddc7", "f77af948-1c36-4058-9e44-4ab030be7c85", "61856695-56ae-4a29-95a6-c24d78c4bc5d", "1665c421-687e-4e9f-ae44-bdacf3a97309", "771d07bc-d309-429c-8593-c19b8fb9b6d9", "0dab892d-7109-4230-9c17-0c10c9741a63", "408c5946-b07f-4dc1-ab1d-091b980ccae3", "f2b12a39-2531-4280-a052-ef2cbf03f5cd", "2c6a5ea8-7184-4e1d-b6e0-1ac248050c28", "76390cb2-dff3-4644-844a-d66ae0f0af25", "3aeabfd8-8de9-4a7a-a6ba-2a86770b241b", "a4bdda53-0c58-48fe-b0cd-3dceff97d1eb", "2b3f9cdd-fc7e-44ad-9bb0-bb2415151be4", "b15f0657-6496-4da3-bb26-c40112607f4e", "6e7d4e2c-ae28-4ede-9196-bad98da61ea1", "3b22e94d-282e-49d3-8fd8-104eef50c869", "0854f6a0-7380-466c-b21b-2d0af6a98d02", "969a6c96-3f6e-4c93-902a-e1dcb3280f8c", "be36b1fc-d932-4d9b-94df-17d1c03c8ce2", "408f8421-d2a8-4c92-8fc6-7b0d58426bce", "f9b879a1-1355-4ee7-8e1d-3b47d4bf8072", "1d3ccebc-799b-4161-babb-5cc5ae1495ea", "f5a23d90-54c2-42e3-9426-fc925b55f5c4", "16713678-05f7-423a-8ad6-41f6f6eef755", "e2db397e-89e1-47b0-bc8f-367a234ac7d3", "c98f13a0-cc75-442e-aae2-4796c737f963", "b2b16850-e11a-483e-982d-d0978fda0d16", "247277fe-b7a1-46a5-a492-10019692e4e7"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   14 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nWe don't manage our business that wa y. We manage our business for the long haul.  We look at our business on \nan annual basis.  And these items do tend to balance out over the course of the year. ", "original_text": "McKesson Corp.  ", "page_label": "14", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "54883497-6044-4c3b-acfe-65b40ed873b0": {"node_ids": ["907e31c8-16e1-40c8-8d43-44b78d08cc6e", "952a12b9-d6a3-459f-a711-fff5da9100fb", "c6a321ed-635f-4133-a19c-ddae2dfb619a", "939dac22-ec6d-4927-907d-79b03d4417a5", "54b748c3-9afe-44c4-b36a-895d4706cd48", "80e05c75-a236-497e-aba1-40e5a2fcfe18", "4360a740-2efe-41b7-9ec4-c161b1679329", "dc9b3723-83af-49be-a3b2-f35dd84c6e99", "8e5d658b-613b-4c87-9d08-57014b8fed89", "f4ce8af9-7674-4627-bda8-41476dfbccda", "272f8d13-d546-47ff-91ae-f8e32bd30c21", "9a51d6c7-5b32-4525-a603-717d087ef74f", "095f701d-43b5-41a0-a7cf-0b3820847784", "de8cb963-2d9f-41e4-b107-efb4eba786fc", "49ca42ad-a794-4dd3-97dc-121a9b5f7759", "20aedfba-e4f3-461e-8c2d-01f29c937f20", "8d5fa321-8486-4ee5-ae15-27c389cd3f2c", "e2750933-3b35-4ddd-b2bb-78ef873bc3d6", "9cdf51d2-52da-41ad-9b01-c50517ab756a", "734f614f-8a29-444d-a1e7-db6685942582", "54a00d97-5371-45da-9a93-8d4672989ff2", "83616195-07fa-4d80-a055-b3630e254146", "a5c9defa-9c96-40ea-93b0-873b7110161c", "a49bb762-dea7-4c5a-9786-f64a4e78b160", "f9c6bdb0-4564-4d67-afb8-92eada705ef6", "182a9263-3bfb-49b3-8663-90101c1ab82a", "402b7bd3-ca18-40a1-9ba2-4bb77eaa4d6e", "cf145a13-5a2b-4eaf-bd4d-8ae0d3f9e043", "cba041a7-4dee-4ec0-87a1-ef2926f1e6e7", "2951060d-c620-49d7-b071-8b8476c321db", "cbfa4b3e-8403-415a-b330-4b06cdb94ce0", "92f79018-f9f5-454c-91a1-416ee0bd0b1d", "f73af628-dae8-4670-9c7e-49cd41e3bf6f"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   15 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Dire ctor, McKesson Corp.   A \nGreat.  Thanks, Lisa. ", "original_text": "McKesson Corp.  ", "page_label": "15", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "9499270a-7af5-4ef0-8315-eb13e53c8613": {"node_ids": ["8c108cd7-5abe-417a-b5eb-016b7d970dee", "a485c554-5068-4b1c-84ad-817b4bed427a", "7a311813-98ab-4f0c-9b35-2c1c688c27f1", "efeaf1f5-74de-4520-8234-28f9d7cd49e4", "23dbebbc-4660-4a2f-a1d7-c10bd9655886", "786a24d8-c50e-46d6-a170-b66c35d140d4", "9a9fd165-cbc6-4193-ae9f-8bbfc7bc2db7", "351ee781-ca26-4489-bfde-20b17498e0a0", "422df89b-387f-4762-a910-57742912377a", "f55171c1-f3b0-4fed-ba42-89abf5fb1894", "baae808c-8101-4048-a1e8-5d31a7ef81c6", "64f1bd92-82d3-4ad5-8f8c-351ffa0a026e", "65649958-a5f5-421b-aecb-3718a7449643", "0f13e637-ba92-4137-91e4-bf15d767c1a2", "740a091f-0af6-44d8-89f3-3cc0218a23eb", "0a5f2b96-8e81-4dd9-b042-72693d92cb33", "f6ae4223-fe77-4935-a8a9-d886c9f7fdb2", "820f29c9-3a64-41ce-8167-f432cf1c1b14", "e5b59432-992f-46f4-8ac5-a8d2bd3b98e7", "44dd30c8-01e7-4e51-ab37-755406c559f9", "2683f5a8-45d5-42b3-8935-dba1703e09d2", "8399d6e8-70ec-447e-a913-d4e6471cf0b4", "ce8e41f7-7f6f-4552-94a8-6eaf9ecb7e32", "9674d575-81ec-4c10-91ca-ac6c22dc28fd", "a2c7c26d-dc90-4889-b798-d43c91625aec", "f0b05edd-597e-4c29-aa5b-c6a65bdb998d", "76fe6634-dc0a-460c-9b1f-608708e03334", "7b5e8d83-69b2-4c0c-9a55-c4c591fad06d", "2a22c804-5ca6-4257-b516-32f7fbc1ee47", "e18924fb-964f-4f23-9182-0a65f26fda23", "b928815e-38c2-40d4-b637-d35d45b8dd96", "83f03ffb-e6eb-42b4-9b4f-05c7c7d79539", "9b904e35-7106-41ed-b0b7-53596872ea2a", "f268ceb1-f566-4a1c-ac0f-8955cded8732", "a4e9e66a-6c71-48ed-9788-0129f1c4971d", "c6d3ef4e-7745-421f-ab09-a30e19763ff9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   16 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nsome timing of investments.  By our calculation , it's about $0.18 to the EPS.  So, as we think about the ongoing \nbenefit of cost cutting, can we just kind of like run rate that $45 million that you say in the fourth quarter?  \n ", "original_text": "McKesson Corp.  ", "page_label": "16", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "fcf436d0-8977-4423-ae40-830e59ee55f9": {"node_ids": ["2bccc890-e091-4c5c-85ba-cc6aa9e42c46", "ae91e9a6-edd5-4026-9c46-e87d9f9ce009", "e423da95-2d38-4c85-9d9a-57d83eb9da49", "300084a9-a3a3-49be-a286-f6f217452209", "15b9f8ad-7743-4f7c-a523-5bfcaccaaa27", "ee24867b-d2fe-4b67-9910-de21e313856e", "827243a2-24a1-456c-844d-5d77a9c6fc57", "2c907959-a6f8-41fd-908f-dd317b67cee1", "28031336-03e8-4383-b7f9-d57dea2dca1a", "483ebc3f-2308-49f4-ae35-4d2d920046f0", "205bd97f-70d9-4232-8045-c5a76c9567e1", "4faa18bd-3f04-44a4-8098-07ddb6027989", "31bce02a-3ab3-4d63-b1db-ab6cc1ff180b", "ce8e4918-6270-407c-adbc-64eeb85cbf09", "91aa5270-01b7-47e7-abb5-236784f64b14", "47ed7284-e789-4604-86da-8d451f156ba0", "7414504b-5b5b-4c96-9e79-b4699a329725", "b61262ce-0946-454d-ba59-4f10361658ce", "c090daf5-9e66-4135-8049-289a618afcaa", "7f2084a2-ca63-4ad2-9562-40beb9a066ab", "75ade40f-fa78-4f99-8481-b05fbe3e5e53", "ade6fe83-d661-407b-9ace-f453f2446e4d", "8ac38b28-df2c-4578-8a83-d29a7a78dfa2", "b9085612-c533-4769-8e79-47f2b61ab6ac", "449be7d3-d35b-4a8c-81fa-378c63ba4bbf", "68910868-73d1-40cf-93f4-424a9728366c", "5d4997ed-9cfa-4c80-a34f-089b163d2be1", "23cce213-dfba-4fbe-8dfc-5cf3ce4a97d9", "fd50eb44-4c33-42fc-9b59-0cc0a4155396", "bc3e2cda-5265-40fb-b865-0aad14f9b2a5", "4ea59e98-cdbe-4689-b35d-d7ef2ad25543", "bef86e86-f9f1-44c0-ab70-81d4dc2918b6", "99be23b1-4127-4716-a184-c7fbe88e5451", "c42a9c67-4b85-430a-ade9-a3ba0dc6ca9d", "8bf1f6e3-ca93-47b6-b262-82964cff6117"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   17 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nacquisition, a set of capabilities that are really oriented around helping manufacturers identify which patients are \nappropriate and should be benefiting from their therapy, finding those patients and getting them started on that \ntherapy, and then ensuring that they stay on that therapy thr ough the full clinically appropriate course so that they \ncan get the best possible outcome.  \n \n So, the first good news in that is that the patient gets the best outcome.  We think it's good for the patient and it's \ngood for the healthcare system. ", "original_text": "McKesson Corp.  ", "page_label": "17", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "ac6a51b6-9c3e-4d62-8ef5-f6e001f035b3": {"node_ids": ["0adf2d6a-1ae7-4f61-9afb-0561964d0904", "ef46d05a-b76d-406d-8d4e-13132fcf369f", "829cbd28-7cd6-434b-80a5-f2cd7e4d7081", "a50a9f7c-a97b-4813-8ee2-25be289b79b5", "808608fc-c58a-4a5a-b4e8-5df612cabce9", "9ca020e3-3e05-4ad3-995c-b9005596c153", "33e25f73-7b51-4f7b-ac43-caca18302646", "e421efaa-a891-404c-93d2-b6c021e4add9", "16827b63-223d-44de-97cd-99a85916ba23", "fd6413ce-d32c-4bfc-8116-0578fe028981", "c49858b4-3039-4e31-a22e-0083516ba4f9", "da691378-ef70-46ed-b9e0-b7714b794b02", "4765a2da-85ba-44a3-a094-8801b508c5a1", "866df582-8f2e-4957-a34b-0acdc58575b2", "efe4629d-cec0-49c3-a656-0558a821e06f", "94e8175c-b0c4-4e10-a673-66d8d6b2c4c5", "525e5693-90ba-4c9f-bbb2-415fdc390271", "0824275f-4d1b-48d3-a319-85ca3db84021", "e81d6b20-f384-40ce-99c8-7b74bda282ad", "287b0305-e7d0-44c0-8e18-93f9ad06a55a", "d0198e2e-49a6-4f16-8576-b8c3ee36d799", "e2536282-da0e-4217-996e-acdd53f797e9", "a6979613-7cdc-4f18-b8aa-de405f56620f", "2dd1f7cc-a76f-446f-904a-d090bc223e0f", "563f1b73-bd64-4d5f-80a0-40eb07415831", "ebe1dafb-0a7c-4146-a32a-d99738947bf0", "351e9e40-e7b1-4ce1-bf25-9705c2f59aa1", "9c121c78-3197-4259-8bd6-6e894b54fbba", "a21d7908-3b86-4d66-9381-08342178ccf3", "5b7420e2-0a73-4aba-b234-9d41614fe889"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   18 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nBrian S. Tyler  \nChief Executive Officer & Director, McKesson Corp.   A \nI'll take the coronavirus.  Maybe before that, we've been around this business for a long time. ", "original_text": "McKesson Corp.  ", "page_label": "18", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "2b148336-aa3d-4525-b1a5-559d8290011d": {"node_ids": ["ecaf43c6-2498-45b8-800b-4297f15de201", "defa66c3-f5d3-4c67-93af-2745f4ba7e1a", "e2cdcc84-dc54-4aea-b7d5-65435bd5ba25", "b2042e6f-9da3-4a88-9ada-78f55962c06f", "2612b332-abd1-4f03-ade5-c958e4a64e8e", "50841597-9b34-4fa8-89f1-e6367f260fd5", "f8735ca3-bf26-4689-8ba0-da071dd45d3d", "f2d12c19-1282-42e1-aca0-9138a2d54c8a", "eac03119-1d2d-44ec-a23a-5ce58e06b9f3", "963e761f-2f04-486d-acf0-713e8cd142ec", "c20c6b96-7fc7-4382-9f82-a70584f16443", "6e8e763f-b1c8-4a6f-afe1-efc8bd05c836", "b470c5d3-1f72-4baf-8c93-497c46a0ceb7", "4a1c08e5-cdbf-4731-936a-d977ed333d37", "ec004370-b16d-46f0-9fec-f30cca13ee85", "bd68a4cb-32fa-44b0-9853-cb01858d80e1", "c5c8ac45-6747-4155-8df1-b55f7c1917aa", "b1ea3200-8e0a-440d-a1dd-f35de316e542", "64726c32-5fa6-4dff-90b0-4d6a5d10b022", "c17b148e-9795-43ac-8f9d-891064202b09", "37bb808a-1a53-4abf-a37e-03a9cfbc0b1c", "17b2c6cb-5630-4f7a-8c07-94db71d1a60b", "3710b61d-d460-41c2-9feb-5f3250578315", "d4a8a010-db67-4ab4-a22f-2659d90f6709", "1c93cbc7-cac1-4ec3-a9b0-3d2f42619461", "89fd4b1b-37ee-4a01-8e4b-7078b259bac2", "17b8ff01-4f25-4c1e-ac70-4a8347c94808", "463e723d-979f-4492-a653-30862917733d", "2bbb2678-bcbd-4986-888b-4b63facc5a38", "d02987d7-6595-424a-8b0c-af089b299a72", "10acac68-9ebd-4946-8fbb-b239fb017bec", "417b0282-e9c1-41d4-8eb8-b59277ada195", "77cc231b-a838-4c14-972b-13f01b61d215", "3e605679-50bb-49cd-b515-5e846d9daf9f", "c693b4b5-65b0-4155-b989-b9ffbd08ca62", "7eecd516-4bf7-40f5-b086-290251ee5fbb", "ceddf902-b0c6-465e-864a-68e5ae8899c7", "796af208-a541-400c-8dc1-5f7a8882a58c", "302bb800-967d-4f6e-84c6-1523e3c322ca"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   19 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nthem properly, in parallel we've really been refining our strategies.  And if you've heard me \u2013 you've probably \nheard me say this before, all good M&A follows a good strategy.  \n \n And so, as we put this strategy together, we've identified the areas that we think we have differentiated \ncapabilities in markets that have good overall growth prospects. ", "original_text": "McKesson Corp.  ", "page_label": "19", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "d5f55c8e-9070-4f52-8251-055d730c7a98": {"node_ids": ["a335f30a-dcd9-4553-be79-7d27dd921369", "56aa17c8-ad91-4064-b2fa-0869852c2de2", "dabc8772-fe01-458e-853f-1a0944e11d42", "1dfac7d1-db90-498e-ab09-55077cb5c996", "6e0e2503-49e2-490b-ba22-554cf445af37", "dfd2e8dd-4da4-4df2-8d60-8237537af393", "17825567-d484-4674-ae0b-eaae72281ee6", "ccd30380-e208-4b2d-ab53-03cdbf99b801", "7d212ff4-1fed-40f8-973c-23b9786acee3", "a0df0668-052e-4d40-8493-a875657f06ba", "6542ffcc-632e-4de6-b49a-f84d92b9246b", "105aa91d-4bb2-4944-9609-6ef976b4f916", "81d7b4e2-97d8-4e42-9985-241b522fdf55", "1a934b7f-ef33-41ea-86fa-cff72b2660eb", "e54c7826-ee32-4a85-b9a2-4b16ba5a95ce", "6c21301c-3bec-439c-b8bd-35dac86b02b5", "4a711d48-00d8-4501-93cc-30cc63f4b10d", "953000e0-7be3-4cdb-b328-f8686606e0e9", "f7d59b91-8fae-4522-af04-ed1e35d7a8a7", "8ed718e5-fc7a-4c03-884d-98194b2d37c4", "d4022c3e-4508-4e9e-9750-02694a816287", "24fffe79-4d26-48c5-bb83-217466b23488", "a2290f6d-9c49-4d56-94ce-a468f6f5500c", "77ecde0f-c3fc-4a41-b1ab-028e75cd7e4d", "02089440-384b-4cc4-bd7a-041489614548", "c4a8b08e-55bf-40a1-bd32-da5ef91f7749", "ab33eec0-2e1b-4f01-91e1-d7210fbe699e", "575ba165-6267-4738-8ecd-daaa28861121", "fa65bfc0-afea-4251-8f1d-692ee15954b9"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   20 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \nEric Percher  \nAnalyst, Nephron Research LLC  Q \nThank you.  A quick one on Europe.  Loud and clear on expense reduction and a little benefit from the UK helping \nthe uptick this quarter on OP profit. ", "original_text": "McKesson Corp.  ", "page_label": "20", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}, "01d9de39-90cd-4a6c-be0b-62af53fead90": {"node_ids": ["15ec13b7-58eb-48d1-b5e7-31c3f8fe315e", "c1a5b2be-102d-4f04-82d1-be16f90ebfe1", "39915d77-5c5d-4673-946f-41759e83a2e5", "a5825f85-8721-4dff-931e-18c7f4b88f38", "018c8b9d-901f-4a17-b7bc-cd233c697e39", "2e13711f-e93a-486f-98f6-36d25132824d", "fd86c9b8-96a8-43d4-89b7-1fba9409aac0", "af9fcaab-0557-403e-b1f9-11a70cb51cc6", "9b9a953b-c94f-4747-8882-6c0ebde6189f", "3915d6b9-d9d7-4cb6-bd45-b94b58dc4e4b", "365aa5ef-007f-4204-92ab-1fbad94c9fc9", "bf01832a-5c6e-4ed0-825c-1bfa80e70ded", "ff832a80-b6a2-4941-83ed-dbdd5f0c226e", "e2d9ba06-4e43-4c09-a63b-8c40726242b0"], "metadata": {"window": "McKesson Corp.   (MCK ) \nQ3 2020 Earnings Call  Corrected Transcript  \n04-Feb-2020   \n \n1-877-FACTSET   www.callstreet.com   21 \nCopyright \u00a9 2001 -2020  FactSet  CallStreet, LLC  \n \n \n \n \nDisclaimer  \nThe information herein is based on sources we believe to be reliable but is not guaranteed by us and does not purport to be a  complete or error -free statement or summary of the available data. \n As such, we do not warrant, endorse or guarantee the completeness, accuracy, integrity, or timeliness of the information.  You must evaluate, and bear all risks asso ciated with, the use of any \ninformation provided hereunder, including any reliance on the accuracy, completeness, safety or usefuln ess of such information. ", "original_text": "McKesson Corp.  ", "page_label": "21", "file_name": "MCK-Q3-FY20-ECT.pdf", "file_path": "pdfs\\MCK-Q3-FY20-ECT.pdf", "file_type": "application/pdf", "file_size": 384583, "creation_date": "2024-05-07", "last_modified_date": "2024-05-01"}}}}